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Abstract 
 
This research empirically examines and compares the adoption of health technologies 
through case studies. The health technologies under review are assisted reproductive 
technologies, cochlear implants, haematopoietic stem cell transplantations, caesarean 
section deliveries, Gamma knife units and kidney transplants in four countries: Japan, 
Korea, the UK and the US.  
The interactions between the micro factors of health technologies and the macro 
environment in the adoption of health technologies are examined on the basis of a literature 
review and analysis of data. The micro factors were evaluated in terms of economic, 
clinical and technical aspects. In assessing the macro factors, payment systems and 
regulations related to the selected health technologies were taken into account. To examine 
the micro factors, the results of health technology assessments in earlier studies were 
reviewed. In order to explore the macro factors, historical changes in the payment systems 
affecting the selected health technologies and legal regulations, including legislation, 
directives, guidelines and court orders related to the technologies, were investigated. The 
adoption level of health technologies was evaluated in time-series and cross-sectional terms, 
measuring the trend of technology adoption and comparing the experience of the four 
countries under review. This research suggests clustering health technologies into “welfare 
oriented technology” and “private benefit oriented technology” by considering the 
economic incentives of adopters, individual desires of consumers and public concern over 
the technology. Private benefit oriented technologies are those which adopters expect to 
increase income from the providers or which meet the personal desires of the consumers. 
For welfare oriented technology, the decision is dominated by the aims of public welfare.  
As the model predicted, the adoption of welfare oriented technologies was higher in the 
health systems under national planning, while that of private benefit oriented technologies 
was higher in the systems whose health provisions accept market conditions.  
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Chapter 1: Introduction 
 
1.1 Research background 
Recent decades have witnessed a significant improvement in the health status of people 
in most of Organisation of Economic Co-operation and Development (OECD) member 
countries, including the four countries considered in the present thesis; Japan, Korea, UK, 
and US. This improvement has been achieved largely by public health measures, health 
education, preventive activities, screening programmes and advances in medical treatment 
(Office of Health Economics: OHE 1994). Health care expenditure has also increased 
rapidly and the issue has become a primary concern of the health policies in almost all 
developed countries and even among developing countries. During the past three decades, 
health spending has almost doubled within OECD countries (OECD 1993; Anderson et al., 
2000). Three factors have been mainly responsible for increasing health costs (Schwartz 
and Mendelson 1992): 1) demographic changes resulting in an increased number of elderly 
patients; 2) rising labour costs; and 3) advancements in health technology (HT) (Kalb 
19901; Newhouse, 1992; Gelijns and Rosenberg 1994; Fuchs 1996; Okunade and Murthy, 
2002). While technological advances have significantly contributed to improving 
healthcare practices and enhancing health status, there have also been increasing questions 
about their long-term ethical, social and economic implications (Robert et al. 1999). Many 
developments, such as genetic treatments, assisted reproductive technologies and 
technologies used for sustaining or terminating life, raise serious and complex medical, 
ethical, legal, economic and social controversies (Perry and Thamer 1999).  
Optimal and appropriate use of HTs has been a major concern in health policies and 
reimbursement strategies of third-party payers. Hence, most countries regulate HTs by law, 
by reimbursement plans, or by restrictions on services to be provided (Jonsson and Banta, 
1999). HTs have been subject to heated disputes involving ethical integrity and equity 
regarding the allocation of health care resources. To guard ethical integrity, the use of HTs 
                                                 
1 Kalb argues that medical technologies may be responsible for as much as 50% of health sector inflation, 
while Newhoue (1992) regards that health technology is responsible for perhaps as much as 75 % of the 
increase in health care spending. 
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has been regulated by law, directives or court orders. Third party payers limit coverage via 
various cost containment measures in pursuit of equitable use of financial resources.  
 
The advent of new HTs has brought not only more input in health care but also 
concerns with cost-effectiveness. There has been intense interest in the determinants of the 
dissemination of HTs. Existing studies to date have been mainly case studies, 
predominantly of single topics. Comparative studies on international level are limited to 
some countries in Europe and/or in English only. To explore the determinants for health 
technology dissemination, it is essential to deal with several topics across diverse health 
systems.  
 
The present research examines the adoption of 6 different HTs in four countries: Japan, 
Korea, the UK and the US. Little attention has been paid previously, specifically to Asian 
countries. In particular, Japan and Korea have been largely ignored, due perhaps to 
language barriers. Economic prosperity in Japan and Korea has, however, recently 
increased the attractiveness of comparative studies. These regions are in a unique position 
in the adoption of health technologies. In both countries, the funding for health care is 
financed via social insurance and health providers are paid through a fee for services (FFS). 
Hence, the choice of medical intervention is largely left to the discretion of the physician 
and/or user. In the UK, the resources for health services are largely financed by general 
taxes and provided by the national health services (NHS). Financial resources are allocated 
to the health authorities (HAs) based on the calculation of weighted capitation targets. The 
NHS as a single entity traditionally managed both the finance and delivery of health 
services. In the US, most health care is provided by the private sector. Health services are 
generally provided on an FFS basis. In tandem with the expansion of Managed Care 
Organisations (MCOs), health service provisions have been fundamentally transformed 
from fragmented care on the basis of retrospective fee payment to comprehensive care on 
pre-paid fixed fees. Due to differences in the financing, payment and delivery methods, the 
health systems of these four countries can be characterised as market oriented in Japan, 
Korea and the US and publicly controlled in the UK. 
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This research makes international comparison across diverse health systems. Cross-
national comparisons are very rare, mainly due to the difficulties out of substantiating the 
multi-factorial influences on the adoption of health care technology. Collecting data of 
comparable quality for each country also presents a major barrier to comparative studies.   
 
1.2 Key concepts 
1.2.1 Health technology 
In defining technology, concerns are generally focused on new and innovative aspects. 
In the literature, the terms “new technology”, “technological innovation” and “innovation” 
are often interchangeable. The term ‘new technology’ commonly refers to a new device, 
process or system targeting limited processes or products.  
While ‘innovation’ and ‘technological innovation’ imply the concept of ongoing 
development, new technology does not. An innovation could be an ‘idea, practice, or 
material artefact’ (Rogers and Shoemaker 1971) and this is true of the adoption of an 
internally generated or purchased device, system, policy, programme, process, product, or 
service is new to the adopting organisation (Damanpour 1991).  
Gatignon and Robertson (1989) classify innovations as minor or major. According to 
them, minor innovations refer to discontinuous innovations while major innovations are 
continuous. There are some other characteristic aspects of innovation. Technological 
innovation is confined to products, services and production technology (Damanpour 1991; 
Damanpour and Evan 1984; Knight 1967) in contrast to ‘administrative innovation’ which 
concerns organisational structure and administrative processes (Damanpour and Evan 1984; 
Kimberly and Evanisko, 1981; Knight, 1967). Technological innovation covers not only 
individual technologies but also system-wide processes of ongoing technological 
development.  
 
There have been three different perspectives in defining health technologies (HTs)’. 
First, in a narrow sense, HT is limited to a drug, machinery, piece of equipment or medical 
or surgical procedure of diagnosis and treatment (OTA 1982, 6; Stocking 1985, 5). Second, 
in an extended sense, HT can include the organisational and supportive systems in medical 
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care (OTA, 1982). Williams (1997) argues that there is no reason to exclude any 
technology related to health care delivery insofar as ‘innovation,’ ‘different,’ ‘new’ or 
‘improved’ could be applied to it2. Finberg and Hiatt (1979) and Abel-Smith (1994) argued 
that artistic, scientific and technological skills need to be included in the conception of HT. 
In their view, HT required materials, procedures, equipment and skilled human resources 
for adoption in health care practice. Raftery and colleagues (2005) distinguished 
differences between the UK and the US in defining HT. A UK definition as described by 
DoH (1992):  
 
“all methods used by health professionals to promote health, prevent and treat disease, 
and to improve rehabilitation and long term care”; 
  
and a US definition from OTA (1976): 
 
“the set of techniques, drug, equipment and procedures used by health care 
professionals in delivering medical care to individuals and the systems within which such 
care is delivered”.  
 
Reflecting these major differences between the UK and the US, they suggested 
different levels from broad interventions (such as organisational structures) through to 
possible components in health practice (individual diagnostic tests, drugs, surgical 
procedures and other intervention). 
 
The terms “health care technology” and “medical technology” have not been clearly 
distinguished. It may be useful to consider medical technologies are those directly applying 
to medical practice, while health care technologies encompass those supporting the overall 
processes of health care. Similarly, medical technology could be described in a narrow 
sense while health care technology could imply a broader view. Highly skilled 
                                                 
2 Williams (1997) describes the concept of health technology as follows:  
“any innovation in the practice of health care delivery, be it a different arrangement of beds (or patients) in a 
ward, a different division of labour among staff, a change in the location of treatment, a new surgical 
procedure, a new drug, a new piece of diagnostic or monitoring equipment, a new prosthetic device, or even 
improved heating or ventilating systems in a hospital” (pp.205-206). 
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professionals who have been specifically trained for certain medical procedures could 
accordingly be considered medical technologies.  
The present research adopts “health care technology” because it implies an overall 
view of medical equipments, skills and procedures. To encompass the various 
characteristics of the technologies, this research prefers to adopt the concept of health care 
technology. 
 
1.2.2 Micro versus macro factor 
This section, based on a brief literature review, outlines micro and macro factors in the 
diffusion of HTs. Decisions tend to be restrained by socio-economic, cultural and political 
environments. Szczepura and Kankaanpää (1996) identified three determinants in 
technology adoption; actors in the process, the environment, and characteristics of the 
technology. Applied to health care, environmental characteristics encompass the method of 
compensation for health services, legal regulations surrounding the adoption health 
technologies and organisational characteristics of potential adopters.  
First, the method for compensating health services primarily determines; 1) who 
decides to adopt, 2) who is responsible for the initial cost to adopt, 3) who decides to use 
and 4) who pays for the use. 
Second, legal regulation, including laws and court decisions can directly control 
technology adoption in healthcare. Most countries regulate the adoption of new drugs, 
medical devices and equipment (Jonsson and Banta, 1999: 1293) in order to guard the 
safety and efficacy of their application. Court rulings can impact on the adoption and use of 
new technologies. Sometimes, a court order to pay for the use of certain technology may 
accelerate the diffusion of that technology (Ferguson et al., 1993) 3.  
                                                 
3 Court decisions on the litigation of insurance coverage often occur where health plans are operated on a 
commercial basis. Courts rule against insurance carriers sued for reimbursement for unproven medical 
procedures when the insurance contract is interpreted in favour of the insured (Ferguson et al., 1993; 
Anderson et al., 1998). In the UK, about 20 cases a year are sent to the High Court in England and Wales to 
determine if medical procedures should be carried out even if a patient refuses or is unable to consent to such 
treatments (Oates, 2000: 1282). According to Oates (p. 1282), three types of cases have been brought for 
court decision: to save life; to allow that patient die peaceably; or yo enhance quality of life of the patient or 
to ensure improvement or prevent deterioration in his or her physical or mental health.  
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Third, actors in health care for technology adoptions are ordinarily health providers 
including physicians and health care organisations. There have been numerous attempts to 
trace the impetus of technology adoption from an organisational standpoint. Frambach and 
Schillewaert (2002) offer three concepts: organization size, organization structure and 
organizational innovativeness. Size is widely found to have positive relationship with 
innovation adoption. Those with larger size of organisations tend to have a greater impetus 
to adopt innovations in order to support and improve their performance. Smaller sized 
organizations are likely to be more flexible and more receptive towards innovative 
approaches (Nystrom et al., 2002; Mansfield, 1968). Damanpour (1991) argues that 
centralisation4 has a negative relationship with innovation. Regarding the strategic posture 
of a firm, the organisations which pursue an innovation-orientation marketing strategy are 
more likely to support activities to promote innovation (Hurley and Hult 1998, Datar et al 
1997).  
 
Regarding the characteristics of the technology per se, the perceived benefits have been 
recognised as major factor for adoption (Robinson 1990, Mansfield 1993). In healthcare, 
potential adopters consider if these are sufficiently favourable to recoup the initial costs 
within a suitable time (Davies, 1979). Following questions are major consideration in the 
decision for adoption (Rogers, 1995); whether new technologies are compatible with 
substitutes, possible to observe how to handle, possible to try, as well as relative advantages. 
Darley and Beniger (1981) proposed two more specific sub-dimensions for the relative 
advantages in Rogers’ concept: capital cost of the innovation and perceived savings.  
 
Many models have attempted to spell out the processes of technological diffusion, 
which are usually studied on the individual or organisational level, mainly derived from 
empirical studies. In the studies of HT dissemination, the primary concern has been to 
identify the factors influencing the spread of health technologies and then to discover the 
relations between these factors and the process of diffusion within given environments 
(Gomulka, 1990: 80). There have been several attempts to cluster, for example, external 
                                                 
4 This variable reflects the locus of authority and decision making and is the extent to which decision-making 
autonomy is dispersed or concentrated in an organisation. 
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factors (Escarce 1996; Frambach and Schillewaert 2002); internal factors, or a mixture of 
both (Mahajan and Peterson 1985); and intrinsic and extrinsic elements (Schoonmaker 
1998). Internal or intrinsic factors focus on the inherent values of a technology, while 
external or extrinsic factors concentrate on the circumstances related to the technology 
adoption.  
 
Table 1-1. Major sources for HT adoption 
Micro factors Macro factors Residual factors 
1) Economic factors  
a. Budget for 
investment 
b. Budget for operation 
c. Financial incentives 
2) Clinical factors  
a. Effectiveness 
b. Safety 
c. Morbidity 
3) Economic and clinical 
factors 
a. Cost-effectiveness 
4) Technical factors 
a. The need to acquire 
new skill to use the 
technology safely 
b. Planning and 
logistic5 
1) Reimbursement systems 
2) Public regulation 
3) Market conditions  
4) Patient demand 
a. Prevalence of disease 
1) Traditions and culture 
2) Attention from media 
3) Role of industry 
4) Information 
a. Conference and 
related activities6 
b. The possibility of 
organising studies to 
document7 
5) Opinion leaders 
b. Innovative person 
who advocate for the 
technology 
 
In healthcare, the forces encouraging or discouraging technology adoption are not 
clearly distinguished by simply juxtaposing internal with external influences or intrinsic 
with extrinsic. Poulsen and colleagues (1998) suggested 18 factors having significant 
influence on health care technology dissemination as follow; budget for investment, budget 
                                                 
5 This concept refers that the necessary planning and logistics to use the technology, including the preparation 
of the operation, the composition of the personnel, the availability of instruments, the length of the operation, 
etc. 
6 Experience and information about the technology from scientific conferences, and: or related activities 
7 The possibility of organising studies, which is affected by problems like the presence of logistical problems, 
the availability of funding, the professional’s interest in the study, the patient’s attitude towards participating 
study, the ethical dilemma of study. 
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for operation, financial incentives, nature of technology8, planning and logistics9, expected 
extra benefit10, scientific evidence11, organizing studies12, training, traditions and culture, 
opinion leaders, competition, conferences and related activities, role of the industry, 
attention from the Media, patient demand, public regulation.  
These components are intertwined and interdependent. “Micro” versus “macro” 
categorisation may be more helpful in uncovering the features in a complementary way. As 
summarised in Table 1-1, we clustered the above diffusion factors suggested by Poulsen 
and colleagues into micro factors, macro factors and residual factors. Most of them are 
consistent with the factors recognised through brief literature reviews on the earlier part of 
this section. 
 
Usefulness that comprises the advantages in micro factors becomes the primary source 
of adoption decision at practice level, while compensation for health services and the 
regulations surrounding the adoption of innovation drive choice at the macro level.  
Table 1-2. Relationship between micro and macro factor by method of finance 
Macro Micro 
Finance system Payment system Delivery system Economic incentives 
of adopters 
Social insurance Retrospective  Fragmented Profit  
General tax Budget allocation Integrated Cost saving 
Private insurance Mixed  
- Prospective 
- Capitation 
- Retrospective  
Mixed 
- Integrated 
- Fragmented 
 
Cost saving and/or  
Profit  
 
Narrowing down to the mechanisms directly associated with health care provision, 
funding, compensation and the delivery of health care are essential at macro level. Table 1-
                                                 
8 The need to acquire new skills to use the technology safely 
9 The necessary planning and logistics to use the technology, including the preparation of the operation, the 
composition of the personnel, the availability of instruments, the length of the operation, etc. 
10 The initial expected value of the technology with respect to effectiveness includes cost-effectiveness, cost-
advantages, safety, morbidity, and convalescence. 
11 The availability and quality of the published scientific evidence with respect to the safety, effectiveness and 
cost-effectiveness 
12 The possibility of organizing studies to document the effectiveness of the technology, which is affected by 
problems like the presence of logistical problems, the availability of funding, the professionals’ interest in the 
study, the patients’ attitude towards participating in a study, the ethical dilemma of a study. 
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2 summarises the relationship between micro and macro factors. Payment system and the 
delivery of health care are primarily stemmed from how the fund for health care is financed.  
In the system where health services are provided under the national plan, funding is 
largely financed by general taxation in a social welfare programme. Health care costs are 
financed by budget allocations. Health providers at all levels of health care practices are 
required to collaborate each other and share responsibility for the outcome of care and the 
use of financial resources within given budget. They are not able to adopt expensive 
equipment or devices unless the responsible authority allots budget to purchase or 
authorises them. In adopting new health technologies, potential adopters tend to pursue 
cost-saving effects. 
Social insurance programmes traditionally pay for health services on a FFS basis. 
Under this circumstance, health care is delivered in a fragmented way and the patient is 
largely free to choose health providers. Consequently, health care provision under social 
insurance is generally run by market mechanisms. The least level of responsibility for the 
outcome of health care is obliged to health providers. Providers under social insurance seek 
to increase the volume of care because retrospective fee schedule shifts the financial risks 
to the insurer. If health providers compete with each other, they may seek advanced 
technologies to take competitive advantages against other providers.  
Health systems financed by private health plan depend on market mechanisms in both 
funding and paying health services. Under market conditions, two different structures can 
exist: 1) the insurer and health care provider are separated, in terms of both function and 
organisation; 2) insurance and health care provision is fused together, as implemented in 
various forms of Managed Care Organisations (MCOs). In the first system, the providers 
are generally compensated through a retrospective fee schedule, while in the second system 
the providers get compensation through prospective or pre-fixed fee schedules. The 
providers with a retrospective fee schedule pursue profit, while those with a prospective or 
fixed fee schedule pursue cost saving by acquiring proficiency from HT adoptions. 
 
There have been many attempts to understand what leads to action for new technology 
adoption. The technology acceptance model suggests an interaction between micro and 
macro factors in the process of technology adoption, specifically between perceived 
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usefulness and perceived ease of use. Legris and colleagues (2003) employed this model to 
examine the mediating role of perceived usefulness and perceived ease of use in relating 
the system characteristics (external variables) to the probability of the system adopting the 
technology. The technology acceptance model suggests that an individual’s perception of 
how easy or difficult it is to use a technology will influence the adopter’s perceptions about 
the usefulness of the technology. Technology adoption is determined by individual 
intentions to use a technology. This is jointly determined by individual attitudes toward a 
technology and its perceived usefulness.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Flow of technology acceptance (modified from Davies, 1989) 
 
The Figure 1-1 shows that external variables affect perceived usefulness and perceived 
ease of use. In healthcare, perceived usefulness and perceived ease of use can press for 
adoption of a technology at practice level, while compensation and legal regulation set the 
policy context. As depicted in Figure 1-1, external variables in the technology acceptance 
model are equivalent to macro variables in the present research, while the components of 
perceived usefulness and perceived ease of use are comparable with micro variables. In the 
present research, perceived usefulness refers to effectiveness that is examined in terms of 
economic and clinical factors, and perceived ease of use is assessed in terms of technical 
factors.  
Perceived usefulness 
(Economic and clinical advantages) 
External variables 
(Payment system, regulation) 
Perceived ease of use  
(Technical advantages) 
Behavioural 
intention to use 
Actual 
system use 
Micro Macro Adoption behaviour 
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The feedback between micro and macro effects guarantees the maintenance of the 
system’s dynamics over time and produces some effect on self-organization (Mella, 2001). 
The feedback arises from necessitating factors - which act on the agents in the system and 
is maintained by the action of recombining factors - which act collectively.  
 
1.2.3 Classification of health technologies 
As well as classifying health systems, HTs can also usefully be classified. HTs have 
been so far clustered into procedures, devices, equipments, and pharmaceuticals. Other 
approaches have been scarcely attempted in classifying HTs. The present research employs 
‘welfare-oriented technologies (WOTs)’ versus ‘private benefit-oriented technologies 
(PBOTs)’ categorised in terms of the major motivation for the adoption of HTs. The main 
forces comprise the purposes for adoption and the agents who decide to adopt, associated 
with the perceived utility of HTs.  
Primarily, the worth of a HT on an adopter is determined by economic terms, that is, 
whether improves income or lessens the cost of health care. If potential adopters pursue 
profits, their main concerns for HT adoption likely be to do with revenue generation, while 
they may pursue cost reduction if they are responsible for finance.  
The value of a HT also matters to the patient who might gain from use of the HT. This 
can be categorised into satisfying personal desire like cosmetic surgery or fulfilling public 
welfare need like a vaccination to prevent infectious diseases. Figure 1-2 shows how 4 
different groups of HTs can be linked to difference dimensions, specifically to the value of 
the HT comprising public versus private welfare and to economic incentives that include 
cost-effectiveness versus provider income.  
 
1.3 Research questions and aims 
Although there have been many attempts to recognised the determinants for health 
technology diffusion, lack of research for clarifying the interaction between micro and 
macro factors raises questions whether their findings are possible to generalise in other 
circumstances. As explicated in previous sections, both micro and macro factors have been 
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convincingly recognised to have significant influences on the diffusion of HTs, but the 
effort to explore the interaction between them has been scarce.  
 
In this research, we have five objectives: 
 To explore the role of micro factors in HT diffusions. 
 To explore the role of macro factors in HT diffusions. 
 To explore the interaction between micro and macro factors in HT diffusions. 
 To recognise residuals in determining HT diffusions. 
 To make recommendations as appropriate. 
 
1.4 Conclusion 
The present research explores major factors in the adoption of HTs. In previous 
research, HTs tended to be considered as an ‘internal’ or ‘intrinsic’ factor and the 
environment characterised as an ‘external’ or ‘extrinsic’ factor. The research reported here 
terms of the HT as a micro factor to be assessed in economic and clinical terms. The 
environment is termed a macro factor, and includes the payment system and regulation  of 
HTs. Through case studies examining the adoption of 6 HTs in 4 countries, the current 
research attempts to explore the interaction between micro and macro factors in HT 
adoption. , This research classifies HTs into WOTs and PBOTs, based on the interaction 
between micro and macro factors.  
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Chapter 2: Research methods 
 
The present study adopts a number of methods to answer the questions stated at the end 
of chapter 1. It undertakes a purposive review of the literature on health systems of selected 
countries and the selected HTs. It also considers a series of case studies in order to assess 
the role of micro factors on the level of HT adoptions. We thus assess evidence from 
studies that have previously examined each HT on clinical and economic terms. 
The retrospective case studies of the adoption of HTs have time-series and cross 
section aspects. The case studies include interpretation of regulations in order to illustrate 
their influence on the adoption and use of selected technologies. These also include reviews 
of reimbursement schemes and their changes over time. Other residual factors are also 
taken into account, including the cultural and historical background related to each HT. 
 
The review compares a set of 6 HTs in 4 countries in terms their relative advantages in 
economic and clinical terms. To review the evaluation of micro factors, we searched a 
range of international computerised database, including Centre for Reviews and 
Dissemination (CRD; DARE, NHS EED and the HTA database), MEDLINE (Ovid version 
for the period January 1966 to January 2004), EMBASE (Ovid version for the period 
between 1988 to January 2004). We scanned the title and abstracts of all references and 
retrieved all those that dealt with clinical outcomes and economic evaluations. Given the 
lack of empirical evidence on the determinants of HT adoption, retrospective case studies 
assessed the influence of compensation schemes for health services and regulations related 
to those technologies. We choose these particular case studies in order to ensure we 
included examples of HT adoption in the three broad areas – device, equipment and 
procedures.  
Some HTs are currently experimental while some others are already being established. 
The sources of data for the case studies were from professional communities, companies, 
governmental organizations and individual specialists. Data was also collected from 
journals and formal and informal documents.  
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Each case study aims to present a comprehensive list of all sources concerning each of 
the six technologies being adopted in the four countries. In an exploratory study of this type, 
case studies are well suited for answering the questions of the how and why the level of 
adoption varies among the countries.  
 
2.1 Selection of topics 
The selected HTs are classified into three groups; medical procedures, devices and 
equipment. Medical procedures include assisted reproductive technologies (ARTs), kidney 
transplantation, caesarean section (CS) delivery and haematopoietic stem cell 
transplantations (HSCTs). Medical device includes cochlear implants. The Gamma Knife 
unit is selected as an example of medical equipment. Pharmaceuticals are excluded due to 
limitations on data availability. For Korea in particular and to some extent for Japan, no 
data were available to do similar studies of drugs. Even for the UK, the most integrated 
health system, data on drugs are available only for primary care, not for hospitals. 
 
These HTs differed in terms of cost, as can be seen from their costs in the UK. The cost 
of caesarean section delivery is least among the selected topics. The mean cost for CS 
delivery in the UK was ranged from £1,004 to £1,406 (Henderson 2001). The cost for 
ARTs is not much expensive if conception is achieved at first time, but repeating treatment 
cycles (sometimes three or more times) imposes a serious financial burden. According to 
Lloyd and colleagues (2003), the cost per ongoing pregnancy was £10,781. Regarding IVF, 
"unstimulated-IUI plus IVF,” and "stimulated IUI plus IVF" were £12,600, £13,100 and 
£15,100 per live birth-producing pregnancy respectively (Pashayan et al, 2006). The costs 
for HSCTs are varied, but are consistently on of the most expensive medical procedure with 
£13,427 for elective and £14,716 for non elective BMT respectively at reference costs 2000 
of the NHS (NHS Executive, 2001). The indicative cost of kidney transplantation is 
£17,000 including induction therapy but excluding costs incurring supports from UK 
Transplant. In the NHS, the cost on maintaining a patient is £30,800 on average per year 
whereas a kidney transplant costs £20,000 in the first year and £5,000 a year per patient 
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thereafter for anti-rejection drugs. Accordingly, the patient has a functioning transplanted 
kidney gains cost benefit in subsequent years of £25,800 per annum (UK Transplant 2007).  
Cochlear implant is a surgical procedure using an artificial device which is relatively 
expensive. Overall cost for cochlear implant is about £12,000 including £10,000 for the 
device.   
To install Leksell Gamma knife unit, about £3 million of capital costs are required 
which includes £2 million to purchase the unit and £950k for site preparation and minor 
equipment. The costs using Gamma Knife unit are varied according to the indications for 
radiosurgery.  
 
Both kidney and cochlear implantations improve the quality of life, though cochlear 
implant is not related with life extension. Discrepancy in coverage across the third-party 
payers implies that third-party payers have differing approaches to cochlear implantation. 
In Korea, for example, public insurance programmes began to cover cochlear implants 
from January 2005. Before the transformation to an insurance coverage approach, the 
Korean government had subsidised cochlear implantation to reduce the cost to patients. In 
the UK, the NHS funded cochlear implants since 1991. Many of private insurance policies 
like HMOs in the US still did not cover the cost, while Medicare provides coverage for 
cochlear implantation (Garber et al., 2002).  
Public authorities and/or third-party payers often control HTs with small volumes but 
requiring high costs hence bring about dispute on inequitable use of financial resources. 
HSCTs and Gamma knife units provide examples.  
 
In deciding whether or not to adopt HTs, the incentives towards adoption vary by 
remuneration method, health provider and patient. Based on the result of economic 
evaluation and public regulation, public authorities support some technologies while 
controlling others. Public authorities support those HTs confirmed to relieve the disability 
of patient. Sometimes public support takes the form of subsidy and support for 
organisations to promote the adoption of HTs. For example, most governments support 
organ donation and allocation activities through specific organisation, such as JNOS (Japan 
Network for Organ Sharing) in Japan, KONOS (Korean Network for Organ Sharing) in 
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Korea, UKTSSA (United Kingdom Transplant Support Services) in the UK, UNOS (United 
Network for Organ Sharing) in US. Public support for aids for the deaf is also widespread. 
In the UK for example, Newborn Hearing Screening, previously known as Universal 
Hearing Screening (UNHS), is provided to identify deafness through neonatal screening. In 
the US, UNHS is currently mandatory in 32 states and it is assumed to reduce the median 
age of identification of hearing impairment from 12 to 18 months to 6 months or less 
(Keren et al, 2002).  
 
Since third party payers are required fair allocation of limited financial resources, they 
seek to control the HTs for conditions not regarded as diseases, such as ARTs for infertility 
and caesarean section delivery without medical indication. Third-party payers are also 
reluctant to provide high cost technologies with low volumes, such as Gamma Knife 
radiosurgery. ARTs represent a unique case. In general, they have not been covered by 
health insurance programmes until recently. In pursuit of birth promotion, some countries 
such as Japan and Korea commenced subsidy while expanding insurance coverage for 
ARTs. On the contrary, public supports for ARTs are being limited in the UK and US. The 
NHS of the UK does not have guideline on the provision of infertility treatment, and 
individual health authorities have the right for coverage decision. About 25% of total ART 
cost in England is funded by the NHS (NICE, 2005). In the US, most health insurance 
programmes do not provide coverage for ARTs, and thus about 85% of total ARTs cost is 
paid by patient from their pocket money (Collins et al, 1995). These brief reviews disclose 
that public supports including the expansion of insurance coverage on ARTs are getting 
increased in pursuit of population growth. It refers that the concern for infertility treatment 
is moving from the matter of personal desire to have baby to public concern to promote 
population growth. 
 
2.2  Selection of countries 
2.2.1 Major health indicators of selected countries 
The major indicators related to healthcare such as the level of health expenditure and 
the ratio between public and private funding indicate the characteristics of a health system. 
 
 
19
Table 2-1 shows the income per capita of the selected countries with the highest in the US 
followed by the UK, Japan and Korea. In terms of GDP (Gross Domestic Product) at PPP 
(Purchasing Power Parity), the US is about double of Korea, and Japan and the UK are in 
the middle between them.  
Table 2-1. Income level of each country (GDP at PPP) 
 
Data source: International Monetary Fund, 2006 
 
Table 2-2 provides demographic data for each country. The total population of the US 
is about 5 times bigger than in the UK. The size of the UK is about 20 % bigger than that of 
Korea, and about half that of Japan. In terms of infant mortality rates, all four countries 
have a similar level, with lowest level in Japan. The total fertility ratio per woman is the 
lowest in Japan with 0.6, and highest in the US with 2 children.  
Table 2-2. Demographics by each country 
Demographic indicators Japan Korea UK US 
Life expectancy at birth 
M 79 75 77 75 
F 86 82 81 80 
Infant mortality rate (per 1,000 live births) 3 5 5 4 
Total fertility ratio (per woman) 0.6 1.2 1.7 2 
Population total (thousand) 128,085 47,817 59,668 298,213 
Data source: World Health Organisation (WHO), World Health Statistics 2006 
 
Table 2-3 shows the health spending of each country. In terms of total expenditure 
relative to GDP, health spending is very high in the US and low in Korea. In terms of per 
capita expenditure, Americans 'consume' about 8 times more money than Koreans. As 
illustrated on Table 2-2, the life expectancy at birth is quite similar between two countries. 
There are huge differences among 4 countries in public funding levels. The majority of 
health spending comes from public finance in the UK, while the proportion is less than half 
of total spending in the US. The highest level of 'out-of-pocket' money in private 
Income Japan Korea UK US 
GDP(at Purchasing Power Parity)  
$ per capita (2005) 
32,649 23,926 35,051 43,444 
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expenditure is in Korea, indicating that consumerist behaviour might be strong. While 
health systems in Japan and Korea are similar, the amount of private finance as a 
proportion of total health expenditure is much higher in Korea than in Japan. This is a 
consequence of higher co-payments and the fact that more items are excluded from 
insurance coverage in Korea. Although private spending is high in the US, health service 
consumers are largely controlled in part by prepaid health insurance programmes. 
 
Table 2-3. Health expenditure by country (2004) 
Health expenditure indicators Japan Korea UK US 
Total health expenditure (% of GDP) 7.8 5.5 8.1 15.4 
Per capita total expenditure on health at average 
exchange rate (US$) (2004) 2823.2 776 2899.7 6096.2 
General government expenditure on heath (% of 
total ) 81.3 52.6 86.3 44.7 
Private expenditure on health (% of total) 18.7 47.4 13.7 55.3 
Out-of-pocket money expenditure on health 
(% of total private expenditure) 
94.9 80.4 91.8 23.8 
Private prepaid plan expenditure on health 
(% of total private expenditure) 
1.9 7.1 8.2 66.4 
Percentage of out-of-pocket money of total 
private expenditure on health 17.74 38.10 12.57 13.16 
Percentage of prepaid plan of total private 
expenditure on health 
0.35 3.36 1.12 36.71 
Data source: WHO, World Health Statistics 2006 
 
In terms of workforce and infrastructure, as illustrated in Table 2-4, Japan and Korea 
differ from the UK and the US in having a much higher hospital bed ratio, whilst having 
much lower physician ratio. The extent of public versus private involvement also differs 
significantly. The fraction of public beds of the total is the highest in the UK at 96% and at 
its lowest in Korea at 18.5%. Private sector involvement is the highest in Korea at 86%, 
followed by Japan and the US with 67 % and 35% respectively, and then the UK, with only 
5%.  
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Table 2-4. Comparisons for Hospitals beds 
 
Data source: a. WHO, World Health Statistics 2006 
           b. OECD, OECD Health Statistics 2001.  
 
2.2.2 Health system of selected countries 
2.2.2.1. Japan 
The health system in Japan comprises a mixture of private health care providers and 
public funding. The fund for health services is financed by social insurance from the 
contributions of the insured and their employers. Total health spending accounted for 7.9 % 
of GDP in Japan in 2002 (OECD, OECD Health Data 2005). Private providers dominate 
the health service. The Ministry of Labour, Health and Welfare determines insurance 
premiums for government-managed health insurance programmes at a fixed proportion to 
the payroll. There is no price competition among insurers, and the insured are not allowed 
to switch insurers. The amount of government subsidy also varies among the insurance 
plans 
Both ambulatory and inpatient services are paid for on a FFS basis. Private physicians 
and hospitals work under the same fee schedule, which sets fees essentially in the same 
way for both.  
Health providers compete with each other to attract customers. Patients are free to go 
any physician or hospital. There is no obliged collaboration among health providers, 
therefore health care services are delivered in a fragmented way.  
 
 Japan Korea UK US 
Hospital beds (per 1,000 population)a 
129 
(2001) 
86 
(2001) 
39 
(2004) 
33 
(2003) 
Physician (per 1,000 population)a 
1.98 
(2002) 
1.57 
(2002) 
2.56 
(2000) 
2.3 
(1997) 
Public beds (% of total bed)b 35.8 18.5 96 33.2 
Private sectorb 67 86 5 35 
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Expenditure has been maintained at a lower level than any other industrialised country. 
Major mechanisms to control health spending are as follows (Ikegami, 1991); 
 A uniform fee schedule controlled by central government 
 A ceiling for the public expenditure 
 Inspection of medical fee claims 
 
First, the regulated fee schedule that is applied evenly across the country has been the 
most significant measure in terms of controlling health expenditure. In the past, health 
services were compensated by contracts between the insurers and medical association, with 
costs reimbursed by per capita per annum. The system was transformed in 1943 to the 
current ‘point system13’. The point based payment system has been a primary method of 
controlling health expenditure (OECD, 1995). Service volume has been greater in Japan 
than in other countries. In 1997, the average length of stay in an acute hospital was 32.9 
days in 2001, which is much higher than other three countries: 11 days in Korea; 6.9 days 
in the UK; and 5.8 days in the US (OECD, OECD Health Data 2003). To tackle the 
problem, a trial of a fixed fee system has recently been carried out in Japan. In 2003, a 
lump-sum payment system based on Diagnosis Procedure Combinations (DPC) was 
introduced to 82 specific function hospitals in Japan. While the US DRG/PPS system is a 
“per case payment” system, the DPC based payment system adopts a “per day payment.” 
By applying a fixed fee system, it is generally believed that the Japanese system provides 
an incentive to shorten the average length of stay (LOS) (Hideo, 2003). 
Second, the Japanese government began to contain overall public expenditure in the 
early 1980s, which pursued to retain it below 45 % of GDP. In relation to health 
expenditure, the main concern was focused on limiting the increase in the fee schedule. 
Health care costs became an obvious target due to rapid increase that gone up 6 % from 
4 % during 1970s. Consequently, the pace was significantly slowed down during 1980s 
Third, the Medical Fee Payment Fund of Social Insurance inspects the medical fees 
claimed by health care providers. The medical fee inspection programme primarily aims to 
detect any error and also examines the appropriate provision of health services. As a result, 
                                                 
13 Each item of medical practice has its point as set by the government. The providers are paid according to 
the points they provided. The unit price of the point is negotiated between the government and medical 
professional groups. 
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the medical fee inspection programme ensures health care providers are aware of their costs 
of care (National Federation of Health Insurance Societies, Japan, 1997).  
Other measures to control health care costs include co-payment and classification of 
hospitals by their function. The co-payment rate varies from 10 % to 30 % of total costs 
incurred in accordance with the insurance plan14. To improve quality of care and efficiency 
in health care delivery, the Medical Service Law of 1992 categorised hospitals into three 
types according to their functional level: ‘acute care hospitals’ which provide advanced 
medical care; ‘chronic care hospitals with recuperation beds’ which accommodate long-
term patients; and other ordinary general hospitals. By an amendment of Medical Service 
Law in 1993, people who are consulted at acute care hospitals (including teaching 
hospitals) without a referral letter have to pay extra fees. 
 
2.2.2.2. Korea 
The health care system in Korea is characterised by a mixture of public funding and 
private provision. Total health spending accounted for 5.6% of GDP in Korea (OECD, 
OECD Health Data 205). Since 1989, the statutory insurance system has covered the entire 
population, except for less than 5% of people who are unable to pay premiums and 
automatically become Medical Aid beneficiaries subsidised by the central government.  
Like Japan, insurers implement a traditional insurance function. Health services are 
delivered in a completely fragmented way. Insurance programme compensates health 
services on an FFS basis.  
The approaches to control health care expenditure have principally relied on the 
following measures; 
 price control 
 excluding services from the insurance coverage 
 co-payment 
 controlling the use of expensive HTs 
                                                 
14 The employees’ insurance programmes reimburse 90 % of total cost for the insured, and 80 % of inpatient 
services and 70 % of outpatient services for the dependent. The insurers of national insurance programmes 
reimburse 70 % of total cost both for the insured and their dependants. The insurers of retired employees 
reimburse 80 % of total cost for the insured, and 80 % of inpatient services and 70 % of outpatient services 
for their dependants. 
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The government strictly controls fee schedules with the system determining the fee 
level15. The medical fee is also subjected to a national retailer price plan. As a corollary, the 
medical fee has been kept in line with retailer price.  
Health care in Korea is highly commercialised. Market mechanism prevails health 
industry due to high proportion of private providers who seek profits (76.8 % of total 
providers as of 1994) (Yang, 1996), free access of patients to the providers and large 
portion of out-of-pocket payments at the point of consumption. Although the fee system is 
uniformly applied to all providers, there are two sources spurring price competition16. The 
large proportion of out-of-pocket money at the point of consumption leads to price 
competition among providers. 
 
2.2.2.3. UK 
Health services are largely provided by public funding in the UK. The National Health 
Service (NHS) was created in 1948 as a publicly financed and centralised system providing 
free universal access to health care. In the aftermath of World War II, the Labour 
government created the NHS as called for by the Beveridge Report of 1942. The NHS 
provides the majority of healthcare from general practitioners to hospitals, long-term 
healthcare, dentistry and ophthalmology. Private health care has continued parallel to the 
NHS, paid for largely by private insurance, but it is used only by a small fraction of the 
population, and generally as a top-up to NHS services. Many NHS services are free at the 
point of delivery, paid for by general taxation; in 2007 the NHS budget was 21.1% of the 
national budget (HM Treasury, Budget 2007). 
                                                 
15 It requires the following four steps. First, the government conducts research on the profitability of health 
care providers for the next year by projecting increases in health care costs. This serves as a yardstick to 
determine the level of fee increases next year. According to the Price Stabilisation and the Fair Trade Act, fee 
increases should be approved by the Economic Planning Bureau that controls overall national economic 
policies. Then, the Ministry of Health and Welfare finally enters negotiations with the medical community to 
arrange the items of medical services covered by insurance and fee rates for each item of service. 
16 First, many services are not covered by insurance. Second, patients pay a high rate of co-payment ranging 
from 20 % to 55 % of total costs. Although the co-payment rate is the same for all providers, patients 
differently perceive the costs of providers from one to another, because patients are liable for co-payment of 
uncovered services completely out of their pocket at the end of each visit. A large proportion of co-payment 
and payment for uncovered items is paid for out of the pockets of patients, making them more sensitive to the 
cost of providers. 
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To improve efficiency in providing health services, Margaret Thatcher's Conservative 
government launched reforms in 1991. As a major principle, a market system was 
introduced into the NHS. Certain GPs became "fund holders" and were able to purchase 
care for their patients. Health authorities were required to purchase the rest of health 
services from NHS hospitals. Thus purchasing and providing were split for the first time in 
the NHS.  
Health reforms under the Labour government that came to power in 1997 have 
encouraged outsourcing of medical services and support to the private sector. Under the 
Private Finance Initiative (PFI), an increasing number of hospitals have been built by 
private sector consortia; hospitals may have both medical services and non-medical 
services (such as catering) provided under long-term contracts with the private sector.  
In 2000, the Blair government introduced the National Health Services Plan, the largest 
program of investment and reform since 1948. The plan envisages increasing health care 
spending to 9.4% of GDP by 2008 (HM Treasury, Spending Review 2002). In the reforms, 
health authorities and all NHS regional offices have been dismantled since 2002. The 
responsibilities are being shifted to primary care trusts (PCTs), which provide 90% of the 
first contact with patients. Health Authorities have transformed from being purchasers to 
having a more strategic role in determining the overall health needs of their areas; assessing 
priorities, promoting public health, and monitoring the quality and effectiveness of both 
commissioners and providers of health care.  
As of the end of 2006, 152 primary care trusts control about 80% of the total NHS 
budget and have control over all local services. These PCTs are able to purchase care from 
public, private, voluntary and not-for-profit health care providers. Hospitals, or NHS 
foundation trusts, operate on a not-for-profit basis and are able to borrow money for 
investment, recruit their own staff. As part of the new NHS framework, the system relies on 
the advice of a newly established organization—the National Institute for Clinical 
Excellence (NICE)—which provides the NHS with guidance on current best practices and 
cost effectiveness related to medicines, medical equipment, clinical procedures, and the 
management of specific conditions. 
 
 
 
26
2.2.2.4. US 
Health care in the United States is provided by many separate legal entities. The US 
spends more on health care than any other nation in the world. Current estimates put US 
healthcare spending at approximately 15% of GDP. Around 84% of citizens have health 
insurance, either through their employer (60%), purchased individually (9%), or provided 
by government programs (27%; there is some overlap in these figures) (US Census Bureau, 
2005). The federal government does not guarantee universal health care to all its citizens, 
but Medicare programmes provide for the elderly, disabled, children, and the poor, and 
federal law ensures public access to emergency services regardless of ability to pay. 
Medicaid programmes financed by state government provide for the poor aside from 
Medicare benefits. Americans without health insurance coverage, currently about 16% of 
the population, or 46 million people, are expected to pay privately for medical services. 
Health insurance is expensive, and medical bills are overwhelmingly the most common 
reason for personal bankruptcy in the United States (Himmelstein et al., 2005).  
Roemer (1991) characterises the US health care system as possessing three major 
features. First, the US spends a great deal of money on health care services. Second, as a 
federated nation, it governs health care systems in a highly decentralised manner at the 
federal, state, and local level. Third, as a free market economy, it incorporates very 
permissive laissez-fair concepts throughout its health care system. The federated political 
system and free market structure have particularly significant implications for health care 
systems. The free market structure has minimised public involvement, and thereby, 
vitalised the participation of private entities in financing and providing health care services.  
The Medicare programme implemented the hospital prospective payment system, 
based on the DRG (Diagnostic Related Group) system, in October 1983. Two mechanisms 
are embedded within the PPS (Prospective Payment System) in order to curtail cost 
increases in health care services. First, by giving financial incentives to hospitals, the 
programme expects them to improve efficiency in providing inpatient services by means of 
reducing the lengths of stays and the quantity and cost of services provided during hospital 
stays. Second, the introduction of Peer Review Organisations (PROs) has also encouraged 
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doctors and hospitals to reduce hospital costs (Prospective Payment Assessment 
Commission, 1994)17.  
As a measure to control health care costs in the private sector, various kinds of 
managed care organisations (MCOs) have been developed including Health Maintenance 
Organisations (HMOs)18, preferred provider organisation (PPO), and point-of-service 
(POS)19.  
 
2.2.3 Classification of health system for the selected countries 
The present research deals with four countries: Japan, Korea, the UK and the US. 
These four countries are unique in that they have different systems of finance and 
compensation for health services. Details on the health systems, along with their incentives 
for HT adoption, are described below sections. 
 
Table 2-5 offers a broad schema describing the key characteristics of the health systems 
of each country in terms of financing and delivery system; by clustering both according to 
the balance between public and private sector involvement. In a similar vein, Propper and 
                                                 
17 Cost control was one of the major objectives of the PROs Cost and utilisation objectives of PROs; this 
included reductions in admissions for procedures that could be safely on an outpatient basis, reductions in 
inappropriate admissions and use of unnecessary ancillary services, and elimination of inappropriate cardiac 
pacemaker implantations or re-implantations (Davis et al., 1991). 
18 The HMO assumes the financial risk for provision of services on a prospective basis and, therefore, 
integrates the functions of insurance and the provision of medical services (Enthoven, 1978). 
19 There are five commonly recognised models in HMOs (Kongstvedt, 1993), which are staff, group, network, 
IPA, and direct contract. PPO is a form of managed care through which employer health benefit plans and 
health insurance carriers contract to purchase health care services for covered members from a selected group 
of participating providers. Most PPOs contract directly with hospitals, physicians, and other diagnostic 
facilities. Providers are selected to participate on the basis of their cost efficiency, community reputation, and 
scope of services. PPOs reimburse the participating providers in full for covered services, except the amounts 
assigned to patients as coinsurance or deductibles, at a discounted price schedule, which compensates the 
providers with a competitive cost advantage relative to cost-based payment systems. Providers participating in 
PPO are reimbursed on FFS basis and totally free to see other insurers’ patients. Members in PPOs have the 
choice of using either in or out of network physicians and hospitals. To control the utilisation and cost of 
health care services, many PPOs implement utilisation management programmes. There are two types of POS 
plans (Kongstvedt, 1993): capitated and primary care POSs and open-access POS HMOs. Under capitated 
POS, primary care physicians are reimbursed through capitation payments or other performance-based 
reimbursement methods. The primary care physician acts as a gatekeeper for referral and institutional medical 
services. The members are not fully covered for services rendered that either are not authorised by the 
primary care physician or are delivered by the providers who are not participating in the POS plan. 
The members enrolled in an open-access POS can choose HMO benefits or indemnity-style benefits for each 
instance of care. The indemnity coverage available under POS options from HMOs typically incorporates 
high deductibles and coinsurance to encourage members to use HMO services instead of out-of-plan services. 
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Green (1999) classify health systems into four types: mainly public provision, public 
finance; mixed provision, public finance; mixed provision, mixed finance; and mainly 
private provision, private finance. Health systems are continually engaged in a dynamic 
process of reform in response to changing needs, new policy directions, and medical 
developments (Blanchette, 1997).  
 
Table 2-5. Health systems by public-private sector intervention (Modified from 
Blanchette, 1997) 
 
Delivery 
Public Private 
Financing 
Public 
Insurance and service 
delivery are handled by a 
single public agency.  
 
The public pays for services 
through taxes or social 
security and the services are 
provided by private 
agencies  
United Kingdom, Sweden, 
Denmark, Finland, Norway 
Canada, Japan, Germany, 
France, Korea  
Private 
The cost is charged directly 
to users (through insurance 
or out-of-pocket payments) 
but services are provided in 
public facilities 
Health care is funded by 
private insurance or paid for 
directly by the patient and is 
provided in private facilities 
No pertinent system exist United States 
 
 
 
As Deber and colleagues (1998) point out, “virtually every country employs some 
combination of financing and delivery models, relying on various public-private 
combinations in various sectors of the health system or for various groups of the nation's 
population (p. 439).” In this vein, it is quite difficult to place a health system into a static 
classification. Traditionally, the NHS was financed via public intervention and the 
provision of health services controlled by public organisations. Constant reforms, from 
Public 
plan 
Market 
mechanism 
Public 
plan 
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internal market transformation through to the reforms of the current Labour government, 
have moved the NHS towards a market-based model. 
 
In summary, the health systems of selected countries are characterised as follows; 1) 
the UK health system represents a public planning in both finance and delivery aspects, 2) 
those of Japan and Korea are categorised into public planning in finance but market 
mechanisms in delivery, 3) the system in the US is recognised as using a market 
mechanism in both terms of finance and delivery. Since health services in both Japan and 
Korea are compensated on a FFS basis while being provided in a fragmented way, a market 
mechanism is being promoted in health care provision. 
 
2.2.4 Health systems and health technology adoption 
Table 2-6 provides an overview of the health systems of the four countries. The health 
systems of Japan and Korea are similar. Finance comes from social insurance; health 
providers are compensated by a FFS system; and health services are provided in a 
fragmented way. Health care providers exploit HTs in order to increase income. Since 
financial risks are transferred to third party payers, health care providers and users are not 
conscious of the costs of using health services. By introducing DRG based payment system 
for some items, health care reforms have been partly attempted by adopting pre-fixed fee 
payment systems in both Japan and Korea.  
Table 2-6. Major components of healthcare system in selected countries 
Country Finance Payment  Delivery  
Japan Social insurance  Retrospective reimbursement Fragmented 
Korea Social insurance  Retrospective reimbursement Fragmented 
UK Tax-funded Budget allocation Coordinated 
US 
Private insurance 
Tax-funded 
Internal compensation 
Contract  
Retrospective reimbursement 
Integrated 
Coordinated 
Fragmented 
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As the ownership of health care facilities predominately lies within the private sector, 
market oriented mechanisms are dominant in health services in both Japan and Korea, even 
though healthcare funds are mostly financed by social insurance schemes. Regarding the 
adoption of health technologies, these systems have the following characteristics: 
 Healthcare providers are largely free to choose medical treatments without 
taking financial risks  
 Most health services are covered by health insurance – as long as the 
intervention is medically required and costs are not unjustifiably high  
 The decision for the adoption of HT is in the hands of health care providers 
 Health providers finance capital cost is in their own decision 
 
In the UK, financial resources for HT adoption were allocated by Department of Health 
to Health Authorities (HAs) on the basis of weighted capitation targets. Traditionally, the 
NHS managed both the finance and delivery of health services as a single entity. To 
improve efficiency in providing health services as well as responsiveness to local needs, a 
series of reforms have been introduced since 1989 with the aim of breaking down the 
traditionally bureaucratic public sector state monopoly  
The New Labour’s White Paper; ‘The New NHS: modern, dependable’, favoured 
partnerships of collaborative networks among entities involved in health service provision. 
As Hunter (2000) notes, “unrelenting performance management is the hallmark of 
Government’s managerial style (p.71)”, the New Labour Government stressed the 
‘management of the NHS’ delivery on waiting list targets and on financial targets.  
In the traditional NHS, the physicians had no need to be cost conscious. The health care 
reforms in recent years have led health care providers to be more cautious in terms of 
resource use. Regarding health technology adoption, the NHS is characterised by: 
 Healthcare providers choosing medical treatments in consultation with patients. 
As the services are provided within given financial resources to HAs, patients 
must wait until financial resources are available for them 
 HAs restrict the HTs to be available on the basis of priority of local needs and 
evidence of effectiveness 
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 Global budget systems limit the availability of money to purchase expensive 
equipment (Rosen and Mays, 1998: 106)  
 
In the US, most health care is provided in the private sector. State and local public 
hospitals account for 22% of the total 6,265 hospitals and contain 157,000 beds. Among 
them, 17% of all hospitals (and 14% of all hospital beds) are owned by the federal 
government (Tradewell, 1998)20. The number of public hospitals has been shrinking 
constantly, and declined 23% from 1975 to 1995. Notwithstanding the dominance of the 
public sector in terms of provision, sources of finance are more mixed. In 1998, the private 
sector accounted for 55.3% of total healthcare spending (OECD, OECD Health Data 2000). 
In terms of population covered under the age of 65 in 1999, private health plans accounted 
for 72.3%, and public insurance programmes for 12.3% (Custer and Ketsche, 2000). The 
remaining 17.4% of the population was without insurance coverage. Public insurance 
programmes through Medicare and Medicaid cover 23.4% of the total population, including 
the people over the age of 65. 
The majority of health care providers in the US appear to pursue financial gain either 
by increasing income or decreasing costs. Traditionally, health services were remunerated 
on an FFS basis, and critics pointed to a tendency towards overspending due by supplier-
induced demand (Ham and colleague, 1990: 71). In an attempt to control health care 
spending, the US Congress passed the Health Maintenance Organisations (HMOs) Act in 
1973 encouraging the formation of managed care organisations (MCOs). The introduction 
of HMOs has brought about a fundamental transformation away from the traditional 
indemnity plan in terms of both delivery and reimbursement system. There was a move 
from FFS-based fragmented services to the provision of comprehensive care for a flat 
prepaid fee. In 2001, about 62.3% of the total population were joined in some form of 
managed care plan (Managed Care On-Line, 2002) covering 177.9 million people.  
By ensuring comprehensive care within given fees, financial risk is transmitted to 
healthcare providers in the managed care arrangement of the US. MCOs thus endeavour to 
control healthcare costs by avoiding hospitalisation and the use of expensive medical and 
                                                 
20 Privatising public hospitals: strategic options in an era of industry-wide consolidation, Reason Public 
Policy Institute, Policy Study No. 242, http://www.rppi.org/ps242.html retrieved on 5 January 2002.     
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surgical procedures in favour of less-expensive options; including outpatient, home, or 
nursing home care (Balder, 1996; 22-27). The front line option is to prevent hospitalisation 
if possible, and keep good quality care at the primary care level.  
 
The DRG based reimbursement system introduced in October 1983 for the Medicare 
beneficiaries is also designed to avoid excessive stays in hospital and gives the hospital a 
financial incentive to discharge patients as early as possible. Hospitals are paid on the basis 
of two fixed "standardised payment amounts" per discharge of Medicare beneficiary; these 
are the operating amount and capital amount.  
General incentives inherent in DRG can be summarised as 1) to reduce the cost of each 
inpatient case stay and 2) to increase the number of inpatient admissions (OTA, 1983). 
Under the current US DRG system, new technology is often underpaid (Princeton 
Reimbursement Group, 2002). As the cost per patient stay can be reduced by using fewer 
interventions, including technological services and labours, the resulting incentive may 
favour in specialisation among hospitals for services encouraging capital intensive 
technologies in fewer institutions (OTA, 1983). 
Competition among healthcare providers creates incentives to equip with state-of-art 
technologies and staffing by dominant figures. Technologies that are cost-saving to 
hospitals will tend to be encouraged in a fixed or flat fee reimbursement scheme. This is 
commonly applied to DRG systems and the services provided by MCOs. By contrast, in 
indemnity plans, where the fees are compensated for on an FFS basis, technologies that 
may contribute to increasing revenues are encouraged.  
 
Competition among healthcare providers creates incentives to equip with state-of-art 
technologies and staffing by dominant figures. Technologies that are cost-saving to 
hospitals will tend to be encouraged in a fixed or flat fee reimbursement scheme. This is 
commonly applied to DRG systems and the services provided by MCOs. By contrast, in 
indemnity plans, where the fees are compensated for on an FFS basis, technologies that 
may contribute to increasing revenues are encouraged.  
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In summary, the reasons for potential adopters to adopt a new technology vary 
according to the health system. Table 2-7 describes relationships among major agents in 
each country in adopting new technology on comparative aspects. It implies that the 
incentive for technology adoption may vary widely depending on the health care system 
 
Table 2-7. Relations among major agents in adopting new technology 
 Japan Korea UK (NHS) US 
Decision maker 
for technology 
adoption 
Individual hospital 
and physician 
DoH, HA, 
Individual 
hospital and 
physician 
Individual health care 
organisation, hospital or 
physician 
Finance for 
technology 
adoption 
Individual hospital or 
physician 
DoH, HA, 
Individual 
hospital 
Individual health care 
organisation, hospital or 
physician 
Decision maker 
for technology use 
Individual hospital or 
physician 
HA, Individual 
hospital 
Individual health care 
organisation, hospital or 
physician 
Who gets profits 
produced by 
adopting new 
technology 
Individual hospital or 
physician 
N/A 
Individual health care 
organisation, hospital or 
physician 
Who gets benefits 
of cost reduction 
created by new 
technology 
Patients, social 
insurance 
Nation 
Patients, private 
insurance, public 
insurance 
Major incentive to 
adopt net 
technology 
Profit maximisation Cost reduction 
Profit maximisation, Cost 
reduction 
 
2.3 Analysis of data 
Micro factors will be assessed in terms of economic and clinical effectiveness which 
are commonly evaluated in terms of cost-effectiveness or overall costs for use. As a method 
to “describe or predict the differential costs and benefits of two or more alternative 
interventions (Ruttens, 1996: 216),” economic evaluation or health care technology 
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assessment has been a major tool to address the role of micro factors playing in the 
adoption of health care technologies. In tandem with a constant rise of health costs, which 
are often associated with new technologies, there have been growing requirements to 
demonstrate the benefit versus cost of new technologies21.   
Economic evaluations have been employed as an aid to the development of treatment 
guidelines, decisions within health care organisations, the introduction of new health care 
technologies, and reimbursement and pricing decisions (Johannesson, 1995). The primary 
role of economic evaluation in health care is to “help decision-making by considering the 
output of competing interventions in relation to the resources they require (Kernick, 
1998:1663).” Economic evaluation provides a basis for decisions about approval of new 
technology. 
 
In cost-benefit analysis, there are two main approaches to assign monetary value to life 
and health (Drummond et al, 1995; Klose, 1999). The first measures market valuations, 
which take into account human capital and friction costs enumerating either the value of a 
person’s life or the indirect cost of disease with reference to a person’s contribution to the 
gross domestic product as measured by wage rates22. The second approach assesses 
“willingness to pay (WTP)” for a technology and its effects based on individuals' 
preferences. WTP is calculated from data on trade-offs between the effect to be evaluated 
and a monetary amount from which WTP measures can be derived. WTP and quality 
adjusted life year gained (QALY) are two preference-based measures of health-related 
outcome. QALY attempts to measure the outcome of a disease in terms of different 
combinations of duration and quality of life. The WTP approach directly asks respondents 
what amount they are willing to pay to give up permanently their previous state as valuing 
a specific health and time profile.  
                                                 
21 In Australia, economic evaluation is a requirement for public sector funding of new drugs (Raftery, 1998). 
Based on economic evaluation, the Australian Pharmaceutical Benefits Advisory Committee decides whether 
drug products should covered by public subsidy (Hailey, 1997). Palmer and colleagues (1999) argue that full 
costs and benefits of all health care problems and all alternative interventions should be assessed to determine 
whether a change in the mix of intervention would increase efficiency. In the US, the Food and Drug 
Administration Modernisation Act of 1997 requires pharmaceutical manufactures to support economic claims 
about their products in pursuit of improving health care economic information exchange while protecting 
consumers from misleading claims (Neumann et al., 2000). 
22 This approach was widely criticised because of its inconsistency with the basic rationale of the economic 
calculus used in cost-benefit analysis, as it requires measures based on individuals’ preferences. 
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In assessing economic advantages, the current research depends on the results of 
economic evaluations located for each HT, considered in terms of overall costs, patients’ 
share, cost per life year gained, or costs per QALYs. Economic information for each topic 
is summarised in Table 2-8.  
 
Table 2-8. Economic evaluation for selected HTs 
 Economic evaluation Comparable approaches 
ARTs 
Cost per cycle 
Cost per live birth 
 
caesarean section 
delivery Cost per procedure Vaginal delivery, 
HSCTs Cost per procedure Chemotherapy 
Kidney transplantation 
Costs per QALY,  
Cost per procedure 
Home dialysis, 
Hospital dialysis 
Cochlear implant 
Costs per QALY,  
Cost per procedure 
Other hearing support 
materials 
Gamma Knife 
Radiosurgery 
Costs per QALY,  
Cost per procedure 
Cost for installation 
Open skull surgery 
 
The clinical and economic advantage varies according to the reason for which each 
technology is adopted, such as success rate, the effect on improving quality of life (QoL), 
prolongation of life, restoring function, preventing disability and avoiding mortality and 
morbidity. The present study depends on the information found in the literature regarding 
the clinical effectiveness of each HT. For the ARTs, clinical effectiveness is often assessed 
in terms of success rate per cycle and the outcomes of ART procedures are compared to 
each other. No specific way has been found of showing the clinical effectiveness of 
caesarean section delivery. Compared to vaginal delivery, adverse effects including 
maternal death rate and complications have been common indicators in assessing 
effectiveness. As for HSCTs and organ transplantations, clinical effectiveness has been 
assessed in terms of survival rate following the transplantation and comparisons of QoL 
between the periods of pre- and post-transplantation. 
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Technical advantage denotes the dominance in technical terms of using a particular 
technology, which described in terms of ease of use on theoretical contemplation. On the 
patient’s side, technical advantage implies comfort, less pain and a shorter time spent on 
diagnosis and treatment. For medical professionals, technical advantage would include 
operational convenience and lower time demands. 
As it is not possible to assess technical advantage in quantitative terms, it is considered 
a residual factor and is assessed by listing the reasons, other than clinical and economic 
rationales, why patients or health care professionals may prefer a particular technology.  
 
The diffusion of HT is a matter of 'speed' and 'level'. Speed refers to how the 
technology has spread over the defined area within a limited time period. The level of 
diffusion concerns the supply of the technology compared with the need for the technology. 
It is, however, difficult to find a method by which to assess the speed of innovation and 
level of diffusion. Major difficulties lie in uncovering the process and timing of adoption 
(Sloan et al., 1986). As all countries experience different circumstances with regard to the 
use of the technologies, the adoption level of health care technology cannot simply be 
recognised by the current adoption.  
 
Theoretical frameworks assessing the dissemination of new technologies fall into three 
groups (Feder and Uy, 1985): time-series studies; cross-sectional studies; and panel-data 
studies.  
Time-series studies attempt to model the pattern of adoption as a logistic function over 
time. Accordingly, these studies measure technology diffusion in terms of adoption by time. 
For example, these approaches assess the percentage of firms employing a new technology 
at each date, or the percentage of products produced by using the technology. As time-
series studies analyse technology adoption in certain regions at a certain time points, these 
approaches make it possible to investigate the effect of regional characteristics on adoption. 
Cross-sectional studies assess technology diffusion by taking a snapshot of a firm’s 
technology in use at certain point in time. These studies aim to measure the impact of a 
firm's characteristics on adoption decisions. Recognising that technology is likely to be 
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unevenly diffused through the regions, population or firms, these studies can provide 
insight into the characteristics of firms associated with acquiring the technology. 
Panel-data studies analyse in parallel details of the characteristics of industry and firms 
in order to understand the adoption choices made at each point in time.  
The present research assesses the diffusion of health care technology in both time-
series and cross-sectional terms, measuring the trend of technology adoption with 
comparisons of four countries. The level of HT diffusion is assessed by comparing the 
number treated with per million population (pmp). The data for the adoption of each HT 
has been collected from various sources, as which summarised on Table 2-9, below.  
 
Table 2-9. Data sources for HT adoptions  
HTs Japan Korea UK US 
ART JSOG KSOG HFEA ASRM 
caesarean section 
delivery MHLW NHIC DOH CDC, NCHS 
HSCT JSHCT 
HSCT Nurse 
Association BSBMT 
IBMTR/ 
ABMTR,  
Cochlear implantation ACITA Local agents D. Marshall A.Q. 
Summerfield 
Gamma Knife 
Manufacture 
JGMSA 
Manufacture  Manufacture Manufacture 
Kidney transplantation JOTN KONOS UKTSSA UNOS 
Note:  
a. JSOG- Japan Society of Obstetrics and Gynaecology  
b. JGMSA- Japan Gamma Knife Support Association 
c. KSOG- Korean Society of Obstetrics and Gynaecology 
d. HFEA- Human Fertilisation and Embryology Authority 
e. ASRM- American Society for Reconstructive Microsurgery 
f. MHLW- Ministry of Health, Labour and Welfare. 
g. NHIC- National Health Insurance Corporation 
h. DOH- Department of Health 
i. BSBMT- British Society of Blood and Marrow Transplantation 
j. IBMTR/ABMTR- International Bone Marrow Transplant Registry and the Autologous Blood 
and Marrow Transplant Registry 
k. ACITA- Association of Cochlear Implant Transmitted Audition 
l. JOTN- Japan Organ Transplant Network 
m. KONOS-Korean Network for Organ Sharing 
n. UKTSSA-United Kingdom Transplant Support Service Authority 
o. UNOS- United Network for Organ Sharing 
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Chapter 3: Assisted Reproductive Technology 
3.1. Introduction 
Infertility is the condition in which one year of unprotected intercourse does not result 
in pregnancy. It is currently estimated that about 60-80 million couples around the world 
suffer from infertility (WHO 1995). Thirty-five % of these cases are attributed to female 
factors, 35% to male factors, and 15% to multiple factors. For the remaining 15% of the 
cases, the cause is unknown (Solursh et al. 1997).  
Medical and scientific advances in ARTs have made various options for conceiving a 
baby, or various medical interventions, available, including ovulatory induction using 
fertility drugs, artificial insemination by way of partner or donor sperm, surgical procedures, 
medical management, and in-vitro fertilisation embryo transfer (IVF-ET).  
Taking fertility drugs is the most common option for infertility treatment. The term 
ARTs, though, usually refers to the more advanced treatments IVF-ET and gamete 
intrafallopian transfer (GIFT) (Ryan 1996). There is a wide range of ARTs that can be 
employed in infertility cases, depending on the cause of infertility. IVF-ET is the first ART 
procedure ever developed, and it remains the most commonly performed procedure. It is a 
procedure that involves retrieving a woman’s eggs and a man’s sperm, then placing both of 
them on a laboratory dish to increase the chances of fertilisation. If fertilisation takes place, 
the eggs are once again placed in the woman’s uterus several days after the retrieval, and it 
is hoped that implantation and embryo development will occur therein, as in a normal 
pregnancy. The first IVF-ET baby, Louise Brown, was born in the UK Since then, the 
number of IVF-ET treatments performed each year has increased, and the success rate of 
the procedure has improved significantly.  
Zygote intrafallopian transfer (ZIFT)23 has the advantage of allowing fertilisation to be 
confirmed, and has demonstrated a higher success rate than IVF-ET when used in 
appropriate cases. Like IVF-ET, ZIFT involves ovarian stimulation, monitoring, and egg 
retrieval, followed by sperm processing and fertilization in the laboratory. Another slight 
                                                 
23 With ZIFT, the fertilised egg that is placed inside the woman’s uterus is allowed to divide only up to the 
two-cell stage and not up to the four- or eight-cell stage, as with the conventional IVF-ET. This fertilised 
egg at the two-cell stage is called a zygote.  
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difference between IVF-ET and ZIFT (besides the stage at which the embryo is transferred 
to the uterus) is the place where the embryo is implanted in the woman’s body. In ZIFT, the 
zygotes are placed directly into the fallopian tube. Therefore, a criterion for performing 
ZIFT is that the female partner must have at least one open and functioning fallopian 
tube.24  
Gamete intrafallopian transfer (GIFT) was developed in 1984 as a variation of IVF-ET. 
GIFT is not very different from IVF-ET. The main difference between the two is that in 
GIFT, fertilisation is naturally achieved within the female partner’s body and not in the 
laboratory. In GIFT, eggs are retrieved from the woman’s ovary through ovarian 
stimulation, and then the sperm and eggs are placed directly into the woman’s fallopian 
tubes to induce fertilisation.  
Intracytoplasmic sperm injection (ICSI) was developed to treat couples who have a 
very poor probability of achieving fertilisation due to the male partner’s extremely low 
number of viable sperms. In ICSI, sperms are injected directly into the centre of the egg 
using a microscopic pipette. 
Intrauterine insemination (IUI) is the simplest and least costly ART. It involves giving 
the woman fertility drugs in the hope that these will help her produce more eggs. Then, 
sperms are injected directly into the uterus.  
There are two types of surrogacy that are also possible options for infertile couples: 
genetic and gestational surrogacy. In genetic surrogacy, a surrogate is artificially 
inseminated with the husband’s sperm. As such, the newborn is genetically related to both 
the husband and the surrogate. In gestational surrogacy, the woman produces eggs, but for 
some reason, she is unable to achieve pregnancy or carry pregnancy to term. In this case, 
the embryo and sperm of the couple who are trying to conceive a baby are placed in the 
surrogate’s uterus through IVF-ET. The surrogate thus simply provides the host uterus, but 
the newborn is genetically related to the couple and not to the surrogate. 
 Table 3-1 summarises the regulation and reimbursement policies in relation to ARTs 
in some OECD countries. As shown in the table, there are huge variations among countries 
                                                 
24 One disadvantage of ZIFT is that the zygote is placed inside the woman’s uterus using a laparoscope, 
which necessarily involves surgical incision. In IVF-ET, there is no need for any incision as the fertilized 
eggs are transferred to the uterus through the vagina. Although laparoscopy is a minor surgical procedure, it 
nevertheless makes ZIFT more complex, risky, and costly than IVF-ET. 
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in terms of their ARTs regulation and reimbursement policies. As ARTs involve the use of 
unnatural processes to aid human reproduction, their development has generated more 
controversy among religious groups, bio-ethicists, and the general public than any other 
medical procedure has (Jones and Cohen 2001). The controversy surrounding ARTs have 
spurred deliberations on the ethical, legal, religious, and public-policy aspects of such 
technologies, which have resulted in the establishment of guidelines and/or legal 
regulations in relation to them. These guidelines and regulations take into account various 
medical perspectives and social circumstances, including cultural traditions. Some negative 
reactions to ARTs stem from the delivery of non-genetically-linked newborns, the 
occurrence of chromosome abnormalities, and the practice of gender selection through 
sperm sorting.  
Table 3-1. Regulation and reimbursement policy for ARTs  
Country Situation 
Australia 
Australia’s Reproductive-Technology Accreditation Committee (RTAC) 
ensures a high standard of care. Australia is the only country in the world 
that provides unlimited government reimbursement for infertility 
treatments, with no restriction on the lifetime use of IVF-ET treatments. 
Austria 
An ARTs-related law was passed in 1991. From January to June of 2000, 
approximately 70% of all IVF-ET treatments (including medication) for 
women aged <40 and for men aged <50 and with tubal dysfunction or male 
infertility were publicly funded. 
Canada 
There is no legal regulation of the use of ARTs. All IVF-ET treatments are 
privately funded, except in the province of Ontario, where only up to three 
cycles in a lifetime are publicly funded, and only for women with 
completely occluded fallopian tubes. 
France 
If the infertility treatment is carried out in a public hospital, the costs are 
fully covered by public funds, but only up to six artificial inseminations 
and four IVF-ET treatment cycles.  
Germany 
The Embryo Protection Act of 1990 prohibits several ART procedures. 
Only up to 14 inseminations, two GIFTs, and four IVF-ET cycles are 
covered by public funding. No health insurance company reimburses ICSI. 
Netherlands 
Public funding covers only up to three IVF-ET cycles. Most private 
insurance companies also pay for three IVF-ET cycles, but they charge a 
co-payment. Commercial surrogacy is prohibited.  
Norway 
Legislation controls infertility treatment, limiting it to heterosexual 
couples. Public funding is available only when the treatment is performed 
in a public hospital.  
Data Sources: Hughes and Giacomini (2001)  
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3.2. Micro Factor Evaluation 
3.2.1. Economic Factors 
An estimation of cost effectiveness can be obtained by comparing the cost of a medical 
intervention with the probability of having a baby through it. Accordingly, the cost 
effectiveness of ARTs has been evaluated by assessing their overall cost and comparing 
this to their success rates.  
The costs of different ARTs vary greatly according to the protocols applied, which 
depend mainly on the number of embryos that are transferred in IVF-ET (Silva et al. 
1997).25 For instance, the standard IVF-ET protocols that transfer two or three embryos are 
less cost-effective than those that transfer only one embryo (Wølner-Hanssen and 
Rydhstroem 1998).  
 
Table 3-2. Cost effectiveness of infertility treatments (results in the UK): Average cost 
per case based on 1991/92 prices 
Treatment 
Average 
Success Rate 
(%) 
Average Cost per Maternity (£) Total 
Cost 
(£) 
Infertility 
Services 
Maternity 
Services 
Hospital 
Sector 
Drug Therapy 
   Amenorrhoea 
   Oligomenorrhoea 
   Endometriosis 
 
     17 
      8 
      8 
 
     235 
   5,000 
     750 
 
   2,924 
   2,925 
   2,925 
 
   271 
   575 
   575 
 
 3,430 
 8,500 
 4,250 
Tubal Surgery      20   13,175    2,220    230 15,625 
IVF-ET      12   19,500    2,608    383 22,491 
Artificial 
Insemination26 
      5    2,800    2,260    920  5,980 
Source: Ryan and Donaldson (1996) 
Although transferring only one embryo may require more treatment, lower multiple-
pregnancy rates lead to greater cost effectiveness. Table 3-2 provides a summary of the 
average maternity care cost related to ARTs in Scotland as an example; it consists of the 
cost of the actual treatment and the expenses incurred through maternity and neonatal care, 
                                                 
25 They found that they could reduce the costs to less than half by modifying the protocols. In their practices, 
the overall costs were reduced from US$7,000-US$11,000 to US$3409 for every cycle that was initiated, 
while keeping the pregnancy rates at a level beyond the national average (30% vs. 18.6%). 
26 Artificial insemination is generally chosen before electing for IVF-ET. IVF-ET is performed if the 
insemination procedures fail to achieve pregnancy in spite of repeated attempts. Artificial insemination 
includes IUI, IVI (intravaginal insemination), and AID (artificial insemination by a donor). 
 
 
45
including the hospital sector, for the treatment of complications. Table 3-3 shows that 
therapy using amenorrhoea achieves a higher success rate at lower costs, while IVF-ET 
appears to be less cost-effective than tubal surgery and drug therapy using amenorrhoea. 
 
Table 3-3. Cost effectiveness of infertility treatments (1992) 
Procedure 
Number 
of 
Procedur
es 
Live-
Birth 
Rate (%) 
Multiple-
Birth Rate 
(%) 
Cost per Delivery 
(US$) 
IUI    103     5.8       0.0       8,674 
CC-IUIa    188     6.3       8.3       7,808 
hMG-IUI     80    17.5      21.0       10,282 
IVF-ET     81    22.2      44.0       43,138 
Tubal Surgery     24    12.5       0.0       76,232 
Donor Oocytes ART     34    32.3      18.0       35,062 
Source: Van Voohis et al. (1997) 
Note: a. clomiphene cirate and IUI 
 
As shown in Table 3-3, in the study by Van Voorhis et al. (1997), intrauterine 
inseminations (IUI), clomiphene citrate and IUI (CC-IUI), and gonodotropin stimulation 
and IUI (hMG-IUI) were less effective than the other ARTs when evaluated in terms of 
their live-birth rate per cycle. Due to the lower costs of such procedures, however, IUI, CC-
IUI, and hMG-IUI proved to be more cost-effective than the ART procedures. Tubal 
surgery through laparotomy performed in cases involving tubal problems was less cost-
effective than IVF-ET. ICSI achieved significant cost savings as well as higher pregnancy 
rates compared to donor insemination, which is a compatible option if the characteristics of 
the semen are poor (Granberg et al. 1996). 
 
“Willingness to pay” for the procedure has also been used as a yardstick in assessing 
the benefits of ARTs in economic terms, as data on ART purchases are generally 
unavailable (Neumann 1997). As summarised in Table 3-4, the general population of the 
UK involved in WTP evaluations was willing to pay 29% of their payroll income for a 50% 
chance of having a child (Dalton and Lilford 1989). Neuman and Johannesson (1994) 
reported that the survey respondents were willing to pay £9,273 on average for IVF-ET if 
they were infertile, and that the procedure had a 10% probability of successful conception. 
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Table 3-4. Willingness to pay for ARTs  
Research WTP 
Expected 
Chances 
Dalton and Lilford (1989) 
29% of the total payroll 
income 50% 
Neuman and Johannesson (1994) £9,273 10% 
 
In conclusion, artificial-insemination technology appears to be more cost-effective than 
IVF-ET, GIFT, and ZIFT. Drug treatments are also generally more cost-effective than IVF-
ET, but the latter is more cost-effective than tubal surgery. It is difficult to conclude that 
any particular procedure is more cost-effective than any particular one, as each measure is 
applied to a specific condition of infertility.  
 
3.2.2. Clinical Factors 
Since ARTs seek to enable infertile couples to conceive and have a child, the clinical 
effectiveness of ARTs is commonly assessed in terms of pregnancy and live-birth rates per 
treatment cycle. At IVF-ET centres worldwide, the probability of sustained pregnancy 
through IVF-ET is one chance in four to six (Davis 1998). As Ryan (1996) noted, the 
important matter to consider in deciding whether to provide ARTs is not the cost of the 
procedure but the outcome of the investment to be made. 
 
In assessing the benefits of ARTs, several factors have been used as major parameters, 
such as the success rates of the procedures, their side effects, and their psychosocial 
impacts. The success rates of the procedures in terms of conception are widely varied 
around the world, and even across individual centres within the country.27  
The results of each procedure in terms of the live-birth rate per cycle are also varied, as 
shown in Table 3-5. In general, IUI, ICSI, donor oocytes, and the transfer of cryopreserved 
embryos appear to have higher success rates compared to IVF-ET, GIFT, and ZIFT in 
                                                 
27 In July 1996, the Human Fertilisation and Embryology Authority (HFEA) of the UK issued a report 
regarding the 25,730 IVF-ET treatments performed across the UK An overall average live-birth rate of 
14.5% was found, within a range of 4.9% at the lowest centre to 23.7% at the highest, as estimated in 95% 
confidence intervals, for an adjusted live-birth rate (Marshall and Spiegelhalter 1998). 
 
 
47
terms of pregnancy rates and live-birth rates. The recent development of ICSI shows high 
pregnancy rates in cases where the man has severe sperm defects. The indication to apply 
ICSI was limited to male-factor infertility 
 
Table 3-5. Results of ARTs  
Birth Organisations Reported Country Year
a PR b (%) LBc (%) 
IVFd 
 
Fresh 
HFEA 
Stimulated UK 1995 19.2  15.7  
Unstimulated UK 1995  3.2   1.7  
JSOB Japan 1997 22.3  15.7  
KAOB Korea 1996 29.6 18.8 
Frozen 
HFEA UK 1995 14.7  11.7 
JSOB Japan 1997 16.6  10.6  
ASRT/SART Registry US+Ca 1995 23.7  19.3  
GIFT 
ASRT/SART Registry US+Ca 1995  27.0 per 
retrieval 
JSOB Japan 1997 30.4 per transfer 10.6 per cycle 
KAOB Korea 1996 33.4 per cycle  2.0 per transfer  
ZIFT 
ASRT/SART Registry US+Ca 1995 32.2 per ET 30.5 per transfer 
JSOB Japan 1997 27.5 per ET 20.0 per transfer 
IUI ASRT/SART Registry US+Ca 1995 31.5 per cycle 22.5 per cycle 
ICSI 
ASRT/SART Registry US+Ca 1995 31.3 per ET 25.4 per ET 
KAOB Korea 1996 26.4 per cycle 15.0 per cycle 
Donor Oocytes ASRT/SART Registry US+Ca 1995 43.3 per ET 36.0 per transfer 
Transfer of 
Cryopreserved
Embryos 
ASRT/SART Registry US+Ca 1995 19.4 (20.7)  15.2 (16.8) 
Data Sources: 1) Japan Society for Obstetrics and Gynaecology (1998)  
            2) HFEA, 1997 Annual Report  
3) Society for Assisted Reproductive Technology and American Society for Reproductive 
Medicine (2002)  
            4) Korean Association of Obstetricians and Gynaecology (1999) 
Note: a. year of data collection 
     b. pregnancy rate 
     c. live-birth rate 
     d. units of success rates in both PR and LR, represented “per cycle” 
 
The application of the technique has been expanded to include cases where the use of 
conventional IVFs has failed, where there is ejaculatory dysfunction and immunological 
infertility problems, and where the woman has undergone chemo/radiation therapy due to 
cancer (Ola et al. 2001). Fishel et al. (2000) found significantly higher fertilization and 
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pregnancy rates with ICSI among those who have tried conventional IVF-ETs without 
success. The most significant advantage of ICSI over donor insemination would be having 
a baby with the same genetic make-up as the father.  
 
While the use of ARTs may improve the chances of pregnancy, these techniques have 
some critical deficiencies. ARTs evince a higher probability of multiple births28 when 
more than one embryo is transferred into the uterus to increase the chances of successfully 
implanting an embryo. Considering the fact that triplets and higher-order multiple-birth 
offspring are about six times more likely to die in their first year compared to singletons 
(Interim Licensing Authority for Human In-Vitro Fertilisation and Embryology29 1991), 
and entail about ten times higher costs per delivery, as determined by Goldfarb et al. (1996), 
it is better to avoid multiple births.30 In 1995, throughout the UK (HFEA 1997), over a 
quarter (28.8%) of the pregnancies achieved through IVF-ET yielded twins, triplets, or 
higher-order multiple-birth offspring. According to the SART (Society for Assisted 
Reproductive Technology) Registry data, 37% of all the ART births in the US were 
multiple births (twins or higher-order multiple births) (CDC 1997).31 
 
There is also a complex set of secondary issues, such as the birth of neonatal infants 
and short- and long-term maternal complications. The risks to the lives of the women and 
their offspring are also generally considered in assessing the advantages of ARTs. 
According to the precedent researches, pregnancies achieved by IVF-ET tend to be more 
complicated than those achieved normally. According to Serour and colleagues (Serour et 
                                                 
28 Since the early 1970s, the frequency of triplet and higher-order multiple gestations among white mothers in 
the US increased by almost 200% (Wilcox et al. 1996). According to Wilcox and colleagues, the number of 
triplets or higher-order multiple births in the US increased from 29.2 pmp in 1972-1974 to 85.0 pmp in 
1990-1991. The use of ARTs is responsible for approximately 38% of this increase, and the additional 30% 
increase was caused by the increase in the cases of child bearing among older women. The remaining third 
of this increase is associated with the use of ovulation-stimulating drugs.  
29 The Interim Licensing Authority for Human In-Vitro Fertilisation and Embryology (ILA) was replaced by 
a statutory body, the Human Fertilisation and Embryology Authority, on August 1, 1991.   
30 To reduce the cases of multiple births, two measures have been applied: limiting the number of embryos 
transferred, and selectively removing the conceptus (or concepti). As the latter choice raises a number of 
medical, ethical, legal, and psychosocial issues (Donner et al. 1990), the former choice is preferred by 
practitioners. The elective transfer of two embryos appears to be effective in reducing multiple births 
without impairing pregnancy rates (Fujii et al. 1998, Devreker et al. 1999). 
31 Multiple births in the general population of the US amount to less than 3% (CDC 1999). 
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al. 1998), the overall rate of complications was 8.3% among those having conception in 
3500 ART cycles.  
The psychosocial burden involved when one elects to undergo ARTs is another of its 
negative side effects (Boivin et al. 1998). As women must go to great lengths to achieve a 
biological pregnancy, including years of diagnosis and assisted reproductive interventions, 
they endure a great deal of psychological distress as well as socio-economic disadvantages. 
As pointed out, couples entering an IVF-ET programme are generally psychologically well 
adjusted (Newton et al. 1990, Edelmann et al. 1994), which can be taken to mean that only 
psychologically well-adjusted couples seek medical help in their efforts to conceive a baby 
(Eugster and Vingerhoets 1999). In general, the distress that accompanies a failed treatment 
is greater among women than among men (Newton et al. 1990, Collins et al. 1992, Slade et 
al. 1997).  
 
3.2.3. Technical Factors 
Since there is no alternative to ARTs when it comes to helping an infertile couple 
conceive of a child, their technical evaluation is limited. A comparison of ARTs confers 
relative advantages to some procedures. In the past two decades, IVF-ET and GIFT have 
been preferred as infertility treatments. The major advantage of IVF-ET and ICSI is that 
they can be applied on an outpatient basis (Kutoba et al. 1999), which would entail lower 
costs, reduce the patient’s psychological stress, involve simpler procedures and 
preparations for treatment, would not require admission, would require fewer medical staff, 
and would improve the communication between the doctors and the patient (Kutoba et al. 
1999). These advantages have also facilitated surrogacy in IVF-ET infertility treatment.  
 
3.3. Macro Factor Evaluation 
3.3.1. Japan 
The field of assisted reproductive medicine has a long history in Japan, with the 
artificial-insemination technique having been first applied in 1982, but no legal regulation 
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on ARTs exists therein. The medical communities32 played as the major guards against the 
misuse of such technologies in the country. In October 1983, the Japan Society of 
Obstetrics and Gynaecology (JSOG) issued its first set of guidelines, entitled Opinion on 
In-Vitro Fertilisation and Embryo Transfer. The guidelines approved of the procedure for 
married couples (Article 3).33 In April 1988, the society issued another set of guidelines, 
entitled Opinion on Frozen Storages and Implantation of the Human Embryo and Ova.34 
The guidelines restricted the freezing of fertilised ova for storage, and rejected the use of 
frozen storage for methods involving embryo donation or surrogacy. The society has also 
issued opinions on such topics as micro-fertilisation in 1992, artificial insemination with 
donor semen (AID) in 1997, and pre-implantation genetic diagnosis in 1998. The society 
approved of egg donation on February 17, 2000 (Mainichi Daily News, February 17, 2000).  
 
The Ad Hoc Committee on ART of the Ministry of Health Labour and Welfare 
approved AID and egg donation on December 2000, but to married couples only. The 
committee also supports embryo transfer fertilised by donor sperm and donor eggs. Under 
the guidelines, both sperm and egg donation can be done only three times, and the age of 
the donor is restricted to below 55 for sperm donation and below 35 for egg donation. 
 
In many cases, infertile couples had to go overseas, to countries where both egg 
donation and surrogacy were allowed. Although JSOG allows egg donation, a recent survey 
carried out by the Latest-Technology Assessment Committee of the Science and Welfare 
Evaluation Committee (Mainichi Daily News, May 6, 1999) revealed that majority of the 
Japanese people see both surrogacy and sperm or egg donation negatively from the point of 
view of a third person.35 As such, doctors performing procedures using a third person’s egg 
(Mainichi Daily Newspaper, June 22, 1998), or for unmarried couples (Mainichi Daily 
Newspaper, August 30, 1998), were expelled from JSOG. Since procedures involving 
surrogacy and technologies using a third person’s sperm or eggs are not deemed publicly 
                                                 
32 The societies include the Japan Society of Obstetrics and Gynaecology, the Japan Society of Fertilisation 
and Implantation, and the Japan Society of Fertility and Sterility. 
33 Japan Society of Obstetrics and Gynaecology (1984). 
34 Japan Society of Obstetrics and Gynaecology (1988). 
35 70.1% of the public answered that it is unacceptable even if the spouse agrees to undertake the procedure. 
Only 3.1% of the respondents accepted gestation using sperm or eggs donated by a third person or 
surrogate mother. 
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acceptable, many couples in Japan who want to undertake these modalities generally go 
abroad, often to the US. In fact, several American agencies recruit clients in Japan and 
make arrangements for infertility treatments in the US. The services match the couples with 
surrogate candidates, reflecting the preference of the couples. From 1993 to 1998, 114 
Japanese children were born in America by way of surrogate mothers or a third person’s 
eggs or sperm (Mainichi Daily News, January 7, 1998).36 Moreover, since 1991, more than 
10 Japanese babies have reportedly been born to surrogate mothers in the US (The Japanese 
Times, May 22, 2001). Some couples go to Korea, especially for surrogacy, where the cost 
is much lower than that in the US. An infertility clinic in Seoul performed five cases of 
surrogacy for Japanese couples in 1992-1993, and received over 10 inquires from Japan 
(Joongang Daily Newspaper, November 22, 1993). The Minister of Health, Labour, and 
Welfare, Mr. Chikara, announced at a House of Council Budget Committee session: “A 
panel compiled a recommendation last year that surrogate birth should be banned because it 
is by no means desirable.” The Japanese government seeks legislation banning surrogate 
childbirths (The Japanese Times, May 22, 2001).  
 
Public health insurance programmes do not cover the costs of ARTs. The reason 
behind the exclusion of ARTs from insurance coverage is that infertility is not regarded in 
Japan as a disease requiring medical treatment. Due to the continued lowering of the birth 
rate (1.38 per couple in 1999 and 1.25 in 2005), the Japanese government set off the so-
called “Angel Plan” to promote childbirth by making the relief of the child-rearing burdens 
of parents a high priority. The first phase of the plan’s implementation, however, from 1995 
to 1999, was unsuccessful. The Japanese government thus set off “New Angel Plan,” which 
was implemented from 2000 to 2004. In accordance with the plan, the Ministry of Health, 
Labour, and Welfare (Policy Bulletin 96, April 1, 2004) encouraged infertile couples to 
avail of ARTs by shouldering its costs up to ¥100k (equivalent to £417 as of May 2007) 
from one to five years.37  
                                                 
36 Among 114 children, 34 were born from surrogate mothers commissioned by 25 couples. Sixty-four 
children were conceived and born with donated eggs, which had been implanted into infertile women’s 
wombs. The remaining 16 children were conceived with a donor sperm.   
37 The fund for subsidy is raised by the central and local governments, each shouldering 50% of the fund. The 
total subsidy paid by the central government in 2004 was ¥88m (£3.6m).  
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In summary, IVF-ET is not regulated by the law in Japan. In many cases, patients go 
abroad to undergo treatments that are not approved by JSOG. Moreover, public health 
insurance programmes do not cover ARTs, but there is a growing consensus among 
policymakers to extend the insurance coverage so as to include IVF-ET.  
   
3.3.2. Korea 
The first successful VIF in Korea was performed in 1985 at Seoul National University 
Hospital. In 2002, about 100 clinics in the country were offering infertility treatments, 
carrying out a total of about one thousand cycles of infertility treatment.  
There is no relevant legal regulation regarding the use of ARTs in Korea. As such, the 
decision to use human fertilisation technologies lies in the obstetricians. No particular 
control is applied to donor insemination, sperm or egg donation, and even to surrogate 
arrangements. In addition, obstetricians are not required to register the number of ARTs 
treatments they have performed; hence, it is impossible to monitor and track the ARTs 
procedures conducted by physicians and undergone by clients. Furthermore, the Bioethics 
and Biosafety Act of 2004 was adopted, which aims to control researches that make use of 
stem cells and the primordial genetic material. Under the law, scientists are allowed to 
conduct embryonic-stem-cell research, but only for the purpose of curing 18 particular 
diseases, including diabetes, Alzheimer’s disease, AIDS, and cerebral palsy. Article 13 of 
the law prohibits commercial dealing in gametes and creating a human embryo for reasons 
other than conception. 
 
Health insurance does not cover any procedure related to infertility treatments.38 Even 
diagnostic tests for infertility are not covered (Official Notice on Health Insurance 
Coverage No. 1492-8112, MOHW 1994). The insurance programme covers complications 
stemming from infertility procedures and natural delivery procedures (Official Notice on 
Health Insurance Coverage No. 65720-404, MOHW 1993). Due to the continued lowering 
                                                 
38 One cycle of IVF-ET costs about £1,600-£2,200. The exclusion of infertility treatments from insurance 
coverage (since infertility is not regarded in Korea as a disease requiring active medical treatment) 
discourages infertile couples from undergoing such treatments.  
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of the birth rate in Korea, the Ministry of Health and Welfare of Korea introduced a benefit 
programme in March 2006, which subsidises infertile couples, giving them two-time 
payments of up to about £1,086 (equivalent to \2 million as of May 2007) each for 
infertility treatment. Couples whose combined incomes are lower than 130% of the income 
of an average wage earner in an urban area (£2,277, or \4.19 million), in the case of a two-
member household, are candidates for the subsidy. 
 
3.3.3. UK 
In the UK, the government set up the Committee of Inquiry into Human Fertilisation 
and Embryology in 1982 (chaired by D. M. Warnock) to review the ethical and legal 
questions arising from the use of ARTs (Brahams 1990). The committee published a report 
in 1984, entitled Human Fertilisation and Embryology: a Framework for Legislation. The 
central point raised in the report was that “reproductive medicine should be regulated, and 
the status of children born as a result of the new and various forms of assisted conception 
should be clarified” (Brazier 1992). The report led to the enactment of the Human 
Fertilisation and Embryology Act of 1990 (Dickens and Cook 1999). Essentially, the act 
was created in response to the public concern over the emerging technology stemming from 
the birth of the first IVF-ET baby, Louise Brown, in the UK in 1978 (Doyle 1999). The act 
mandates all clinics to secure licenses from the Human Fertilisation and Embryology 
Authority (HFEA) to be able to carry out the following activities (HFEA 1996):39 
 bringing about the creation of an embryo; 
                                                 
39 Johnson (1998) categorises statutory regulation into two broad forms: flexible general prohibitions and 
inflexible specific prohibitions. According to him, flexible general prohibitions include activities that are 
permitted (given a special license). Scientists or doctors are not obliged to conduct these activities, and they 
should thus apply for a license in HFEA if they wish to do so. Flexible general prohibitions, which are 
prohibited unless a license is granted, include the following activities (p. 1774): (1) bringing about the 
creation of an embryo by initiating the process of fertilisation (for treatment and research); (2) keeping or 
using an embryo (for treatment or research); (3) placing a spermatozoa or an embryo in a woman’s uterus; 
(4) storing gametes for use in research involving the creation of an embryo; (5) using donated spermatozoa 
or eggs in the course of providing a woman with infertility treatment services; and (6) mixing human 
gametes with the live gametes of an animal. 
Inflexible specific prohibitions refer to those activities that are simply not acceptable to venture into 
under any circumstance, including the following (p. 1773): (1) placing non-human gametes or embryos in a 
woman’s uterus; (2) keeping an embryo alive in vitro after the appearance of the primitive streak, which is 
taken to have appeared not later than 14 days after the mixing of the gametes; (3) replacing the nucleus of 
an embryo’s cell with a nucleus taken from the cell of any other person or embryo, or the subsequent 
development of an embryo. 
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 keeping and using an embryo; 
 storing gametes; 
 using donated sperms or eggs in the course of providing a woman with infertility 
treatment services; and 
 mixing human gametes with the live gametes of any animal. 
 
The Human Fertilisation and Embryology Act of 1990 also makes it a criminal offence 
for any person, under any circumstance, to place in a woman’s uterus:  
 a live embryo other than a human embryo; or 
 any live gamete other than a human gamete. 
 
The Code of Practice translates the requirements of the Act (Deech 1999), including 
those that relate to such matters as staff and facilities, standards of clinical practices, 
record-keeping, screening, counselling, and the welfare of the child, or the child’s guidance. 
The HFEA (2001) Guidelines cite requirements in relation to the following: 
 the number of pre-embryos to be transferred;40 
 the development state of the pre-embryo at the time of transfer; 
 the day of the embryo’s transfer; 
 the age of the female partner;41 
 the ovarian reserve, as expressed, for example, by the three-day follicle stimulating 
hormone level and the unidentified but inherent variability among programs; 
 the development of new knowledge regarding the implantation window;  
 and the difference between the implantation rates of fresh and cryopreserved 
materials. 
 
HFEA can revoke the license of a scientist or doctor if he or she violates any of the 
guidelines promulgated by the Code of Practice. The 1985 Surrogacy Arrangements Act 
legalised surrogacy in the UK, except when the arrangements between the infertile woman 
                                                 
40 The fifth edition of the Code of Practice limits the number of embryos that may be transferred to a single 
cycle to three (HFEA Annual Report 1998). 
41 Eggs should not be taken from female donors beyond 35 years of age, unless there are exceptional reasons 
for doing so. As for sperm donors, HFEA recommends an age limit of 45. This paternal age, however, is 
currently under review.  
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and the surrogate mother are made for commercial purposes. This legal stance on the issue 
of surrogacy is clearly based on the following two principles (Brazier et al. 1997): 
 surrogacy must not be commercialised; and 
 surrogacy arrangements should not be enforced. 
 
 
Regarding NHS funding for infertility services, the central government does not have 
guidelines regarding what health authorities should offer couples who are seeking infertility 
treatment. NHS funding for the investigation of fertility problems is generally available, but 
there is a wide variation regarding, and often limited access to, treatments using ARTs 
(National Collaborating Centre for Women’s and Children’s Health 2004). In Scotland, up 
to three IVF-ET cycles are publicly funded. Elsewhere, individual health authorities are 
accorded the right to determine whether funding should be provided to a particular ART 
treatment. Accepting the recommendation of NICE (National Institute of Clinical 
Excellence) Guidelines of 2004 (NICE, 2004), British government provides at least one 
free IVF cycle for women between the ages of 23 and 39 from April 2005 (BBC News, NHS 
to offer one free IVF cycle, 25 Feb. 2004). The NICE guidelines suggest that couples should 
be offered NHS funding for up to three cycles of IVF when the chances of success are more 
than 10%.  
 
Table 3-6. The use of eligibility criteria for funding by HAs (%) 
Eligibility 
Criteria 
Ovulation 
Induction Insemination Tubal Surgery IVF/ICSI/GIFT 
Yes      29      33      26       64 
No      53      43      50        4 
Not funded       9      15      15       23 
Not known       9       9       9        9 
Data Sources: DoH, Survey of NHS Infertility Services (1997-1998) 
 
As summarised in Table 3-6, there are huge variations among HAs in terms of the 
funding policies for infertility treatment. Many HAs provide ovulation induction, 
insemination, and tubal surgery without any criterion for funding, while IVF, ICSI, and 
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GIFT are strictly controlled by HAs. The 23 HAs that responded to the survey that was 
conducted in this study do not provide IVF-ET, ICSI, and GIFT. About 94% of those 
among them that provide infertility services limit the coverage based on certain criteria. 
The eligibility criteria include the following (DoH, Survey of NHS Infertility Services 
1997-1998):  
 the maximum and minimum ages of both the man and the woman;  
 the maximum number of the couple’s previous children;  
 the maximum number of children from a previous relationship, and the minimum 
length of the relationship; 
 the minimum length of residence in the HA; and 
 the maximum number of previous cycles other than those that meet the above 
criteria. 
 
A report on the provision of infertility services in the UK (Kennelly and Riesel 1997) 
revealed that most health authorities (76%) have a formal statement of policy on purchasing 
infertility services. The formalisation of policies on infertility services among health 
authorities has remarkably increased by 21% from 1993. The policies set limits on who can 
receive NHS funding. The College of Health data (Kennelly and Riesel 1999) show that the 
number of NHS-funded IVF treatments is falling: from 12.7 cycles funded per 100,000 in 
1997 to 10.8 cycles in 1998. 
While most tests and investigations are carried out by NHS, around 80% of the IVF-ET 
treatments are carried out privately (NHS Direct 2001).42 Since many health authorities 
regard ART interventions as required for social rather than biological reasons, and as they 
believe that such interventions are resorted to for the treatment of childlessness and not of 
infertility, most health authorities provide limited funding for tubal surgery (Evans 1995). 
The most common restrictive policy is that pertaining to the maximum age at which a 
                                                 
42 NHS Direct. Available at: http://www.healthcareguide.nhsdirect.nhs.uk/info/advice/subfertility.stm. 
Accessed November 24, 2001. According to Brinsden (1994), 95% of couples requiring advanced fertility 
care pay for such care themselves. 
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woman can be given funding for such purpose.43 Based on the results of previous surveys, 
Kennelly and Riesel (1997) concluded that: 
 the number of IVF-ET treatments funded by NHS has rapidly increased; 
 the number of authorities who have adopted formal policies on infertility treatment 
is increasing; and 
 while many authorities are using similar protocols for assessing a couple’s 
eligibility for infertility treatment funding by HAs, the details are greatly varied.   
 
The payment arrangements for infertility treatments vary according to the 
characteristics of the treatments. While most health authorities provide ovulation induction 
and tubal surgery based on a block gynaecology contract, in-vitro fertilisation is largely 
provided based on a specific fertility contract. The number of treatments paid for by health 
authorities has increased. While there is an increasing trend in the proportion of authorities 
paying for over 50 treatments (11% in 1994, 20% in 1995, 22% in 1996, and 26% in 1997), 
the number of authorities that are paying for less than 50 treatments has declined. NHS 
funded the infertility treatments of only 12.7 persons out of 100,000 in 1997, which 
represents an increase from the 9.3 persons out of 100,000 whose infertility treatments were 
funded in 1996. Furthermore, spending on ARTs varies among health authorities, ranging 
from zero to £500,000. According to the results of a survey that was conducted of NHS 
infertility services (HFEA, Survey of NHS Infertility Services 1997-98), a large proportion 
of the HA respondents did not have detailed data on the amount of their spending for 
infertility services, or data on such separate from their general gynaecology budget.  
In the absence of instructions from their parent donors, unclaimed embryos must be 
destroyed within five years after their creation (HFE Act 1990). In 1996, about 3,300 
cryopreserved embryos belonging to about 900 couples who had lost touch with the 
infertility clinics where such embryos were extracted from them, and who could not be 
reached, were destroyed upon orders of the government. To prevent the endless, expensive 
                                                 
43 According to Kennell and Riesel (1997), as of 1996, a vast majority of districts specify minimum and 
maximum ages for women undergoing infertility treatment (35 and 40 years old, respectively), with a 
median age of 38. As for men, 20 districts also set minimum and maximum ages for undergoing infertility 
treatment (45 and 60 years old, respectively). 
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storage of abandoned embryos, the embryos can be stored on a limited basis for an 
additional five years (maximum), with the consent of both donors (Foster 1998).44  
 
3.3.4. US 
In the US, the Fertilisation Clinic Success Rate and Certification Act (FCSRCA)45 was 
introduced on the federal level in 1992 to prevent false or inflated success claims by 
individual clinics (CDC 1999). As the ART market expanded, there were growing concerns 
on whether the providers of ART services were exaggerating the success rates of the ARTs 
procedures they performed, thus misleading consumers as regards the inflated success rates 
of clinical pregnancy and live births. According to the Ethics Committee of the American 
Fertility Society (1994), the Federal Trade Commission charged several infertility clinics 
with inflating their success rates. To address this issue, FCSRCA requires clinics 
conducting IVF-ET procedures to report the exact number of procedures they carried out, 
and the number of the live births they facilitated.46  
 
At the state level, some states are involved in the legal regulation of ART practices for 
specific techniques. The legal issues related to reproduction involving donors and 
surrogates vary across the nation. First, as regards donor sperms, over 30 states clarify the 
legal responsibilities of the donors, which exclude their rearing role, and charge the 
consenting father with all the duties and rights related to the rearing of the resulting 
offspring. Second, as regards donor eggs, only three states (Oklahoma, Texas, and Florida) 
have legislation addressing the rights and duties related to the rearing of children born 
through treatments involving egg donations. Third, only the state of Texas has enacted 
legislation addressing the rights and duties related to the rearing of the offspring resulting 
from a treatment involving a donor pre-embryo. Fourth, as regards surrogacy47, the state 
                                                 
44 The additional storage period is allowed after the donor reaches the age of fifty-five.  
45 FCSRCA was promulgated to provide the public with reliable information concerning the effectiveness of 
infertility services and to ensure the high quality of such services by providing for the certification of 
embryo laboratories (p. 39374). 
46 FCSRCA was first published in 1997 in three volumes, grouped according to the geographic regions of the 
US: western, eastern, and central (Meikle et al. 1999). 
47 It is estimated that there have been over 6,400 surrogate births in the United States. Of these, there are less 
than 30 documented cases in which the surrogates attempted to renege on the contract and retain custody 
and control of the child.   
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law regulates the legality of surrogacy, looking into whether surrogacy contracts are legal 
and/or enforceable, and whether there is any amount of money that is part of the 
contract.48 In seven states (New York, Michigan, Massachusetts, Utah, Arizona, New 
Mexico, and Washington), all forms of surrogacy, paid or not paid, are against the law. 
With varying degrees of state intervention, seven states (Florida, Arkansas, Tennessee, 
Virginia, Ohio, New Hampshire, and Nevada) recognise surrogacy and allow its practice. 
In four states (Louisiana, Nebraska, North Dakota, and Indiana), surrogacy contracts are 
not enforceable but are allowed. California is the only state that has a “case law” regarding 
surrogacy.49 A recent court decision in California has fostered a legal climate for surrogacy 
and egg donation agreements that have already been favourable in California. In the case of 
Buzzanca50, the court made a ruling on whether a married couple that was now divorced 
were the parents of a baby conceived through surrogacy involving an anonymous donor 
sperm and egg.51  
 
The legal issues on embryos deal with the locus and scope of control over embryos 
created in the course of the use of ARTs. The US does not have a national policy regarding 
abandoned embryos. Moreover, the state intervention into the storage and disposition of 
embryos is marginal. Thus, gamete providers are largely left alone when it comes to 
deciding on whether their embryos will be transferred, cryopreserved, donated, or discarded. 
Based on their own guidelines, fertility clinics usually have a written agreement addressing 
the intention of their couple clients with regard to their leftover embryos (Foster 1998). 
                                                 
48 The surrogacy law in the US is summarised from http://www.surrogacy.com/legals/map.html (the 
American Surrogacy Centre, Inc.), accessed February 14, 2002. 
49 In the state of California, a “case law” from the courts is recognised as constituting the law. 
50 An infertile married couple, Johnson Buzzanca and his wife Luanne, had entered into a surrogacy contract, 
and Jaycee was conceived as a result of the implantation of an anonymous embryo donation into the 
gestational surrogate. About one month before Jaycee was born, John petitioned for the dissolution of their 
marriage. While Luanne claimed that she was the lawful mother of Jaycee, John denied his parenthood of 
Jaycee. The surrogate also disclaimed being Jaycee’s legal mother. Based on the Uniform Parentage Act, to 
be a child’s legal parent, one must either be genetically related to the child or must have given birth to him 
or her. Jaycee thus became a “parentless” child owing to the surrogacy arrangement. Finally, the California 
Court of Appeals ruled in March 1998 that John Buzzanca and Luanne Buzzanca are the legal father and 
mother of Jaycee.  
51 The information is summarised from Surrogacy and Egg Donation Law in California (Pinkerton T. M.), 
the American Surrogacy Center, Inc. Available at: http://www.surrogacy.com/legals/article/calaw.html, 
accessed January 16, 2002. 
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Only three states (Louisiana, Minnesota, and Illinois) have established a legal basis for 
banning the disposal of pre-embryos.  
 
The American Society for Reproductive Medicine’s Ethical Committee also plays a 
significant role in the application of human reproductive technologies.52 First, as for the 
disposition of abandoned embryos, the Ethics Committee maintains that it is ethically 
acceptable for a programme to consider embryos to have been abandoned if more than five 
years have passed since the contact was entered into with the couple (The Ethics 
Committee of the American Society of Reproductive Medicine 1997).  
 
Although IVF is an effective treatment for infertility, most health plans do not provide 
coverage for the technology. Accordingly, most couples seeking fertility treatment pay for 
the treatment themselves. American Society for Reproductive Medicine (ASRM) estimates 
that about 30 to 40% of IVF services were partially covered in 1993 by insurance (Collins 
et al. 1995). Although 14 states in the US have mandated insurers to provide some form of 
infertility care, only six states out of the 14 oblige insurers to cover infertility treatment. 
There are also various limits on the conditions in which such treatments are payable 
(ASRM 1999a). For example, although Arkansas requires all insurers providing maternity 
benefits to cover the cost of IVF-ET, the state exempts HMOs from doing so. Maryland 
also excludes HMOs from the insurance coverage law. In Illinois, where the mandate offers 
comprehensive infertility services, a significant number of patients are excluded from 
                                                 
52 The ethical considerations for ARTs cover the American Society for Reproductive Medicine’s position on 
several aspects of reproductive medicine, including (The Ethics Committee of the American Fertility 
Society 1994): 
- the constitutional aspects of proactive liberty; 
- the American law and ARTs; 
- the moral right to reproduce, and its limitations; 
- the commercialisation of ARTs; 
- the moral and legal status of the pre-embryo; 
- the procedures of ARTs; 
- the use of gametes; 
- the cryopreservation of oocytes and pre-embryos; 
- the use of micro techniques such as microinjection, assisted hatching, blastomere separation, and 
zona drilling; 
- pre-implantation genetic diagnosis; 
- surrogate and gestational host mothers; 
- research on pre-embryos; and 
- HIV testing and reproductive medicine. 
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coverage (Gleicher 1998).53 In 1997, 22% of large firms whose employees are enrolled in 
an HMO covered IVF-ET, an increase of 19% from the year before (Murray 1998).54 
According to the Alan Gumacher Institute (1993, quoted from Neumann 1997, 1217-8), 
14% of large plans and 16% of preferred provider organisations offer IVF-ET coverage. 
Insurance companies and health plans have been reluctant to cover infertility services in the 
US due to a lack of consensus on such services (Robertson and Schneyer 1997).55 ARTs 
were also excluded in the Clinton National Health Security Plan (Baker and Paterson 1995).  
 
So far, the adoption of ARTs has been driven by market principles associated with 
commercialism among the providers, the demand for such by infertile couples, and the high 
number of surrogate mothers available. According to Blank and Merrick (1995), some 
private clinics use aggressive marketing techniques, and certain firms have been accused of 
inflating their success rates. To attract patients seeking infertility treatment, several clinics 
have begun offering eligible patients the option of paying on a “shared-risk,” “warranty,” or 
“outcome” basis (Wozencraft 1996, quoted from Robertson and Schneyer 1997).56 
Robertson and Schneyer (1997) regard the use of a shared-risk payment plan as a doctor–
provided form of risk-of-failure insurance. The programme is being adopted solely as a 
                                                 
53 Government employees are excluded from the coverage, while patients under Medicare coverage, as well 
as the employees of small companies, self-insured companies, and churches, are covered.  
54 Research that has examined whether the infertility services can be developed in a managed-care plan in a 
way in which the cost is lowered while providing quality services support the increase of infertility services 
without increasing costs by managing structured programmes (Douglas et al. 1996, Arnold 1997, Blackwell 
et al. 1998). This implies that if an appropriate model is developed, then ART adoption will be remarkably 
increased in the US This is presumed from the fact that the number of cycles per capita in Canada and in 
France, where IVF-ET is covered by national insurance programmes, is three and five times higher, 
respectively, than that in the US (Collins et al. 1994). Even in the US, the adoption of IVF-ET per capita is 
twice as high in those states where insurance coverage is mandated for IVF-ET than in those states where 
the insurance does not cover the service (Sahni 1994).   
55 Tabbush and Gambone (1998) argue that health plans hesitate as those insured have privately held 
information about whether they will need the covered benefits for ARTs; thus, adverse selection occurs. 
Due to the information asymmetry between the insurer and the insured, some health plans that have 
extended their coverage to include infertility services have experienced poor economic outcomes. 
Robertson and Schneyer maintain that because IVF-ET is expensive, elective, often unsuccessful, and of no 
interest to most consumers, insurers and managed-care plans remain reluctant to cover the services and, in 
some cases, have withdrawn coverage after they provided such.   
56 Under a shared-risk arrangement, the clinics charge the patients a fee that is initially higher than the fee 
that they charge other ordinary IVF-ET patients. If the procedure is successful, they keep the entire fee. If 
no pregnancy occurs, they refund 90-100% of the fee (The ASRM Ethics Committee. 2002) 
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marketing tool for patients. Murray (1997) enumerates the effects of a shared-risk plan, 
which he describes as a “money-back guarantee,” in the following:  
 
IVF-ET money-back guarantees may also be very successful marketing ploys as it 
seems likely that many infertile couples will consider IVF-ET but will not actually pursue it. 
For some, the anticipated cost may be a major hurdle. Warranty programmes may be a 
great way to tempt people to make that enormous emotional leap from thinking about IVF-
ET to committing themselves to try it (p. 293). 
In the US, therapeutic donor insemination is also largely commercially oriented (Baker 
and Paterson 1995). Infertile couples purchase gametes from commercial sperm banks that 
operate nationally and that ship the donor sperms to across the country (Baker and Paterson 
1995).  
Legislation concerning surrogacy may also facilitate infertility treatment. Although 
surrogacy laws have been proposed many times in many states, most of these proposals die 
in the congressional committees.57 From 1997 to 1999, a surrogacy bill was proposed 18 
times in 13 states (Organisation of Parents Through Surrogates, Inc. 2002). The bill was 
eventually passed only in Wyoming, Indiana, New Jersey, and California, and it is only in 
New Jersey that paid surrogacy is a crime.  
The newly developed technology ICSI was approved by the Practice Committee of the 
American Society for Reproductive Medicine (formerly the American Fertility Society) on 
October 24, 1994, and by the Board of Directors of the American Society for Reproductive 
Medicine on November 5, 1994 (Practice Statement Committee, ASRM, 2002 ). 
 
3.4. The Adoption of ARTs 
3.4.1. Japan 
Table 3-7 shows the number of ART cycles in Japan. As of 2004, there were 627 
registered ART centres in Japan (Japan Society of Obstetrics and Gynaecology 2005). The 
accumulative total of babies from 1986 to 2004 who were conceived via ARTs was 
135,575. In 2004, 18,168 babies were born through the use of ARTs, and 30% of these 
                                                 
57 The proposed bill was circumscribed in Illinois, Connecticut, Texas, Indiana, New Jersey, and Minnesota, 
and the law was enacted in Wyoming, Oklahoma, Pennsylvania, New Jersey, and California.   
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(5,538 babies) were gestated through ICSI (the number of babies gestated through ICSI has 
increased rapidly). In 2004, 129 babies were born through AID, which represented a 
decrease from 188 in 1998. 
JSOG has been collecting data on ARTs treatments since 1986. The Ethics Committee 
of JOSG on Practices and Researches began to collect such data from all registered ART 
centres in 1993. In 1999, JSOG established the Registration and Inspection Committee as a 
subcommittee of the Ethics Committee on Practices and Research. The committee is 
responsible for collecting and reporting assisted-human-reproduction activities in Japan.  
 
Table 3-7. The number of infertility treatment cycles conducted in Japan 
 IVF-ET ICSI GIFT ZIFT AID 
1992  16,521 (12,297)     963 (610)   658 (628)  225 (207)  
1993  20,732 (15,174)   2,608 (1,785) 1,101 (991)  141 (103)  
1994  25,523 (17,231)   5,510 (3,804)   869 (782)  142 (138)  
1995  27,763 (19,020)   9,536 (6,672)   533 (168)  318 (305)  
1996  29,854 (20,764)  13,438 (8,626)   370 (343)  277 (220)  
1997  31,764 (25,672)  16,621 (11,517)   401 (365)  178 (155)  
1998  42,068 (29,465)  18,657 (12,823)   503 (452)  490 (380)  
1999  46,586 (31,468)  23,015 (15,849)   286 (280)  132 (119) 3,497 (1,711) 
2000  4,2623 (30,576)  26,712 (17,185)   179 (122)  176 (139) 5,699 (1,570) 
2001  45,498 (33,056)  30,369 (19,979)   104 (91)  102 (78) 5,838 (1,350) 
2002  50,655 (36,617)  34,824 (22,900)    96 (95)   76 (67) 3,649 (2,521) 
2003  62,514 (41,828)  38,871 (25,675)   157 (119)   88 (75) 4,374 (1,176) 
2004  71,502 (48,742)  44,698 (29,582)   100 (76)   39 (37) 3,994 (1,498) 
Data Sources: Japan Society of Obstetrics and Gynaecology (1994, 1995, 1996, 1997, 1998, 1999, 2000, 
2001a, 2001b, 2003, 2005) 
Note: The number in brackets refers to the number of patients treated.  
 
A number of factors have manifested a significant effect on the adoption of ARTs in 
Japan. First, in the absence of any legal control, the by-laws of the professional community 
have played a significant role in approving the adoption of new technologies. Second, the 
professional community prohibits the adoption of technologies that may conflict with the 
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rights of the offspring, such as egg donation and surrogacy. Lastly, the public health 
insurance programmes do not cover ARTs and thus have had no influence on the latter’s 
adoption.  
 
3.4.2. Korea 
Over 10,000 infertile couples seek ARTs every year in Korea. As the success rate of 
ARTs procedures has improved, the couples who avail of these techniques are becoming 
more active in undertaking the treatment. As of 2006, there were 92 centres registered in 
the Korean Medical Association as carrying out ARTs (Korean Society of Obstetrics and 
Gynaecology 2006).  
Following the first successful live birth from IVF-ET, a private infertility medical 
centre became enthusiastically involved in infertility treatment. The centre58, which is well 
known throughout the world as a leading infertility clinic, possesses most of the historical 
records in Korea relating to the adoption of ARTs. The centre had the first successful cases 
of GIFT (1986), ZIFT (1988), and ICSI (1994), and even a successful surrogate case (ko 
1995).59  
Although ARTs are regarded as well-established procedures, many infertile couples 
also seek various other methods, including religious, traditional, and folk remedies, while 
undergoing medical treatment for infertility. Some couples undergo ARTs alongside 
Oriental medicine, including acupuncture and herbal medicine, whose infertility treatments 
are primarily focused on body temperature as well as the fertilisation tract, especially in the 
uterus.60  
                                                 
58 The clinic, previously a specialised clinic for obstetrics, became a general hospital under the name CHA 
Hospital. 
59 The detailed history of the adoption of ARTs is as follows (Ko 1995): 
 Oct. 1985 - first IVF-ET baby born in Seoul National University Hospital 
 June 1986 - first baby from a frozen sperm born in Korean University Hospital 
 Sep. 1986 - first baby from a frozen sperm born in a private clinic (CHA Hospital) 
 Nov. 1988 - first baby from a frozen embryo born in a private clinic (Je-il Hospital) 
 Dec. 1988 - oocyte in CHA Hospital 
 Nov. 1988 - first successful surrogate case reported in the annual meeting of the Korea Society of 
Obstetrics and Gynaecology 
 March 1990 - first IVF-ET procedure using natural ovulation conducted 
 Feb. 1994 - the first ICSI conducted in CHA Hospital 
60 Specialists in Oriental medicine believe that a fertilised embryo is not conceived in the uterus if the body 
temperature of a woman is lower than normal. To treat infertility, therefore, herbal medicine, acupuncture, 
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As shown in Table 3-8, the preferred ART in Korea has been shifting from IVF-ET 
towards the newly emerged ICSI.  
 
Table 3-8. The number of treatment cycles in Korea  
 IVF-ET ICSI GIFT ZIFT 
1992 5,852  198 295 
1993 6,536  330 180 
1994a 856 175 110 236 
1996 6,527 1,603 51  
2001c 7,740 4,987 63  
2002d 9,292 6,704 2 9 
2003e 8,192 7,488 4 3 
Data Source: Assisted-Reproductive-Technology Committee, Korean Association of Obstetricians and 
Gynaecologists (1997-2006)   
Note: a. The data represent only the cases reported by 63 out of 87 registered infertility centres.  
     b. The data represent only the cases reported by 35 out of 92 registered infertility centres. 
     c. The data represent only the cases reported by 56 out of 90 registered infertility centres. 
     d. The data represent only the cases reported by 73 out of 92 registered infertility centres. 
     e. The data represent only the cases reported by 48 out of 91 registered infertility centres. 
 
Cultural factors are thought to be responsible for the rapid diffusion of ARTs in Korea. 
The single most significant factor spurring ART has been the desire to have a son (rather 
than a daughter. The first son succeeds the family group as the head of family. He is called 
‘seed sibling’ of the family group and succeed the bloodlines, and hence, carrying on the 
family lineage. He is obliged to have the sacrifice rites for ancestors up to three generations 
at least, as anniversary memorial ceremonies bestowing respect on them. The rituals are 
also performed on traditional holiday including New Year’s day and thanks giving day. 
Although current civil law confers equal distribution of family fortune among siblings, 
most family wealth is traditionally inherited to the first son.. Although three countries in 
Asia, that include China, Japan and Korea, have similar tradition based on Confucianism 
and respect a rank within a family, a status of men in a family is different among these 
                                                                                                                                                    
and other measures are administered to the patients. The success rate of infertility treatments in Oriental 
medicine is around 45% on average. Fertilisation occurred in some cases where the couple had been 
diagnosed in Western medicine as incapable of achieving fertilisation due to reasons such as blocked 
fallopian tubes (Seoul Broadcasting System 1994). 
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countries. In Korea, the first son is regarded as a lineal decent of family who has to tend his 
filial piety to his parents and obliged to live together with his parents to take care of them. 
In contrast, China and Japan have a patriarchal system that regards a man as the leader of 
the extended family who share a common life in China or as a leader who controls family 
members and all of family members should be subordinated to him in Japan.  
In this respect, failure to give birth to a son, and the consequent discontinuation of the 
bloodline, is regarded as the most serious impiety against one’s ancestors in Korea. As only 
a son can inherit the family name, sons have been strongly preferred in Korea.61 It has thus 
been a generally accepted practice for men who are unable to foster a son with their licit 
wives to have a “breeding concubine.”62 This tradition continues today in the form of 
surrogacy. Since official data on surrogacy are not available, it is difficult to identify the 
number of real cases. When infertile couples choose the surrogacy option, they first try to 
find a surrogate mother among their sisters and relatives on either side of the family (Chang 
1999: personal communication).63 Traditionally, infertile couples chose surrogate mothers 
from among their sisters and relatives, but they increasingly tend to seek surrogate mothers 
from among Korean Chinese residents in Korea as this entails lower costs. Of late, however, 
infertile couples tend to seek surrogate mothers through international marriage-matching 
agencies, which generally find partners in China or among Korean-Chinese residents who 
are illegally residing in Korea.64 According to a former nurse of a leading infertility centre, 
of the five to seven surrogate cases performed in the centre, about two to three cases 
involved Korean-Chinese surrogate mothers from China or Korea (Jung et al. 2000). At 
present, over 100 surrogate cases are performed in Korea every year (Im 2001).  
                                                 
61 The current sex ratio in Korea explicitly represents the tradition, with the male-to-female ratio at birth 
being 112.8 on average for the past 10 years, and 110.2 in 1998 (Korean Statistical Office, Summary of 
Vital Statistics). 
62 The term literally means a “seed receiver” in Korean. 
63 K. W. Chang was a biologist in the infertility clinic in Severance Hospital, Yonsei University Medical 
Centre. 
64 The author obtained the information from a leading private infertility clinic, and then contacted a private 
marriage-matching agency to inquire if the agency can find a surrogate mother. The chief executive officer 
of the agency said that they can make arrangements for a surrogate mother.  
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According to a survey carried out by Joongang Daily Newspaper, Korean people 
generally do not accept surrogate childbirth.65 It may thus be hard to legitimately regularise 
surrogate childbirth in Korea in the foreseeable future. However, as the Korean Medical 
Association declared in its Code of Conduct on November 15, 2001, surrogate childbirth is 
authorised unless it is commercially oriented; as such, surrogacy cases in Korea are 
expected to increase. 
According to a staff member of a private infertility centre (data obtained via personal 
communication), the fee for surrogate services is determined through negotiations between 
the couple and the surrogate mother. The couple commonly makes an up-front payment of 
about £17,000 and gives the surrogate mother a monthly compensation of £1,200 to cover 
the income that will be lost by the latter during gestation. The couple also covers all the 
other medical costs that will be incurred throughout the process. All infertility clinics 
carrying out infertility treatments through surrogacy are very reluctant to release detailed 
information regarding their practices.66 Table 3-9 reveals the surrogacy practices in the 
period 1992-1993.  
 
Table 3-9. Characteristics of the surrogate mother 
 1992 1993 
Number of surrogate mothers   14     7 
Age of surrogate mother (average)   36.1    33.9 
Data Sources: Assisted-Reproductive-Technology Committee, Korean Association of Obstetricians and 
Gynaecologists (1997)  
 
The realities pertaining to the spread of ARTs in Korea may be summarised as follows: 
 there have been no specific guidelines from either the professional community or 
public authorities; 
                                                 
65 Sixty % of the survey respondents want surrogate childbirth banned, and 29% accept it unless the surrogate 
arrangements are commercial. Only 9% accept surrogate childbirth even when done for commercial 
purposes (Hong 2001). 
66 Infertile couples, especially the women, feel a sense of shame over their condition. As such, most infertility 
clinics have a side gate so as to provide couples with a discreet access to the clinic. Infertility in women has 
been traditionally regarded as a critical physical defect, and used to be a major motivation for men to expel 
their wives from their families.  
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 since public insurance programmes do not provide benefits for infertility 
treatments, providers are encouraged to offer ARTs while infertile couples are 
discouraged from availing of such technologies due to the cost burdens involved; 
and 
 cultural factors have been a significant impetus for infertile couples seeking ARTs.   
 
3.4.3. UK 
The first live-born IVF-ET pregnancy in the world took place in the UK in 1978. 
According to the HFEA data (HFEA 2007), over 114,858 babies were born by means of 
ARTs from 1991 to 2004. During the period, over 700,000 treatment cycles were carried 
out and undergone by 480,000 patients.  
One in seven couples have trouble conceiving, and about 43,700 couples seek fertility 
treatment each year from the 75 clinics around UK- some NHS, but mostly private 
(Burridge, 2001). The number of patients in the UK undergoes IVF-ET treatment increase 
every year, and the number of patients seeking treatment that was 33,713 in 2006 as 
increased by 455% from 1991 (HFEA, HFEA Register data 1991-2006). Up to 8,000 
infertile women and 600 surrogates may seek surrogacy arrangements (van den Akker 
1999). According to van den Akker (1999), two agencies deal with partial surrogacy, and 
only six of the clinics that have an HFEA license for infertility services have experience in 
IVF-ET surrogacy.  
As depicted in Table 3-10, the use of the IVF-ET treatment has steadily increased in 
the UK while the use of DI has rapidly decreased. Micromanipulation, which includes ICSI 
and SUZI, was introduced in 1992. With higher live births in micromanipulation (22.4% 
compared to 19.3% in conventional IVF-ET and 10.3% in DI), there has been a steady 
increase in the number of treatment cycles using it. At present, micromanipulation 
represents 44% of all ARTs procedures conducted in the UK. The number of treatment 
cycles using conventional IVF increased in the early 1990s, but has either remained steady 
or only slightly decreased since that time. In 2004, 10,880 babies were born through ARTs, 
and 4,587 (42%) of these were conceived through micromanipulation including ICSI and 
SUZI.  
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Table 3-10. The number of cycles applied 
 IVF-ETa ICSI & SUZIb DIc 
1991   6,609 (6,146)     33 (32)     9,303 (4,301) 
1992  18,201 (12,959)    128 (120)    26,078 (7,642) 
1993  21,239 (16,137)    578 (504)    24,230 (7,634) 
1994  23,517 (18,304)   1,284 (1,120)    21,484 (7,257) 
1995  25,414 (19,895)   3,822 (3,351)    18,001 (6,296) 
1996  27,203 (20,914)   6,176 (5,393)    14,913 (5,583) 
1997  25,033 (19,734)   8,917 (7,680)    13,305 (5,106) 
1998  23,551 (18,619)  11,906 (9,656)    11,579 (4,496) 
1999  22,237 (18,528)   12,077 (10,198)    10,207 (4,224) 
2000  22,722 (18,191)  12,728 (10,464)     8,354 (3,575) 
2001  22,344 (17,951)  13,858 (11,401)     7,580 (3,181) 
2002  22,479 (17,818)  14,921 (12,077)     7,323 (3,143) 
2003  21,889 (17,516)  15,521 (12,587)     7,322 (3,113) 
2004  23,283 (18,461)  16,698 (13,463)     6,888 (2,951) 
2005  23,704 (19,119)  17,523 (14,390)     5,839 (2,639) 
2006  22,076 (17,964)  19,506 (15,938)     4,001 (2,054) 
Data Sources: HFEA. A long-term analysis of the 1991-2006 HFEA Register Data.  
Note: a. IVF-ET includes micromanipulation but excludes frozen-embryo replacements.  
     b. micromanipulation only, without IVF 
c. The DI and GIFT data use donor gametes both for stimulated and unstimulated donor  
  insemination treatment cycles. 
     d. The numbers within the parenthesis refer to the numbers of patients who underwent the  
       procedure. 
 
The UK is uniquely positioned in the field of ARTs in several aspects, namely: 
 the first successful IVF-ET was performed in England; 
 the first surrogate mother was an English woman; and 
 the UK established the first public authority to control and monitor the application 
of ARTs. 
 
3.4.4. US 
ARTs have been used in the US since 1981 to help women achieve pregnancy (Perone 
1994). It is estimated that over 6.1 million people in the US suffer from infertility (ASRM, 
Patient’s Fact Sheet, 2002) Acording to Centres for Disease Control (CDC) (2000), 48,391 
babies were born in 1998 as a result of ARTs undertaken in 390 ART clinics.  
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Table 3-11. The major ART procedures used in the US (1985-2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data Sources: Society for Assisted Reproduction, The American Society for Reproductive Medicine (1988- 
2007) 
Note: a. standard IVF-ET 
      b. standard IVF-ET+ICSI 
      c. number of patients 
 
As shown in Table 3-11, in most of these cases, the ART that was employed was IVF-
ET, and fresh embryos developed from the women’s own eggs were used. The number of 
ART centres in the US tripled in the past decade since the mid-1980s. The number of IVF-
ET cycles increased more than 10 times in the same period. The combination of high cost 
and limited insurance coverage is regarded as the primary obstacle in availing of infertility 
treatment in the US (Gleicher 1998).67 
In recent years, the proportion of IVF-ET procedures with ICSI has rapidly increased 
because the chances of fertilization when performing IVF-ET in combination with ICSI has 
                                                 
67 According to Neumann et al. (1994), in the US, the cost incurred per successful delivery with IVF-ET 
increased from US$66,667 for the first cycle to US$114,286 by the sixth cycle, on average. However, for 
couples in which the woman is 40 years old or above, and where there is a diagnosis of male-factor fertility, 
the cost rises from US$160,000 for the first cycle to US$800,000 for the sixth. Griffin and Panak (1998) 
found that the cost of live delivery with ARTs in 1993 was US$59,484 on average: US$69,448 for IVF-ET; 
US$49,469 for GIFT; and US$15,500 for cryopreservation.  
 
 IVF-ET GIFT ZIFT 
Fresh Frozen   
1985     2,389    289/105c      56 - 
1986     2,864    824/319c     466 - 
1987     7,561      490    1,968 - 
1989    13,445     2,124    1,694 - 
1990    14,150     3,290    3,692     1,081 
1991    24,671 -    5,452     2,104 
1992    29,404 -    5,767     1,993 
1993    31,718 -    4,992     1,792 
1994    39,390 -    4,214      962 
1995    36,035a     5,052b    3,741     1,078 
1996    30,598    14,049    2,878     1,200 
1997    33,032    18,312    1,943     1,104 
1998    35,333    23,604    1,293     1,054 
1999    63,639      838      945 
2000    73,406      549      763 
2001    79,042      340      661 
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also increased. In 1995, about 11% of the fresh, non-donor ART cycles performed used 
ICSI, most often to overcome problems with sperm function or motility. The rate increased 
by approximately 30% in 1996, then increased to approximately 40% of the ART cycles 
performed in 1998 (CDC 2000). As shown in Table 3-10, the increase in the percentage of 
IVF-ET procedures where fresh embryos were used represents the increased cycles adopted 
in combination with ICSI. According to the annual reports on ART, the procedures using 
ICSI showed higher live-birth rates than the non-ICSI group. The increases in the adoption 
of ICSI are regarded as related to the improved success rate of live births, even though the 
risk of congenital malformation exists in children born from ICSI (Wennerholm et al. 2000, 
Causio et al. 1999).  
 
In the US, both the regulation and policy changes in insurance coverage impacted the 
spread of ARTs. From 1985, state laws were enacted in some states, particularly those in 
which the insurance coverage includes infertility treatment, at the outset in Maryland. 
Owing to the passage of legislation in many states from 1987, as shown in Table 3-11, the 
number of ART cycles performed significantly increased after 1987. 
FCSRCA of 1992 regularised surrogacy contracts. The law on surrogacy, however, has 
customarily been determined at the state level, with little federal intervention. While some 
states have established laws permitting surrogacy, and some have passed laws outlawing 
surrogacy, the majority of states have yet to address the issue. In these states, lawyers 
representing families opting for surrogacy have, out of necessity, taken innovative 
approaches. According to Weltman (1996), about 5,000 cases legally contracted for 
surrogate births in the past 15 years.  
 
In summary, the following factors have significantly affected the adoption of ARTs in 
the US:  
 insurance coverage mandated by state laws beginning in 1985, which spurred ART 
adoption starting from the late 1990s; and 
 FCSRCA of 1992, which made infertility clinics cautious about the success rate of 
ARTs, and hence restrained the adoption of the procedures without pertinent 
indications. 
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3.5. Conclusion 
 
Since it is impossible to evaluate micro factors in terms of cost-effectiveness, unit cost 
for each procedure was assessed. The unit cost for IVF-ET in Japan, Korea and the UK are 
broadly similar. The cost in HMOs of the US is similar to the other three countries, and the 
costs in other health plans of the US were much higher, by up to five times. The cost for 
surrogacy was especially high in the US. The costs of ARTs are also varied among the 
procedures, with highest in ICSI followed by IVF-ET. Although the cost is high when 
undertake ICSI, success rate in terms of both pregnancy and live birth rate is also higher in 
ICSI compared to IVF-ET. 
 
Table 3-11 summarises the regulation and finance on ARTs in four countries. No legal 
regulation has been enacted other than the UK where ART practices have been regularised 
by the Surrogacy Arrangement Act 1985 and the Human Fertilisation and Embryology Act 
1990 defines the legal status of a surrogacy contract including the child’s legal mother as 
the woman carrying it regardless of whether mother and child are genetically related 
(Brinsden et al 2000, 925). The UK also regulates the number of embryos that can be 
implanted. 
In Japan, the Japan Society of Obstetricians and Gynaecologists guidelines constitute 
official approvals to regularise the practice of ART. With strong conformity of its members, 
any infertile couple seeking a procedure that JSOG members do not support should have 
gone abroad.  
In Korea, no legal regulation has been enforced either by public authorities or by the 
professional community. The adoption and use of ARTs is fully in the hands of 
obstetricians and infertile couples. Accordingly, the use of any technology assisting 
reproduction simply depends on the ethical stance of individuals and their income levels.  
Both in Japan and Korea, cultural traditions focusing on genetic linkages contributed in 
impeding technology adoption especially technologies requiring a third person donor such 
as AID, egg donation and surrogacy.  
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In the UK, the relatively higher level of ART is plausibly a result of legal regulations 
providing approval of practice unless it breaches the code of practice. In addition, the UK’s 
leading role in the development of ART where the first IVF-ET was successfully achieved 
may have contributed to its relative popularity.  
 
Table 3-12. Summaries of regulation and reimbursement policy on ARTs 
 IVF-ET DI Egg donation Surrogacy 
Regulation 
Japan 1983 by JSOG 
self-regulation 
1997 by JSOG 
self-regulation 
1999 by JSOG 
self-regulation 
Not being 
supported and  
consensus has 
not yet been 
grown  
Korea No regulation 
but consensus 
grown to 
accept in the 
public 
 
No regulation 
and consensus 
has not yet 
been grown to 
accept in the 
public. 
No regulation 
and consensus 
has not yet 
been grown to 
accept in the 
public. 
No regulation 
and consensus 
has not yet been 
grown to accept 
in the public. 
UK The Human Fertilisation and Embryology Act 
1990:  
The Surrogacy 
Arrangement 
Act 1985 
US No federal legislation governing ARTs.  
 
 
The Fertilisation 
Clinic Success 
Rate and 
Certification Act 
1992 supports 
surrogacy 
contract 
The Fertilisation Clinic Success Rate and Certification Act 1992 
requires reporting success rates.  
Financing 
policy 
Japan Not covered by public insurance programme 
Korea Not covered by public insurance programme 
UK Reimbursement complicated: in Scotland, up to three IVF-ET cycles 
publicly funded. Elsewhere, individual authorities may choose no to 
provide coverage and the majority infertile couples fund privately.  
US Insurance coverage policy is varied according to individual state. 
Thirteen states have mandates for infertility treatment coverage. Most 
infertile couples fund privately. 
* Note: The information for the UK and the US is partly quoted from Hughes (2001) 
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Left under market mechanisms in the UK, significantly high costs have been enough to 
limit adoption of these procedures. 
In the US, there is no legal limit even on embryo storage, and decisions about this issue 
have been left to individual clinics. In pursuit of fair trade, the Fertilisation Clinic Success 
Rate and Certification Act (FCSRCA)68 of 1992 obliges ART clinics to release correct data 
on success rate.  
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Figure 3-1. Total ART cycles pmp, four countries, 1991-2006 
Note: the data in all four countries include ICSI 
 
The use of ARTs by country over time as Figure3-1 shows increases in all countries 
except the UK. The increase is striking for Japan. Following the introduction of ICSI in 
1992, its adoption rapidly spread while other technologies have been circumscribed. The 
adoption of ICSI has been much faster in Korea and Japan compared to the other two 
countries. 
While the number of IVF-ET cycles including ICSI is high in Japan, in terms of 
cumulative total, overall usage of ARTs is distinctively higher in the UK. On the contrary, 
both IVF-ET cycles and overall ART usage are much lower in the US compared to the 
other case study countries. Also, both levels of IVF-ET cycles and overall ART usage were 
                                                 
68 FCSRCA was intended to provide the public with comparable information concerning the effectiveness of 
infertility services and to assure the quality of such services by providing for the certification of embryo 
laboratories (p. 39374). 
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quite similar between Japan and Korea in the past, but adoption levels in Japan have been 
taken up rapidly which is mainly attributed to public funding.  
Donor insemination is very high in the UK, accounting for over half of total ARTs until 
1993. Since then, DI has been fallen while micromanipulation including ICSI and SUZI 
increased rapidly. Although there is no comparable information on donor insemination in 
Japan and Korea, it is highly unlikely that there would be much donor inseminations in 
these countries. In Japan, DI was prohibited by the JSOG until 1997. In Korea, DI is 
limited by the importance attached to “blood lines.” The proportion of donor insemination 
is also much lower in the US at around 10 % of ARTs. 
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Chapter 4: Caesarean-Section Delivery 
4.1 Introduction 
Caesarean section refers to a major surgical procedure in which a baby is removed 
from the uterus by making an incision into the abdomen, and then into the uterus. This 
procedure is used as an alternative to vaginal delivery, and can be indicated in certain 
conditions. Caesarean section birth rates are rising worldwide, and many factors have been 
cited for this phenomenon. WHO (1985) considers a caesarean section ratio of 10% as 
being reasonable. However, many parts of the world far exceed this level. Caesarean 
section delivery is a global epidemic, with Korea having the highest rates (43% in 1999). In 
the UK, the caesarean section ratio averaged 12.8% from 1980 to October 1999, ranging 
from 10 to 17.4% (Savage 2000).69 In the US, the rate of caesarean section increased from 
5% in 1970 to 16% in 1978, and then peaked at 24.7% in 1985. The US Department of 
Health and Human Services set targets in 1991 to reduce the overall caesarean section ratio 
to 15%, and the primary rate to 12%, by 2000 (Healthy People 2000).   
 
Caesarean section deliveries are typically performed because (1) the mother has already 
undergone caesarean section during a previous delivery, and the doctor believes that a 
“repeat” is necessary to avoid rupturing the uterus; or (2) the woman experiences 
complications during pregnancy. Caesarean section also reduces the risk of rare 
neurological disorders like cerebral palsy. In many cases, caesarean section is required to 
save the life of the baby or mother. According to an NICE guideline (2004), the clinical 
indications for planned CS, which should be scheduled before the onset of labour, are as 
follows: 
 breech presentation; 
 multiple pregnancy; 
 preterm birth; 
 undersized foetus (too small for its gestational age); 
 placenta previa;  
                                                 
69 In Scotland, the caesarean section ratio rose from 9% in 1976 to 16% in 1995 (The Scottish Office 1997). 
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 cephalopelvic disproportion; 
 HIV-positive mother; and 
 primary genital herpes simplex virus (HSV) infection occurring in the third 
trimester of pregnancy. 
 
As caesarean section delivery requires more resources than vaginal delivery and is 
partly a matter of choice, electing caesarean section for non-medical reasons seems to draw 
controversy.70 Caesarean section ratios are attributed to many complex factors in both 
medical and non-medical reasons. Advancements in technologies used in the delivery of 
babies have cultivated a philosophy of medical education and practice to regard pregnancy 
and birth as situations requiring medical intervention. Cultural pressure fostering caesarean 
section births comes from superstitious beliefs, especially in Korea, that the fate of a person 
is predetermined by the moment of birth. Caesarean section births are also guided in 
tandem with judicial circumstances, including court orders and usual practices seeking to 
avoid malpractice claims. Caesarean section cases forced by judicial order have been 
particularly evident in the UK and US. Furthermore, there have been some cases in which 
doctors were threatened with malpractice if they did not opt for a CS. In addition, caesarean 
section delivery is fostered by both the obstetricians and women giving birth. On the part of 
the obstetricians, the motive is personal benefit insofar as surgical procedures generally 
guarantee higher income than non-surgical procedures. On the part of the women giving 
birth, a caesarean section birth is often the preferred means of delivery since it will allow 
them to schedule delivery at their own convenience, and since it can allow them to avoid 
the pain usually experienced during labour or any physical changes following birth.71 
Many women also choose caesarean section delivery to avoid prenatal damage.72  
                                                 
70 Gabay and Wolfe (1994) estimated that over one-half of the caesarean sections performed in 1987 were 
unnecessary and resulted in 1.1 million extra hospital days in the US and a cost of over US$1 billion. 
71 According to Jackson and Irvine (1998), 38% of the elective caesarean section deliveries that had been 
performed in District General Hospital in Watford, England were performed on account of maternal request. 
Of all the births in the hospital, 18.8% were delivered by CS, 9.1% of which were elective CSs and 9.7% 
emergency CSs. In the Radcliffe Hospital of the UK, the proportion of CSs performed by maternal request 
has increased from 1% in 1986 to 30% in 1996 (MacKenzie 1999).  
72 Al-Mufti et al. (1997) found in their survey that 17% of obstetricians would choose an elective caesarean 
section in the absence of any clinical indication, mainly out of fear of perinatal damage. 
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The selection of caesarean section is also closely related to the schemes involving the 
payment of the cost of delivery.73 Women with private insurance policies are more likely 
to choose instrumentally assisted deliveries, including CSs, than those covered by public 
insurance programmes (Stafford 1990, Stephenson 1992, Fisher et al. 1995, Roberts et al. 
2000, King 2000, Murray 2000).  
Some other demographic and socio-economic elements appear to influence caesarean 
section ratios. In the US, caesarean section delivery is more likely to be chosen by married 
mothers and white mothers (Gruber and Owings 1996) since the choice of delivery via 
caesarean section is closely related to socio-economic status, including access to insurance 
coverage. Generally, the likelihood of a caesarean section delivery rises with maternal age 
(Sizer et al. 2000, Gruber and Owings 1996, Braveman et al. 1995): as the maternal age 
increases, the spontaneous vaginal-delivery rates fall while the instrumental-delivery rates, 
elective and emergency caesarean section ratios, labour induction rates, and epidural rates 
rise. Braveman and colleagues (1995) also found that insurance, maternal age74, education, 
prenatal care initiation, hospital teaching status, ownership, and region are significant 
predictors of caesarean section delivery.75  
 
4.2. Micro Factor Evaluation 
4.2.1. Economic Factors 
The economic evidence is focused around the cost of CS compared to vaginal birth. 
Compared with home births, caesarean section birth costs are much higher. Caesarean 
section deliveries, as well as natural deliveries, have not been evaluated adequately (Petrou 
et al. 2001). As summarised in Table 4-1, the costs cited in published studies and in the 
NHS reference costs widely vary for each mode of delivery. 
 
                                                 
73 Cai et al. (1998) found that the expansion of insurance coverage, in a system where the physicians were 
compensated on a fee-for-service basis, was mainly responsible for the increase of caesarean section ratios 
in Minhang District, Shanghai, China.  
74 In the UK, Sizer and colleagues. (2000) found that as the maternal age increases, the spontaneous vaginal 
delivery rates fall, and the instrumental-delivery rates, elective and emergency caesarean section ratios, 
labour induction rates, and epidural rates rise. 
75 Gregory and colleagues (1999) found that the Medicaid-insured women who delivered their babies in 
private non-teaching hospitals had an overall caesarean section delivery rate that was 2 to 2.5 times that of 
similar women who delivered at public hospitals (24.5% vs. 9%). 
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Table 4-1. Range of costs cited in published studies and in the NHS reference costs (£) 
 Range of Costs 
NHS Reference Costs including 
postnatal staya 
Excluding 
Postnatal 
Stay 
Including 
Postnatal 
Stay 
Spontaneous 
vaginal delivery 341-886 629-1,350 
520-889 
Instrumental 
vaginal delivery 606-968 242-1,794 
921-1,416 
CS 1,004-1,486 1,238-3,551 1,449-2,122 
Data Sources: Henderson et al., (2001)  
Note: a Inter-quartile range of uncomplicated non-elective cases quoted from  
 
The caesarean section delivery cost variations are closely related to the length of stay 
(LOS) after the delivery. As shown in Table 4-2, the LOS following caesarean section 
delivery in the US is about double that following vaginal delivery, mainly due to the 
maternal complications that occur during and after delivery.  
 
Table 4-2. LOS by type of delivery: 1980-1998 
Type of Delivery 1980 1985 1990 1995 1998 
C-Section 6.5 5.2 4.5 3.6 3.7 
Vaginal Delivery 3.2 2.7 2.3 1.7 2.1 
All Deliveries 3.8 3.3 2.8 2.1 2.5 
Data Sources: CDC, Vital and Health Statistics, National Hospital Discharge Survey: 1998 Annual Summary  
 
Although caesarean section delivery is much more costly compared to vaginal delivery, 
it has been proven to be a cost-effective approach in situations where the mother and/or 
baby experiences distress, or to preventing infectious diseases. Elective caesarean section 
deliveries appear to be a cost-effective intervention when they prevent the vertical 
transmission of HIV among women receiving various antiretroviral therapy regimens, who 
refrain from breastfeeding (Halpern et al. 2000).76 As vaginal delivery has been 
demonstrated to increase the risk of causing cervical cancer to recur among women who are 
                                                 
76 It should be considered that, although elective caesarean section remained cost-effective, results were 
sensitive to variations in vertical transmission rates and to paediatric HIV treatment costs in their study. The 
International Perinatal HIV Group (1999) found that elective caesarean section reduces the risk of 
transmission of HIV from mother to child independently of the effects of vertical transmission.  
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afflicted with the disease, caesarean section deliveries are recommended for pregnant 
women with cervical cancer (Sood et al. 2000). 
 
4.2.2. Clinical Factors 
In general, caesarean section deliveries offer some benefits, such as the following:  
 they can save the lives of newborns and their mothers, or prevent the potential 
complications that may arise from a delayed vaginal birth;  
 the pain of labour may be minimized or avoided; and  
 it is possible to time the delivery. 
 
Although elective caesarean section cannot prevent all risks associated with childbirth, 
by avoiding labour and prolonged pregnancy, mothers can avoid such problems as 
unexpected intrauterine death77, permanent brain damage due to labour78, and the risk that 
the baby would weigh >1,500 gat birth.79 
 
Being a major surgery, caesarean section delivery, however, entails many risks. Hall 
(1994) reported that elective lower-segment caesarean section is associated with a much 
higher risk of maternal death. The rate of mortality after caesarean section delivery is 4.5 
times greater than after vaginal delivery (Schuitemaker et al, 1997). Although some deaths 
following caesarean section delivery are related to maternal illness rather than to the 
surgery (NIH 1980), many of such deaths are caused by infections. The higher risk of 
maternal death in caesarean section delivery is also associated with the use of general 
anaesthesia, which is not required in vaginal delivery. On the other hand, individual 
medical conditions such as heart problems may increase the risk of death in vaginal 
delivery compared to caesarean section delivery.  
                                                 
77 This problem occurs in about 1 in 600 pregnancies (Hiller et al. 1998). 
78 It is estimated that one in 1,750 labours result in hypoxic ischaemic encephalopathy, whereas intrapartum 
events account for about 10% of all babies with cerebral palsy (Nelson and Ellenberg 1986). 
79 Death at birth occurs in about one in 1,500 cases in the UK (Confidential enquiry into stillbirths and deaths 
in infancy 4th report 1997). 
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The surgery that is performed in caesarean section delivery increases the risk of 
maternal death, hysterectomy, haemorrhage, surgical injury to the other organs, infection80, 
blood clots, and re-hospitalisation due to complications (Lydon-Rochelle et al. 2000, 
Schuitemaker et al. 1997, van Ham et al. 1997). According to Hillan (1995), only 9.5% of 
the respondents in their study who underwent caesarean section delivery did not experience 
any postoperative problem. 
Furthermore, potential long-term complications may arise from the scar tissue 
adhesions resulting from caesarean section delivery, such as pelvic pain, bowel problems, 
and pain during sexual intercourse. Scar tissues also make subsequent CSs more difficult to 
perform, increasing the risk of injury to other organs and the risk of chronic problems from 
adhesions. In addition, scar tissue, which stimulates the incidence of placenta previa and 
placenta accreta, increases dramatically with each successive caesarean section (Ananth et 
al. 1997, Asakura and Myers 1995, Hemminki and Merilainen 1996). 
 
4.2.3. Technical Factors 
Caesarean section delivery is beneficial to a mother’s psychological state. Those who 
have undergone an emergency caesarean section retrospectively report having had minimal 
psychological distress, having hardly perceived the risk of incurring a serious injury during 
delivery, and having had significantly greater satisfaction with pain relief (Maclean et al. 
2000). Psychologically adverse effects have also been reported, however, including: (1) 
more symptoms of post-traumatic stress (Ryding et al. 1998)81; (2) more reports of 
psychosomatic symptoms during the first year after delivery (Garel et al. 1988); and (3) 
                                                 
80 According to Henderson and Love (1995), the overall infection rates for women who delivered through 
primary and secondary caesarean section in a Canadian community teaching hospital were 42.1% and 
46.1%, respectively. 
81 The study compares the psychological reactions of women after emergency caesarean section (EmCS), 
elective caesarean section (ElCS), instrumental vaginal delivery (IVD), and normal vaginal delivery (NVD), 
assessing the longitudinal change of post-traumatic stress from a few days postpartum to one month 
postpartum. The Emcaesarean section group reported the most negative delivery experience at both times, 
followed by the IVD group. At a few days postpartum, the Emcaesarean section group experienced greater 
general mental distress than the NVD group did, but less than that experienced by the Elcaesarean section 
and IVD groups. At one month postpartum, the Emcaesarean section group showed more symptoms of 
post-traumatic stress than did the Elcaesarean section and NVD groups, but not when compared to the IVD 
group. An unplanned instrumental delivery (Emcaesarean section or IVD), therefore, should be regarded as 
a pointer with respect to possible post-traumatic stress. 
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deterioration in mood and a diminution of self-esteem (Fisher et al. 1997).82 In general, 
women who have undergone unplanned caesarean section deliveries are likely to show less 
adaptive responses and more ineffective responses than those who have undergone planned 
caesarean section deliveries (Reichert et al. 1993, Ryding et al. 1998). 
 
4.3. Macro Factor Evaluation 
4.3.1. Japan 
In Japan, no legal regulation exists to control caesarean section deliveries. The health 
insurance programmes in the country exclude normal delivery in their coverage plans 
because they do not regard normal delivery as a medical treatment.  
Compensation schemes do not confer any benefit on obstetricians for caesarean section 
delivery. While a single normal delivery in Japan costs about £760, the fee for caesarean 
section delivery during working hours is only about £470, and £820 during non-working 
hours. In the case of first-time delivery, mothers who undergo normal delivery stay in the 
hospital for about eight days after birth (for additional normal deliveries, mothers stay in 
the hospital for seven days after birth). On the other hand, mothers who undergo caesarean 
section delivery stay in the hospital for about 11 days. Considering the longer hospital stay 
after caesarean section delivery, and the comparatively lower fees involved, obstetricians 
and hospitals prefer normal delivery.  
 
In summary, the health insurance policy in Japan, which does not cover normal 
delivery, is unique, and the cost of normal delivery is much higher than that of caesarean 
section delivery. 
 
4.3.2. Korea 
Like Japan, there is no legal regulation controlling caesarean section delivery in Korea. 
The fee differences between normal and caesarean section deliveries in the country, 
                                                 
82 They found that significant adverse psychological effects were associated with the mode of delivery. 
Women who had undergone spontaneous vaginal deliveries were most likely to experience a marked 
improvement in mood and an elevation of self-esteem across the late-pregnancy to the early-postpartum 
interval. In contrast, women who had undergone caesarean section deliveries were significantly more likely 
to experience deterioration in mood and a diminution of self-esteem. 
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however, may encourage obstetricians to choose caesarean section deliveries. According to 
the National Health Insurance Corporation (2000), the average length of stay for vaginal 
delivery in the year 2000 was 2.9 days, and 7.2 days for caesarean section delivery. The 
cost of caesarean section delivery then, therefore, was 2.6 times higher than that of vaginal 
delivery. In 1999, the average cost of caesarean section delivery in Korea was £532, while 
that of vaginal delivery was £205. In 1991, the fees for vaginal and caesarean section 
deliveries were £58 and £206, respectively. The data indicate that although the gap between 
the fees for vaginal and caesarean section deliveries narrowed in the 1990s, the rate of 
caesarean section deliveries continued to increase. It has been strongly assumed in Korea 
that the higher fee for caesarean section delivery on account of the longer hospital stay 
required by it and the use of expensive items, including high-priced antibiotics, during the 
conduct of the procedure is mainly due to the preference of both physicians and hospitals 
for caesarean section delivery.  
 
Table 4-3. Fees by deliveries and payment systems, 1999 
Payment  
Teaching 
Hospital 
General 
Hospital 
Hospital Clinic Average 
On FFS 
 
Vaginal 
Delivery 
Average 
LOS(day) 
3.5 3.2 3.1 2.5 2.9 
Average 
Cost 
£229.37 £215.77 £172.89 £149.18 £176.56 
caesarean 
section 
Delivery 
Average 
LOS(day) 
8.2 7.6 7.6 6.6 7.2 
Average 
Cost 
£557.12 £528.02 £445.41 £400.75 £457.99 
On 
DRG83 
Vaginal 
Delivery 
Severity 0 £285.35 £271.61 £243.98 £221.65 - 
Severity 1 £369.58 £352.98 £319.67 £291.82 - 
Severity 2 £567.78 £543.70 £495.33 £455.18 - 
caesarean 
section 
Delivery 
Severity 0 £576.11 £551.08 £500.58 £457.78 - 
Severity 1 £608.57 £583.27 £532.25 £487.64 - 
Severity 2 £621.25 £595.31 £543.12 £497.72 - 
Data Sources: The Ministry of Health and Welfare, 1999 DRG Guidelines. 
 
In Korea, the choice between FFS and DRG is discretionary and is in the hands of 
the providers. As shown in Table 4-3, although the gap between the fees of vaginal and 
                                                 
83 The DRG system was partly introduced in February 1997 as a three-year demonstration project. The items 
covered by the DRG scheme expanded each year, and more hospitals eventually accepted it. At the time the 
system was launched, only 54 hospitals, mostly public organisations managed by the central or regional 
governments, participated in the scheme.  
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caesarean section deliveries has significantly narrowed under the DRG scheme, it is still 
unlikely that the rate will decline if measures related to cost reimbursement will be 
implemented. Rather, obstetricians and hospitals prefer caesarean section delivery under 
the DRG programme since this scheme is more financially beneficial to the providers. The 
financial advantage is much greater for caesarean section delivery when its fee is paid by 
DRG than by FFS. In the flux of fierce opposition against the DRG system led by the 
Korean Medical Association, the Korean Society of Obstetrics and Gynaecology also 
proclaimed opposition against the DRG system in September 2003. Consequently, majority 
of the members of the Korean Medical Association hesitated from employing the DRG 
system. Although they acquired compensation based on FFS, the fee was still much higher 
in caesarean section delivery (£104.40) than in natural delivery (£81.26).84 
 
The recent data on the comparison of the fees of normal and caesarean section births, 
as shown in Table 4-4, suggest that all types of providers offering delivery services may 
still prefer caesarean section delivery. To reduce the caesarean section ratio, the Ministry of 
Health and Welfare set off a series of measures in the year 2000. The first action was the 
public disclosure of the caesarean section ratios of individual centres providing childbirth 
services, unveiled by the National Health Insurance Corporation. The great variation among 
obstetrics clinics and hospitals provoked public fury. In December 2004, the Ministry of 
Health and Welfare organised the Ad Hoc Committee for the Decrease of caesarean section 
Deliveries. The committee marked as its target the reduction of the caesarean section 
delivery rate to 20% by the year 2010. Towards this end, the committee set forth the plan of 
developing standard protocols as regards caesarean section indications and of continuing to 
publicise the caesarean section ratios of individual clinics. Since then, the National Health 
Insurance Corporation has been publicising the caesarean section ratios of individual clinics, 
indicating the likelihood that their patients will undergo caesarean section delivery as high, 
moderate, and low, with the clinics strictly adhering to the protocol. The second action was 
a fee policy for delivery. In 2007, the Ministry of Health and Welfare drastically raised the 
                                                 
84 The fee refers only to the delivery, and excludes the accompanying fees, such as the physician’s fee and the 
meals.  
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natural-delivery fee to £154.11, which is much higher than the caesarean section delivery of 
£131.03 based on FFS. 
 
Table 4-4. Fees by deliveries and payment systems, 2005  
 
Fees (Average ) LOS (Per Day) 
Normal Delivery 
caesarean 
section 
Delivery 
Normal Delivery 
caesarean 
section 
Delivery 
 Total  £304.28  £515.90 3.2 7.0 
 Special hospital  £396.21  £644.31 3.5 7.9 
 General hospital  £345.26  £612.02 3.3 7.5 
 Hospital  £311.60  £517.56 3.3 7.1 
 Clinic  £279.95  £460.99 3.1 6.7 
Data Sources: The Ministry of Health and Welfare, Brief Report on caesarean section Rates, July 26, 2006 
 
As seen in Table 4-5, the actual fee was much higher when paid through the DRG 
system. Although the fee for the delivery itself is lower at present in the FFS system for 
caesarean section delivery, the overall fees are still much higher in caesarean section 
delivery. 
 
Table 4-5. Fee differences between the DRG group and the FFS group (£) 
Fees 
1999 2000 
Vaginal 
Birth 
Caesarean 
Birth Differences 
Vaginal 
Birth 
Caesarean 
Birth Differences 
DRG 206.19 499.30 293.11 208.66 500.37 291.71 
FFS 207.19 433.71 267.68 184.68 451.59 266.91 
Differences 40.15 65.58  23.98 48.77  
Data Sources: Ko et al. (2000) 
 
In summary, the average cost of caesarean section delivery was more than two times 
higher than that of normal delivery in 1999, which was four times higher in 1991. Although 
the Ministry of Health and Welfare introduced the DRG scheme for caesarean section 
delivery in 2003 to reduce the gap between caesarean section delivery and normal delivery, 
the compensation for childbirth is still higher in caesarean section delivery. In 2004, HIRA 
started to disclose to the public the caesarean section ratios of individual centres; the 
centres with high rates were then condemned as moral hazards. In addition, the public 
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disclosure of the caesarean section ratios hints the probability of choosing caesarean birth 
in each centre.  
 
4.3.3. UK 
The much higher rates of caesarean section delivery in the UK compared with the 
WHO recommendation have raised some questions. The Royal College of Obstetricians 
and Gynaecologists, on behalf of the Department of Health, carried out a comprehensive 
nationwide study on caesarean section births in 2001 to determine why these differences 
exist, and to determine the best way of addressing the inequality. The results of the study 
became the basis for the development of clinical guidelines for caesarean section delivery 
and of the National Service Framework for Children guidelines. The results of the study 
carried out by the National Audit in response to concerns over the variation in the caesarean 
section ratios across the country also support the development of the guidelines. 
 
So far, no legal regulation of caesarean section delivery exists in the UK. Due to the 
higher caesarean section ratios and the accompanying cost burden on the society, caesarean 
section ratios have been a sensitive issue on the part of the public and among policymakers. 
In the UK, each 1% increase in the caesarean section ratio results in an increase of £5 
million in costs to the NHS (Drife 1997). According to Reference Cost 2000 (DoH 2000), 
the national average cost of non-elective caesarean section admission is £738, with an inter-
quartile range of £505 to £874. The national average cost of caesarean section delivery is 
£1,738, with additional costs coming primarily from the use of the facility and the longer 
stay in the hospital.85  
 
The women’s choice stance in the UK is well epitomised in the practice guidelines 
established by the Ethics Committee of the Royal College of Obstetricians and 
Gynaecologists, as quoted in the immediately preceding section. Maternal choice is now a 
major factor stimulating caesarean section delivery. According to Eftekhar and Steer (2000), 
                                                 
85 The costs included herein relate to the delivery episode itself, and no costs are incurred in health terms for a 
healthy baby. If a baby requires health care for a medical condition, then the baby becomes an admitted 
patient in its own right. The costs of the child’s treatment are shown vis-à-vis the relevant treatment 
categories (e.g., special-care baby unit, cardiac surgery, etc.), as necessary. 
 
 
88
maternal request accounted for 14% of the caesarean section deliveries carried out in 
Chelsea and Westminster Hospital in 1999. The vast majority of requests were prompted by 
the woman’s fear of foetal and neonatal injuries potentially occurring during delivery and 
pregnancy, followed by infertility (Tranquilli 2001). In addition, maternal requests for 
caesarean section are more likely for those who have already undergone one (Tranquilli 
2001, Quinlivan et al. 1999, Jackson and Irvine 1998, Geary et al. 1997), or for those who 
have experienced an obstetric complication during pregnancy, such as breech presentation 
(Tranquilli 2001, Quinlivan et al. 1999, Jackson and Irvine 1998). The experience of a 
difficult birth was also a factor in maternal requests (Churchill 1997, Turnbull et al., 1999). 
Changing Childbirth Report (DoH 1993) outlined guidelines for choosing the mode of 
delivery, the kind of professional healthcare providers, the place of delivery, and the degree 
of intervention. The Audit Commission Report (1997) further stated that maternity services 
needed to become more women-centred.   
The Human Rights Act of 1998, which came into force on October 2, 2000, states that 
women have the right to opt for caesarean section delivery, with the involvement of a 
senior consultant. Article 2 of the Act ensures that “everyone’s right to life is protected by 
law.” The passage and implementation of this Act is regarded as a way of holding the 
medical staff accountable for taking adequate and appropriate steps to protect or preserve a 
life, in addition to preventing any harm from befalling a patient (Gillman 2000). Elective 
caesarean section is also supported by specialists in the obstetric community. There has 
been a consensus to confirm a patient’s right to autonomy, which should be respected as 
long as the woman is fully informed (Paterson-Brown 1998, Amu et al. 1998).  
 
In addition, European decisions and the legal commentary on Article 2 raise the right of 
a patient to demand for the involvement of senior staff members and the right of a woman 
to choose how her baby will be delivered. The medical-staff members are required to take 
note of, and to respect, a woman’s preference for how she wishes her baby to be delivered. 
Article 3 prohibits inhumane or degrading treatment or punishment. Article 8 states that 
everyone’s right to privacy, family, home, and correspondence must be upheld and 
respected. A person’s privacy includes a person’s physical and psychological integrity. 
Accordingly, the Act urges obstetricians to undertake caesarean section delivery even when 
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a woman chooses it out of fear of pain or fear that an accident would occur during labour. 
In practice, obstetricians report that the woman’s desire to deliver by way of caesarean 
section influences the final decision as to the method of delivery.86  
 
The caesarean section ratio is also influenced by the human resources in NHS. 
According to the Royal College of Midwives, more women are being forced to undergo 
caesarean section delivery because of the shortage of midwives (The Times, November 7, 
2000).87 In 1997-98, about 30% of all deliveries were conducted by hospital doctors, and 
70% by midwives. At present, more deliveries are being handled by doctors. The overall 
balance between the two professions has steadily changed over the years. During the period 
1989-90, about 24% of all deliveries were conducted by doctors, and the remaining 76% by 
midwives. As virtually all spontaneous deliveries then were conducted by midwives, the 
shift partly accounts for the increasing proportion of caesarean section deliveries.88 
Savage and Francome (1993) explored the reasons for the rise in the caesarean section 
ratio in Britain by conducting a nationwide survey.89 Out of the total of 623 responses, the 
major reasons given by the obstetrician respondents for caesarean section deliveries were as 
follows: 
 litigation (125/20.06%); 
 heightens safety (52/8.34%); 
                                                 
86 According to a survey conducted by Al-Mufti et al. (1996), 31% of female obstetricians are likely to 
prescribe an elective caesarean section delivery even in the case of first-time pregnancy or delivery and a 
likely uncomplicated one. This implies a potential demand for caesarean section delivery.  
87 This was discussed by midwives, obstetricians, and members of the National Childbirth Trust at a 
conference jointly organised by the Royal College of Obstetricians and Gynaecologists, the Royal College 
of Midwives, and the National Childbirth Trust. It was conceded in this conference that there is an 
important link between the lack of continuous support by midwives during labour and the rising incidence 
of medical intervention, including CS, in childbirth. In the US, Blanchette (1995) compared the caesarean 
section delivery rates of a group cared for by certified nurse-midwives (CNMs) in a public facility and of a 
low-risk group cared for by physicians in a private setting. They found that the caesarean section birth rate 
in the group cared for by CNMs (13.1%) was about half of that in the group cared for by physicians 
(26.4%). 
88 Recently, midwives have been deserting NHS in droves. While some 90,000 are registered, only about 
32,000 are practising in the health service. According to the Royal College of Midwives, this can cause 
anxiety and contribute to an ever-rising rate of CSs and other avoidable interventions that are more 
dangerous than natural birth (Bennett 2001). More midwives enter private practice as it brings better 
income and greater freedom. To resume one-to-one, continuous care with a midwife during labour, the 
British government plans to invest £100 million cash (Guardian, May 2, 2001). This may make it possible 
to recruit an extra 2,000 midwives and to modernise maternity units. 
89 Consultants were asked an open-ended question. All but nine of the 232 consultants in England and Wales 
responded, and four of the 74 in Scotland. Over 50 different reasons were given by the consultants.  
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 allows foetal monitoring (49/7.86%); 
 effective in reducing perinatal mortality (37/5.93%); 
 increases the expectation of the parents (34/5.45%); 
 addresses breech presentation (34/5.45%); and 
 allows better monitoring (32/5.13%). 
 
The reason most frequently mentioned by the obstetricians was malpractice litigation, 
followed by staffing problems and misinterpretation of the foetal condition.  
 
In summary, the Human Rights Act of 1998, which respects maternal choice of 
delivery, and the dearth of midwives in NHS, have been regarded as the major factors 
influencing the choice of the kind of delivery in the UK 
 
4.3.4. US 
Various attempts have been made to curb the caesarean section delivery rate in the US, 
such as the issuance and implementation of legal regulations, public policies, guidelines for 
practices, and reimbursement policies of insurers by various authorities at both the national 
and state level.  
At the federal level, the Newborns’ and Mothers’ Health Protection Act (NMHPA) of 
199690 mandated that the coverage for hospital stays on account of childbirth generally 
cannot be less than 48 hours for normal deliveries or 96 hours for caesarean section births 
(Federal Register 1998, Vol. 63).91 After the enactment of the law, the average charges of 
                                                 
90 Maryland passed the first maternal-length-of-stay legislation in 1995. The law was passed in Illinois in July 
1996. In the fall of 1996, President Clinton signed the Newborns’ and Mothers’ Health Protection Act, 
which supplements the state laws by covering those receiving care in a state without legislation, those who 
are insured by a company headquartered in another state, and those working for a self-insured employer 
(Raube and Merrell 1999).   
91 The Newborns’ and Mothers’ Health Protection Act of 1996 (NMHPA) was enacted on September 26, 
1996 to provide mothers and their newborn children with protection during the critical days immediately 
following birth. To ensure that mothers and newborns would receive adequate care, the law establishes a 
minimum hospital stay in connection with childbirth. The law applies to group health plans, health 
insurance issuers (e.g., insurance companies, HMOs) that offer insurance in connection with group health 
plans, and health insurance issuers who sell coverage in the individual market. For group health plans and 
health insurance issuers in the group market, the law is effective for the plan years beginning on or after 
January 1, 1998. For the individual market, the law applies to health insurance coverage on or after January 
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delivery increased, but more for vaginal delivery than for caesarean section delivery (Udom 
and Betley 1998).92 
 
At the state level, a law imposing practice guidelines on obstetricians for caesarean 
section births was implemented in Florida in 1992. The law also required hospitals to 
establish peer review boards that would evaluate the caesarean section deliveries performed 
in such hospitals. For the monitoring of the law’s implementation, hospitals are required to 
report each caesarean section case to a state agency. The impact of the law in reducing the 
caesarean section birth rates was greater in terms of reducing the primary cases of CSs than 
in terms of reducing the repeat cases, especially in the first quarter of 1993 (Studnicki et al. 
1997).93  
 
Various public authorities have also participated. The concern regarding caesarean 
section deliveries was focused on repeat deliveries. The actions towards vaginal birth after 
caesarean section (VBAC) began in the late 1980s.94 When the National Institute of Health 
introduced the NIH Consensus Development Programme in 1980, national guidelines for 
the use of caesarean section were also introduced (NIH 1981). The dictum “Once a 
Caesarean, always a Caesarean” began changing gradually starting in the early 1980s. In 
1981, when the vaginal birth after caesarean section rate was only 3%, the National 
Institute of Health began to encourage trials or labour. In an effort to follow the national 
                                                                                                                                                    
1, 1998. The interim rules for the individual market apply to health insurance coverage offered, sold, issued, 
or renewed in effect, or operated in the individual market on or after January 1, 1999. 
92 In Maryland, the average charge for vaginal delivery increased by 10% while that for caesarean section 
increased by 6.7%. 
93 In their research, significant decreases in the number of repeat CSs were found in groups representing 
72.6% of the population, while significant decreases in primary CSs were found in groups representing only 
36.5% of the births without a prior CS. Reductions in the number of repeat CSs were achieved both among 
Medicaid beneficiaries and among those privately insured, whereas reductions in the number of primary 
CSs were found almost exclusively among commercially insured mothers, where the existing rates are the 
highest. 
94 About 65 to 88% of women are able to deliver vaginally after having had a caesarean section delivery 
(Flamm et al. 1988). Many studies (Flamm et al. 1994, Cowan et al. 1994) reported that the risk of the 
rupture of the previous uterine incision and of a potential catastrophic occurrence for both the mother and 
the baby was quite uncommon in a trial of labour in a woman with a single prior low-transverse caesarean 
section delivery. There have also been controversial reports that warn of maternal and neonatal 
complications, such as those associated with prior caesarean section delivery. McMahon et al. (1996) 
conceded that the rate of maternal morbidity associated with a previous caesarean section delivery is higher 
than the rate of maternal morbidity associated with a repeat caesarean section delivery (Sachs et al. 1999).  
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guidelines, regulations have been implemented by various authorities at both the national 
and state level. In October 1988, the American College of Obstetricians and Gynaecologists 
(ACOG) issued a physician practice guideline stating that a prior caesarean section would 
no longer justify the performance of a repeat caesarean section.  
In 1990, the target caesarean section ratios were proclaimed in the objectives of 
“Healthy People 2000.” To prevent disease and promote better health, the US Department 
of Health and Human Services developed a set of objectives, contained in the “Healthy 
People 2000” programme, as part of the decade-long effort in 1990. The objectives were set 
to reduce the overall caesarean section birth rate to below 15 per 100 deliveries by the year 
2000 (Healthy People 2000)95, and to reduce the financial burden and risks of maternal 
death as well as the morbidity and perinatal morbidity associated with caesarean section 
delivery.  
Recently, ACOG released a document to help hospitals and physicians review and 
reduce their caesarean section birth rates where appropriate, compared with evidence-based 
goals set by an expert working group addressing the Health People 2010 objectives of the 
US Department of Health and Human Services (ACOG News Release, August 9, 2000).  
ACOG’s efforts to reduce the number of repeat caesarean sections in the US have been 
going on for more than a decade. In October 1988, ACOG issued a physician practice 
guideline stating that a prior caesarean section no longer justifies the performance of a 
repeat caesarean section. ACOG also recommends that the cervix should be dilated by 4 
centimetres or more before a diagnosis of failure to progress is made.96  
 
As the choice of caesarean section delivery is a sensitive concern for payers, the latter 
have made various attempts to curb the caesarean section ratios. Historically, the financial 
incentives to opt for a caesarean section delivery have been greatest among those who have 
a private insurance plan, and less among those who have a public health insurance plan. 
Needless to say, those who have no insurance plan had the least financial incentives to opt 
for a caesarean section delivery. Patients with private or HMO insurance plans are nearly 
                                                 
95 The primary caesarean section delivery rate and the repeat delivery rate targets were 12 and 65 per 100 
deliveries, respectively. According to Wolfe (1994), the optimum national caesarean section ratio should be 
nearer 12%. 
96 According to Gilford and Morton, out of one million caesarean section deliveries performed in the US each 
year, about 294,000 are done because of lack of progress in labour. 
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seven times more likely to have a repeat caesarean section delivery as an elective procedure 
compared to those with Medicaid or self-pay plans (Hanley et al. 1996). As such, women 
with Medicaid coverage are more likely to undergo a vaginal delivery than women with 
private insurance plans are (Wagner and Matts 1999).  
 
To moderate the differentials between the physician fees for caesarean section and 
vaginal births, many private insurers and state Medicaid plans have attempted to equalise 
the physician fees for caesarean section and vaginal deliveries. Gruber et al. (1999) suggest 
that reducing the physician’s fee for caesarean section delivery can cause reductions in the 
caesarean section ratio. They argue that the fee effect is sufficiently large to explain over 
one-half, and up to three-quarters, of the differentials between the caesarean section 
delivery rates of private and public health insurance coverage. There are evidences (Darby 
1992, Keeler and Fok 1996)97, however, that lowering the fee differentials will have only a 
marginal effect in terms of reducing the caesarean section ratios. Under Medicare, the 1993 
RBRVS (Resource-based Relative-Value Scale) scheme compensated vaginal deliveries 
more than it did caesarean section deliveries based on the physicians’ workloads by the 
product of time. The scheme put the vaginal delivery cost at a slightly higher level than that 
of caesarean section delivery (Keeler and Brodie 1993).  
Due to lower reimbursements, many private practitioners refuse to perform caesarean 
section procedures on women with public health insurance policies or with no insurance 
policies.98 As a result, those women who are unable to receive care from private 
practitioners often end up going to public hospitals. 
For HMOs, caesarean section ratios are similar to the rates of private insurance plans, 
which usually pay obstetricians on a fee-for-service basis. In HMOs where the salaries of 
obstetricians are fixed, no particular financial incentives for caesarean section delivery are 
                                                 
97 Keeler and Fok (1996) studied the impact of an insurance reform under California Blue Cross that 
equalised the physician’s fees for vaginal and caesarean section delivery, causing a relative 21% decline in 
the physicians’ fee for caesarean section delivery. They found only a modest 0.7% reduction in the 
caesarean section ratios, perhaps because the physician’s fee is only a small fraction of the total cost of 
caesarean section delivery. A large part of the cost comes from the two extra hospital days that caesarean 
section delivery requires on average. Gruber et al. (1999) argue that the findings of Keeler and Fok do not 
necessarily have predictive power on the effects of Medicaid fee changes because there has been a positive 
relationship between physician’s fees and treatment intensity, as underpinned by Yip (1998).   
98 Medicaid reimbursements vary widely from state to state, and are typically only half or less than half of the 
fees paid by commercial insurers (Alan Guttmacher Institute 1987). 
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presented, and thus, the caesarean section ratio is much lower. Some studies (Weinstein and 
Trussell 1998, Oleske et al. 1998) also support the view that the expansion of managed-care 
organisations in the healthcare industry has no meaningful impact on the caesarean section 
ratios.  
 
In summary, the efforts to curb the rate of caesarean section deliveries from the early 
1980s have been persuasive. NIH introduced a national guideline for caesarean section in 
1981, which was set to promote vaginal birth after caesarean section. The professional 
community joined the public in 1988 in the campaign for vaginal birth after caesarean 
section. Further forceful action was then taken by the federal government, which set as a 
target the reduction of the nationwide caesarean section ratio to below 15% in the Healthy 
People 2000 project. The actions of third-party payers were also forceful, cutting down the 
physician’s fee for caesarean section delivery, thereby minimizing the fee differences 
between natural delivery and caesarean section delivery. 
 
4.4. The Adoption of caesarean section delivery 
4.4.1. Japan 
In Japan, the caesarean section ratios have been kept at a much lower level compared to 
most other countries, but the number of caesarean section cases is increasing. The rate 
doubled between 1984 and 1999 and rapidly increased from the late 1990s, as shown in 
Figure 4-1. The Ministry of Labour, Health, and Welfare attributes the recent increases of 
the caesarean section ratios to the increase in the mother’s age at the birth of her first 
baby.99 As reported in the media, malpractice litigations often prod obstetricians to choose 
caesarean section delivery. 
                                                 
99 Table F-4-1. Mother’s age at the birth of her first child 
1965 1975 1985 1989 1995 1999 2000 
25.7 35.7 26.7 27.0 27.5 27.9 28.0 
Data sources: Ministry of Health, Labour, and Welfare, Japanese Government 2000 Vital Health Statistics.  
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Figure 4-1. Caesarean section ratios in Japan (% of total birth rates on September 
each year). 
Data sources: Ministry of Health and Welfare. (2008). Survey on health care organisation and the brief 
summary on hospital report.  
 
In the past the obstetricians was very reluctant to choose caesarean section delivery 
mainly because of fee compensation. The obstetricians prefer normal delivery because it is 
not covered by public health insurance plans and are therefore free from outward 
monitoring. Since most private providers try to avoid caesarean section births, women who 
may need a caesarean section birth end up going to public hospitals. This results in lower 
caesarean section birth rates in private hospitals and birth clinics than in public hospitals. 
As depicted in Figure 4-1, caesarean section deliveries have been increasing. The 
following reasons behind the increase have been pinpointed (Asahi Newspaper, 10 July 
2006): 
 The shortage of obstetricians encourages them to choose caesarean section 
delivery to save the time in labour100. The obstetricians have decreased fear of 
malpractice litigation. Clinics and hospitals prefer CS delivery to reduce 
pressure on obstetricians and to reduce the risk of a malpractice suit.  
                                                 
100 Japan Society of Obstetrics and Gynaecology and Japan Association of Obstricians and Gynaecologists 
submitted a petition in November 2005 to the Ministry of Health, Labour and Welfare complainting 
shortage of obstetricians and requiring fee increase for their practices including childbirth. 
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 Increasing malpractice litigation, as much that the cases related to obstetrics 
occupy 10% of total high court cases 
 other factors including increasing maternity age and changing attitudes of 
women towards pain and safety.  
4.4.2. Korea 
The caesarean section ratio in Korea is the highest in the world. At its peak, the rate 
was over four times higher than the WHO guideline. As shown in Figure 4-2, the caesarean 
section ratio in Korea has risen from 6% in 1985 to 13.3% in 1990, and it continued to rise 
to 21.3% in 1995, and then to 43% in 1999. The caesarean section ratios in Korea have 
declined since 1999 mainly due to the public’s efforts to curb the rates by assessing, with 
the assistance of the Health Insurance Review Agency (HIRA), whether the choice of 
caesarean section delivery is justified by their clinical condition. The caesarean section 
ratio of each hospital or clinic is also publicly announced. As such, women can foresee the 
probability of their choosing caesarean section delivery. Hospitals and obstetricians become 
cautious in choosing caesarean section delivery because they know that their practices will 
be inspected by HIRA and that they will be publicly blamed if their rate turns out higher 
than that of the others. 
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Figure 4-2. Caesarean birth rate trends in Korea. (1985-2005) 
Data sources : 1) The National Health Insurance Corporation (2002)  
2) The Ministry of Health and Welfare (2006a), caesarean section delivery rate for the recent  
five years (the data were released on August 28, 2006 upon the request of Hyo-Seok Kim, a 
member of the National Assembly)  
Note: a. The date includes only six months (from July to December). 
b. The date includes only six months (from January to June). 
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The Ministry of Health and Welfare (2006b) came up with the following list of the 
major factors promoting the choice of caesarean section delivery:  
 delayed maternity – the average maternal age at the time of giving birth in 2005 
was 30.1 years old, and those aged above 35 were 12.1% (advanced age at the time 
of giving birth often causes complications, including gestosis and placenta previa; 
as such, caesarean section delivery is often the mode of delivery chosen by 
pregnant women with advanced ages); 
 defensive practice to avoid malpractice litigation; 
 increasing vaginal birth after caesarean section due to the rise in the caesarean 
section ratio for the delivery of the first baby;  
 higher fee for caesarean section delivery than for natural delivery (£311 for 
virginal delivery versus £528 for caesarean section delivery); and 
 misconception regarding caesarean section delivery (caesarean section delivery is 
preferred so that the time of delivery can be chosen to ensure the good fortune of 
the baby, to maintain the shape of the mother’s body after delivery, and to avoid 
pain while giving birth). 
 
Among the aforementioned factors promoting the choice of caesarean section delivery, 
Magnier (2001) pinpointed that the highest caesarean section ratio is fuelled by the belief 
that such delivery is safer, can help one avoid legal conflicts, and makes it possible to 
ensure the good fortune of the baby by selecting the time of its birth.  
Many commentators suggest that the judicial precedent set in malpractice suits, which 
have generally ruled in favour of cases in which caesarean section delivery was carried out 
during childbirth, has been the most significant factor in driving up the number of 
caesarean section deliveries. Consequently, obstetricians often recommend undertaking 
caesarean section delivery even though the risks of childbirth are marginal. In a survey by 
WomenLink, 80% of women who have experienced caesarean section childbirth claimed 
that their obstetricians guided their choices (Yeonhap News, July 8, 2000).101 As 
underscored by the Ministry of Health and Welfare, and as mentioned in an earlier chapter, 
                                                 
101 Of the remaining 20%, 15.6% of the women decided by themselves to have a caesarean section delivery, 
while the other 4.6% were persuaded by family members to do so.  
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the belief that one’s destiny is predetermined by the “Four Pillars” (the year, month, day, 
and hour of one’s birth) motivates mothers to deliver a child through caesarean section. 
When mothers are recommended or have decided to undergo caesarean section delivery, it 
is common for them to schedule the date and time of their childbirth in consultation with a 
fortune teller.   
 
The caesarean section ratios do not significantly differ according to the type of 
organisation, with only slightly higher rates in teaching hospitals. The rates were widely 
varied among health providers in the year 2000, ranging from 11.8% at the lowest to 84.8% 
at the highest (National Health Insurance Cooperation 2000). Even among the teaching 
hospitals, the rates were varied, ranging from 24.2% to 61.2%. Kim et al. (1992) found that 
education and household income levels were major predictors of the variance of caesarean 
section ratios. They disclosed that the rates were higher among those who had higher 
education and higher income.  
 
Caesarean section delivery rates escalated until 1999, and then began to decline from 
2000. Ko et al. (2001) proved that the disclosure of the nationwide caesarean section ratio 
by the National Health Insurance Corporation was the primary factor that led to the 
reduction of the caesarean section ratio after 2000. In 2000, the caesarean section delivery 
rate dropped by 38.6%; after 2000, it decreased by 10.2%.  
As shown in Table 4-6, the caesarean section delivery rates were higher in the groups 
that used the DRG scheme than in those that used the FFS scheme. The caesarean section 
ratio in the DRG group was about 4% higher than that in the FFS group. This indicates that 
a change in the reimbursement policy from the FFS to the DRG scheme would promote 
caesarean section deliveries (Lee and Yu 1999). The influence of the DRG system on the 
caesarean section ratio increase is limited, whereas the compensation from an insurance 
programme is at the discretion of the health providers (whether they would get their 
remuneration based on FFS or DRG). As of August 2006, 19.2% of the total of 1,862 
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obstetrician clinics got their compensation based on the DRG system (Health Insurance 
Review Aagency-HIRA, 2006)102.  
 
Table 4-6. Differences between the caesarean section ratios of the DRG and FFS 
groups 
 
1999 2000 
Increase Total 
Births 
Caesarean 
Births 
Caesarean 
Rate 
Total 
Births 
Caesarean 
Births 
Caesarean 
Rate 
DRG 55,334   25,048    45.3 24,937   9,727    39.0   -6.3 
FFS 44,684   18,473    41.3 13,144   4,582    34.9   -6.5 
Data sources: Ko et al. (2000) 
Note: The data are limited to the cases obtained from the clinics and hospitals that have over 100 cases where 
the compensation was claimed based on the DRG scheme. 
 
4.4.3. UK 
The largest and most comprehensive study on caesarean section childbirths conducted 
in the UK has revealed that one in five deliveries is a caesarean section delivery (Thomas 
and Paranjothy, 2001). According to the study, the caesarean section ratios in England and 
Wales increased from 1% in 1946 to 2.6% in 1958, then to 4.8% in 1970. The rate doubled 
in the 1970s, increasing from 4% in 1970 to 9% in 1980. It then slowed down in the 1980s 
and reached 12% in 1990. However, once again, the rates rose to almost double during the 
1990s.  
At present, more than half of the caesarean section births in the UK are emergency 
operations. In 2003-04, about 9.6% of the deliveries in England were elective CSs, and 
13.1 % were emergency CSs (Department of Health, NHS Maternity Statistics: 2003-04). 
As estimated, the cases in which the mother or foetus, or both, were in danger of dying 
unless surgical intervention was performed accounted for about 5.8 to 8.5% of all births in 
England in 1993 (Francome et al. 1993). In line with the worldwide consensus, the 
professional community in the UK believes that a 10% caesarean section ratio, or less, is an 
adequate measure (Savage 2000).  
                                                 
102 The data was calculated from the list joined in DRG based payment system released by Health Insurance 
Review & Assessment Service (HIRA) on website: 
http://www.hira.or.kr/common/dummy.jsp?pgmid=HIRAF010105000000 accessed 7 October 2006. 
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Figure 4-3. Caesarean section delivery ratios (1980-2005/06) 
 
Data Sources: DoH (2005). NHS Maternity Statistics, England: 2003-2004 
 
As seen in Figure 4-3, the caesarean section ratio in the UK continues to increase. 
There have been much controversy, however, surrounding UK’s unreasonably high 
caesarean section ratio, and several factors contributing to such have been pinpointed. 
First, majority of the obstetricians in England and Wales are now prepared to agree 
to maternal requests for caesarean section delivery in the absence of the obstetric necessity 
for such (Cotzias et al. 2001).103 Some of the most common reasons offered for this are 
patient pressure (89%), fear of litigation (35%), and the practice of evidence-based 
medicine (32%). Such change in the obstetricians’ attitude towards maternal requests for 
caesarean section delivery is a significant shift. In the 1980s, if the obstetricians were asked 
how they would respond to a maternal request for caesarean section delivery in an 
uncomplicated pregnancy, the majority indicated that they would refuse (Johnson et al. 
1986, Hall 1987). The Changing Childbirth policy in the UK recommends giving way to 
maternal choice in obstetric decision-making (DoH 1993). The Changing Childbirth policy 
apparently changed the people’s attitudes and encouraged the acceptance of woman-centred 
care (Guardian, September 27, 2000). Although the British government tries to control 
unnecessary choice of caesarean section delivery by steering through NICE guidelines 
                                                 
103 In the research, 69% of the respondent obstetricians responded that they would agree to an elective pre-
labour caesarean section delivery maternal request  
.  
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issued in 2004 that maternal request alone can not be the indication, it has not yet been 
successful to control it.  
 
Second, the shortage of midwives has forced women to go to hospitals for delivery, and 
consequently contributed to increasing the number of caesarean section deliveries in the 
UK As the Royal College of Midwives argues, the shortage of midwives is also a major 
factor in spurring hospital births, and therefore, in increasing caesarean section deliveries. 
Figure 4-4 shows the decreasing proportion of midwives involved in overall deliveries that 
dropped from 75.6% in 1989-90 to 66.1% in 2003-04 periods.  
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Figure 4-4. Persons conducting deliveries 
Data Sources: DoH (2005). NHS Maternity Statistics, England: 2003-2004 
 
4.4.4. US 
The rate of caesarean section deliveries in the US has rapidly increased since 1965, 
peaking in 1988. In the subsequent years, the rate levelled off until 1996. According to 
Young (1997), few insurance companies, hospitals, and physicians were interested in 
reducing the caesarean section ratio, and many refused to admit that unnecessary caesarean 
section childbirths were being performed throughout the 1980s. Since recently, there are 
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signs that the caesarean section ratio is again increasing, though still low. Nearly 7% of the 
primary CSs and 40% of the repeat CSs in the US in 1998 may have been unnecessarily 
performed (Koroukian et al. 1998).  
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Figure 4-5. Total, primary CS, and VBAC ratios in the United States, 1970–9. 
 
Data source:  1) CDC (2005) ) Trend in caesarean rates for first births and repeat caesarean rates                          
for low-risk women: United State, 1990-2003. National Vital Statistics Reports, Vol. 54(4), 
p.82. 
2) National Center for Health Statistics (NCHS). (2001). National Vital Statistics Reports. 
Vol. 49(1) 17 April  
3) (CDC) (2005) Trend in caesarean rates for first births and repeat caesarean rates for low-
risk women: United State, 1990-2003. National Vital Statistics Reports, Vol. 54(4), p.82. 
Note: 1) Total rate refers to the percentage of all live births by caesarean section delivery. 
      2) Primary rate refers to the number of primary caesarean section deliveries per 100 live births to 
women who have not had a previous caesarean section delivery. 
      3) VBAC refers to the number of vaginal births after a previous caesarean section delivery per 100  
         live births to women with a previous caesarean section delivery. 
 
Figure 4-5 shows the most dramatic change in 1989, the first full year after the ACOG 
guidelines were introduced. In 1989, the vaginal birth after caesarean section (VBAC) ratio 
increased remarkably while the rate of primary caesarean section births decreased. Since 
then, VBAC ratio continued to increase until 1996. Santerre (1996) argues that the ACOG 
guidelines may have influenced the practice of VBAC in the US. The decrease in the 
caesarean section ratio starting from 1989 has been attributed to an increase in VBAC. As 
the ratios of caesarean section deliveries and VBAC are inversely related to each other, the 
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overall caesarean section ratio has been falling as VBAC ratio has been increasing. The US 
Department of Health and Human Services attributes the increase in the total caesarean 
section ratio since 1996 to the rise in the number of primary caesarean section deliveries 
and the decline in VBAC rate (DHHS, HHS News, 8 August 2000).104 The participation of 
women in VBAC is associated with various socio-economic factors. According to King and 
Lahiri (1994), the likelihood of receiving a VBAC increases with maternal education and 
the level of care provided by the hospital.105 The probability is higher among women who 
are participating in HMOs than among women who are receiving care at public hospitals. 
The vaginal birth after caesarean section rate varies according to the source of payment. 
According to Oleske et al. (1998), Medicaid appeared to have a significantly higher rate of 
vaginal birth after caesarean section, while the total and primary caesarean section delivery 
rates were much lower than those with Medicaid and private managed-care plans. 
Customers and customer groups such as the Public Citizen Health Research Group were the 
main bodies who publicly criticised the high rate of caesarean section births. 
There are also various changes in childbirth practices that have happened 
simultaneously with technological advances in obstetrics. The percentage of mothers 
receiving electronic foetal monitoring, ultrasound, and induction and labour stimulation has 
increased. The practice whose frequency has increased the most, nearly doubling, was 
induction. For those with induced deliveries, the increase in the number of caesarean 
section deliveries was greater than that for those with natural births due to failure to 
progress (Seyb et al. 1999, Sheldon et al. 1996, Maslow and Sweeny 2000, Alexander et al. 
                                                 
104 The total caesarean section ratio has gone up 4% from 1998 to 1999, and the rise is primarily attributed to 
the increase in the number of primary caesarean section deliveries. Another factor that contributed to the 
rise in the total caesarean section ratio was the marked decline in the rate of VBAC, which fell to 11% in 
1999 and rose to 17% in 1996. Recent research has shown that the diverging trends in the caesarean 
section and VBAC rates after 1996 may be the result of the increased risk of experiencing major maternal 
morbidity related to attempting VBAC (McMahon et al. 1996). The major increase in maternal morbidity 
in the VBAC group is mainly attributed to the infectious complications and injury to the pelvic organs 
(Boe et al. 1998, Judith et al. 2001). The main risk of VBAC is uterine rupture, which happens in about 
1% of the cases (Flamm et al. 1994). In the case of uterus rupture, there can be catastrophic medical and 
medico-legal consequences (Scott 1991). Flamm (1998) states that the rising rates in repeat caesarean 
section deliveries in the US may be associated with the controversy surrounding the recent VBAC consent. 
105 The odds are higher in hospitals with intensive-care facilities than in those with intermediate neonatal-care 
facilities. 
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2001, Sims et al. 2001).106 Especially, labour induction is highly likely to result in repeat 
caesarean section deliveries with women who have not previously experienced a vaginal 
delivery (McNally and Turner 1999, Yeast et al. 1999).107 
Figure 4-5 also shows the rapid y decrease in VBAC since 1998 that has been fallen 
from 28.3% at the peak in 1996 to 10.6% in 2003. Pinette and colleagues (2004) showed 
that the drastic drop could be attributed to the revised guideline of ACOG on VBAC in 
October 1998 and July 1999. The revised guideline requires the presence of a surgeon, 
anaesthesiologist and operating personnel through out the labour for patients with prior 
caesarean section. According to them, the critical reasons for the decline in VBAC were 
patients refusing VBAC after counselling and inability to meet ACOG guidelines.  
 
4.5. Conclusion 
 
There are big variations in caesarean section ratios among those selected countries, 
with Korea at the highest. These can be attributed to the following differences between 
countries: 
 payment scheme for covering birth costs 
 Judicial rulings on labour procedures 
 cultural influences  
 
Figure 4-6 shows the change of caesarean section delivery ratio by countries and times. 
The ratio in Korea was lower than other three countries until the end of 1980s, which may 
be related with income. The most significant factor for the difference between Japan and 
Korea is insurance coverage. In the US, nation wide campaigns through “Health People” 
project were successful to keep control the adoption of caesarean section delivery by 
mainly promoting vaginal births after caesarean section delivery. In the UK, national policy 
to respect consumer’s right that esteem maternal request in choosing caesarean birth has 
                                                 
106 According to Alexander et al., the independent risk factors in the induced group for caesarean section 
delivery include nulliparity, undilated cervix prior to labour, and epidural analgesia. According to Maslow 
and Sweeny, elective induction placed nulloparas at a twofold higher risk for caesarean section delivery. 
107 In the research conducted by McNally and Turner, the repeat caesarean section ratio after the trial of 
induction course was 37.3%, while the caesarean section delivery rate was only 3.9% among women who 
had previously delivered vaginally. 
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been a significant influence for continuous increases since the early 1990s. The National 
Sentinel Caesarean Section Audit Report (RCOG, 2001) found that 3 % of women 
requested elective caesarean section delivery in the absence of any medical indications and 
these requests were agreed to in about 50 % of cases.  
0
5
10
15
20
25
30
35
40
45
50
Korea US UK Japan
Korea 6 13.3 21.3 36.1 43 38.6 40.5 39.3 38.2 37.7 37.5
US 5.5 10.4 16.5 22.7 24.1 24.4 24.7 22.8 22.7 22.6 22.3 21.8 21.2 20.8 20.7 20.8 21.2 22 22.9 24.4 26.1 27.5
UK 9 10.4 11.3 12.4 12.9 13.8 15 15.5 16.3 17 18.2 19.1 20.6 21.5 22 22 22.7 22.9 23.5
Japan 7.3 8.4 10 11.2 12.6 14.7 15.2 17.4
70 75 80 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05
Figure 4-6. Changes in caesarean section ratios by countries and times (1970-2005) 
 
In 1999, when caesarean section ratio was at the peak in Korea, it was about three 
times higher that in Japan as summarized in Table 4-7.  
 
Table 4-7. Comparison of caesarean section delivery ratio to all births in 4 countries, 
1999 
Nation 1999 2002 
Japan 14.7 15.2 
Korea 43 39.3 
UK(England only) 20.4  22. 
US 22 26.1 
 
In Japan, health insurance programmes exclude normal births from their coverage plans. 
Vaginal deliveries are not classified as medical interventions, but caesarean section 
deliveries are covered. As a consequence, fees for normal deliveries are much higher than 
caesarean deliveries. That obstetricians do not prefer caesarean deliveries is confirmed by 
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the variations in caesarean delivery ratios, which are higher in public hospitals than in 
private practice. The unit cost for normal deliveries (£1,500~£2,500) is three times higher 
than costs for caesarean deliveries (£470~£820). Natural births are however preferred by 
obstetricians, as they are not monitored by the insurers. Accordingly, the much lower levels 
of caesarean section deliveries in Japan is largely a result of market forces, which pursue 
the private benefits of providers. In recent years, however, the caesarean section delivery 
ratio has rapidly increased due to the shortage of obstetrician and fears of malpractice 
litigation as weall changes in the attitudes of women giving birth to pain  
In Korea, three major reasons led to it having the world’s highest caesarean ratio. First, 
financial incentives provided higher compensation to obstetricians to encourage the use of 
caesarean deliveries. Second, the courts, which ruled against obstetricians for not 
performing caesarean section, have motivated obstetricians to perform caesarean section. 
Third, as caesarean section makes it possible to induce labour, many women prefer to have 
a caesarean section delivery in the hope of ensuring good fortune for their new born baby. 
Cultural beliefs stemmed from ‘the Book of Changes’ that is one of three major bibles of 
Confucianism guiding the way to avoid bad luck and encourage good luck require babies to 
be born at astrologically propitious dates and times. According the ‘Book of Changes,’ the 
fate of an individual is primarily determined by the time, date, month, and year of his/her 
birth. 
Obstetricians also recommend caesarean deliveries to avoid malpractice litigations. 
According to an opinion poll by Consumer’s Right, 59.9 % of obstetricians recommend 
caesarean delivery to avoid malpractice litigation (Women Newspaper, 24 Dec. 2004). To 
encourage normal births, social insurance programmes began to fully cover costs of normal 
births without any co-payments by the mother since 1 Jan. 2005. Kim and Ko (2002) found 
that the level of caesarean section delivery ratio is consistent by obstetricians and times. 
They assumed that the choice is not much related with clinical condition but about the habit 
of obstetricians. 
In the UK, the caesarean section delivery ratio has continued to increase. As a result, 
public concern has prompted policy makers and healthcare professionals to address this 
increasing trend. The most dramatic changes in caesarean section ratios have been 
attributed to the increase in the proportion of elective caesarean section deliveries 
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performed during labour at the woman’s request (MacKenzie, 1999)108. A survey 
(Paterson-Brown et al, 1998), identified that 31% of 85 London based female obstetricians 
with an uncomplicated singleton pregnancy at term would choose an elective caesarean 
section for themselves. This represents a changing view of women on choosing delivery 
methods109. It also means that the concept of a prophylactic caesarean section is becoming 
accepted since almost a third of female obstetricians would choose it for themselves. 
Another survey (Van Roosmalen, 1999) in the Netherlands found that only 8 out of 567 
obstetricians (1.4%) would opt for caesarean section in an uncomplicated singleton 
pregnancy, indicated a big difference110.  
In the US, the caesarean birth ratio was among the highest in the world by the mid 
1990s. The ratio varied according to the source of payers. Efforts to reduce the caesarean 
section ratio were instigated by the US government and the professional bodies. The NIH 
Consensus Development Programme formally commenced an initiative to reduce caesarean 
ratio in 1980. In tandem with the NIH programme, ACOG issued guidelines that 
recommend reducing primary caesarean and prompts vaginal births after caesarean. 
Especially, the ACOG guideline proclaimed in 1988 contributed to increasing VBAC ratios 
and thereby reduced caesarean section ratios until the VBAC ratio relapsed its control in 
1996. Consequent ACOG guidelines issued 1998 and 1999 hastened the decrease of VBAC 
because it was difficult to meet the guidelines, leading to increased CS ratios. 
                                                 
108 According to the MacKenzie, of 911 caesarean births performed during labour in 1976 and 1986 none 
were carried out at the woman’s request while 6 % were done in 1996.  
109 80 % of these doctors indicated fear of perineal damage as their main reason. Though a relatively lower 
proportion of Irish obstetricians compared to London based study, a consistent trend towards preferring 
caesarean birth if the obstetrician was female or younger (Gurgan et al., 2001). 
110 Mascarenhas and colleagues (1994) argued that the difference between caesarean section rates in Britain 
and the Netherlands is due that women's choice is denied in the Netherlands because the midwife decides 
when and to whom to refer the woman when problems arise, whereas in Britain women can opt for an 
elective caesarean section after discussion with their obstetrician. 
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Chapter 5: Haematopoietic-Stem-Cell Transplantation 
5.1 Introduction  
Haematopoietic-stem-cell transplantations refer to all types of high-dose myeloablatice 
therapy and progenitor-cell transplants (HDT/PCT), including and umbilical-stem-cell 
transplants (or cord blood transplants). Being applied in place of conventional 
chemotherapy (CC), HSCTs are rapidly developing as treatment options for patients who 
have soft-tissue cancer as well as haematopoietic and immunological disorders. During the 
past three decades, HSCT has evolved from an experimental treatment for a small group of 
diseases to a standard procedure for a wide range of blood and haematopoietic disorders 
and solid tumours. With an increasing understanding of the immune system, supportive 
care, and new pharmacologic agents, bone marrow transplants have now become a first-line 
treatment option for some haematopoietic disorders, and are currently being accepted as an 
established treatment option.  
HSCTs are costly procedures, and most of the patients who are undergoing these 
procedures remain pancytopenic for three to four weeks, which may result in serious 
morbidity or even mortality (Hillner et al. 1992, Gulati and Bennett 1992, Dufoir et al. 
1992, Welch and Larson 1989, Nemunaitis et al. 1991).  
 
There are two different types of BMTs: autologous and allogeneic transplant 
(Lennard and Jackson 2000). Allogeneic transplants are for the following: 
 severe aplastic anaemia; 
 chronic myeloid leukaemia; 
 acute myeloid leukaemia in first complete remission (patient < 50 years old); 
 myelodysplasia (patient < 50 years old); 
 acute lymphoblastic leukaemia in first complete remission (certain subtypes); 
 severe congenital immunodeficiency; 
 acute myeloid leukaemia and acute lymphoblastic leukaemia in second complete 
remission; and 
 thalassaemia. 
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Autologous transplants, on the other hand, are for the following: 
 acute lymphoblastic leukaemia (certain subtypes); 
 Hodgkin’s disease in second complete remission; 
 non-Hodgkin’s lymphoma in second complete remission;  
 multiple myeloma; and 
 solid tumours such as ovarian cancer. 
 
In autologous transplants, the recipient becomes his or her own donor. The bone 
marrow is extracted from the patient prior to the transplant, and may be “purged” to remove 
lingering malignant materials. In allogeneic transplants111, a donor provides the stem cells 
for transplantation to a recipient. The new bone marrow infused into the patient must match 
the HLA of the patient’s own marrow as closely as possible. Allogeneic transplants are 
much more complex than autologous transplants, with more potential risk. For allogeneic 
BMTs, the patients must wait until a suitable donor is found; this is very time-consuming 
and often frustrating.112 Recently, cord blood transplants have also become available. A 
cord blood transplant is performed when it is not suitable for the patient to undertake an 
autologous or allogeneic BMT. As cord blood can be extracted through a relatively simple 
and quick procedure after birth, it involves a much lower risk of the baby’s acquiring the 
graft-versus-host disease (GVHD).  
In terms of both the length of hospital stay and the average hospital charges, stem cell 
transplants are more advantageous than conventional BMTs.113 Proponents of autologous 
peripheral-stem-cell transplants provide a more rapid haematopoietic reconstitution of the 
bone marrow after high-dose chemotherapy and/or radiotherapy regimens are conducted to 
treat various malignancies (OTA 1995).    
 
                                                 
111 A case in which the donor is the identical twin of the patient is called syngeneic BMT. 
112 A major limitation to the use of hematopoietic-stem-cell-transplant therapy, however, is the limited 
availability of suitable donors. About 30% of patients who may benefit from transplantation therapy are 
still unable to find a 0-1 HLA antigen disparate donor, with a disproportionately larger number of 
unsuccessful searches in patients who are racial and ethnic minorities (Wagner 2002). 
113 According to the Ohio Bone Marrow Transplantation Consortium, the average length of hospital stay is 29 
days, and the average hospital charges are US$94,220, in autologous peripheral-stem-cell transplantation, 
while the average length of hospital stay is 38 days, and the average hospital charges are US$127,692, in 
autologous bone marrow transplantation (OTA 1995).  
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The incidence of diseases that can be indications for HSCT varies according to age, sex, 
and region. As such, it may be difficult to compare whether a country has a higher HSCT 
rate than others. The incidence rates of most diseases are slightly higher in males than in 
females. The incidence rates of non-Hodgkin’s lymphoma (NHL) widely vary across the 
globe and also between males and females.  
Overall, the incidence rate of the disease is highest in the white group in the US, while 
the rate in Hiroshima, Japan, which was presumed to be high due to its atomic-bomb 
exposure during the Second World War, is much lower. Between the two BMT procedures, 
autologous BMT is more common. Some 5,000 autologous BMTs are performed each year 
in the US, outpacing allogeneic BMTs. In the UK, 61% of the total 2,738 cases in 2005 
were autografts, and 39% were allografts (British Society of Dlood and Bone Marrow 
Transplantation, 2008). Table 5-1 shows the rate of adoption of allogeneic BMT in some 
countries (Silberman et al. 1994). The circumstances of the adoption of allogeneic BMTs in 
the UK and in the US are quite similar. Access to allogeneic HSCTs varies from nation to 
nation; there was a twofold difference in rates between the country with the highest rate 
(France, 13.4 pmp) and that with the lowest rate (Germany, 5.6 pmp) among the 10 
countries selected. 
 
Table 5-1. Annual rates of allogeneic BMT (in pmp, 1989-1991) 
Country Transplants 
Transplants  
per Year (pmp) 
France 1,708 13.4 
Sweden  168  9.0 
Canada  576         8.9 
Australia  369         8.8 
UK 1,000         8.2 
US 4,873         8.1 
New Zealand   59         7.4 
Netherlands  232         6.6 
Germany  757         5.6 
Data Sources: Silberman et al. (1994) 
 
As shown in Table 5-2, HSCTs are being applied to a wide range of diseases to which 
these have not been indications in the past. The number of allogeneic transplants conducted 
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around the world is slightly higher than that of autologous transplants.114 Allogeneic 
transplants prevail over autologous transplants for leukaemia patients, while the reverse is 
true in the case of Hodgkin’s disease, non-Hodgkin’s lymphoma, plasma cell disorder, and 
breast cancer patients.  
Table 5-2. Distribution of diseases and HSCTs in the CIBMTR database (2006) 
Disease Allogeneic Transplants 
Autologous 
Transplants 
Acute lymphoblastic leukaemia 21,115 1,419 
Acute myelogenous leukaemia 31,736   6,507 
Chronic myelogenous leukaemia 23,915    694 
Chronic lymphoblastic leukaemia  1,949    561 
Hodgkin’s disease   957 12,247 
Non-Hodgkin’s lymphoma 8,063   29,752 
Plasma cell disorders 2,765   23,791 
Breast cancer   162   23,045 
Neuroblastoma   169    2,669 
Ovarian cancer    21    1,666 
Lung cancer    9      58 
Sarcoma (soft-tissue, bone, and others)   54     221 
Ewing sarcoma   59     798 
Wilm tumour  6     716 
Myelodysplastic syndromes 9,002     247 
Other types of leukaemia 1,414     266 
Modulloblastoma 4     138 
Germ cell tumour 7     535 
Brain tumours 5     517 
Testicular cancer 9    1,026 
Other malignancies 493     789 
Autoimmune diseases 48     307 
Severe aplitic anaemia 8,226 - 
Inherited erythrocyte abnormalities 4,361 - 
SCID and other immunodeficiencies 3,034 - 
Inherited metabolism disorders 1,516 - 
Histiocytic disorders 522 - 
Other non-malignancies 327 - 
Total 119,993 109,140 
Data sources: CIBMTR Progress Report, January-December 2006  
Note: The data are aggregated, as submitted by IBMTR centres worldwide.  
 
                                                 
114 IBMTR (Centre for International Blood and Marrow Transplant Research) is composed of a network of 
more than 400 transplant centres in 47 countries worldwide. CIBMTR estimates that its database includes 
about 65% of all the allogeneic HSCTs done in North and South America, about 30% of all the allogeneic 
transplants done elsewhere, and about 60% of all the autologous HSCTs done in North and South America. 
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To facilitate BMTs, bone marrow donor registries have been established in most 
countries, and they cooperate to match patients with donors on an international level. Bone 
Marrow Donors Worldwide (BMDW) started in 1988 as an initiative of the 
Immunobiology Working Party of the European Group for Blood and Bone Marrow 
Transplantation (EBMT). Among the 3,858 allogeneic BMTs carried out in the EBMT 
member-countries in 1995, 20% (764 cases) were performed with volunteer bone marrow 
donors (Gratwohl et al. 1996).115 In February 1989, the first edition was distributed, which 
contained the donor files of eight registries, totalling 155,000 volunteer bone marrow 
donors.116 In December 1999, 54 registries from 35 countries participated in BMDW. The 
donors registered in BMDW numbered over six million. With nearly three million 
registered donors, the National Marrow Donor Program (NMDP) of the US presently has 
the largest bone marrow donor pool among the registries in BMDW.  
 
5.2. Micro Factor Evaluation 
5.2.1. Economic Factors 
HSCT is selected when there is no other suitable alternative, and is therefore regarded 
as a last resort for the patients. It often leads to serious complications, however, and 
sometimes even death, and entails a high financial burden. Accordingly, HSCT has been 
performed sparingly or has been subjected to other cost containment measures. Therefore, 
its use requires a careful consideration of its potential benefits and harm to the patient and 
to the society as well.  
BMT is one of the most expensive cancer treatments available at present. Johnson et al. 
(1998) found that high-dose chemotherapy combined with peripheral-blood-stem-cell 
transplantation (PBSCT) was one to two times more costly than conventional 
                                                 
115 To make transplants available to a greater number of eligible patients, registries of volunteer bone marrow 
donors have been developed, which allows stem cell harvest from unrelated but matched donors. There are 
now over six million donors registered on national donor panels worldwide (Lennard and Jackson 2000).  
116 The pioneer registries were: 
- Anthony Nolan Research Centre (United Kingdom); 
- France Greffe de Moelle (France); 
- National Marrow Donor Program (USA); 
- Europdonor Foundation (Netherlands); 
- German Registry of Bone Marrow Donors, Ulm (Germany); 
- Italian Bone Marrow Donors (Austria); and 
- Marrow Donor Program Belgium (Belgium).  
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chemotherapy in the treatment of acute leukaemia. According to their research, the use of 
BMT was found to cost approximately 1~1.7 times more than PBSCT. 
Increasingly, autologous PBSCTs are preferred. Expecting advantages over BMT117, 
physicians perform PBSCT for their patients under certain conditions.118 The advent of the 
management of chemotherapy and transplants reduces the costs associated with autologous 
stem cell transplantation. Intensive high-dose chemotherapy supported by autologous stem 
cell treatment has become a common approach for NHL (Woronoff-Lemsi et al. 1997). 
According to a study conducted by Meisenberg et al. (1998)119, high-dose chemotherapy 
combined with autologous stem cell rescue reduces the costs significantly, as the technique 
is increasingly being delivered in outpatient settings.   
Compared with BMT, the length of stay post-reinfusion was significantly shorter in 
patients receiving PBSCT (Redaelli et al. 2004). As a result, the transplant admission costs 
were also lower in the PBPCT groups than in the BMT-alone group.120 Through 
comprehensive meta-analysis, Johnson et al. (1998) also confirmed that the introduction of 
PBSCT in place of BMT would reduce HDT/PCT. Messori et al. (1999)121 have found that 
BMT (even the second BMT) significantly prolongs survival, and thus has an acceptable 
cost effectiveness profile in comparison with conventional chemotherapy. As Johnson et al. 
(1998) argue, however, it is widely regarded that the cost effectiveness of HDT/PCT has 
yet to be conclusively determined.  
 
In summary, the cost of PBSCT is lower than that of BMT, but the cost of BMT is 
higher than that of CC. Accordingly, PBSCT is regarded as better than BMT and CC, if 
                                                 
117 Woronoff-Lemsi et al. (1997) found that the PBPCT group had relatively better clinical outcomes 
compared with the ABMT group. The average cost of the patients in the ABMT group was also higher 
than that in the PBPCT group.  
118 Primary among these advantages is that PBPCT typically engrafts faster than stem cells from the marrow 
do (Schmitz et al. 1996, Schultze 1997, Gradishar 1999). 
119 The average length of stay was reduced from 17.3 days to 8.2-2.7 days in the three different treatment 
settings. The mean costs were also reduced from US$39.7k to US$36.2-29.4k in the three treatment 
settings.  
120 The transplant admission cost of PBPC was 22,089 Canadian dollars, and 32,289 Canadian dollars in the 
bone marrow group.   
121 The study analysed 167 patients treated with a second BMT, who relapsed after their first allogeneic 
transplant for leukaemia, and 299 patients treated with conventional chemotherapy. Using an incremental 
cost of US$90,000 per patient, the cost effectiveness ratio of the second BMT in comparison with the CC 
was calculated to be US$52,215 discounted per discounted life-year gained. 
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only in terms of cost. The overall cost effectiveness of HDT/PCT, however, has yet to be 
proven.  
Although it is unclear what the best option for patients is, better survival profiles are 
found among those who are undergoing both BMT and PBPCT treatments than among 
those undergoing only chemotherapy. Borgmann and colleagues (1995)122 acknowledged 
that HLA-identical siblings resulted in a statistically greater likelihood of leukaemia-free 
survival than did chemotherapy in children with ALL. Burnett et al. (1998) found that the 
addition of autologous BMT to intensive chemotherapy substantially reduced the risk of 
relapse in all the risk groups, leading to an improvement in their long-term survival. On the 
contrary, in a study conducted by Varterasian et al. (1997), allogeneic BMT registered a 
slightly better survival rate for multiple myeloma than PBSCT did.123  
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Figure 5-1. All ages’ survival rates (five-year) 
Data sources: National Cancer Institute (2000). SEER Cancer Statistics Review 1973-1996. 
 
Some studies suggest conclusive results in terms of the cost effectiveness of BMT or 
PBSCT. Their true efficacy however in terms of prolonging the life of persons afflicted 
                                                 
122 The study, which was carried out in Germany, compared the treatment results for children who underwent 
ABMT with those for children who underwent chemotherapy. 
123 The survival period of the BMT patients was 15 months, ranging from two to 84 months, and 11 months 
for the PBSCT patients, ranging from two to 84 months.     
 
 
116
with the aforementioned diseases remains unproven. What is explicit is only that the 
PBSCT group also has a significantly faster haematopoietic reconstitution.124 
Although no definitive evidence of it has been provided so far, the survival rates of 
patients with haematopoietic disorders have steadily improved, as shown in Figure 5-1.  
 
5.2.2. Clinical Factors 
The improved survival of patients has been bought about by logical and incremental 
drug randomization, better supportive care and the early incorporation of scientific 
advances into national trial (Will 2003) 
The clinical advantages of HSCT are generally assessed in terms of the length of 
survival after the transplant and health-related QoL. Health-related QoL is commonly 
measured by comparing the ante- and post-transplant states. The complications of HSCT, 
such as the graft-versus-host disease (GVHD) and relapse, are also significantly considered 
in evaluating its clinical advantages.  
Most studies that provide evidence of allogeneic or autologous BMT long-term 
survivors show an acceptable quality of life (QoL). Belec (1992) demonstrated that 92% of 
their autologous BMT patients perceived their QoL as acceptable. Molassiotis et al. (1995) 
identified the differences between patients with autologous BMT and those with allogeneic 
BMT. According to them, those patients who underwent an autologous transplant had 
                                                 
124 According to Powles et al. (2000), the PBSCT group showed a median of 17.5 days for neutrophil 
recovery, and 20.5 days for platelet recovery, which were 23 days and 27 days, respectively, in the BMT 
group. According to Mary Horowitz, the head of the International Bone Marrow Transplant Registry 
Statistical Center in Milwaukee, more than 5,000 patients in the US so far have undergone transplants of 
donor peripheral blood stem cells. Based on the results of studies that investigated the results of stem cell 
transplants, it was found that patients who have undergone blood stem cell transplant begin producing 
white blood cells and platelets (white blood cells help blood clot) more quickly than did those who have 
undergone bone marrow transplant. As a result, the number of days in which patients are at risk of 
developing a life-threatening infection or uncontrolled bleeding is reduced. Blood-stem-cell-transplant 
patients also require fewer red-blood-cell and platelet transfusions [Blood & Bone Marrow Transplant 
Newsletter (1999), Issue 46, Vol. 10(2)]. 
A case-controlled analysis performed by Liberti et al. (1994) assessed the effect of the stem cell source on 
the autograft in a group of patients with malignant lymphoma that had been reported to the European Bone 
Marrow Transplant Group (EBMT). According to the results of the study, the progression-free survival 
was similar in the two types of transplants (38.5% PBSCT vs. 36.4% ABMT). The overall relapse and 
progression rate of the PBSCT patients was 51.2%, compared with 50.1% for the ABMT patients. The 
differences were not statistically significant. For both groups, the transplant-related mortality was 6%. It 
was concluded that in these closely matched groups, there is no difference in PFS between patients 
undergoing PBSCT and those undergoing ABMT. However, the patients who had been autografted with 
PBSC had a more rapid engraftment and a lower toxicity. 
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mainly psychological difficulties in their post-transplant life, whereas those patients who 
underwent an allogeneic transplant developed more physical problems.  
There are also controversial results that show the improvement of QoL in autologous 
BMTs as being marginal.125 Moreover, many question whether autologous BMT can lead 
to a superior QoL more than the incumbent chemotherapies can.126  
Although most autologous BMT recipients show improved physical and psychosocial 
functions, research evidence indicates that about a quarter of such patients develop some 
degree of psychosocial morbidity.127 Poorer sexual functioning, correlated with increased 
fatigue and decreased emotional functioning, was also identified (Wingard et al. 1992, 
Baker et al. 1994, Andrykowski et al. 1995, Molassiotis et al. 1995, Watson et al. 1999, 
Winer et al. 1999). The patients in the BMT group were also more prone to infertility than 
those in the CC group (Watson et al. 1999).128    
Based on the meta-analysis of HDT/PCT, the micro-impetus on the dissemination of 
HSCT is summarised as follows: 
 PBSCT has a relative advantage compared to BMT and CC in terms of 
cost; 
 BMT is better than CC in terms of cost; 
 HSCT’s and CC’s cost effectiveness in terms of prolongation of life has yet 
to be proven; and  
 the relative advantage of HSCTs against CC in terms of QoL also has yet 
to be conclusively proven. 
   
                                                 
125 Fannie and Martha (1996) found that there were only slight improvements in the patients’ QoL after 
ABMT. 
126 No significant differences in QoL were found in the improvement between the ABMT and CHOP groups. 
The allogeneic BMT patients reported significantly poorer global QoL compared with that obtained after 
both ABMT and intensive-consolidation chemotherapy (Watson et al. 1999). 
127 Wolcott et al. (1986) found that 25% of the BMT patients in their study had significant emotional distress, 
physical dysfunction, low self-esteem, and less than optimal life satisfaction. However, the passage of 
time since the patients underwent BMT had no correlation to their psychosocial improvement (Molassiotis 
and Morris 1999). 
128 Twenty-seven % of the patients included in their study believed that they became infertile due to the 
treatment. The infertility rates by treatment type were 64% in the allogeneic BMT patients, 51% in the 
ABMT patients, and 10% in the CCT patients.  
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5.2.3. Technical Factors 
A bone marrow transplant is a physically, emotionally, and psychologically taxing 
procedure for both the patient and his or her family. The patient should tolerate debilitating 
pain for several weeks. Some patients find the accompanying emotional and psychological 
stress more problematic than the physical discomfort. The psychological and emotional 
stress stems from several factors. Patients undergoing a transplant can feel isolated. The 
special precautions taken to guard against infection while the immune system is impaired 
can leave a patient feeling detached from the rest of the world, and cut off from normal 
human contact.  
During the recuperation period, the patient feels very sick and weak. Complications 
like infection, bleeding, graft-versus-host disease, or liver disease can develop after a bone 
marrow transplant, which can cause the patient additional discomfort. A patient also feels 
pain, however, that is usually controllable by medication. In addition, mouth sores can 
develop, which can make eating and swallowing uncomfortable. Temporary mental 
confusion sometimes occurs, which can be quite frightening for the patient.  
After being discharged from the hospital, a patient continues his or her recovery for 
two to four months. Patients usually cannot return to full-time work for up to six months 
after the transplant.  
 
5.3. Macro Factor Evaluation 
5.3.1. Japan 
Major events in Japan related to HSCTs are as follows (Kono, 2004): 
 1981: insurance coverage for allogenic BMT 
 1991: JMDP (Japan Marrow Donor Programme) established  
 1994: insurance coverage for PBSCT 
 1998: insurance coverage for CBCT 
 2000: insurance coverage for allogenic PBSCT 
As summarised above, insurance coverage has been also provided from the early stage 
of HSCT adoption and expanded in accordance with the advent of HSCTs.  
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Since the Japanese people regard the atomic bombings during the Second World War 
as a national disaster, the Japanese government shouldered all the medical costs of the 
treatment of physical problems associated with radiation exposure (Section 3, The Special 
Treaty Act for the Victims of the Atomic Bomb of 1994). The Radiation Effects Research 
Foundation (RERF) estimated that 87 of 176 leukaemia deaths among the 50,113 RERF 
Life-Span Study survivors were associated with significant exposure to radiation (Radiation 
Effects Research Foundation , 2007). 
Activities for establishing assistance through legislation for the victims of the atomic 
bomb were begun in 1953 by the city councils of both Hiroshima and Nagasaki. They 
requested support for the disabilities caused by exposure to the bombs. The relief 
movements for the bombing victims began with the Assistance Act for the Bereaved 
Families of Those Who Died in the War of 1952 (.The Research Institute for Radiation 
Biology and Medicine, Hiroshima University, 2001) The Special Treaty Act for the 
Victims of the Atomic Bomb of 1968 provided comprehensive support for the victims, 
including medical care and financial support for livelihood. As the 50th anniversary of the 
bombing nears, the Act was revised in 1994 to increase the funding for the treatment of the 
victims. The Act of 1968 provided comprehensive medical care for patients with leukaemia, 
leukopenia, aplastic anaemia, liver diseases, dermatopathy, dysthyroid lung cancer, and 
cataracts. The Act of 1994 increased funding for medical services, health care, and 
livelihood for the victims.  
 
The Ministry of Health and Welfare organised three research groups to promote BMT 
in 1990. Based on the recommendation of the research group, the Japanese government 
established the Japanese Marrow Donor Programme (JMDP)129 in 1991.  
The main role of JMDP is that of a bone marrow donor bank. It had 306,897 registered 
volunteer bone marrow donors at the end of March 2008 (JMDP, 2008). By that time, 
24,690 patients were registered with JMDP as cumulative total and 2,412 patients were on 
the waiting list. Most patients registered with JMDP, however, have been matched with 
                                                 
129 JMDP has a regional office in each municipality, and carries on an active campaign to recruit volunteer 
bone marrow donors throughout the country. Before JMDP emerged, the Japan Marrow Donor Registry 
Promotion Conference (JMDRPC) was launched in April with 13 registries. It is now composed of 48 
registries across Japan. JMDRPC is mainly involved in recruiting volunteer bone marrow donor and 
advocating patients’ benefits (Japan Marrow Donor Registry Promotion Conference 2001). 
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donors. In 1994, JMDP began to recruit bone marrow donors in collaboration with 100 
public healthcare centres run by the government to provide primary healthcare services to 
the people. The number of volunteer bone marrow donors registered with JMDP has 
rapidly increased since the early 1990s. JMDP has also been actively involved in matching 
the bone marrow donors with the patients at the international level. JMDP keeps 
cooperative relationships with Korea, Taiwan, and the US by supplying these countries 
with bone marrow donors.  
In Japan, health insurance programmes cover BMT, just like other ordinary medical 
treatments. All actual costs incurred for the donor-matching services are compensated from 
the health insurance plan where the patient is enrolled. The insurance also shoulders the 
transportation fees for one visitor during the time the patient is admitted in the hospital for 
a bone marrow donation. The costs reimbursed by the health insurance in 1999 for about 
one month of BMT treatment ranged from £24,000 to £30,000 (National Cancer Centre, 
Japanese government, Cancer Statistics in Japan -1999). The patient’s share in the payment 
of the BMT cost during the first month following transplantation is about £1,530 when the 
patient stays in an ordinary bed.  
Two other policies also support the BMT activities in Japan. First, any donor who 
suffers an accidental injury in the course of a bone marrow donation is to be compensated 
under JMDP’s accidental-insurance policy.130 Second, Japan’s public sector provides an 
official furlough for its employees when taking a leave of absence for bone marrow 
donation.   
 
In summary, the public authorities in Japan have been very supportive of HSCTs due to 
the public consensus that most of the diseases afflicting its people were largely caused by 
the atomic bombings in the cities of Hiroshima and Nagasaki during the Second World War. 
To promote the welfare of the victims and their families, the government introduced 
welfare programmes to provide them with support. Moreover, the country’s health plans 
                                                 
130 The accident insurance policy covers the cost from the time the donor leaves his/her home to the time that 
the donor returns to his/her home. If the donor dies, the insurance company pays ¥100 million. If an 
incident happens to the donor that will require medical treatment, the insurance pays a ¥5,000 
compensation per day for hospital admission for a maximum of 180 days, and also pays ¥3,000 per day 
for the medicines taken from the visiting outpatient dispensary. 
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have covered the cost of BMT at the early stage of its adoption, and JMDP has played an 
active role in promoting bone marrow donation among the people. 
 
5.3.2. Korea 
In Korea, the first successful allogenic BMT was performed in 1981. The first attempt 
to apply BMT for solid tumour was on 1990 that applied for breast cancer patient. 
Insurance coverage commenced in January 1992 for allogenic BMT and extended to 
autologous PBSCT in December 1997 
 
In Korea, there are no specific regulations for BMT. The country’s health insurance 
programmes limit their BMT coverage to the candidates approved by the Assessment 
Committee for HSCT. The guidelines for the assessment of the BMT candidates exclude 
patients who are over 40 years. To be approved, patients aged above 40 must meet the 
conditions below in each group of diseases: 
 AML: in first remission; 
 CML: in the chronic phase; 
 ALL: in first remission (patients below 15 years old can be covered when in 
second complete remission); and 
 aplastic anaemia: patients who have had transfusions less frequently and not 
beyond a year from the time of the diagnosis. 
 
Health insurance in Korea started to cover autologous BMTs and PBPCTs beginning 
December 1, 1997.131 Those patients who meet the following conditions are covered by the 
insurance for BMTs or PBPCTs: 
 malignant lymphoma; 
 ALL (acute lymphoblastic leukaemia): in first remission (in second remission 
for patients below 15 years old); 
 AML (acute myelogenous leukemia ); 
 multiple myeloma;  
                                                 
131 NFMI has so far not covered autologous BMT and PBPCT because these technologies are generally 
regarded as experimental.  
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 breast cancer; and 
 others (cancer patients who can avail of chemotherapy can be candidates if the 
Assessment Committee for BMT approves of them). 
 
The Assessment Committee for BMT approves more than 80% of all the applicants for 
insurance coverage.132 As most physicians selectively apply their patients for insurance 
coverage for HSCT based on the guidelines133, the acceptance rates by the Assessment 
Committee are high. 
 
Charities have been active in supporting the amounts of the treatment interventions that 
patients must pay for themselves. The Korean Heart Foundation134 and the Korea Welfare 
Foundation have been major charitable resources. Community Chest of Korea, a centralised 
charity fund established in 1999, raises about £268 million a year and allocates this amount 
for social-welfare programmes across the country. Since its establishment, the organisation 
has provided financial support amounting to approximately £1.07 million each year for 
children with cancer and haematopoietic diseases. While the Korean Heart Foundation and 
the Korea Welfare Foundation support HSCT costs for patients who have been approved 
for insurance coverage, the Korea Union Fund supports such costs regardless of the 
absence of approval by the insurer. In 1999, about 20% of all the patients who underwent 
HSCTs received financial support from charities. 
To help patients find volunteer bone marrow donors, the Ministry of Health and 
Welfare established the Korean Marrow Donor Programme (KMDP) within the Korea Red 
Cross in 1994.  
                                                 
132 Personal communication with the person in charge of HSCT in the National Health Insurance Cooperation. 
133 For those patients whose physicians recommend applying for health insurance to be able to avail of BMT, 
the hospitals claim to provide insurance benefits for BMT. In some cases, though, the claims are preceded 
by the requirement of the patients, although the physicians in charge believe that the committee will not 
accept the claim. As the hospitals in Korea compete against one another, the physicians generally 
cooperate with the patients and advocate the latter’s requirements.    
134 The Korean Heart Foundation supports patients who are regarded as financially incapable of paying for 
￦BMT or PBSCT. The foundation supports up to 15 million (equivalent to £8,250 as of February 3, 
2000)  of the cost that is not covered by health insurance; the patients should pay for the remaining 
amount themselves. The Foundation also supports the costs of pre-BMT work-up and follow-up after 
￦ ￦transplantation. Since the patient’s share of the cost of BMT or PBSCT ranges from 10 million to 20 
million, the support given by the Korean Heart Foundation covers a large part of the total cost of the 
procedure for each patient. 
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In summary, no legal regulation regarding HSCT exists in Korea. As listed in the 
chronicles, health insurance programme began to cover allogeneic BMTs beginning in 
1992, nine years after the first allogeneic BMT was performed in a human in Korea. The 
insurance plan extended the criteria for allogeneic BMTs to candidates with various 
diseases, as connoted in the chronicles. Beginning in December 1997, insurance coverage 
was given to autologous BMTs. From the beginning to the present, the public health 
insurance programme has had a limit on the coverage based on its own guidelines. Several 
charity programmes provide financial support for the patient’s share, which is largely 
focused on children. KMDP plays key roles in expanding the country’s marrow donor pool. 
 
5.3.3. UK 
In the UK, the first BMT was performed in 1973. A small number of BMTs had been 
carried out in other centres within and around London, but the major BMT activity was 
concentrated in four units in London: Royal Marsden Hospital, Hammersmith Hospital, 
Westminster Hospital and Westminster Children’s Hospital, and Royal Free Hospital.  
Under the NHS market reforms, commissioned bone marrow transplants were 
performed by individual health authorities in a fragmented manner. In pursuit of a more 
equitable use of resources, health authorities were required to use such resources for the 
benefit of the whole population; thus, priorities had to be set. The much-publicised case of 
Jaymee Bowen135, popularised as “Child B,” illustrates the dilemma regarding the 
allocation of limited resources (Ham and Pickard 1998). It has been widely reported as an 
example of explicit rationing in the market-reformed NHS. 
In the flux of subsequent NHS reforms, the Regional Specialised Commissioning 
Group (RSCG) was established on April 1, 1999, and was given the responsibility of 
ensuring the effective working out of arrangements for specialised commissioning, 
including HSCTs. Planning is conducted on a subregional/network basis, and individual 
health authorities produce the services within the agreed plan. Bone marrow transplants are 
commissioned through a consortium. The current arrangements for specialised-services 
                                                 
135 It concerned a young leukaemia sufferer who had been refused a second transplant by Cambridge Heath 
Authority in 1995. The child’s father challenged this decision in the High Court, which ordered the 
Authority to reconsider its refusal. The decision was upheld by the Appeals Court.  
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commissioning are based on the national guidelines (Guidelines on Commissioning 
Arrangements for Specialised Services) published in April 2003. These guidelines 
amplified the advice given in Shifting the Balance of Power: The Next Steps issued in 
January 2002, which emphasised that Primary-Care Trusts (PCTs) are the primary 
commissioners of healthcare services for their local populations, and that they are expected 
to act collaboratively when commissioning specialised services. 
Specialist hospitals carrying out blood and marrow transplantations are represented in 
the adult and/or paediatric BMT consortium. The centres providing paediatric BMTs that 
are members of the Paediatric BMT Consortium are: 
 Great Ormond Street;  
 St Mary’s;  
 United Bristol Healthcare Trust;  
 The Royal Marsden;  
 Barts and The London; and 
 University College London Hospitals.  
 
The Anthony Nolan Bone Marrow Trust, which plays a significant role in the 
promotion of BMT, was founded in 1974 as the first volunteer marrow donor registry. The 
Anthony Nolan Bone Marrow Register had a pool of 43,000 potential donors in 1982, and 
the number of its volunteers had increased to 345,000 as of the end of October 2001 
(Anthony Nolan Trust, 2005 Staticslcal Data).  
The National Blood Service established the British Bone Marrow Donor Registry 
(BBMR) in 2002. In 2002-2003, BBMR enrolled 42,634 new potential donors on its 
register. The BBMR has become the fastest-growing bone marrow register in the country, 
and is now the eighth largest of its kind in the world. BBMR’s growth in the past three 
years, acquiring nearly 90,000 enrolments, enables the support of more transplants 
(National Blood Service, 2008). The bone marrow donor registries of the UK are linked to 
an international register of bone marrow donors worldwide (BMDW). For those patients 
who are hoping to receive a bone marrow transplant from a BBMR donor, the average 
waiting time from the beginning of the search to the receipt of the bone marrow is 133 days 
(House of Commons, 2007). 
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In an effort to provide cord blood for transplant purposes, the NHS Cord Blood Bank 
was set up in 1996 as a part of NHS.  
In summary, traditional budget allocation has been transformed to purchasing by Has, 
and then to specialised commissioning for HSCTs. In tandem with the establishment of 
RSCG, HSCTs are commissioned through a consortium among HAs. Afterwards, PCTs 
become the primary commissioners for HSCTs, which act collectively.  
 
5.3.4. US 
The first BMT was performed by Dr. E. Donnal Thomas in the US. Since then, major 
advents in HSCTs have been achieved in the US, except the development of umbilical cord 
blood transplantation that was carried out in France in 1988. In tandem with scientific 
advancements, national policies to support HSCTs also have been institutionalised. In 1984, 
the US Congress passed the National Organ Transplant Act (NOTA). The Act contained 
guidelines for the evaluation of unrelated bone marrow transplants and of the feasibility of 
establishing a national donor registry. Its operations began in 1986. The name of the 
NBMDR was changed to NMDP following the establishment of a national registry based 
on the Organ Transplants Amendments Act of 1988. In the 1990s, the activities of NMDP 
rapidly expanded. In 1991, NMDP established the Office of Patient Advocacy, which was 
intended to help patients overcome the financial barriers in obtaining a transplant. In 1992, 
NMDP developed the Search Tracking and Registry (STAR), a computerized system that 
automatically manages all the steps of an unrelated stem cell or bone marrow transplant, to 
improve the speed and efficiency of searches. Since it began its operations, NMDP has 
recruited over 7 million potential bone marrow and blood stem cell donors amd nealy 
70,000 cord blood units on NMDP Registry (NMDP, 2008). Nearly 334,000 new 
volunteers join NMDP Registy with about 33,000 net vet voluteers each month. 
In the US, most HSCTs have been carried out through private funds. Medicare covers 
immunosuppressive drugs for an approved bone marrow transplant based on the 
Consolidated Omnibus Budget Reconciliation Act (COBRA) of 1993. The coverage was 
applied for 12 months in 1996. Then, it was extended gradually, and it currently covers 36 
months. Medicare extended its coverage for autologous stem cell transplants, beginning 
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October 1, 2000, to include persons aged above 65 who have multiple myeloma (Blood & 
Marrow Transplant Newsletter, 2000). 
In the private sector, many health plans provided coverage for BMTs in the past decade 
as BMTs have become a more routinely treatment modality for solid tumour cancer. Many 
health plans now cover HDT/PCT. According to the General Accounting Office (GAO), 
the insurance coverage for HDT/PCT is rapidly growing, and at least seven states, 
including Virginia, mandated health plans to provide insurance coverage for patients with 
certain conditions (Davis 1996).  
To achieve broader coverage from payers for established indications for blood and 
bone marrow transplants, the American Society for Blood and Marrow Transplantation 
(ASBMT) organized the “Managed-Care Initiative.”136 Moreover, as a part of the initiative, 
the development of evidence-based reviews and position statements on the effectiveness of 
autologous and allogeneic haematopoietic-stem-cell transplants for specific diseases was 
initiated (ASBMT 2000).  
In summary, the overall landscape of the US insurance coverage for HSCTs is difficult 
to describe. Various health plans have different policies on HSCT coverage. As some states 
mandate health plans to cover HSCTs, lawsuits are also increasing against the coverage 
limits of insurance plans. Except for umbilical-cord blood transplants, many health plans 
increasingly expand coverage policies for HSCTs. The volunteer donor recruitment 
activities by NMDP have significantly contributed to improving donor availability. 
 
5.4. The Adoption of HSCTs 
5.4.1. Japan 
Over 2,000 HSCTs are carried out yearly in Japan, and about half of these (46.9% in 
1991-2002) involve allogeneic BMTs. Every year, around 6,000 new patients who might 
benefit from an HSCT emerge. In 1995, the annual mortality rate from leukaemia was 4.9 
per 100, 000 persons (Ohno 1998). Leukaemia (including chronic myeloid leukaemia, acute 
                                                 
136 The strategy of the Managed-Care Initiative is threefold (ASBMT 2001): (1) to bring together a coalition 
of stakeholders to address the issues of third-party reimbursement for blood and marrow transplantation; 
(2) to document, for specific diseases, the efficacy of blood and bone marrow transplantation; (3) to 
advocate on behalf of the BMT patients among those who decide or influence treatment reimbursement 
decisions. 
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leukaemia, Hodgkin’s disease, and non-Hodgkin’s lymphona), multiple myeloma, and 
aplastic anaemia, were responsible for 5.93% (5.49% in males versus 6.61% in females) of 
the total deaths in 1999 (National Cancer Centre, Cancer Statistics in Japan - 1999), 
The number of HSCTs has rapidly increased since 1990, as shown in Figure 5-2. 
According to the results of the nationwide survey carried out by the Japan Society for 
Haematopoietic-Cell Transplantation (JSHCT)137, transplants from unrelated donors have 
significantly increased since 1994. Autologous PBSCT takes the largest proportion of the 
total HSCTs, followed by allograft BMTs with unrelated donors. The number of allograft 
BMTs with siblings is decreasing, while the number of cord blood transplantations has 
been rapidly increasing since 2000. Since 1990, when the Ministry of Health and Welfare 
(currently MHLW) of the Japanese government began to support HSCT, the number of 
HSCT cases has rapidly increased. 
Figure 5-2. Japan’s transplant activity totals 
Data sources: 1) The Japan Society for Hematopoietic Cell Transplantation, Annual Report of Nationwide 
Survey 2003  
2) The Japan Society for Hematopoietic Cell Transplantation, Annual Report of Nationwide 
                                                 
137 The Bone Marrow Transplantation Committee of the Japan Society for Paediatric Haematology started 
nationwide surveys on stem cell transplants for child patients in 1983. The Japan Society for 
Hemaetopoietic-Cell Transplantation (formerly the Japan Society for Bone Marrow Transplantation) started 
the survey in 1993, separately from the survey for children. The first survey involved adult patients who 
underwent transplants between July 1990 and June 1993. From 1994 to 1997, the office of the society in 
Kanagawa Children’s Medical Centre and the Aichi Cancer Centre Research Institute separately performed 
surveys for child patients and for adult patients, respectively. The medical centres that participated in the 
surveys were 112 paediatric departments, 124 internal-medicine departments, 1 surgery department, 6 
gynaecology departments, 14 urology departments, and 14 other departments, or a total of 271 departments.  
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Survey 2006 
 
JMDP has greatly contributed to the promotion of BMT in Japan. As listed in the 
chronicles, JMDP launched a donor-recruiting programme in January 1992, and the 
Japanese government introduced an official furlough for bone marrow donors in 1993. By 
virtue of public support for bone marrow donation, the number of BMTs from unrelated 
donors significantly increased. With the expansion of the marrow donor pool, the chances 
of matching patients with volunteer donors through JMDP increased. Of the total, the 
number of BMTs with unrelated donors increased from 2.1% in 1991 to 24.3% in 2002. By 
the end of 2002, 643 umbilical-cord blood transplants had been carried out in Japan. 
PBSCT has also been increasing since its inception in 1995. 
Figure 5-3. HSCT activities in Japan (1991-2005) 
Data sources: Japan Society for Haematopoietic-Stem-Cell Transplantation, 2006 Annual Nationwide Survey 
Report. 
 
In summary, HSCTs were carried out at 19.5 pmp in Japan in 2005. The public 
authorities have been very supportive, due to the consensus of that the incidence of 
leukaemia is closely related with the atomic bombings during the Second World War. With 
a strong national consensus that the bombings were a national disaster requiring public 
support for the victims, the Japanese people actively participated in marrow donations. The 
Japanese government has promoted the recruitment of marrow donors through JMDP, by 
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giving the latter financial support. Insurance programmes cover all sorts of HSCTs from the 
beginning of their adoption. As shown in Figure 5-3, the number of umbilical-cord blood 
transplants remarkably increased from 1998, when their insurance coverage was initiated. 
 
5.4.2. Korea 
Currently, about 700 BMTs are carried out each year in 28 BMT centres in Korea. 
Since 1981, when BMT was initially introduced, 3,820 cases have been performed by the 
end of August 2001 (Korean Haematopoietic-Stem-Cell Transplantation Nurse Association 
2001). The incidence of leukaemia in Korea increased from 1,162 in 1987 to 1,696 in 1998, 
accounting for about 3.7% of the total cancer cases in 1987 and 2.6% in 1998 (Department 
of Disease Control 2000). While the incidence in terms of the total numbers increased, the 
proportion of total malignant cancers decreased. Haematopoietic diseases in children, 
including leukaemia and malignant lymphoma, accounted for 33.4% of the total cancer 
cases, making them the largest type of cancer among children.    
   
Figure 5-4. BMTs in Korea (1983-2003) 
Data Sources: Korean HSCT Nurse Association (2003)  
Note: 1) The data for allogeneic HSCT include autologous HSCT until 1994. The number of  
       autologous HSCTs from 1990 to 1994 were 46, which was 19.1% of the total HSCTs. 
     2) The majority of autologous HSCTs are PBSCTs.  
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Recently, the number of PBSCTs has been increasing, accounting for 39.3% as of the 
end of August 2001. As shown in Figure 5-4, the number of HSCTs significantly increased 
in 1991, 1995, 1996, 1998, and 1999. The single most important factor spurring BMT 
activities in Korea was insurance coverage policy. Before insurance coverage was extended 
to include allogeneic BMTs, BMTs remained at less than 30 cases a year. Due to insurance 
coverage, the demand for BMTs has remarkably increased. Consequently, the number of 
centres performing BMTs also increased, as shown in Figure 5-5. Until 1989, only one 
medical centre was able to carry out BMTs. Since the early 1990s, many other centres have 
engaged in various bone marrow and stem cell transplants. In 1992, when health insurance 
programmes started to cover BMTs, five medical centres were joined together to carry out 
BMT. The increases in HSCTs in 1995, 1996, and 1998 were mainly due to the increase in 
the number of medical centres performing HSCTs. Particularly, the increased entrants in 
HSCT programmes and the expansion of insurance coverage to include autologous BMTs 
and PBPCTs in December 1997 are seen as the major causes of the recent increases. 
 
 
Figure 5-5. New entrants involved in BMT each year (1992-1998) 
Data Sources: National Health Insurance Corporation (1999 : personal communication) 
 
Competition within the hospital industry has played an important role to spur medical 
centres to join HSCT activities. New entrants owned by conglomerates like Samsung and 
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Hyundai have been major forces for the takeoff in 1993. Following the involvement of 
conglomerate-owned hospitals in haematology services, other teaching hospitals have also 
started to provide BMT. 
 
The increased number of BMTs from unrelated volunteer donors has also contributed 
to the growth of BMTs during the latter half of the 1990s. As shown in Figure 5-6, BMTs 
from unrelated donors started in 1996 in Korea. The case “Sungduk Bauman”138 gained 
considerable media attention and significantly promoted BMTs involving unrelated donors 
in 1996.   
 
Figure 5-6. BMTs from unrelated donors (1994-1999) 
Data sources: 1) The number of registered volunteer bone marrow donor was obtained from 
       the Bone Marrow Team in the Research Centre for Blood Transfusion, Korea  
       Red Cross (personal communication). 
2) The number of BMTs from volunteer donors registered in KBMD was  
              obtained from KBMD (personal communication). 
 
In summary, four factors have been major influences for HSCT adoption. First, the 
changes in insurance coverage in 1992 encouraged the adoption of the procedure. Second, 
the competition among hospitals, which was propelled by the entrance of conglomerate-
                                                 
138 Sungduk Bauman was a second-generation Korean immigrant who settled in the US He was a member of 
the US Military Academy. He was required to undergo BMT due to leukaemia, and the US Military 
Academy actively campaigned to find a suitable bone marrow donor. The campaign gained considerable 
media attention, and its influence spread to Korea. Sungduk Bauman has found a volunteer donor in Korea 
and underwent BMT in July 1996 in the US 
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owned hospitals in the competition, promoted the adoption of HSCT, which they adopted 
as a marketing strategy to demonstrate their advanced technologies. Third, public actions 
spurred bone marrow donations, which began with the establishment of KMDP and which 
grew stronger in 1995, during the nationwide campaign to find a suitable donor for a 
Korean-American leukaemia patient living in the US. Fourth, charity funds also played a 
significant role. Even though public health insurance programmes cover BMT costs, the 
patient’s share of the cost can be very high, ranging from £10 thousand to £27 thousand. In 
most cases, charity funds have supported almost the whole share of the eligible patient. 
 
5.4.3. UK 
The first BMT was performed in 1973 in the UK Over 2,000 HSCTs are currently 
carried out in the UK every year, and over 24,500 people in Britain are newly diagnosed 
with cancer of the blood, including leukaemia (Leukaemia Research 2007), as shown in 
Table 5-3. According to Leukaemia Research, 1,200 children are diagnosed with cancer 
every year in the UK, or one in 9,000. Among them, about 40% are diagnosed with blood 
cancers, the most common of which is acute leukaemia.  
 
Table 5-3. Annual incidence of blood-related cancer in the UK 
Diseases Diagnosed Number of New Cases Each Year 
ALL in children 
ALL in adults 
450 
200 
AML in children 
AML in adults 
50 
1,950 
CLL 2,750 
CML 750 
Total leukaemia 6,150 
Hodgkin’s lymphoma 1,400 
Non-Hodgkin’s lymphoma 8,450 
Total lymphoma 9,850 
Myeloma 3,300 
Myelodysplasia 3,250 
Myeloproliferative disorders 1,900 
Aplastic anaemia 130 
Total 24,500 
Data sources: Leukaemia Research. 2007 
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As shown in Figure 5-7, the adoptions of HSCTs (both autografts and allografts) have 
been increasing since the 1990s. The increases have been bigger, though, with autografts 
than with allografts since 1993. Further increases were observed after the first umbilical-
cord blood transplant at Great Ormond Street Hospital for Children in 1996.  
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Figure 5-7. HSCTs in the UK (1990-2004) 
Data sources: British Society of Blood and Marrow Transplantation (BSBMT)., 2007 
Note: Data regarding cord transplantation from 2001 are available on the BSBMT database.  
 
 
5.4.4. US 
The first successful BMT in the US took place in 1968 at the University of Minnesota 
(National Marrow Donor Programme, 2001). In 1973, the first unrelated bone marrow 
transplant was performed in New York. Over 10,000 HSCTs are currently performed in the 
US each year. Figure 5-8 shows that the adoption of auto PBSCT has been rapidly 
increasing since 1994 as much fractioned 58.8% of total in 2006, while that of auto BMT 
has been decreasing. Allograft PBSCT has also been increasing during the same periods.  
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Figure 5-8. HSCTs carried out in the US (1989-2006) 
Data sources: CIBMTR (personal communication) 
Note: 'The data presented here are preliminary and were obtained from the Statistical Center of the Center for 
International Blood and Marrow Transplant Research. The analysis has not been reviewed or approved 
by the Advisory or Scientific Committee of the CIBMTR.' The data may not be published without the 
approval of the Advisory Committees 
 
The National Cancer Institute (1999) verified that leukaemia accounted for 31% of all 
cancer cases in people younger than 15 years of age and 25% of all cancer cases in people 
younger than 20 years of age in the data for the period 1990-1995. In the US, there are 
approximately 3,250 children a year diagnosed with leukaemia, and 2,400 with acute 
lymphoblastic leukaemia (ALL).139 Since the early 1970s, the incidence rates of lymphoma 
in the US have almost doubled140, while those of other cancers have been steady or have 
been decreasing. In the US, the lifetime risk of being diagnosed with leukaemia is 1.03%, 
and the risk of dying on account of leukaemia is 0.73% (as estimated based on the SEER 
database), while the risks of acquiring NHL are 1.71% and 0.89%, respectively. The risk of 
being diagnosed with multiple myeloma is 0.50% and the risk of dying on account of it is 
0.38%.   
 
                                                 
139 The proportion of leukaemia in the total childhood cancer cases varies markedly with age—17% in the 
first year of life, rising to 46% for two- and three-year-olds, and then decreasing to only 9% for 19-year-
olds. 
140 The reasons for this increase are not certain. Persons infected with the human immunodeficiency virus 
(HIV) have a much higher risk of developing lymphoma. 
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Figure 5-9. HSCTs from unrelated donors by year (1987-1998) 
Data Sources: NMDP (2001) 
 
The major factor influencing the increase in the overall number of HSCTs has been the 
extensive adoption of auto PBSCT in the US, which has increased significantly since 1993. 
The National Marrow Donor Programme (NMDP) has significantly contributed to the rise 
in the number of BMTs performed in the US. By the end of October 2000, NMDP had 
facilitated 11,422 unrelated stem cell transplants (NMDP 2000), and by the end of 1999, 
NMDP had facilitated 9,237, 1,357 of which have been for racial-minority patients 
(National Marrow Donor Program 2000). As shown in Figure 5-9, the number of donors in 
the registry and that of the HSCTs from unrelated donors have increased every year. 
 
5.5. Conclusion 
 
As a relatively expensive procedure, its overall advantages needed to be confirmed in 
both economic and clinical terms. The cost burden to a patient undertaking HSCTs varies 
by procedures depending on patient’s condition and co-payment rules. Amongst HSCTs, 
some procedures have better outcomes in economic terms as detailed in Table 5-4. 
Peripheral blood stem cell transplant (PBSCT) was estimated to be less expensive, 
approximately 80-85 % the cost of BMT in the short term but equivalent in the long term 
(Kasteng et al, 2007). The prolongation of life and QoL has yet to be reliably proven 
among the procedures of HSCTs. 
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Table 5-4. The costs of HSCTs, by procedure 
Note:  a. total costs 
b. per life year added 
c. average hospital charge 
d. average hospital length of stay 
         e. Office of Health Technology Assessment (1995) 
 
Figure 5-10 shows that HSCTs are much higher in the UK and the US than Japan and 
Korea. IBMTR/ABMTR (International Bone Marrow Transplant Registry and the 
Autologous Blood and Marrow Transplant Registry) considers the real number of HSCTs is 
up to twice as high. If correct, the true number in the US would be more than twice as much 
in comparison with the UK. Reflecting the incidence rate, the level of HSCT adoptions is 
similar in three countries; Japan, Korea and Korea, except the US. In all countries, the 
number of peripheral blood stem cell transplant s rapidly increased from the early 1990s. 
Rapid increases occurred in the UK in 1993 and followed by the US in 1994 and in Japan 
in 1995. The transformation of BMT is considered to have been mainly driven by clinical 
reasons. The use of peripheral blood stem cells has become routine, as they can be collected 
on an outpatient basis and also promote a consistent acceleration in haematopoietic 
reconstitution after engraftment (Byrne JL and Russel, 1998)141.  
                                                 
141 The more rapid haematological recovery with peripheral blood stem cell transplant  reduces the mortality 
associated with autografting to 2% (Holyoake and Franklin, 1994).  
Researcher Data collection Setting Disease 
Costs 
BMT PBSCT 
Kasteng et al (2007) 
Literature 
review 
Canada 
Italy, France, 
Netherlands, 
UK, US 
Leukaemia  
$50,000~ 
$100,000 
80~85% 
of BMT 
Waters et al 
(1997) 
1994-96 US haematological 
malignancies 
$114,862a $100,542 
Woronoff-Lemsi et 
al. (1997) 
1992-1993 
(ABMT) 
1993-1994 
(PBPC) 
France NHL $35,381b $41,759 
Uyl-de Groot et al 
(1995) 
 US  $30,592b $21,809 
Faucher (1994)  US  $23,290b $19,770 
Bredeson et al 
(1997) 
April 1993-
Dec. 1994 Canada NHL, HD, MM $32,289
b $22,089 
Black et al (1982) 
Jan. 1982-June 
1982 UK AML £37-54,000  
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Figure 5-10. The trends of BMTs in pmp  
Data sources:  
1) For the UK- Data provided by the A.Gratwohl and H. Baldomero, EBMT Activity survey, Basel 
Switzerland (personal communication). 
2) For the US- International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant 
Registry (personal communication on 22 Feb.2001 with Melodee L. Nugent, Information 
Specialist/Biostatistician). The raw data are confidential. The analysis has not been reviewed or approved 
by the Advisory Committees of the IBMTR and ABMTR.  The data may not be published without the 
approval of the Advisory Committees. 
3) For Japan- the Japan Society for Hematopoietic Cell Transplantation, Annual Report of Nationwide Survey, 
1998, 1999, 2001.  
4) For Korea- Korean Haematopoietic Stem Cell Transplantation Nurse Association, 2001 
Note: IBMTR and ABMTR regard the data represent approximately 40 % of all the allogeneic transplants and 
about half of all autotransplants in the US. Taking this into account, the number of BMT is assumed as 63 
in pmp in 1998, which is approximately twice higher than current capture.  
 
The adoption of HSCT increases in all four countries. In the UK, the adoptions took up 
during 1990s, afterward the market reforms. In Korea, the increase has been more intensive 
during the late 1990s. Auto peripheral blood stem cell transplant is growing significantly in 
both the UK and the US, while allo-peripheral blood stem cell transplant and cord blood 
transplants are increasing at remarkable levels in Japan. According to the technology 
assessment in the terms of on economic and clinical aspects, peripheral blood stem cell 
transplant is commonly preferred because the unit costs are lower and the length of hospital 
stay is shorter compared to other procedures.  
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Chapter 6: Cochlear Implantation 
6.1 Introduction 
A cochlear implant is an electronic device designed to support the hearing and 
communication functions of individuals who have a profound hearing impairment and who 
are thus unable to hear even with hearing aids. A deaf person is typically unable to 
recognise sounds as the sensory receptors of his or her inner ear, called hair cells, are 
damaged or diminished. Cochlear implant provides two classes of patients with sound 
inputs (Summerfield and Tomlison 1996), namely: 
 children and adults who lost their hearing after learning a spoken language 
(postlingually deafened); and 
 young children who either lost their hearing before acquiring a spoken language or 
who were born deaf (prelingually deafened). 
  
A cochlear implant bypasses the damaged hair cells of the inner ear and electronically 
stimulates the auditory nerve, enabling individuals to receive sound inputs. Part of the 
device is surgically implanted in the skull, behind the ear, and tiny electrode wires are 
inserted into the cochlear. The other part of the device is external and has a microphone, a 
speech processor that converts sounds into electrical impulses, and connecting cables.  
Cochlear-implant technology has evolved from a device with a single channel to 
systems that transmit more sound information through multiple channels. Single-channel 
systems deliver one stream of electrical information to a single electrode placed in the outer 
turn of the cochlear. Multi-channel systems deliver quasi-independent streams of 
information to several electrodes simultaneously.  
WHO estimates the global cases of disabling hearing impairment as 250 million as of 
the year 2001, which was approximately 4.2% of the world’s population then (Smith 2004). 
As of 1999, an estimated 32,000 patients worldwide have received cochlear implants, and 
annually, approximately 6,000 implants are performed on a global basis, and the numbers 
increase each year (Sargent 2004).  
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6.2. Micro Factor Evaluation 
6.2.1. Economic Factors 
Cochlear implants, which are highly sophisticated devices, are expensive and require a 
careful evaluation of the candidates for receiving them, a delicate surgery, and, in many 
cases, years of training in order to provide optimum benefits (Cohen 1995). According to 
Summerfield and Marshall (1995), the cost of cochlear implants greatly varies between an 
adult and child, as shown in Table 6-1, but is generally higher for children than for adults 
primarily due to the longer time required for assessing the suitability of child patients, for 
maintaining their implants, and for follow-up treatments.   
Table 6-1. Cost comparison of cochlear implant for adults and children 
 Adult Child %* 
Cost of managing the implant in the first year £8,039 £11,320 140.8 
Hardware (Nucleus 22-channel) £20,969 £24,250 115.6 
Cost of management over the subsequent 11 years, 
including the cost of upgrading the hardware £23,318 £42,565 182.5 
Note: * cost of cochlear implant for a child as a percentage of that for an adult 
 
The data shown in Table 6-2 indicate cost effectiveness of cochlear implants in terms 
of cost per QALY.142 On account of controlling factors such as potential pre-operative 
complications, morbidity, and shorter life expectancies, Wyatt et al. (1996)  concluded that 
the cochlear implant is highly cost-effective for geriatric patients as well. National Institute 
of Health (NIH) of the US (1995) also argued that cochlear implants for adults are quite 
favourable compared to other medical procedures. NIH also regards the cost-utility 
estimates for children quite favourably, but withholds its conclusion on the cost or the 
potential cost-saving effects that will accrue in the area of rehabilitation and education. 
Francis et al. (1999), however, concede that there are significant short-term effects on the 
use of educational resources, reducing the demand for support services by children with 
profound hearing impairments and diminishing the expenditures by the school systems 
throughout the US.  
                                                 
142 Summerfield and Tomlinson (1996) emphasise that the cost effectiveness of cochlear implants may be 
improved by ensuring that the procedure is carried out by appropriately trained specialist teams, with a 
sufficient caseload to maintain their skills, and by operating specialist centres. 
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Table 6-2. Data on the cost effectiveness of cochlear implants 
Source (Year) Country 
Cost-Utility 
Ratio 
(Cost/QALY) 
Remarks 
Summerfield and Marshall (1995) UK £11,440a Multichannel 
Summerfield and Tomlinson (1996) UK £13,300b  
Hutton (1995) UK 
£24,257 
£15,293 
Prelingually deafened 
Postlingually deafened 
Wyatt et al. (1995) US US$15,593  
Evans et al. (1995) US US$15,900  
Cheng et al. (1999) US US$12,787  
Palmer et al. (1999) US US$14,670 Multichannel 
Note: a. If the benefits are discounted at 6% per annum or £5,722/QALY if the benefits are not  
       discounted   
b. The discounted cost of implantation and long-term management was £36,400 for adults and  
  £57,400 for children. 
c. Applying the improvement of the quality of life of adults, which is calculated as 0.23 points per  
annum, to children receiving implantation at age 4 (years), and assuming a life expectancy of  
74 years, the QALY to be gained is calculated to be 16.33 in children. The cost per  
undiscounted QALY gain is estimated to be £1,345.70, and per discounted QALY gain,  
£10.341.  
 
6.2.2. Clinical Factors 
Many factors affect auditory performance after cochlear implantation. Overall, 
multichannel cochlear implants significantly improve the recipients’ performance in terms 
of speech understanding, and achieve a rating of health utility within six months of the 
implantation (Palmer et al. 1999).143 In the Nottingham Paediatric Cochlear Implant 
Programme, the majority of children who received cochlear implants below the age of five 
years developed intelligible spoken language three years after the implantation 
(O’Donoghue 1996). The clinical outcomes of cochlear implants are summarised in Table 
6-3. Cheng et al. found (1999) that more rapid gains in speech perception are associated 
with undergoing a transplant at an earlier age, and that speech perception results are 
independent of cause or age of deafness after 1 year of implant use. Geier et al. (1999) 
identified that the patient’s duration of being deaf, and age at which the patient had the 
transplant have significant and independent effects on short-term postoperative 
performance. In addition, the results show that the improvement rate of speech recognition 
                                                 
143 The authors measured health utility using the Health Utility Index (UHI). The HUI incorporates domains 
related to spoken communication and hearing.  
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is dependent upon the duration of deafness, at least in the first three months after 
implantation.144 
 
Table 6-3. Outcomes of cochlear implantation performed on postlingual adults  
Outcome Measure Researches Achieved 
Identification of some common 
environmental sounds 
Summerfield and Marshall (1995) 97% 
Horn et Al. (1991) 85% 
Kelsall et al. (1995) 100% 
Summerfield and Tomlinson (1996): 
in children 
70% 
Greater benefits to lip-reading than 
those achieved pre-operatively with 
an acoustic hearing aid 
Summerfield and Marshall (1995) 80-90% 
Correct identification of some 
words in sentences without lip-
reading 
Summerfield and Marshall (1995) 50% 
Summerfield and Tomlinson (1996): 
in children 50% 
 
According to Harris et al. (1995), as shown in Table 6-4, the overall quality of life 
reaches a high level one year after cochlear implantation, and is maintained at a level 
higher than that before the implantation. In addition, the annual-income level nearly 
doubled after cochlear implantation.145 Depression widely varied according to time, with 
the level dropping significantly until one year after implantation, and worsening over time.   
The National Institute of Health Consensus Development Conference Statement (1995) 
clarified that the cost benefit of cochlear implant for adults are quite favourable compared 
to other medical procedures. Although the procedure for children could not yet be 
evaluated as it was still in the early stages, the statement concluded that the cost-utility 
estimates for children were also quite favourable.  
                                                 
144 Patients who had been implanted at a younger age and those who have had deafness for smaller 
percentages of their lives achieved the highest levels of short-term postoperative speech recognition. 
Patients who had been deaf for ≥60% of their lives demonstrated a slower rate of speech recognition 
improvement than those with shorter durations of deafness, but still continued to improve with increased 
implant experience. 
145 Palmer et al. (1999) also support the improved income levels of those who had undergone cochlear 
implantation, compared with those who had not undergone the procedure.  
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Table 6-4. Time series evaluation of the improvement after cochlear implantation 
Scale 
Time Related to Implantation 
Before 6 Mos 1 Yr 2 Yrs 2 1/2  
Yrs 
3 Yrs 
Depressiona 14.78 11.00 6.5 11.7 12.2 20.3 
Satisfaction with life areasb 3.72 4.24 4.53 4.18 4.46 3.98 
Quality of life and well-beingc 639 645 720 698 686 711 
Personal incomed 8.9 9.6 10.5 11.1 11.3 11.4 
Data sources: Harris et al. (1995) 
Note: a. Scored on a 0-60 scale, where a lower score is better and a score of 15 indicates a significant level of 
depression 
b. Scored on a 0-6 scale, where a higher score is better. The variables that were taken into account 
include work, money, home life, social contacts, housing and neighbourhood, health, religion, 
children, recreation, and relaxation. 
c. Scored on a 0-1.0 scale, where 0=death and 1.0=asyptomatic, full function. The quality of life was 
measured based on three scales of function: mobility, physical activity, and social activity.  
d. A higher score is better in hearing..  
 
6.2.3. Technical Factors 
A cochlear implant works by providing direct electrical stimulation to the auditory 
nerve, bypassing the usual transducer cells that are absent or non-functional in a deaf 
cochlear. The implantation procedure is considered delicate but not complex or risky. 
Major complications are usually related to surgical technique, and they include flap 
necrosis, improper electrode placement, and rare facial nerve problems. Minor 
complications include dehiscence, infection, facial nerve stimulation, and dizziness 
(Kveton and Balkany 1991, Cohen and Hoffman 1991).  
 
6.3. Macro Factor Evaluation 
6.3.1. Japan 
The Japanese government is greatly concerned with the early detection of hearing 
impairments. In 2000, the Ministry of Health, Labour and Welfare (MHLW) of the 
Japanese government appropriated £286k for a pilot study with the aim of developing a 
national screening system for the early detection of hearing impairments. MHLW classified 
Nuclear 22 as an Advanced Medical Technology (AMT)146 from 1994, and extended the 
                                                 
146 As of October 1, 2000, 68 new medical technologies were admitted as sophisticated HTs. The system, 
which approves of certain experimental technologies, including sophisticated HTs, commenced in 1984. 
The system encourages the development of innovative medical technologies while limiting the overuse 
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health insurance coverage to include it. In the past, health plans provided insurance 
coverage when the procedure was performed in one of three designated medical centres: 
Teikyo University Medical Centre, Ehime University Medical Centre, and Miyasaki 
University Medical Centre. As of February 2001, there were 64 hospitals that carried out 
cochlear implantation, and 10 rehabilitation centres that provided hearing training to those 
who have undergone the procedure (Association of Cochlear-Implant-transmitted Audition 
2001). 
Voluntary organisations that support cochlear implantation, such as the Association of 
Cochlear-Implant-transmitted Audition, have called for insurance coverage for the Nucleus 
24 channel, and social insurance programmes began to cover it in 2000. In 1999, MHLW 
also classified CLARION as an AMT and, as such, enabled its insurance coverage in 
2000.   
The actual cost of cochlear implantation varies according to the age of the patient at the 
time of surgery. As of April 2007, the cost of the procedure for children who are eligible 
for “self-sustenance support system” is £229 and £436 for adults. In tandem with insurance 
coverage, the cost of cochlear implantation is subjected to a “refund system for the high 
cost of medical practice,” which pays back 20% of the total 30% of the patient’s share 
when the total cost exceeds £262 (¥63k) within a month at one hospital.147 
 
                                                                                                                                                    
and misuse of the technologies. To qualify as an SHT, the technology should have had at least five clinical 
trials where its effectiveness, safety, cost benefits, and potential for propagation should have been proven.  
A technology becomes an approved SHT through the following procedures: 
 developing or introducing it as an innovative technology; 
 proving its safety, clinical effectiveness, cost benefits, and potential for propagation;  
 ethical inspection (Ethics Committee, MHW); 
 evaluation, with at least five cases of clinical application; 
 review in an SHT subcommittee; 
 review in the Expert Committee of the Central Social Insurance Council; 
 obtaining SHT approval; and  
 publicising it. 
To obtain qualification to adopt an AMT, medical centres should satisfy the conditions pertaining to 
staffing, equipment, and facilities. Medical centres that satisfy these requirements are called AMT-approved 
Medical Centres. Unless a patient goes to any of the medical centres that have been designated to perform 
specified AMT procedures, he or she is obliged to pay extra fees especially charged for the AMTs.  
147 If the total incurred cost within a month exceeds ¥63,600, the health insurance programme refunds the 
entire excess amount under the scheme for costly medical services. For the majority of patients who 
require cochlear implantation, local governments take responsibility for shouldering the full cost of the 
procedure as part of the social-welfare programmes for the disabled.   
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6.3.2. Korea 
In Korea, the involvement of public authorities in cochlear implantation issues is 
limited. The only support given by the government for cochlear implantation was its 
exemption from import tariffs.148 Government involvement began in 2001, when an 
inquiry commission was sent to Australia, spurred by the petition for insurance coverage 
for cochlear implantation. The appeal was made by the parents’ association of deaf children 
“Resonance.” In 2002, the Ministry of Health and Welfare allocated a subsidy of £1 million 
for cochlear implantation. Public subsidy continued until 2004: £0.5 million in 2003 and 
£1.3 million in 2004 (The Ministry of Health and Welfare 2002, 2003, 2004), supporting a 
quarter of the total cost for children aged below 10 years via a means test. Following the 
commencement of insurance coverage for cochlear implantation, donations flowed from the 
private sector. Korea Telecom began its related charity work in 2005, donating £275,000 a 
year for cochlear implantation procedures, and Samsung began undertaking related charity 
work in 2007, supporting cochlear implantation procedures by donating £760,000 every 
year. About 700 patients can benefit from both these charities, which exceeds the total 
number of cochlear implantation procedures carried out every year.  
6.3.3. UK 
As of 2001, eight programmes performed cochlear implantation procedures in the UK 
(National Service Division, Common Service Agency 2001).149 In Scotland, cochlear 
implantation is offered in two centres (The National Service Division, Common Service 
Agency 2001). Cochlear implantation is currently funded through a specialised 
commissioning of NHS (NHS Northwest Regional Office, Annual Report on Specialised 
Commissioning 2000-2001). To promote efficiency in the provision of cochlear-implant 
services, an Audit Commission review of specialised services (1997) suggested that health 
authorities move from being passive purchasers to being active commissioners of 
                                                 
148 According to Section 28 of the Customs Law, based on Section 37 of the Handicapped-Persons’ Welfare 
Law, the Korean government does not charge duty for the import of implantable hearing aids from 
overseas. Various forms of aid for the blind, deaf, and physically impaired are exempted from surcharges.  
149 Great Ormand Street Hospital Cochlear-Implant Programme; National Cochlear-Implant Programme at 
Beaumont Hospital (Ireland); Northeast England Cochlear Programme; North Wales Cochlear-Implant 
Programme; Nottingham Paediatric Cochlear-Implant Programme; The Portland Hospital, London; South 
of England Cochlear-Implant Centre; University College London.  
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specialised services, including cochlear implantation. Although the costs are high150, the 
number of patients is small: as few as two or three such procedures are being carried out by 
each authority, thus making annual budgeting difficult. Moreover, with the small number of 
cochlear-implantation patients, it was difficult for the health authorities to compare the 
related services across hospitals.151 To address these problems, some authorities forged a 
consortium with other authorities for the purchase of specialised services and to diminish 
the risks involved in the procedure and improve the quality of commissioning.152  
The British government supports the detection of hearing impairment disabilities at the 
earliest possible stages in order to improve the chances of hearing recovery. Public policies 
aimed at identifying hearing impairment disabilities have been adopted since the 1940s. 
The 1944 Education Act gave local authorities the means to implement hearing screening at 
the pre-school and grade school level (Davis et al. 1997). The pre-school screening 
programme was first developed in the 1950s and was administered by health visitors to 
children aged about 9 months. The Health Visitor Distraction Test (HVDT)153, which 
included screenings for pre-school children, was used in the late 1990s to test children aged 
7-8 months for hearing impairments. To detect such impairments as early as possible, 
targeted neonatal screening was introduced in many districts beginning in 1994. As the 
infant distraction test has low specificity and low sensitivity, which can lead to the 
worsening of hearing loss and to a situation in which it would be too late to start the proper 
treatment, screening for hearing impairment during the neonatal period has been stressed. 
According to a recent research (Fortnum et al. 2001), 16% of hearing-impaired children 
still need to be detected in their postnatal years using the current universal neonatal hearing 
screening.  
 
                                                 
150 In the UK, the individual cost of cochlear implantation is about £30,000. 
151 According to the results of the Audit Commission national survey of cochlear implants, there is a 20% 
variation in the prices of cochlear implants. The components that were used to gauge the prices were 
inconsistent. 
152 According to the Audit Commission, less than one-third of the authorities are part of the consortium for 
cochlear implants.   
153 HVDT is a universal programme for detecting hearing-impaired children. 
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6.3.4. US 
In the US, cochlear implantation costs £21,000 (Garber et al. 2002). According to the 
Cochlear-Implant Association, Inc. (CIAI) (2001), private health plans provide coverage 
for cochlear implantation procedures in almost all cases. The Medicare programme, the 
Veterans Administration, and Medicaid in some states, as well as Children’s Special 
Services, Tricare154, and Vocational Rehabilitation Agencies155 also generally provide 
coverage for the procedure.  
A vast majority of the patient population is covered by public insurance programmes 
such as Medicare and Medicaid. While the overall insurance coverage rate is higher 
compared with the general population156, the reimbursement rate is substantially lower than 
the number of those with private insurance. Blanchfield and colleagues (2001) estimates 
that 31% of the patients with a severe to profound hearing impairment have only public 
insurance, 40% have a combination of both public and private health insurance, and only 
23% has only private insurance. In contrast, an estimated 13% of the general population 
have only public insurance, 12% have public and private insurance, and 61% have only 
private insurance.  
Patients pay an average minimum of 20 to 30% of the charges approved by the 
insurance plan (Cochlear Implant Research Centre, University of Iowa, 2001). The 
Medicare programme defines cochlear implants as a prosthetic device, thereby provides 
coverage whether the surgery is performed on an inpatient or outpatient basis that has been 
effective from May 1998 (Listen-up, 2008). If the surgery is taken on inpatient basis, the 
patient is responsible only for the deductible that was $768 in 1999. Patients are liable for 
their coinsurance if they undertake sugery on an outpatient basis, which is 20% of total 
hospital charges that are rated on the basis of Medicare fee schedule.  
Due to the restrictive Medicare remuneration policies, healthcare providers for cochlear 
implantation have lost interest in offering this procedure (Cochlear Implant Association, 
Inc., 2001).  
 
                                                 
154 A federally funded insurance programme for active military personnel 
155 Each state has a vocational rehabilitation agency. 
156 This is due to the large proportion of Medicare-eligible elderly in the hearing-impaired population, and the 
public programmes’ perception that disability and eligibility are linked. 
 
 
148
Efforts to detect babies who cannot hear started in the early 1990s in the US. In March 
1993, the NIH Consensus Development Conference Statement (No. 92) recommended that 
all babies be screened for hearing disabilities prior to hospital discharge since they are 
already in the hospital. The quality standards and consensus for the early identification of 
permanent childhood hearing impairment (PCHI) have also been proposed by the Joint 
Committee on Infant Hearing (1994), which mandates that all infants with hearing 
disabilities should be identified before the age of 3 months, and that the treatment of the 
condition should be started at the age of 6 months.  
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Figure 6-1. Number of universal neonatal hearing screening programmes (1990-
1999) 
Data sources: National Centre for Hearing Assessment and Management (2007) 
 
As shown in Figure 6-1, the number of newborn hearing screening programmes in the 
US began to rise substantially in the early 1990s. According to White (1997), the reasons 
behind these significant increases can be summarised as follows: 
 as a part of the Healthy People 2000 plan, the government set a goal that all 
children with a permanent congenital hearing disability would be identified 
before they reach 12 months of age; 
 technological developments such as the development of automated auditory 
brainstem response (ABR) equipment, and the effectiveness of transient 
evoked otoacoustic emissions, provided new tools for hospitals to use in 
newborn hearing screening;  
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 the National Institutes of Health held a Consensus Development Conference, in 
which they examined all the data related to the early identification of hearing 
disability and made recommendations in March of 1993; and 
 the 1994 Joint Committee on Infant Hearing (JCIH) Position Statement 
endorsed the goal of the universal detection of infants with hearing disability, 
and recommends the option of evaluating infants before their discharge from 
the newborn nursery.  
 
The number of hospitals that are implementing universal newborn hearing screening 
has rapidly increased since the early 1990s. According to NCHAM (National Centre for 
Hearing Assessment & Management), 33 babies are born each day in the US with as 
referring 12,000 to 16,000 yearly and universal newborn hearing screening programme 
screened 92.9% of all newborn babies in 2005 and 95.7% in 2006 respectively (NCHAM, 
2008). 
 
6.4. The Adoption of Cochlear Implantation 
6.4.1. Japan 
According to a survey carried out by MHLW of the Japanese government in 2001 
(MHLW 2002), there were about 346,000 individuals with hearing and language problems 
that grouped with over six degrees of disability. The Ministry of Health and Welfare 
considers that about 0.14% of the total population (about 172,000) are over three degrees of 
disability. The first cochlear implantation was carried out at Tokyo University Hospital in 
1985. Following the approval of the importation of Nucleus 22 Contour in 1991, cochlear 
implants rapidly increased in 2000. 
As shown in Figure 6-2, the number of cochlear implantation procedures performed 
has significantly increased since 1994, when public insurance programmes began to cover 
the procedure. As opposed to other countries, where the number of cochlear implantation 
procedures generally lies at 50%, the number of cochlear implantation procedures 
performed in Japan is much higher for adults than for children, reaching 66.4% of the 
cumulative total by the end of 2004. The advent of new products also promotes cochlear 
implants. Out of the cumulative total of 3,070 cochlear implantation procedures performed 
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by September 2003, 1,700 were carried out using Bionics products, including CLARION 
and CLARION HiFocus. 
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Figure 6-2. The number of cochlear implantation, Japan (1985-2006) 
 
Data sources: Association of Cochlear-Implant-transmitted Audition (ACITA 2007: personal communication).  
 
6.4.2. Korea 
A total of 137,822 persons were included in the disabled-person registration list as of 
September 2004 (Ministry of Health and Welfare 2004), which represents 0.28% of the 
total population of Korea. Among these, 68,192 had disabilities with over three degrees of 
severity. If estimated based on the Japanese guidelines, the candidates for cochlear 
implantation in Korea will be around 34,000. The first cochlear implantation procedure in 
Korea was performed in 1988, and 2,353 cochlear implantation procedures had been 
carried out by the end of 2006. About half of the implantees were children, and the number 
of children who undergo such procedure is rapidly increasing, as shown in Figure 6-3.  
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Figure 6-3. The number of cochlear implantation, Korea (1988-2006) 
 
Data sources: Personal communication with the device supplier of local agents (Starkey Korea,  
       Kwangwoo Medics). 
 
Following the start of public subsidy for cochlear implantation in 2002, and until 2004, 
the number of cochlear implantation procedures performed rapidly increased. In 2003 and 
2004, government subsidy benefited 58 and 100 cochlear-implantation patients, 
respectively (Ministry of Health and Welfare 2003, 2004b). The patient who obtains the 
government subsidy, however, still pays about £9,500 from his or her own pocket, which 
still significantly holds back the accessibility of the procedure. By virtue of the insurance 
coverage that was commenced in January 2005, the total share of the patient in the cost of 
cochlear implantation was reduced to about £2,000. In addition, charities also encouraged 
hearing-impaired patients to undergo cochlear implantation. Korea Telecom, for instance, 
shouldered the full cost of cochlear implantation and follow-up for 130 patients from 
September 2004 to May 2007 (Daily Seoul, May 10, 2007). 
 
6.4.3. UK 
In the UK, approximately 840 children are born each year with severe hearing 
impairment disabilities (Davis 1993).157 Summerfield and Tomlinson (1996) estimate that 
                                                 
157 The authors defined hearing impairment on the better ear as occurring at 40 dB HL over the frequencies 
0.5, 1, 2, and 4 kHz. Davis et al. (1997) found that the current health services in the UK may not be able to 
reach about 400 of these children by the time they become one and a half years old, and about 200 of these 
children by the time they become three and a half years old. Using the prevailing estimates derived from 
Trent Region, the number of children who might be hearing-impaired in the UK was calculated.   
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there are approximately 4,000 suitable candidates for cochlear implantation in the UK, and 
1,600 of these candidates may seek and receive the procedure. Each health authority may 
be required to accommodate two or three cochlear implantation procedures a year, with 0.5 
cases of postlingually deafened patients and two cases of prelingually deafened patients 
(Summerfield and Marshall 1995).158    
In 1990, there were very few cochlear implantation procedures performed in the UK159 
Special support from the government commenced in 1990, which encouraged many 
hearing-impaired individuals to avail of cochlear implantation (Summerfield and Marshall 
1995). The Department of Health initiated the “The National Cochlear-Implant 
Programme” in 1989 and 1990. Under the programme, funding from the central 
government is provided to partially support the cost of cochlear implantation. The 
programme was launched in 1990 for adults and children who were to undergo cochlear 
implantation at selected hospitals. The programme was initiated in Scotland in 1991, and in 
Northern Ireland in 1992. Since then, most of the cochlear implantation procedures have 
been performed under the national programme.160  
According to Summerfield and Marshall (1995), the national programme partially 
supported the cost of cochlear implantation for 92% of the adult implantees. In line with the 
national programme, 10 implant centres were established to improve accessibility. As a 
result, the number of centres providing cochlear-implantation services increased from 6 to 
16. As shown in Figure 6-4, the number of children who undergo cochlear implantation has 
rapidly increased since 1994. This is partly attributed to the evaluation carried out by 
Summerfield and Marshall in 1995, which stated that cochlear implantation is cost-
effective, and that the earlier the implantation is performed, the better the results will be. 
Screening programmes for hearing impairment during the neonatal period, which have been 
stressed since 1994, are also regarded as having facilitated the increase in the number of 
children who undergo cochlear implantation. 
 
                                                 
158 The Audit Commission (1997) also estimates that two or three cochlear implantation procedures may be 
required every year for each health authority. 
159 By 1990, about 60 people in the UK had undergone cochlear implantation. 
160 Under the national programme, majority of the patients, both adults (74%) and children (96%), were 
implanted with the Nucleus 22-channel system. The Ineraid system was used by 12% of the adult patients 
and 2% of the child patients. The UCH/RNID system was used by 10% of the adult patients (Summerfield 
and Marshall 1995). 
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Figure 6-4. Total cases implanted (1983-1999) 
Data sources: David Marshall (personal communication) 
 
6.4.4. US 
Blanchfield et al. (Blanchfield 2001) estimate that severe to profound hearing 
impairments in the US affects at least 464,000 persons, but possibly as many as 738,000. 
According to them, seniors represent 54% of the total, and those aged 18 to 64 represent 
38%. Children under 18 years of age represent approximately 8%. Based on the Bureau of 
Census data from 1998, it is estimated that a minimum of 5,600 children under two years of 
age are profoundly hearing-impaired. According to Christiansen and Leigh (2002), 50 % of 
cochlear implants were performed for adults in 1990, but the proportion for children 
increased to 95% in 2002.  
The data collected from Advanced Bionics Corporation and Cochlear Corporation 
reveal that 23,888 cochlear implantation procedures (82.88 pmp) have so far been carried 
out in the US (Summerfield et al. 2004).161 Garber and colleagues (2002) uncovered, 
through a hospital-wide survey in 1999, that hospitals lost more than $10,000 per device for 
inpatient surgery and about $5,000 per device for each outpatient. They argued that 
financial disincentives are likely to curb access to cochlear implants. Rand Corporation 
                                                 
161 The data were quoted from the 7th International Cochlear-Implant Conference, Manchester, UK, 
September 5, 2002.  
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(2002) also showed that insurance reimbursements that do not cover the physicians’ fees, 
the audiologists’ fees, and the hospital fees appear to limit access to cochlear implantation, 
especially for Medicare and Medicaid patients. In similar vein, Corporation Limited 
(Cochlear™, 2008), which has an approximately 60% market share in the US, estimates that 
a large part of the reimbursement for cochlear implantation comes from private health 
insurance, comprising more than 60%.  
 
6.5. Conclusion 
 
Cochlear implants support the hearing and communication abilities of individuals with 
profound hearing impairments who are unable to hear. A micro factor analysis confirms the 
economic, clinical and technological advantages of cochlear implants.  
 
There are currently about 120,000 people worldwide with cochlear implants, which 
increased from about 20,000 in 1998 (Cochlear Implant Online, 2008). The choice to give 
children the opportunity to hear through the cochlear implant is increasing at a remarkable 
rate. The estimation for the prevalence of the hearing impaired and the candidate for 
cochlear implants widely varies among the selected countries.  
As described in detail in chapter 6, the estimation for the demand of cochlear implant 
varies among four countries. The Ministry of Health, Labour and Welfare (2002) of 
Japanese government regards that there are about 385,000 people with hearing and 
language problems. Among them, about 86,000 individuals may require a cochlear implant 
In Korea, the Ministry of Health and Welfare (2004) estimates that about 0.28 % of the 
total population (representing 137,822 people) has hearing impairment. Among them, 
around 34,000 people are regarded as potential beneficiaries of a cochlear implant. 
In the UK, approximately 840 people are reported as having a permanent hearing 
impairment at birth (Davies, 1993). There are approximately 4,000 suitable candidates for 
cochlear implants in the UK, or 133 per 100,000 populations (Summerfield and Tomlison, 
1996). 
More than 25 million Americans suffer from hearing loss, including one out of four 
people older than 65 (FDA, 2001). The prevalence of severe to profound hearing 
impairment in the US accounts for at least 464,000 persons but possibly as many as 
 
 
155
738,000 persons (Blanchfield et al, 2001). The data on Table 6-5 shows the number of 
cochlear implants per million populations from 1996 to 2004. Until 1996, the number of 
implants was much higher in the UK and the US with 23.7 and 20.1 in pmp than the Japan 
and Korea that was 5.9 and 3.5 in respectively. Although the level of cochlear implant has 
been rapidly increased in both Japan and Korea, accumulative sum in pmp is still much 
lower than the UK and US. The increases were fast in Japan and Korea, with Korea at the 
front. The level of diffusion was the highest in the US.   
 
 
Table 6-5. Comparisons of changes in cochlear implant 
 
1996 2002-2004 
Cumulative total PMP Cumulative total PMP 
Japan   753 5.9 3,632 28.3 (2003) 
Korea   161 3.5 1,496 32.3 (2004) 
UK 1,399 23.7 3,872 65.2 (2003) 
US 5,343 20.1 21,688 72.7 (2002) 
Data sources: 1) Association of Cochlear-Implant-transmitted Audition (ACITA 2007: personal 
communication). Available at: 
http://www.normanet.ne.jp/~acita/info/arekore2.html#arekore1 (only a bar chart is 
provided, without the actual numbers). Accessed April 21, 2007. 
2) Personal communication with the device supplier of local agents (Starkey Korea,        
Kwangwoo Medics). 
3) Personal communication with Dr. David Marshall at the Medical Research Council 
Institute of Hearing Research, University Park, Nottingham, England  
4) Summerfield, A.Q., G.M. O’Donoghue, J. Graham (2002). Cochlear 
implantation and meningitis in the UK, 7th International Cochlear Implant 
Workshop, 15 September 2005, Manchester, UK. 
 
 
Figure6-5 shows the number of cochlear implants in the three countries162. Because the 
manufacturers were reluctant to release sales data, it was impossible to collect true data for 
the US by year. 
                                                 
162 Due to very low volume in Korea un the end of 1990s, the graph was composed with number of 
transplantation rather than in imp. To help recognition in pmp, Table 6-6 provide cumulative total 
numbers with counts in pmp 
 
 
156
0
100
200
300
400
500
UK 3 3 4 10 11 29 45 92 129 158 257 304 354 382 356 397
Japan 1 2 10 17 17 19 33 65 96 113 163 217 234 256 241 421 407 447 451 422
Korea 3 9 13 15 20 30 19 24 28 40 25 52 130 162 282 339 305
84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00' 01' 02' 03' 04'
Figure 6-5. Number of cochlear implant by countries (1984-2004) 
 
In Japan, the first cochlear implant was carried out in 1985. There were 3,632 cochlear 
implants by the end of 2004. Since public health insurance programmes began coverage of 
Nucleus 22 implantation in 1994, cochlear implants have increased. There are 69 hospitals 
carrying out cochlear implants in 2004. Rapid increase during the year of 2000 is mainly 
attributed to the provision of insurance benefits from social insurance programmes for both 
Nucleus 24 channel and CLARION. Based on ‘high unit cost refunding system,’ which 
paybacks exceeding certain amount of patient’s share incurred within a month, the patient 
pays up to about £270 (￥63,000, exchange rate at August 2007) and get refunds from 
insurance exceeding it, meaning that the bulk of £14.3k cost is covered by insurance. For 
the disabled registered as first degree and second degree, the patient pays only £8.6 
(￥2,000) and the remaining is supported by local government based on welfare benefit 
programmes for the disabled.  
In Korea, the first cochlear implant was performed in 1988, 408 cochlear implants had 
been carried by the end of 2000 and 2,353 by the end of 2006. 72 % were in children. The 
higher proportion of cochlear implant in children is attributed to the government’s subsidy 
that supported aged under 10 in the period 2002~2004 periods. No subsidy is provided for 
adults. Charities also aided children under 18.  
There are some other reasons behind this hasty increase from 1999: 1) the local agency 
providing Nucleus products changed in 1999. Advanced Bionics and Med-El began 
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marketing in Korea since 2000 and competition among them has been increasingly, 2) 
public insurance programmes began to cover the cost from 1 Jan. 2005 lowering patient’s 
share from about £13,382 to £2,000 meaning that about £9,382 is covered by insurance, 3) 
charities from private sector flooded in tandem with the commencement of insurance 
coverage.  
In the UK, the first adult was given a cochlear implant in 1983, but it was not until 
1987 that the first child received a cochlear implant. 180 profoundly deaf children who may 
require a cochlear implant are born annually. The unit cost of one type of multi-channel 
implant, with surgery and rehabilitation programme about £22,000 (£30,000 for a child). 19 
centres in the UK perform cochlear implant operations for children (RNID Helpline)163. 
“The National Cochlear Implant Programme” from 1990 encouraged cochlear implants. 
Central funding supports a portion of costs for cochlear implantation. The majority of 
patients have had cochlear implants under the national programme. The programme 
supported parts of costs for 92 % in adults. 10 implant centres were established to improve 
accessibility. As Cochlear implants in children have rapidly increased since 1994 as a result 
of financial supports and expansion of implant centres. Economic evaluation (Summerfield 
and Marshall, 1995) also may have spurred cochlear implantation. Screening programmes 
for hearing impairment in neonate, which has been stressed from 1994 may have facilitated 
cochlear implants in children. 
 
In the US, Medicare and Medicaid provide coverage for cochlear implantation. Most 
health insurance health plans also provide some level of benefit for cochlear implantation. 
Commercial health insurance programmes, such as Aetna, Blue Cross and Blue Shield, and 
Prudential have been the least restrictive for cochlear implants while managed care plans, 
especially HMOs, remain the most restrictive. 
Blanchfield et al. (2001) estimated that 71 % of cochlear implant procedures and users 
were covered under public insurance programmes of a federal or state health plan, such as 
Medicare, Medicaid, Veterans Administration, or Vocational Rehabilitation. The devices 
and other services associated with cochlear implants are covered by Medicare, Medicaid, 
the Veterans Administration and most private health insurance programmes. Private health 
                                                 
163 The Royal National Institute for Deaf People. Cochlear implant fact sheet.   
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programmes provide coverage for prosthetic devices and necessary procedures related to 
diagnosis and implantation including post-operative rehabilitation. Medicare coverage for 
cochlear implant became effective 1 October 1986, was revised in April 1998. Coverage for 
cochlear implant is limited to FDA-approved devices. Coverage and payment level in 
Medicaid programmes for cochlear implants are widely varied among different states. 
Medicaid programmes in several states have provided cochlear implants for children. The 
Early Periodic Screening, Diagnosis and Treatment programme requires states to provide 
benefits to be the only medically necessary means of treating a particular child. Medicaid 
coverage also includes any medically necessary service associated with the cochlear 
implant for the patients under aged 21.  
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Chapter 7: Gamma Knife Radiosurgery 
7.1 Introduction 
Gamma Knife radiosurgery is a method of administering high-dose radiation with 
surgical precision to a very specific area of tissue within the cranial region, while affecting 
an extremely small volume of the surrounding healthy tissue.164 Lars Leksell in Sweden 
developed this technology in 1967, and is currently marketing Leksell Gamma Knife®. The 
product has gradually gained acceptance and has spread more widely in the past 20 years.  
Gamma Knife radiosurgery has been recognised as highly effective in the treatment of 
certain malignant and benign brain tumours, arteriovenous malformations, and trigeminal 
neuralgia. In addition, the use of such procedure as a treatment for Parkinson’s disease, 
epilepsy, and intractable pain is showing promising research results. Its clinical applications 
continue to expand, with no mortality and minimal morbidity reported. Its present major 
indications include:  
 benign tumours such as meningiomas, acoustic tumours, and pituitary adenomas; 
 primary or recurrent malignant brain tumours;  
 solitary or multiple brain metastases;  
 arteriovenous malformations (AVMs);  
 trigeminal neuralgia;  
 intractable pain secondary to cancer; and  
 movement disorders such as Parkinson’s disease and essential tremor.  
 
A non-invasive procedure, stereotactic radiosurgery reduces the surgical risk and 
patient discomfort, resulting in a shorter hospital stay and a lower risk of developing 
complications. 
The first Leksell Gamma Knife® was installed in 1968 at Sophiahemmet, a private 
hospital in Sweden. As of December 2004, 204 units have been installed worldwide, as 
                                                 
164 The individual beams do not harm healthy tissue as they travel through the brain, but as they arrive at the 
abnormal target tissue, the concentration of all 201 beams has the capacity to destroy that tissue’s ability 
to survive. 
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shown in Table7-1. All in all, 42% of the total units are installed in the US, followed by 
Japan, which accounts for about 23% of the installed base.  
Table 7-1. Number of Gamma Knife units installed throughout the world 
North America (86) Canada (1), US (85) 
Asia (82) 
Japan (47), China (16; 1 in Hong Kong), Korea (8), India 
(3), Philippines (1), Singapore (1), Taiwan (5), Thailand 
(1) 
Europe165 (25) 
Austria (2), Belgium (1), Croatia (1), Czech Republic (1), 
France (2), Germany (5), Italy (4), Netherlands (1), 
Norway (1), Spain (1), Sweden (2), Switzerland (1), UK 
(3) 
Latin America (5) Argentina (2), Brazil (1), Mexico (2) 
Middle East (6) Jordan (1), Turkey (2), Egypt (1), Iran (2) 
Data Sources: Elekta (personal communication-2004)  
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Figure 7-1.  Approximate cumulative number of patients treated with Gamma Knife 
(1986-1999). 
Data sources: Leksell Gamma Knife Society. Indications treated in June 1999. (personal coomunication) 
Note: The 1999 data were projected from January-June 1999. 
 
Gamma Knife has been in use for over 30 years now, and has treated more than 
135,000 patients worldwide so far (American Shared Hospital Services 2000).166 As shown 
                                                 
165 Elekta is of the opinion that the number of Gamma Knife units installed in Europe is relatively low due in 
part to budget restrictions and uncertainties surrounding the levels of reimbursement among public 
healthcare principals. The company also believes that the new applications of Gamma Knife treatment 
methods have been an important factor in the rapid spread of Gamma Knife (personal communication with 
a marketing staff of Elekta). 
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in Figure 7-1, the total number of patients who had been treated with Gamma Knife 
doubled every two or three years. 
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Figure 7-2. Cumulative indications treated with Gamma Knife. 
Data sources: Leksell Gamma Knife Society. Indications treated in June 1999. (personal 
communication) 
 
 
Majority of the indications have been brain tumours, accounting for 75% of the total 
number of patients, as seen in Figure 7-2. Over one-hundred kinds of brain tumours have 
been reported to World Health Organisation. As the number of indications that may benefit 
from Gamma Knife radiosurgery is increasing, it is difficult to postulate the demand for its 
use. Bearing in mind the incidence of brain tumour, which has been a major indication of 
Gamma Knife radiosurgery, it is possible to approximate the demand.  
 
7.2. Micro Factor Evaluation 
7.2.1. Economic Factors 
It is generally accepted that the fact that Gamma Knife radiosurgery requires shorter 
hospitalisation and consequently incurs lower costs is an important economic advantage of 
the procedure compared to the conventional surgical procedures (Unger et al. 1999, 
                                                                                                                                                    
166 American Shared Hospital Services. The data were retrieved from the company’s Web site. 
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Königsmaier et al. 1998167, van Roijen et al. 1997168, Rutigliano 1995169). Through a 20-
year Medline database search, Mehta et al. (1997) found that the Gamma Knife 
radiosurgery results compare extremely well with resection in terms of the cost parameters 
for all the courses of the procedure.170 In addition, Ott (1996) found that Gamma Knife 
radiosurgery has a 30% cost advantage over surgical resection in craniotomy. Johansson171 
in Elekta maintains that Gamma Knife technology saves roughly 3,000 hospital bed-days 
and 500-700 intensive-care units in Europe.  
As a great deal of capital is required for equipment purchase, there is an argument that 
capital cost effects must be considered in a cost effectiveness analysis (van Roijen et al, 
1997). In the radiosurgery treatment of patients with acoustic neurinoma, the capital cost 
amounts to about 40% of the healthcare cost (van Roijen et al. 1997).172 The argument that 
programs with high investment costs make up only a minor fraction of the total cost of the 
healthcare sector may lead some people to make the conclusion that investment costs and 
capital costs can also be regarded as variable costs, at least in the long run. This does not 
imply that capital costs can be treated indirectly in a cost-effective analysis. However, the 
capital costs for adoption, priced at about £23.3 million, become a significant variable in 
the decision to adopt the treatment procedure. 
There are some conflicting views, however, as regards the superiority of radiosurgery 
over surgical intervention. Using a decision analysis model, Porter et al. (1997) recognised 
                                                 
167 The research compared the cost effectiveness of Gamma Knife and that of the linear accelerator. 
168 According to them, the cost of radiosurgery is much lower (the direct cost of microsurgery amounted to 
Dfl. 20,072, and of radiosurgery, Dfl. 14,272; the indirect costs were Dfl. 16,400 and Dfl. 1,020, 
respectively), while the general health rating of radiosurgery was better than that of microsurgery.  
169 Rutigliano et al. (1995) revealed that, compared with surgical resection, radiosurgery had a lower 
uncomplicated procedure cost (US$20,209 vs. US$27,587), a lower average complication cost per case 
(US$2,534 vs. US$2,874), and a lower total cost per procedure (US$22,743 vs. US$30,461). In their study, 
radiosurgery was disclosed as more cost-effective (US$24,811 vs. US$32,149 per life year) and as having 
a better incremental cost effectiveness (US$40,648 vs. US$52,384 per life year) than surgical resection. 
170 The cost of surgery, compared to that of radiosurgery, was higher for each item: hospital cost (3.1), 
professional fees (1.0), medial hospital days (7.2), operating room (4.4), central supply (6.6), pharmacy 
(11.7), radiology (2.1), recovery room (27.6), anaesthesia (3.8), laboratory (34.7), ICU (1, 35), and other 
costs (4.7).  
171 Personal communication. His assumption is based on the fact that the average European Gamma Knife 
centre treats approximately 250 patients annually. 
172 Another example of a procedure where the capital cost amounts to a significant fraction of the total 
treatment cost is the extracorporeal shock-wave lithotripsy of uretarial stones and gallstones. The capital 
cost of the equipment accounts for about 45% of the total treatment costs in the treatment of gallstones, 
and for about 40% in the treatment of uretarial stones (SBU 1990). Likewise, for some diagnostic 
procedures, such as CT scans and MRIs, the capital cost is high. 
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that although radiosurgery is less expensive, surgery yields almost one full quality-adjusted 
life year (QALY) more than radiosurgery173 does, primarily because of the haemorrhages 
that occur during the latent period after radiosurgery. 
 
7.2.2. Clinical Factors 
Since Gamma Knife does not require an incision, and in most cases is applied with 
only a mild sedation and local anaesthetic, the risks of infection and adverse reaction are 
eliminated.  
The benefits of Gamma Knife radiosurgery in terms of clinical effectiveness have been 
widely recognised in the following: 
 melanoma metastases (Mehta et al. 1997, Rutigliano et al. 1995, Seung et al. 
1998) ; 
 meningiomas (Iwai 1999, Subach et al. 1998, Pendl et al. 1997) ; 
 pituitary adenomas (Mokry et al. 1999); 
 Parkinsonian tremor (Duma et al. 1998); 
 epilepsy (Sims et al. 1999, Bartolomei 1999); 
 glomas tumour (Sims et al. 1999, Liscak 1998, Eustacchio et al. 1999) ; 
 arterio-venous malformation (Sims et al. 1999, Nicolato et al. 1997174, Aoki et 
al. 1996) ; 
 trigeminal neuralgia (Regis et al. 1995); and 
 trigeminal schwannomas (Noren 1998, Unger 1999). 
 
                                                 
173  This results in a US$7100/QALY incremental cost effectiveness for surgery, using a decision analysis 
model to analyse the cost effectiveness of surgery vs. radiosurgery for operable AVMs. In their research, 
surgery confers a 0.98 quality-adjusted life year (QALY) advantage over stereotactic radiosurgery in the 
treatment of small AVMs, at an additional cost of US$6,937 per patient. They thus refer to an incremental 
cost effectiveness ratio of US$7,100 per QALY for a patient treated surgically. According to them, such 
result is sensitive to only two variables: surgical morbidity and surgical mortality. The preferred treatment 
strategy changes to favour stereotactic radiosurgery only at the extreme high end of the possible range for 
these variables, when the rate of permanent neurological morbidity resulting from surgery exceeds 12%, 
or when the surgical mortality rate exceeds 4%. 
174 The research was carried out in Italy with 721 patients who had stereotactic GK radiosurgery from 
February 1993 to February 1996, including 20 who were of paediatric age (3%). Of the 78 AVMs, 7 (9%) 
were diagnosed in children. The results suggest that in children, as in adults, the use of stereotactically 
delivered irradiation represents a safe and effective technique that attains the complete obliteration of 
AVMs previously considered surgically inaccessible. 
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Whereas the uses of Gamma Knife radiosurgery indicate successful outcomes, the 
results are not always favourable. Although Gamma Knife radiosurgery entails highly 
localised therapy, thus confining the damage to the target, the risk of injury increases with 
the size of lesion and the radiosurgery dosage (Brada and Kitchen 2000).175 Minor adverse 
effects have also been reported. Local pain, swelling in the scalp, and headaches are 
common complaints that have been reported in the short term after surgery. A number of 
patients also complained of skin reddening and irritation, nausea, and seizures. Though 
uncommon, some delayed complications have been reported as well, such as the local loss 
of hair in the superficial lesions, local brain swelling at the treatment site, and local necrosis 
at the treatment site. 
 
7.2.3. Technical Factors 
Gamma Knife can also be a good option for those patients who are not candidates for 
traditional surgery due to their age or medical conditions. Patients undergoing Gamma 
Knife treatment also do not need to worry about the side effects that accompany chemo or 
conventional radiation therapy, such as hair loss, scarring, or disfigurement.  
In most cases, Gamma Knife patients resume their normal activities within one or two 
days following the treatment, compared to weeks or months for those undergoing 
conventional surgery. The advantages of the use of Gamma Knife radiosurgery can be 
summarised as follows (Unger, Walch, and Papaefthymiou et al. 1999; Unger, Walch, and 
Haselsberger et al. 1999; van Roijen 1997; Königsmaier et al. 1998; van Roijen et al. 
1997): 
 economic advantages; 
 elimination of the risks of infection and adverse reactions; 
 short treatment time; 
 short hospitalisation and no convalescence; 
 high cure rate; 
 very low morbidity; and 
 high patient satisfaction and quality of life. 
                                                 
175 They found an increased risk of rebleeding in patients, with an annual rebleeding rate of 6%.   
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7.3. Macro Factor Evaluation 
7.3.1. Japan 
Gamma Knife radiosurgery had been grouped in SHT, and thus, costs were not covered 
under the insurance programme. Beginning April 1, 1996, public health insurance 
programmes in Japan began covering Gamma Knife radiosurgery.  
The costs for GKR vary according to the insurance programmes providing coverage. 
The total cost of using GMK is about ¥700,000 (equivalent to £40,000 as of December 
2000) in Japan. Currently, those belonging to the Employee Health Insurance (EHI) 
programme and National Health Insurance (NHI) programme, who should share 30% of the 
total cost, pay about ¥240,000 (£1,200), plus ¥2,400 (£120) for meal services and ¥210 (£1) 
for gowns.  
To curtail the health expenditure increases, the Japanese government cut the 
compensation rate for health services by 2.7% in April 2002 (1.4% for medical practices 
and 1.3% for pharmaceuticals). This significantly impacted the income of hospitals. Along 
with health reforms aimed at curbing health spending, the Japanese government classified 
the hospital beds in August 2003 as acute, specialised, or nursing care through applications 
from hospitals and healthcare facilities. The classification of hospital beds to improve their 
utilisation in accordance with a patient’s needs led hospitals to focus on their main 
competence, which increased the competition among the acute-care hospitals furnished 
with advance technologies (Nikkei Healthcare). Subsequently, the acute-care hospitals 
sought to extend their market share by building coalitions with other healthcare providers 
grouped in other functions. 
 
7.3.2. Korea 
In Korea, public health insurance programmes did not cover Gamma Knife 
radiosurgery until March 2004. In the early 1990s, the cost was about ￦9 million 
(equivalent to £4,500 as of December 2004), including the cost of MRI, then it dropped to 
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about ￦7 million (£3,500).176 With the extension of the insurance coverage to include 
Gamma Knife radiosurgery, the patient paid only 20% of the total cost of the treatment (the 
total cost of the treatment was around £1,500). The public insurance programme in Korea 
refunds a patient’s entire share in excess of £1,800 and incurred within a month following 
its coverage.  
A lease company, Hanbul Lease, provided hospitals with loans to install Gamma Knife 
units, with the contracts redeeming within five years. The company, like others acting as 
intermediaries of high-cost medical equipment such as Gamma Knife, MRI, and CT, went 
out of business following the Asian financial crisis177 in the late 1990s. As such, no more 
units were installed thereafter. The collapse of the leasing companies in the aftermath of the 
financial crisis was another significant factor that led to a halt in the diffusion of medical 
technologies in Korea. Due to the lower value of the Korean currency, the leasing company 
was dissolved, which discontinued the distribution of Gamma Knife in the latter part of 
1997. After 2001, another company entered the market and resumed the trade of Gamma 
Knife. 
 
7.3.3. UK 
There are three main sources of payment for Gamma Knife radiosurgery: private 
insurance companies, self-pay, and NHS. Prior approval is required for both privately 
insured and NHS patients. The composition of patients by payment sources at Cromwell 
Hospital in London in 2000 is shown in Figure 7-3.178  
 
                                                 
176 Based on Section 17 of the Detailed Enforcement Regulations of the Customs Law, imported Gamma 
Knife units are subject to tax cuts. According to Section 18, teaching hospitals may obtain a 50% tax cut 
when they use the units for clinical practices. Currently, the tariff rate in Korea is 8%. Assuming a 50% 
tax cut, a teaching hospital will have to pay a custom tax of about £108 thousand when importing a 
Gamma Knife unit. If the hospital buys any medical device or a reagent for research priced at over 1 
million Korean won (equivalent to £524 as of January 2001), they will receive a 90% tax cut.  
177 In Korea, the Asian financial crisis caused numerous companies to go bankrupt. As the credit ratings for 
foreign loans were downgraded, the Korean currency was significantly devalued, and the country’s 
external debt remarkably increased.  
178 A Gamma Knife unit was installed in 1988 in Cromwell Hospital. 
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Figure 7-3. Sources of payment for Gamma Knife use 
Data sources: The data was obtained from the website of Cromwell Hospital in London in October 
2005 (personal communication) 
 
Gamma Knife radiosurgery is an item included in specialised services, and thus should 
be referred to a consortium arrangement. Regional offices were made accountable for 
developing new and effective arrangements to address these concerns. Consequently, all 
regions moved to establish Regional Specialist Commissioning Groups (RSCGs) in 1998 
and 1999 (NHS Executive, London Regional Specialised Commissioning Group Annual 
Report 1999/2000).179 
 
                                                 
179 In Trent Region, the health authority placed high local priority to genetic services and stereotactic 
radiosurgery in the fiscal year 1999/2000. The RSCG of the Trent Region Health Authority established a 
review group in 1999 to consider the future provision of stereotactic radiosurgery. The review group 
examined the issue in light of the Region Office’s decision not to support the replacement of the existing 
Gamma Knife unit at Central Sheffield University Hospital with a new Gamma Knife unit, but to support 
instead the short-term lease of a new Gamma Knife unit pending its replacement in due course with a 
dedicated linear accelerator (LINAC). At the May 2000 meeting of RSCG, it was agreed that Central 
Sheffield University Hospital NHS Trust should continue to function as a national centre for stereotactic 
radiosurgery, albeit using LINAC instead of Gamma Knife. The dedicated LINAC should be installed as 
soon as possible so that the Gamma Knife lease could end in three and a half years’ time, as scheduled. 
The continued use of the adapted LINAC at Nottingham City Hospital NHS Trust was not supported. If 
the Gamma Knife unit will not be replaced when its lease ends and one more unit will be installed in 
London, three Gamma Knife units will be operated in London. 
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7.3.4. US 
Since Food and Drug Agency (FDA) approval in 1989, Gamma Knife radiosurgery has 
been performed extensively in the treatment of various brain disorders. In the US, 
American Shared Hospital Services, Inc., a heavy shareholder of GK Financing LLC 
(GKF), plays a significant role in providing Gamma Knife radiosurgery services.180 GKF 
provides Gamma Knife services, primarily on a usage-only basis, to major university 
hospitals and large metropolitan medical centres. GKF typically contracts with customers 
for periods of 10 to 15 years. Along with the provision of Leksell Gamma Knife, GKF 
assists the medical facility in the planning and design of its Gamma Knife centre, assists in 
the negotiations with the third-party payers, and provides ongoing marketing support for 
Gamma Knife services. Typically, GKF provides the Gamma Knife unit, which costs about 
US$2.9 million, and the medical centre is responsible for the site and installation costs. 
GKF is typically reimbursed (on a usage-only basis) between US$7,500 and US$9,500 per 
procedure.  
Regarding the adoption of the Gamma Knife unit, the CON (Certificate of Need) 
requirements vary from state to state in their application to the operations of both GKF and 
its customers. In some jurisdictions, GKF is required to comply with the CON procedures 
to be able to provide its services, while in other jurisdictions, the customers must comply 
with the CON procedures before availing of the GKF services. 
Most insurance plans (including Medicare), managed-care plans, and indemnity plans 
in the US cover Gamma Knife radiosurgery.181 A significant fraction of the current 
contracts are reimbursed by the medical centre to the company on a fee-for-service basis.  
Since October 1, 1997, the Gamma Knife services for Medicare hospital inpatients 
have been reclassified based on the DRG scheme. Consequently, it is estimated that 
                                                 
180 Eighty-one % of GK Financing LLC (GKF) is owned by American Shared Hospital Services, and 19% by 
Elekta, the manufacturer of Gamma Knife. Currently, GKF operates nine proprietary therapy clinics using 
Gamma Knife units (Elekta 2000, 1998/1999 Annual Report). 
181 As an example, Aetna US Healthcare covers the following surgical procedures for the treatment of 
trigeminal neuralgia when the patient selection criteria listed below are met (Aetna US Healthcare 
Coverage Policy Bulletin, No. 374): 
- percutaneous glycerol rhizotomy (or injections);  
- percutaneous radiofrequency rhizolysis/rhizotomy;  
- balloon microcompression;  
- microvascular decompression; and  
- use of Gamma Knife. 
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medical-centre revenues have been reduced by the Medicare DRG programme by 
approximately 30%. APC (Ambulatory Product Classifications) Scheme 182 categorises 
Gamma Knife radiosurgery as a conventional radiation therapy. Therefore, the two 
procedures receive the same reimbursement amounts. This categorisation makes no 
distinction with regard to the types of resources utilised for each procedure classification. 
Therefore, regardless of the resource consumption and the clinical outcomes, all the 
procedures within a group qualify for equal reimbursement. Specifically, stereotactic 
radiosurgery receives the same reimbursement per session that conventional radiation 
therapy does. This will result in a significant decrease in the reimbursement that will be 
given to Medicare-covered Gamma Knife patients who are treated on an outpatient basis. 
 
7.4. The Adoption of Gamma Knife Radiosurgery 
7.4.1. Japan 
By the end of 2004, 47 Gamma Knife units had been installed since May 1990, when 
the University of Tokyo adopted the first unit. Currently, Japan has the second highest 
number of Gamma Knife units in the world, next to the US. As shown in Figure 7-4, 
hospitals adopted more Gamma Knife units when public health insurance programmes 
began to cover Gamma Knife radiosurgery. 
Since April 2003, a high-medical-cost refunding system was introduced, which 
reimbursed patients who paid an amount beyond a certain limit within a month.183 The 
                                                 
182 The Omnibus Reconciliation Act (OBRA) of 1986 directed HCFA to develop a prospective payment 
system for hospital outpatient care. Ambulatory Payment Groups (APGs) were developed in response to 
this directive. The Balanced Budget Act of 1997 (BBA) requires HCFA to implement this outpatient 
prospective-payment system (OPPS) by January 1, 1999. It is anticipated that most hospital outpatient 
services will be included in the new OPPS, as well as in free-standing ambulatory surgery centres. 
DHHS has proposed a new payment system, Ambulatory Product Classifications (APC), which affects 
all outpatient services, including those performed in a hospital-based or free-standing facility. Effective 
July 1, 2000, Medicare reimbursed the facility component of hospital-based outpatient services using the 
APC system. The APC consists of 346 clinically homogenous classifications or groupings of codes that 
are typically used in outpatient billing. Outpatient services is to be bundled with fixed rates of payment 
determined according to specific regional and national factors, similar to that of the inpatient PPS. Overall, 
the system is expected to reduce payments for select services and to encourage the most efficient use of 
resources for outpatient care. 
183 The basis for refund varies in accordance with the income level. A large-income earner who earns more 
than ¥560,000 (£2,800) a month can receive a refund of the entire amount paid by him or her for the 
treatment in excess of ¥139,800 (£700) in a month, while the ceilings are ¥73,200 (£366) for ordinary 
earners and ¥35,400 ((£177) for those in the lower-income bracket who are exempted from general 
taxation.    
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number of unit installations increased again as a consequence of the introduction of the 
refunding system. With increased units, the poor level of utilisation per unit resulted in 
financial burden to the hospitals. In an effort to overcome that hurdle, individual hospitals 
sought to increase the number of patients who have suitable indications for the application 
of the unit by networking with other hospitals for the sharing of the unit.  
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Figure 7-4. The number of Gamma Knife units installed (1990-2004) 
 
Data Sources: Japan Gamma Knife Support Association (personal communication) 
 
7.4.2. Korea 
Gamma Knife was adopted in Korea before it was adopted in Japan. The Asan Medical 
Centre, which belongs to the Hyundai Group, introduced the first unit in May 1990. As 
shown in Table 7-2, by the end of 2005, eight Gamma Knife units had been installed in 
Korea, and one more unit was scheduled to be installed. There are more hospitals that are 
considering the adoption of Gamma Knife units. However, many hospitals hesitate to adopt 
the unit because of the number of hospitals that already operate the units and the difficulties 
in achieving profit out of the use of the unit. Those professionals who are using Gamma 
Knife technology acknowledge that the market for patients who require Gamma Knife 
radiosurgery in Korea is too small, and thus, the existing supply of the units already 
exceeds the demand for them. As a result, hospitals tend to drop their fees in order to 
compete with other hospitals.  
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Table 7-2. Installation of Gamma Knife units in Korea 
Hospital Installation 
Asan Medical Centre (Hyundai 
Conglomerate) 
May 1990/ replaced in May 
1996 
Kyung Hee University Hospital March 1992 
Yonsei University Medical Centre April 1992 
In Je University Paik Hospital  October 1994 
Seoul National University Hospital December 1997 
Seoul Samsung Hospital December 2001 
Busan National University Hospital October 2003 
Chun-Nam National University Hospital April 2004 
Kyung-Buk National University 
Hospital 
January 2005 (scheduled to be 
installed) 
Data Sources: Elekta Korea (personal communication) 
 
 
Increased competition and the low level of compensation for health services impel the 
adoption of Gamma Knife units as well as other high-end technologies in Korea. First, 
competition based on advanced facilities and equipment has been triggered in the aftermath 
of the large-scale entry of conglomerates into the hospital industry, as typified by Asan 
Medical Centre and Samsung Hospitals. To compete with other hospitals, the leading 
conventional hospitals began to construct new facilities equipped with advanced medical 
equipment. Second, the financial difficulties of hospitals spurred them to adopt advanced 
technologies. Of the total, 8.9% went bankrupt in 2001, 6.5% in 1999, and 7.4% in 2000. 
This phenomenon was caused not only by the introduction of a new system in 1999 that 
separated the dispensary from medical practice, but also by the low level of compensation, 
which has been the main yardstick for controlling healthcare expenditure. Ever since the 
policy separating medical practice and pharmaceutical services was implemented, patients 
have moved from ambulatory-care physicians to tertiary-care hospitals. The fall in patient 
numbers has resulted in the failure of many hospitals. As a strategy to improve their 
competitiveness and income, hospitals adopt expensive medical equipment. The following 
data support the claim that the adoption of the aforementioned advanced technologies is 
common in Korea. As shown in Table 7-3 and Table 7-4, the number of expensive 
equipment being adopted by Korean hospitals is the highest in the world. 
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Table 7-3. CT installation in 1997 (pmp) 
Nation Japan US Korea Australia 
CT 55.4 26.2 17.48 13.8 
Data Sources: Yoon et al. (1997) 
 
Table 7-4. MRI installation in 1997 (pmp) 
 
MRI Pmp GDP 
MRI 
against 
GDP 
MRI pmp 
against 
GDP 
US  4,002   14.2   29,964    5.88    0.95 
Japan   270   21.5   33,289    3.57    1.30 
Germany   650    7.9   25,596    1.11    0.62 
Korea   234    5.1   10,307    1.0    1.0 
UK   157    2.7   21,832    0.31    0.24 
France   138    2.4   23,789    0.25    0.20 
Data Sources: Ad Hoc Committee on Diagnostic Radiology, Korean Radiological Society (2000) 
 
7.4.3. UK 
The National Centre for Stereotactic Radiosurgery in Sheffield opened as the 
Department of Health funded the unit for a five-year research project, which commenced 
patient treatment in September 1985. In bringing the research project to an end in 1990, the 
Department of Health recognised the unit as a supra-regional speciality, once the efficacy 
of the treatment had been proven. The unit was the third installed for clinical use in the 
whole world. It remained the only unit in Britain until 1998, when a second unit was 
installed at Cromwell Hospital in London.  
The third unit was installed at Barts and London NHS Trust in 1999, as a joint private 
finance initiative (PFI).184 Since the first installation by PFI, no further adoption has been 
                                                 
184 Public Private Partnerships (PPP) is the umbrella name given to a range of initiatives involving the private 
sector in the operation of public services. The key difference between PFI and the conventional ways of 
providing public services is that in the former, the public does not own the asset. The authority makes an 
annual payment to the private company providing the building and associated services, like a mortgage. 
The PFI is one of a range of initiatives introduced by the last Conservative government, aimed at 
increasing the private-sector involvement in the provision of public services. The Labour government has 
sought to “reinvigorate” PFI by streamlining the process and concentrating on “viable” projects. UNISON, 
the largest trade union in the UK, with over 1.3 million members, officially opposes PFI in NHS for the 
following three reasons. First, under PFI, the government can borrow money at preferential rates of 
interest. Over the long term, the cost of providing new facilities through private investment will thus 
become higher. Second, the banks and operating companies will also want profits, as opposed to the 
government’s not-for-profit ethos. The profit levels are also kept confidential. Third, the private-sector 
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promoted so far. A new initiative involving the London Radiosurgical Centre, Bart’s and 
The Royal London NHS Trust, and The London Clinic, together with a £3. 5-million 
investment, has brought the non-invasive Gamma Knife to the London Radiosurgery 
Centre (GP Newsletter Issue 27, December 1999, London Radiosurgical Centre, Ltd.). 
 
7.4.4. US 
In 1995, malignant brain tumours accounted for 12,062 deaths in the US, and 947 
deaths were due to benign brain tumours. If the reported cases of brain tumour deaths for 
uncertain and unspecified behaviour were included, the total deaths caused by brain 
tumours would amount to 15,928 (Preston-Martin and Mack 1996). The Central Brain 
Tumour Registry of the United States (CBTUS) reported an incidence rate for all primary 
brain and central-nervous-system tumours, including the pituitary and pineal glands, of 
11.8 per 100,000 for 1990-1993 (Davis, Bruner, and Surawicz 1997). The incidence rate of 
primary malignant brain tumours is 5.8 cases per 100,000 person-years. The rate is higher 
for males (7.0 per 100,000 person-years) than for females (4.7 per 100,000 person-years) 
(Ries 1998). 
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Figure 7-5. The installation of Gamma Knife units in the US (1987-2000) 
Data sources: Elekta (personal communication) 
                                                                                                                                                    
provision of services will lead to a loss of accountability and control. In PFI hospitals, for example, the 
needs of the PFI consortium will be the key factor in decision-making, not the needs of NHS. PFI was also 
firmly opposed by BMA at its annual representative meeting in 1996 (BMJ News, July 6, 1996). In the 
words of Dr. Stephen Watkins, chairman of the BMA’s Public-Health Committee, “We must say that we 
are not prepared to hand over NHS money to the private sector at an exorbitant interest rate.”  
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The first Gamma Knife system was installed in 1987 in the Presbyterian University 
Hospital of the University of Pittsburgh in the US. From then until June 2000, 61 Gamma 
Knife units were installed in the US, which accounted for 43% of the total number of units 
installed around the world. As shown in Figure 7-5, the installation of Gamma Knife units 
has rapidly increased over the years. 
GKF has played a significant role in spreading Gamma Knife units in the US. Since it 
is GKF that provides the Gamma Knife unit to the buyers, those hospitals that want to 
adopt the unit are required only to provide a site for the unit and to shoulder the installation 
costs. After the installation of the unit, GKF is paid from US$7,500 to US$9,500 for each 
procedure. Since the annual patient volume for all the reporting Gamma Knife centres is 
approximately 175, GKF takes in an estimated US$1.3 million to US$1.66 million a year.  
Although the reimbursement policy reduces the fees for the use of Gamma Knife 
radiosurgery as a result of the latter’s reclassification in the Medicare DRG, this has 
minimally influenced the adoption of the Gamma Knife unit by hospitals.  
 
7.5. Conclusion 
 
Potential demand for using Gamma Knife radiosurgery varies among the case study 
countries. According to The Committee of Brain Tumour Registry of Japan, 12.76 per 
100,000 of the population have been reported as brain tumour patients in Japan. During 
1993, the newly registered number of primary and metastasis brain tumour patients185 was 
5,076 in Japan. As shown in Table 7-5, the reported number of patients is much lower in 
Korea186 than the other countries. The incidence level in the UK is quite similar to that of 
the US, which is about half of the incidence level in Japan. Further investigations on the 
incidence of brain tumours and other diseases of which Gamma knife radiosurgery can be 
applied are required to appropriately compare the demand for Gamma knife unit. 
 
                                                 
185 Metastasis is the spread of cancer from one part of the body to another. The original location is called the 
primary tumour. Metastatic tumours are tumours that arise at sites away from the original location. Cancer 
cells from the primary site can break away and enter the body's circulatory system blood stream, lymph 
system or spinal fluid and travel to distant locations. The most common pathway for metastasis to the 
central nervous system is via the blood stream. Tumours in the brain are the most common form of central 
nervous system metastasis.  
186 According to Central Cancer Registry in Korea of the Ministry of Health and Welfare, the data covers 
about 80 % of cancer patients across the country. 
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Table 7-5. Incidence of brain tumour (per 100,000)  
Japana Koreab UKc USd 
12.76 2.7 6.5 6.9 
Data sources: 1) The Committee of Brain Tumour Registry of Japan. Report of Brain Tumour Registry of        
Japan (1969-1993) 10th Edition, Neuralgia, supp. Vol. 40, Jan. 2000. 
2) Annual Report of the Central Cancer Registry in Korea (Based on Registered Data from 128 
Hospitals) (2001) Central Cancer Registry Centre in Korea, Ministry of Health and Welfare, 
Republic of Korea 
3) Office for National Statistics, Office of National Statistics Series MBI No. 25 published 
1998 
4) National Cancer Institute, SEER Cancer Incidence, 1992-1998 
Note: a. the number refers to 1989-1993 
     b. the number comprising tumours in eye, brain and other parts of central nervous system  
     c. the number refers to 1992 
     d. the number refers to 1992-1998 as comprising tumours in brain and other nervous system 
 
In terms of a million per one unit, as shown in Table 7-6, Japan is the highest in 
adopting Gamma Knife technology among the case study countries. Adoption in the US is 
quite similar to that of Japan, while the UK has the lowest level.  
 
Table7-6. Populations per one unit of Gamma Knife (Unit: million) 
Japan Korea UK US 
2.71 5.95 19.74 3.39 
 
Health insurance programmes in Japan have covered Gamma knife radiosurgery since 
1996. The decision for adopting Gamma Knife is fully made by health care providers 
including physicians or hospitals. Public insurance programmes have covered Gamma 
Knife radiosurgery since 1996. The situation in Korea is broadly similar to that of Japan. 
Taking into account the incidence of brain tumours, potential demand is believed to as 
much as five times higher in Japan compared to Korea. The public insurance programme 
has covered Gamma Knife radiosurgery since 2002 in Korea.  
 
Gamma Knife radiosurgery is regarded as better than surgical intervention in economic, 
clinical, and technical terms. The Gamma Knife unit differs from other HTs with its high 
capital cost requirement for installation and high operation cost subsequently. 
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Chapter 8: Kidney transplantation 
8.1 Introduction 
Kidney transplantation is required when a patient has irreversibly deteriorated renal 
functioning generally caused by glomerulonephritis, pyelonephritis, diabetes mellitus, 
polycystic kidney disease, or vascular disease (chiefly, hypertension). When a patient falls 
into a condition in which there is a decline in the capacity of his or her kidneys to extract 
excess fluids and poisonous wastes from the blood, the state the patient is in is called 
chronic renal failure, and the patient eventually reaches the point called end-stage renal 
disease (ESRD).   
The current possible approaches to managing ESRD patients are continuous 
ambulatory peritoneal dialysis (CAPD), home dialysis, hospital dialysis, and kidney 
transplantation. Based on the results of a cost-benefits analysis, transplantation is preferred 
by younger patients. Primarily, the decision as to which treatment modality will be resorted 
to depend on the availability of an organ donor, the physical condition of the patient, and 
the latter’s ability to cope with the alternative treatment modalities.   
 
Reflecting cultural heritage, there are huge differences in the legislation around the 
world that authorise organ procurement and direct organ donation. The primary role of 
legislation has been to authorise legitimacy for organ procurement from donors. It also 
becomes a barricade restricting organ transplant when the law prohibits commercial trading 
in organ donation for transplant purposes. The legislation in some countries requires 
medical professionals to promote organ donation, while that in some other countries stands 
for a passive position on organ procurement.  
 
Among the different organ transplantations, only kidney transplantation is generally 
accepted as better than the other compatible renal-replacement treatments for patients with 
ESRD (Douzdjian et al. 1998, Evans and Kitzmann 1998).  
The adoption of overall organ transplantation is greatly varied, ranging from 86.1 pmp 
at the highest to 9.6 at the lowest among some OECD countries, as shown in Table 8-1.  
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Table 8-1. Organ transplants in 2003 (pmp) 
Country Kidney Liver Heart Heart+ 
Lung 
Lung Pancreas Kidney+ 
Pancreas 
Total 
Austria 47.9 18.4  7.8  0.1  10.9   0.9   4.1  86.1 
Spain 49.8 24.0  6.7  0.1   3.4   0.1   1.6  85.7 
US 47.6 18.0  6.5  0.1   3.5   1.6   2.8  80.1 
Norway 52.8  8.3  9.6  0.2   4.2   0.4   2.4  77.9 
France 34.7 13.4  4.6  0.3   1.3   0.1   1.1  55.5 
Sweden 38.5 13.4  4.0  0.2   3.0   1.1   0.2  55.5 
Italy 29.4 15.8  5.6  0.0   1.2   0.4   0.9  53.3 
Germany 28.4 10.4  4.5  0.2   2.3   0.3   2.1  48.2 
Netherlands 35.5  6.0  2.5  0.1   2.0   0.1   1.0  47.2 
UK 28.5 10.6  2.5  0.3   2.3   0.2   0.7  45.1 
Korea* 18.0 10.2  0.3  0.0   0.0   0.2 -  28.7 
Japan  6.8  2.8  0.0  0.0   0.0   0.0   0.0   9.6 
Data sources: International Registry of Organ Donation and Transplantation. Definitive data of 
international transplant activity (IRODAT 2003 
Note: * Korean Network for Organ Sharing (KNOS) 2003 Annual Report  
 
Figure 8-1. The prevalence of ESRD therapy (pmp). 
Darta sources: United States Renal Data System (USRDS), 2007 Annual Data Report. 
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The prevalence of ESRD is widely varied among the selected countries. The prevalence 
of patients who require renal-replacement treatments is high in the US, Japan and Korea 
than the UK, as shown in Figure 8-1. The difference may primarily be due to the variation 
among the countries in terms of the primary diseases therein that causing chronic organ 
failure.187 The incidence of ESRD patients is also greatly varied even within a country, 
according to the country’s social and economic conditions and ethnicity. In the US, for 
example, the rate of ESRD incidence in 1998 in terms of pmp was 199 in the white 
population and 829 in the black population (USRDS, USRDS 1998 Annual Data Report 
1998). 
 
Figure 8-2. The ratio of ESRD patients with a functioning graft. 
Data ssources: United States Renal Data System (USRDS), 2007 Annual Data Report  
Note: The data for Japan is a fraction of cumulative total patients in cumulative total incidence of patients 
with ESRD 
                                                 
187 According to the USRDS 1998 Annual Data Report, 41% of the total cases in 1994-1996 were caused by 
diabetes. The proportion of the cases caused by diabetes in 1996 in Korea was 30.8% (Korean Society of 
Nephrology 1997). The incidence of ESRD cases stemming from diabetes in the US was 113 pmp in 1996, 
and 39.6 pmp in Korea (in the same year). 
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Figure 8-2 shows the ratio of ESRD patients who live with a functioning graft. In 
Norway, about 80% of the total ESRD patients live with a functioning graft, while only less 
than 1% of the ESRD patients in Japan do so. The ratio of ESRD patients with a 
functioning graft in Korea is higher than that in the US, Germany, and Italy, while the 
adoption of kidney transplantation is the lower than in the aforementioned Western 
countries in terms of pmp. The proportion of ESRD patients living with functioning grafts 
is much higher in Norway, Sweden, and the UK, which have traditionally financed health 
services through a global budget system, with financial resources collected from taxes. As 
for the ratio of patients living with a functioning graft among the patients taking renal-
replacement therapies, Norway, Sweden, and the UK are ranked the highest in descending 
order. 
 
Figure 8-3. Ratio of live-donor and cadaveric-donor kidney transplants (pmp).    
Data sources: 1) European Dialysis and Transplant Association (EDTA), Statistical Data 1995 
2) ESRD Registry Committee, Korean Society of Nephrology (1997). Current status of renal 
replacement treatment in Korea. Korean Journal of Nephrology, Vol. 27(10): S459-S481. 
3) United States Renal-Data System, 2004 Annual-Data Report  
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The source of organs for transplantation is also greatly varied from country to country. 
As shown in Figure 8-3, the number of kidney transplants performed with living donors is 
much higher in the northern regions than in the southern areas in Europe, and is presumably 
associated with the legislative variations in those areas.188 The proportion of living-donor 
transplantation is extraordinarily high in Japan and Korea. 
 
There have been various attempts to meet the organ demand for transplantation 
purposes, and the approaches that are employed include efforts to increase organ donation 
from both living and cadaveric donors. There is a consensus to ban commercial trading in 
human organs for transplantation purposes. As such, the major approaches to meeting the 
demand for organs have been focused on increasing organ donation from the deceased. 
These approaches have been imposed in organisational and institutional terms, which are 
generally put together.  
In the UK, the Human Tissue Act of 1961, as amended by the Corneal Tissue Act of 
1986, first authorised hospitals to presume that human tissue may be removed for 
transplantation purposes unless it is known that the deceased or his or her relatives object to 
such donation. To ensure that there is no financial loss on hospital side that cares potential 
cadaveric donors and carries out organ procurement, NHS reimburses a £1,000 ad hoc fund 
to intensive-care units for the care of cadaveric donors.189  
In the US, the Organ Procurement and Transplantation Network (OPTN) was 
established by the National Organ Transplant Act (NOTA) of 1984 to increase organ 
donation for transplantation purposes, to promote efficiency in managing the process of 
organ procurement and transplantation, and to prevent the wastage of organs.190 To ensure 
                                                 
188 In Norway, the Transplant, Anatomy, and Organ Donation Act of 1973 permits organ donation from a 
living person, even from one who is under the age of 18 years, if there is parental or guardian’s consent. In 
Austria, the principle of “presumed consent” plays a significant role in organ transplantation. The law in 
Austria allows automatic removal, except in situations in which the deceased has expressed an objection 
to such during his or her lifetime (Bill et al. 1994). 
189 Although the reimbursement policy is not positively accepted by medical professionals since they regard it 
as unethical and as not contributing in practice to increasing organ donations, the policy itself seeks to 
increase the number of organs available for transplantation purposes. Beverly Cornforth, Transplant 
Information Officer for the West Midland, points out that medical professionals regard the reimbursement 
policy as unfavourable in ethical terms and as not contributing to increasing organ donations (personal 
communication). 
190 OPTN, now operated by United Organ Sharing Network (UNOS), plays a central role in the whole process 
of transplantation, such as in organ procurement, allocation, and transplant. 
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that all potential cadaveric donors can be considered for organ donation, the Omnibus 
Budget Reconciliation Act of 1986 requires “routine inquiry,” which obliges medical 
professionals to exhort the families and relatives of potential donors to donate their 
relative’s organ for transplantation purposes upon the latter’s demise.  
 
The legislation can also promote organ donation from cadaveric donors by authorising 
organ procurement unless there is evidence that the deceased person objected to donating 
his or her organ when he or she was still alive. This principle is called “presumed consent.” 
The much higher rate of adoption of organ transplantation in Austria is regarded as 
primarily resulting from the principle of presumed consent. The Swedish Transplant Act of 
1996 also admits the principle of presumed consent.191  
 
There have also been great efforts to encourage organ donation from living donors. As 
the available donors from among family members and relatives are inevitably limited, 
organ donation from unrelated living donors has been emphasised. The question is whether 
a donation from an unrelated donor is justifiable. Medical communities strongly support 
organ donation from unrelated living donors. Based on the results of in-depth studies, Daar 
and Sells (1990) concluded that “organ donation between non-related individuals who have 
a demonstrable enduring relationship is permissible.”  
The Department of Health of the UK has examined the legitimacy of transplantation 
from unrelated living donors and confirmed that it is perfectly legal in the UK for strangers 
to serve as organ donors (Salaman 1997). The Human Organ Transplant Act of 1989 
regulates transplants from living unrelated donors, while banning commercial dealing in 
human organs. The Unrelated Live Transplant Regulatory Authority (ULTRA) is a special 
government agency that authorises organ transplantation from living unrelated donors.192  
To increase the availability of transplantation from living donors, some organisations 
that are promoting organ transplantation coordinate a swap of donors among donor 
                                                 
191 Section 3 of the Act allows any biological material intended for transplantation or some other medical 
purpose to be taken from a deceased person unless the deceased person objected to such action in writing 
or spoke against it when he or she was still alive, or, at the very least, if there is some other reason to 
regard the action as contrary to the deceased person’s intentions, based on such evidence as the deceased 
person’s participation in anti-organ-transplant group activities. 
192 In the fiscal year 2003-2004, 100 unrelated-living-donor kidney transplants were performed in the UK 
(UK Transplant, The Transplant Activity in the UK 2003-2004). 
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volunteers, mainly from the families of the recipients. By exchanging donors with better 
histocompatible recipients in the organ-sharing pool, the availability of kidneys for 
transplantation purposes can be significantly increased relative to the size of the pool 
sharing and the intention to swap.193  
 
To meet the demand for organs for transplantation purposes, market approaches have 
been considered to increase organ donations (Schwindt and Vining 1986, Rinehart 1988). 
Arguments in support of commercialism are persuasive in the US (Spurr 1993, Brigid 
1996)194, although rampant commercialism is precisely banned by the laws in most 
countries and is also condemned by Word Health Organisation (1991).195 While the laws 
throughout the world reject, or at least do not accept, the trade of human organs, many 
cases of commercial dealing have been reported across the world.196 A review of the many 
reported episodes involving organ sale may prompt one to conclude that the trade of human 
organs seems to be flourishing in developing countries, where no systems are in place to 
prevent it.  
 
                                                 
193 Of the total of 941 kidney transplants that were performed in Korea in 1996, 16 cases of living-donor 
transplants were matched by a voluntary organisation, the Organ Donation Action Centre, which 
coordinates a donor swap programme (personal communication). 
194 Brigid argues that the governmental policy monopolises the organ supply, causing a severe shortage of 
transplantable organs, as induced by the National Organ Transplantation Act of 1984.   
195 The guiding principles of WHO on human-organ transplantation (1991, EB87.R22) prohibit giving and 
receiving money, as well as any other commercial dealing in organ donation (Guiding Principle 5). WHO 
is particularly concerned with the protection of minors and other vulnerable persons from coercion and 
improper inducement to donate organs (Guiding Principle 4).    
196 On June 23, 1992, BBC2 broadcasted a programme entitled “The Great Organ Bazaar” (quoted from Sells, 
1992). According to Sells, 2,900 such cases were reported in the Chinese People’s Daily in 1991. The 
programme reported legalised organ selling in China. The programme organizers learned that the kidneys 
obtained from executed criminals were being transplanted into paying foreign recipients. The Federal 
Bureau of Investigation of the US revealed similar stories after they arrested two Chinese men who 
offered multiple kinds of solid organs for transplantation purposes, which they procured from executed 
prisoners (Josefson 1998). Josefson also disclosed, as quoted from China Journal, that 4,367 people were 
executed in China in 1996, and that of the 2,000 kidney transplants performed in China that year, up to 
15% involved foreigners who supposedly dealt with the executed persons’ organs on a commercial basis. 
It is also well recognised that traffic in organs is customarily settled in India, where living kidney donors 
are solicited by agents via advertisements (Sells 1992, Reddy et al. 1990). 
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8.2. Micro Factor Evaluation 
8.2.1. Economic Factors 
There have been various attempts to verify which approach is more useful in terms of 
costs vs. benefits. Kidney transplantation is generally accepted as a more cost-effective 
approach than any other conventional modalities to care for patients with chronic renal 
failure. Based on the median graft survival time that is 10 years, the cost saving for the 
patient with functioning graft compared to dialysis is £241,000 or £24,100 per year for each 
year (UK Transplant Fact Sheet 4). 
 
Table 8-2 .Cost-effectiveness evaluation of renal replacement modalities (per patient) 
Study Indicator of 
evaluation 
Discount 
Rate 
Transplant CAPD Hospital 
Dialysis 
Klarman et al, 1968, 
USA (￡)  
QALY 
6% 7,460  12,100 
Kontodimopoulos and 
Niakas, 2008, Greece 
(€)  
QALY 
5% 11,981 54,504 60,353 
Kaminota, 2001, Japan 
(￥) (23)  
DALY 
 
CAD-2,322 
LRD- 1,809 
 9,546 
Note: 1. CAD- cadaveric donor, LRD- living related donor 
     2. DALY refers Disability Adjusted Life Year 
 
The data in Table 8-2 give an idea about the cost-effectiveness of each approach in 
terms of cost per QALY or DALY gained. Haemodialysis in hospital is regarded as the 
most expensive measure while kidney transplantation is the least costly choice in each 
study. It should be noted that the evaluation of the cost effectiveness of renal-replacing 
therapies can vary according to the time and place covered by the research. In addition, the 
cost of transplantation also greatly varies according to which immunosuppressive regimen 
the physician employs197, and according to the other cost structures of the hospitals. The 
results of studies conducted on the costs and benefits of kidney transplant consistently 
                                                 
197 According to Abella (24), in a research conducted in Canada, the difference between the cost of the use of 
Neoral and of Sandimmun was US$772 (US$2,228 vs. 3,000) during 12 weeks of treatment. Sandimun is 
the brand name of cyclosporine A (CyA), which is produced by Sandoz Pharma. The company also 
developed Neoral, which is a new microemulsion formulation of CyA that is meant to overcome the 
problem associated with inconsistent absorption.  
Shield and colleagues (1996) found that the cost per year of the graft survival of a kidney transplant with 
OKT3 was US$30,474, while the cost of the conventional regimen, using CyA, was US$32,687.     
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indicate that kidney transplant is the most effective treatment modality in economic terms. 
As reviewed, the results of studies conducted on the costs and benefits of kidney transplant 
consistently reveal that kidney transplant is the most effective treatment modality in 
economic terms.  
 
8.2.2. Clinical Factors 
QoL among kidney transplant patients is generally higher than those who rely on other 
treatment modalities. Numerous studies have attempted to prove the changes of QoL based 
on longitudinal aspects comparing ex ante and post transplant situations. In most studies, 
patients indicate a better QoL after their transplantation in comparison with treatment with 
dialysis (Niechzial et al, 1997; Trobojevic and Zivkovic, 1997; Piehlmeier, 1996; Gudex, 
1996).  
Patients living with functioning graft regard their pre-transplant QoL as much lower 
than the prospect for post transplantation. Improvements of QoL are observed most 
significantly in social activities and working ability after transplantation compared with 
patients in ESRD and those undergoing haemodialysis (Trbojevic and Zivkovic, 1997.  
 
8.2.2.1. Life-saving Effect 
Lenisa and colleagues (1995) examined the cost effectiveness of haemodialysis, kidney 
transplantation, and kidney-pancreas transplantation for diabetic ESRD patients. As shown 
in Figure 8-4, their study indicated that the beneficial effects of both kidney and kidney-
pancreas transplantation lasted throughout the lifetime of the patients who underwent them, 
longer than haemodialysis, which has lower care costs, did. The survival rates of the 
patients in the haemodialysis group were significantly lower. The survival rate of the 
haemodialysis patients was 55% at five years, and 94% and 87%, respectively, for the 
patients who underwent kidney or kidney-pancreas transplantation.  
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Figure 8-4. Differences in the patients’ survival rates by treatment 
Data Sources: Lenisa et al. (1995) 
 
8.2.2.2. Quality of Life (QoL) 
The QoL of kidney transplant patients is generally higher than that of patients who rely 
on other treatment modalities. Numerous studies have attempted to prove the changes in 
QoL based on longitudinal factors, comparing ex-ante and post-transplant situations. In 
most studies, the patients indicate a better QoL after their transplantation in comparison 
with those who have undergone dialysis (Niechzial et al. 1997, Trobojvic and Zivkovic 
1997, Piehlmeier 1996, Gudex 1996).  
Patients living with functioning graft regard their pre-transplant QoL as much lower 
than the prospect for post-transplantation.198 Improvement in QoL are observed most 
significantly in the social activities and working ability of the patients who have undergone 
transplantation than in the ESRD patients and those undergoing haemodialysis (Trbojevic 
and Zivkovic 1997).199  
                                                 
198 In a research done by Adang et al. (1998), QoL prior to transplantation was prospectively given a mean 
rating of 5.23 on a 10-point scale; this score increased to 7 after successful transplantation. During follow-
up assessment at 5, 12, and 18 months after successful transplantation, patients retrospectively scored their 
pre-transplant QoL as 3.27, 3.14, and 3.05, respectively.  
199 According to the 1997 annual report (20th Annual Report) of the Australia and New Zealand Dialysis and 
Transplant Registry (ANZDATA), 86% of all the patients with functioning grafts in Australia indicated 
that they are normal or able to carry out normal activity. Only 49% of all the patients with dialysis scored 
themselves as normal (12%) or able to carry out normal activity (37%). The patients’ recognition of QoL 
is slightly higher in New Zealand in both groups of patients (91% and 52%, respectively). 
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8.2.3. Technical Factors 
Organ transplant is not an easy choice on the part of both the patients and the surgeons 
because of organ shortages, high costs, and psychological distress from the fear of graft 
failure and the loss of one’s life. Apart from the costs incurred at the time of transplant and 
afterwards for immunosuppressive therapies are availed of, organ transplant entails 
enormous social costs for the management of infrastructure related to organ procurement, 
the matching between the donors and the recipients, and delivering the harvested organs to 
the transplant centres.  
As for ESRD, kidney transplant is regarded as also offering a technical advantage as 
patients can save the time they would otherwise spend for dialysis. Whether the patients 
choose hospital or home dialysis, the modalities take considerable time, and they would be 
prone to infection if they choose to undergo home dialysis.   
As such, it can be concluded that kidney transplant has more technical advantages than 
any other modality of renal-replacement therapy, while heart and liver transplant are hard 
to regard as offering technical advantages for the patients.   
 
8.3. Macro Factor Evaluation 
8.3.1. Japan 
The major events in Japan in relation to organ transplantation are as follows 
(Transplant Communication 2001): 
1956  First kidney transplant 
1964 First liver transplant 
1968 First heart transplant 
1980 Cornea and Kidney Transplant Act came into effect 
1983 Study Group for Brain Death was established in the Ministry of Health and 
Welfare 
1984 First heart transplant of a Japanese citizen in the US 
1985 Study Group released the Guideline for Brain Death Judgement 
1989 First case of partial liver transplant from live donor 
1990 Ad Hoc Committee on Brain Death established 
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1994 Organ Transplant Act was introduced in the House of Commons 
1995 Japan Kidney Transplant Network established 
1996 Amended Organ Transplant Act was introduced in the House of Commons 
1997 Organ Transplant Act came into effect 
Japan Organ Transplant Network (JOTNW) established (extended from 
Japan Kidney Transplant Network) 
1999 First legal organ transplants (heart, liver, kidney and cornea) from brain 
death donor 
 
Regarding organ transplantation from cadaveric donors, a brain death bill came into 
effect in Japan at the end of 1997 after a debate that lasted for 30 years. In Japan, early 
transplantation attempts using organs from cadaveric donors were strongly condemned by 
the public and even by medical communities. The first case of heart transplant was 
performed in Japan in 1968, when there was neither an accepted guideline on brain stem 
death nor a law authorising organ transplant from cadaveric donors. Moreover, there was 
no consensus among medical professionals regarding transplantation using organs from 
cadaveric donors. Such practice sparked mistrust in physicians strong enough to impede the 
development of brain death criteria by medical professionals (Feldman 1994).  
The second attempt, which was made in 1984 with an allegedly mentally incompetent 
cadaveric donor, spurred official involvement in brain death issues and organ 
transplantation using organs from deceased persons. Two months after the controversial 
transplants were carried out, the Life Ethics Problem Study Parliamentarians League was 
formed, with professionals and officials as members.  
MHLW organised the Brain Death Advisory Council, and the Council declared the 
criteria for brain death in December 1985. In 1988, an investigative team of the Liberal 
Democratic Party (LDP) recommended the establishment of the Ad Hoc Committee on 
Brain Death and Organ Transplantation as a consulting body to the Prime Minister. In 
January 1992, the Ad Hoc Committee on Brain Death and Organ Transplantation submitted 
a final report that defined brain death as being equivalent to the conventional concept of 
death.  
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In 1994, the draft of a law on human-organ transplants using organs of brain-dead 
persons was proposed. The enactment was voted into a law in 1996, and the legislation was 
enacted on October 16, 1997. Meanwhile, JOTNW was established in 1995. Currently, 
organ procurement and distribution is managed by JKTNW as a single entity. The 
nationwide network consists of seven regional blocks. The scope of JKTNW was extended 
to cover all organ transplants in October 1997, and the Japan Organ Transplant Network 
(JOTNW) was launched as a corporation aggregate. To promote organ donation from 
potential brain stem death donors, JOTNW made donor cards available at city halls, public 
health centres, post offices, and driving test centres across the country.  
There was considerable controversy surrounding the first case of brain death organ 
transplantation. Although the public attitudes on the use of organs of deceased persons in 
transplantation appear to be positive200, there are practical impediments to organ 
transplantations using organs from cadaveric donors. First, although the opinion poll 
suggested positive views on the transplantation of an organ from a deceased person, the 
will to donate an organ when they become potential donors was weak.201 Second, the law 
limits harvesting organs from a deceased person if his or her relatives object to such, even 
when the deceased left consent (Hiraga 2000).202  
 
The cost information in Japan for the treatment of renal failure is summarised in Table 
8-3. The costs of kidney and liver transplantation have been covered by public health 
insurance since 1978. The insurance programme also covers the overall care following the 
operation, at an approximate cost of £7,800-£10,500 a year after the transplantation. Since 
kidney transplantation is categorised as an “advance medical technology (AMT),” the 
public health plan shoulders its overall cost in excess of £332 (¥63,600). Patients who are 
                                                 
200 According to a Minichi Daily News poll, 74% of the public had a positive view of organ transplants 
conducted from the first brain-dead donor (Minichi Daily News, May 13, 1999). 
201 According to the survey by Home Office of the Japanese government, 35.4% of the respondents indicated 
they would not donate while 32.6% of them responded they would donate if they were in a brain death 
state (Asahi Newpaper, August 26, 2000- The result of a survey on the attitudes towards organ donation). 
202 By law, nobody younger than 16 years old can donate organs, and children younger than six may not 
receive them. Relatives have the power to veto organ donation even though the deceased person left 
written documents for organ donation.  
According to the survey by the Home Office, 69.9% responded that consent from both the potential 
donor and relatives is required. 20.6% responded it would be acceptable to donate through the consent of 
the potential donor only. Very few respondents (2.1%) accepted donation through the consent of relatives 
only.   
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taking dialysis therapy that is fully subsidised by public funds are regarded as disabled, 
according to the Disabled Act. 
Table 8-3. Cost comparison by treatment 
Kidney 
transplant 
one month after 
transplantation, including 
surgical costs 
£12,500 
£29,000 
for the first year 
up to two years £520-
£780/month 
£6,200-£9400 
Hospital 
dialysis 
 £2,700/month £31,300/year 
CAPD  £2,660/month £31,000/year 
Data sources: Transplant Communication No. 4  
 
In summary, organ transplantation, particularly from cadaveric donors, has not been 
accepted in Japan because the early attempts to gain public support failed even within the 
medical community. Although the Organ Transplantation Act came into effect more than 
30 years after the first attempt of transplantation using an organ from a cadaveric donor was 
made, the public attitude towards the donation of an organ from the deceased is still largely 
negative.  
Public insurance programmes cover the overall cost of kidney transplantation, and the 
patients who avail of dialysis therapy receive full support for their dialysis treatment 
through the latter’s full subsidy by public funds.   
 
8.3.2. Korea 
There have been long debates on brain death in Korea. The Korean Society of 
Nephrology, the Korean Society of Transplantation, and the Seoul National University 
Hospital initiated public debates on cadaveric transplants in March 1988, when a proposal 
requiring brain stem death legislation was conjointly issued to the Korean Medical 
Association.203  
                                                 
203 In October 1988, the Korean Medical Association held public hearings on brain stem death and proposed 
that the Korean government legalise brain stem death after achieving a consensus on the definition of 
death and on the criteria for brain stem death among medical professionals.  
 
 
191
The first case of cadaveric-kidney transplant was performed on January 25, 1990. Since 
then, the public concern regarding kidney transplant has flourished. The first successful 
transplant case motivated medical professionals to rush into the practice of cadaveric-organ 
transplant. Seoul National University Hospital’s issuance of brain stem death criteria on 
December 2, 1992 spurred debates on brain stem death. Subsequently, the Korean Medical 
Association released its Decree on Brain Death on March 4, 1993. Since then, most 
teaching hospitals carrying out organ transplantation set transplant coordinators in place to 
enhance integrated collaboration among the transplant teams within the hospital. Transplant 
coordinators also cooperate with the transplant teams in other hospitals, and with voluntary 
organisations, in terms of organ procurement and delivery.  
The Ministry of Health and Welfare (referred to at that time as Ministry of Health and 
Social Affairs) asked the Korean Medical Association to study brain stem death in response 
to the proposal submitted by the Korean Medical Association, and as a reaction to the first 
successful cadaveric-kidney transplant case. Debates on brain stem death among the public 
have also become fiercer, as organ procurement from the deceased is strongly opposed by 
the Academy of Confucianism.204 The Academy of Confucianism strongly stands against 
brain stem death and cadaveric-organ transplant as the philosophy of Confucianism regards 
any hurt or harm inflicted on a person’s body as an act of impiety against his or her parents. 
Although there was significant resistance against cadaveric-organ transplantation, the 
legal basis for the use of organs procured from cadaveric donors was introduced in 1995. 
The Cadaver Anatomy and Preservation Act of 1995 authorised the use of tissue and organs 
from the deceased for the purpose of research and treatment.205 The Act authorised the use 
                                                 
204 The Academy of Confucianism is centred on “Sung Kyun Kwan,” which has been a centre of 
Confucianism tradition in Korea. Sung Kyun Kwan was established more than 600 years ago. There are a 
number of Confucian schools, though, that are independent institutes. The Academy of Confucianism, 
which represents all Confucian schools in the country, has a significant influence on legislation related to 
cultural traditions, such as the Family Law.  
205 Tissue and organs can be used, and authorisation should be given by the family of the deceased person 
(Section 4). It is not necessary to obtain the permission of the family in the following circumstances: 
 when the deceased person has agreed to the matter in writing; 
 when no family or relative has appeared to take over the cadaver for more than 60 days after the 
person’s death; and 
 when all the physicians, at least two, who have been in charge of the treatment of the deceased 
person agree that there is a particular reason to carry out an anatomical procedure to identify the 
cause of death of the deceased person (Article 3).  
This article is premised on the fact that an anatomical procedure must be immediately carried out, but 
that it is impossible to find the family to obtain permission from them. 
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of human organs and tissues with the consent of the deceased person’s family or relatives, 
and thereby legalised cadaveric-organ transplantation. Before the law was enacted, organ 
transplantation had been performed under an implicit consensus accepting that the results 
of organ transplantation are desirable for individual patients and for the society as a whole 
insofar as it does not cause any harm to the persons who donate organs. 
Under this tacit consensus, public authorities had never been involved in organ 
transplant activities until police arrested a group of brokers, even though several episodes 
of commercial dealing in human organs had been revealed by the media. In August 1997, 
the government submitted a draft of the Organ Transplant Act to the Parliament, and the 
Act came into effect in January 2000. The Act admitted brain stem death and legalised 
organ transplant from cadaveric donors.  
Meanwhile, the Ministry of Health and Welfare established the Organ Transplantation 
Information Centre (OTIC) in the National Medical Centre in July 1998.  
The primary role of OTIC is to coordinate between organ transplant centres and 
voluntary organisations promoting and managing registries in their own organisations. The 
government’s intention in establishing OTIC was to put up a single network throughout the 
country that could match organ donors and recipients based on a single list.  
As there was remarkable opposition from existing non-governmental organisations 
(NGOs) involved in donor recruitment and matching that were reluctant to give up their 
roles, OTIC was unable to centralise the functions of matching patients with donors and of 
registering volunteer organ donors. There were six active NGOs involved in the promotion 
of organ donation and in the registration of organ donors then. Some of them specialised in 
certain organs while others dealt with all kind of organs, including those from cadaveric 
donors and from living donors, as well as cadavers, and provided the latter to medical 
schools for research purposes .  
As the Organ Transplant Act came into effect, the Korean Network for Organ Sharing 
(KONOS) took over the role of OTIC as a national authority responsible for: (1) matching 
recipients and donors; (2) authorising organ transplant; and (3) managing the data regarding 
organ transplants. KONOS is commissioned to prevent commercial organ dealing, manage 
the fair distribution of organs for transplantation purposes, and foster organ transplant 
activities to save those patients with irreversible organ failure. 
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So far, KONOS’s role of centralising organ transplant activities related to the 
management of donors, and of matching donors with recipients, has not yet been properly 
settled. Some NGOs still hold tenaciously to their role of matching and registering donors.  
Regarding the funding for kidney transplantation, the costs are remunerated by the 
public health insurance programme based on a fee-for-service scheme in Korea. Since the 
insurance scheme was gradually expanded, the scheme’s growth might have a significant 
influence on the adoption of kidney transplantation in the country.206 Although public 
health insurance covers the costs, the patient should still pay about £11,000, including the 
costs incurred for donor-patient matching. 
In addition to the legal and reimbursement system, there were several events that 
influenced the adoption of kidney transplantation in Korea. First, brokerage was promoted 
as the mass media frequently debated on brain stem death and condemned commercial 
dealings in human organs. Although the intention of the media was to give a warning 
regarding brokerage, the profuse media attention ended up boosting commercial dealings in 
human organs in the country in the late 1980s.  
To tackle the serious problem of kidney sales from living donors, Yonsei Medical 
Centre’s Severance Hospital207 voluntarily launched a programme in December 1991, in 
which it scrutinised the recipient-donor relationship and tried to determine whether a 
kidney donation is motivated by a commercial purpose. The programme confirms 
recipients and donors only if the “Screening Committee,” of which the Department of 
Social Services is in charge, deems that the case does not involve commercial dealing. The 
programme diffused into other hospitals, and the programme had spread throughout most of 
the country‘s teaching hospitals by the end of 1993. Reflecting on the voluntary activities in 
the hospitals, the police investigated brokerage in organ trafficking. As a result of its efforts, 
                                                 
206 A social insurance scheme for health services was launched as a compulsory programme in July 1977, 
covering wage earners and their dependants in firms with 500 employees or more. The scheme covered 
8.6% of the total population in the first wave of social insurance in Korea (Shin and Lee 1997). In 1979, 
the insurance scheme was expanded to include public-sector employees and employees in private schools 
and universities. In the same year, the scheme was also expanded to include employees in firms with 300 
employees or more. As a result, by 1979, the health insurance scheme had covered 37.3% of the total 
population. The scheme continued to expand, covering employees in smaller firms as well as those who 
were self-employed. By July 1988, the employees in firms with five employees or more were required to 
join the health insurance scheme. By 1988, the insurance scheme had covered 45.5% of the total 
population, and by July 1989, it had been expanded to include the whole population of Korea. 
207 A leading figure in the field of kidney transplantation in Korea, Severance Hospital has performed more 
than one-third of the total kidney transplants in the country.  
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the police arrested a cohort of brokers in February 1994. The screening procedure is 
routinely required for all living-donor transplantation cases, including transplantations 
using organ donations from families and relatives, by the amended Organ Transplantation 
Act of 2001. 
NGOs also played a significant role in matching patients with donors. Particularly, an 
agency named “Korean Organ & Tissue Donation Programme (KOTDP)” started a relevant 
programme in 1991. KOTDP operates a donor swap programme, which exchanges donors 
in the donor-sharing pool to ensure the high quality of HLA matching. As there were many 
patients for whom it is impossible to secure an organ for transplant purposes despite the 
existence of willing donors, the KOTDP launched this programme. In principle, a patient is 
required to bring one donor in order to be matched with a suitable donor.208 
 
8.3.3. UK 
Organ transplantation in the UK was initially authorised by the Human Tissue Act of 
1961, as superseded by the Corneal Grafting Act 1952. A special health authority, the 
United Kingdom Transplant Service Support Authority (UKTSSA), was established in 
1968 to coordinate transplantation activities. UKTSSA holds information on the recipient 
candidates and the possible organ donors, provides organ-matching and tissue-typing 
services, and can also arrange for the transport of organs for transplantation. The Authority 
was originally established in 1991 as the UK Transplant Support Service Authority 
(UKTSSA), which was the only special health authority in the UK In July 2000, UK 
Transplant was formed, with the new, extended mandate of increasing the organ donation 
rates. 
The Human Tissue Act of 1961, as amended by the Corneal Tissue Act of 1986, sets 
out the condition in which cadaveric donations shall be legal. After a public scandal over 
the sale of organs for transplantation in a private hospital in London in 1988, the Human 
Organ Transplant Act was enacted in 1989. The Act bans commercial dealings in human 
                                                 
208 Since KOTDP does not restrict the donor within the bloodline family, the possibility of commercial 
dealing involved still exists in the donor swap programme of KOTDP. The chances that commercial 
purposes can be involved, however, are very low because social workers in KOTDP scrutinise the 
relationship between the patients and the donors they have brought with them if money is involved in such 
relationship. 
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organs and creates a number of offences related to this, among these being that an offence 
is committed by any person who pays or accepts payment for the supply of an organ 
intended for transplantation. It does not matter whether money changes hands before or 
after the organ is removed. The Act regards transplantation taking place outside the UK as 
an offence if there is any commercial dealing involved in it. Brokers of organs involved in 
organ dealing are also committing a criminal offence. According to the law, the Unrelated 
Live Transplant Regulatory Authority (ULTRA) assesses unrelated living donors if they 
intend to get monetary rewards for their organ donation.  
The Act penalises all of those involved in commercial transactions related to organs for 
transplantation. Organ transplant activities in the UK are managed by UK Transplant. As a 
public health authority, UK Transplant manages all the donors and recipients in the UK, 
and its services also cover the Republic of Ireland. The major task of UK Transplant is as 
follows: 
 management of the organ donor register; 
 matching and allocation of organs for transplantation; 
 maintenance of the database for all patients waiting for an organ donation; 
 maintenance of a comprehensive database that includes the clinical data 
regarding the transplant recipients, their donors, and the outcomes of the graft; 
and 
 analysis and audit of all organ transplants.  
 
The National Organ Donor Register was launched on October 6, 1994 as a 
computerised database of potential organ donors, including information on people who 
wish to donate their organs when they die. As of February 1997, about four million people 
were on the register. The number of individuals on the NHS Organ Donation Register 
(ODR) registration list has increased to 11.2 million at the end of fiscal year 2003-2004. 
Majority of the new registrants continue to come from driving license applications and 
reminders through the Driver and Vehicle Licensing Agency (DVLA), from the General 
Practitioner registration, and through applications for a Boots Advantage Card (UK 
Transplant, Transplant Activities in the UK 2003-2004). 
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In pursuit of fair and effective matching of the donor and the recipient, the Tissue-
typing Reference Laboratories of UK Transplant also serve laboratories associated with 
transplantation in the UK and the Republic of Ireland. Some transplant units’ tissue-typing 
laboratories in the UK are linked with the computer systems of the UK Transplant is a 
network system, called the UK National Transplant Network (UKNTN). Through an onsite 
PC linked with UKNTN, transplant units can send patient registration and follow-up data to 
update the national transplant database.   
While organ transplants from cadaveric donors and related living donors are directly 
managed by UK Transplant, those from unrelated living donors are carried out after 
receiving permission from the Unrelated Living Transplant Regulatory Authority (ULTRA), 
having confirmed that no payment is involved.    
There are a number of voluntary charity organisations that promote organ donation. 
Transplants in Mind (TIME), which was founded in 1990 and has 27 member organisations, 
including the British Organ Donor Society (BODY) and The Kidney Foundation, plays the 
role of an umbrella organisation for charities with an interest in promoting organ donation. 
As a part of its activities, TIME organises and coordinates the British Transplant Games 
(BTG), which were launched in 1978 and are held annually, in July. BTG aims at catching 
the attention of the public and media. Combined with BTG, every year the Torch Relay 
links the previous venue to the current year’s venue.  
 
8.3.4. US 
Regulatory development related to organ transplant in the US has a long history, and 
there have been various events related to organ transplantation. As it is difficult to describe 
these events in detail, this section attempts to summarise the major events, as follows 
(Sloan et al. and Schuck 1989, Childress 1989, Rettig 1989):  
 1968 - the Uniform Anatomical Gift Act of 1968 approved the use of 
organs from brain-dead donors 
 1970 - the “brain death” legislation in Kansas became the first state to 
enact “brain death” legislation 
 1972 - through the Social Security Amendments, Medicare started to 
provide benefits for patients with ESRD, including kidney transplantation; 
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the Medicare programme covers immunosuppressive therapies after kidney 
transplants for one year 
 1974 – the National Health Planning and Resources Development Act 
applied for a Certificate-of-Need (CON) of the system (regionalism in 
organ transplants) 
 1976 – the Southeast Organ Procurement Foundation (SEOPF) organised 
the acquisition and sharing of organs among transplant centres  
   
 1978 – through the Social Security Amendments, Medicare coverage was 
extended to include immunosuppressive therapies from one to three years 
 1979 – the Medicare coverage for the heart was limited to the 
transplantation procedures performed by Dr. Shumway at Stanford 
University   
 1984 - the National Organ Transplant Act (NOTA) established the Organ 
Procurement and Transplantation Network (OPTN) and prohibited 
commercial dealing in human organs 
 1986 – the United Network for Organ Sharing (UNOS) was awarded a 
contract to operate OPTN 
 1986 – the Omnibus Budget Reconciliation Act required membership in 
OPTN for all transplant hospitals, for organ procurement and routine 
inquiries(required request)209, and for potential cadaveric donors 
 1986 – it was indicated in the Report of the Task Force on Organs that 
organs and tissues ought to be distributed on the basis of objective criteria 
and not on the basis of accidents of geography  
 1986 - Federal Register 37164 was established to expand the Medicare 
coverage to include heart transplants for limited beneficiaries and that are 
performed in limited centres that meet the specific criteria 
                                                 
209 In response to the organ shortage, Arthur Caplan (1984) suggested a “required request” approach to 
increase organ donation. The rapid spread of the “required request” approach indicates that it has been 
strongly endorsed by majority of the US states (Anderson and Fox 1988).209 The Omnibus Budget 
Reconciliation Act of 1986, which came into effect in November 1987, made procurement organisations 
contingent upon the establishment of a required-request protocol, to be reimbursed by the 
Medicare/Medicaid fund (Culpepper 1996).  
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 1987 - the Catastrophic Health Insurance Act of 1987 authorised Medicare 
reimbursement for outpatient-based immunosuppressive therapies  
 1987 – the Amendment to the Uniform Anatomical Gifts Act simplified the 
process of organ donation and endorsed the right of individuals aged 
beyond 18 years, of their families, and their guardians (by extension) to 
make a decision regarding organ donation 
 1987 – through Federal Register 10935, HCFA formally rescinded its rule 
that barred heart transplant from coverage as a medically reasonable and 
necessary service 
 1988 – the Amendment to NOTA provided for the fair allocation of organs 
for transplantation purposes 
 1990 – the Amendment to NOTA provided for the equitable distribution of 
organs among patients nationwide who need transplantation  
 1990 - when OPTN was inspected by the Office of the Inspector General, 
the latter pointed out that organ distribution remains confined primarily to 
the individual service area of the OPOs, and as such, does not meet the 
expectations 
 1990 - the Patient Self-Determination Act was created to enhance patient 
awareness of organ donation through the issuance of advance directives 
 1997 – the National Organ and Tissue Donor Initiative (NOTDI) was 
organized to increase consent to donation and to ensure that the families of 
cadaveric donors are asked to donate their deceased relative’s organs  
 
The following paragraphs describe the major events in greater detail. In the US, organ 
transplantation was initially authorised by the Uniform Anatomical Gift Act of 1968, which 
legitimised the use of organs from the deceased. The Social Security Amendments of 1972 
admitted all ESRD patients as Medicare beneficiaries by categorising them as disabled.  
In October 1984, the US Congress passed the National Organ Transplant Act (NOTA). 
The law marked a historical turning point in the organ transplantation activities in the US 
by introducing the Task Force on Organ Procurement and Transplantation and the Organ 
Procurement and Transplantation Network (OPTN). The Act also clearly proclaimed anti-
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commercialism in organ transplantation. Before this Act was passed, there was no specific 
regulation forbidding commercial trading in human organs.  
 
In 1986, the newly passed Omnibus Budget Reconciliation Act of 1986 was introduced, 
which mandated that all organisations involved in organ procurement and transplantation 
be members of OPTN210, and that unless a hospital is a member of OPTN and abides by its 
rules and requirements, Medicare and Medicaid programmes that are the primary payers of 
organ transplantation211 will not reimburse the costs incurred for such procedure.  
In the US, organ transplant activities are performed within the centralised Organ 
Procurement and Transplant Network (OPTN). The United Network for Organ Sharing, a 
non-profit company, was awarded the federal contract in 1986 to establish and operate 
OPTN. The Department of Health and Human Service (DHHS) of the US government 
renews the contract every three years. 
The Omnibus Budget Reconciliation Act of 1986 also has a significant role in the 
history of organ transplants in the US. The Act obliges medical professionals to ask all 
potential organ donors if they have an intention to donate their organs. This obligation has 
been termed “required request” or “routine inquiry.” The NOTA Amendment of 1988 
proclaimed the fair allocation of organs for transplantation, and the 1990 Amendment to 
NOTA required the equitable nationwide distribution of organs among patients who need 
organ transplantation. 
On December 15, 1997, the US Vice President announced a series of new US 
government initiatives to increase organ donation, and launched the new National Organ 
and Tissue Donation Initiative (NOTDI). The Clinton Administration’s new NOTDI seeks 
to achieve a substantial increase in organ donation and transplantation (DHHS, 1997 
Federal Register, December 19, 1997: 66745-48).212  
                                                 
210 The Omnibus Budget Reconciliation Act added Section 1138 to the Social Security Act, which obliges 
hospitals to be members of OPTN to be able to perform organ transplantation. OPTN is a central 
organisation that performs a variety of functions under a contract with DHHS of the US government. 
OPTN is a non-governmental organisation that is responsible for the procurement and allocation of organs 
for transplantation. 
211 Since 1993, Medicare and Medicaid have reimbursed 93% of the total cost of transplants (HCFA 1996). 
212 The new NOTDI seeks to improve the collaborative organ donation process, specifically between 
hospitals and OPOs, and to increase organ donation (Federal Register, December 19, 1997: 66745-48). 
According to DHHS (1998), the primary goal of NOTDI is to increase the consent to organ donation. To 
increase the families’ willingness to consent to organ donation, NOTDI encourages all citizens to make a 
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The Beneficiary Improvements and Protection Act (BIPA, or Public Law 106-554) 
provides a significant enhancement in Medicare coverage for immunosuppressive 
medications needed by a transplant recipient (HRSA 2001). It started extending coverage 
for the transplant recipient for life on December 21, 2001, whereas it previously extended 
coverage for the transplant recipient only for 36 months. 
Figure 8-5. Primary sources of payments for organ transplantation in 1997 
Data Sources: UNOS (personal communication, unpublished) 
 
As shown in Figure 8-5, the primary source of payment for transplants is greatly varied. 
Although the Medicare programme covers the cost of all kidney transplants, private 
insurance programmes finance a large proportion of such transplants. In 1997, the Medicare 
programme covered 59.1% of all cadaveric-donor kidney transplants in the country, and 
38.35% of all living-donor kidney transplants. In the case of living-donor kidney 
transplants, private insurance programmes covered 48.7% of the total cost. For other organ 
transplants, private insurance programmes have shouldered a large part of the total cost: 
                                                                                                                                                    
personal decision and to share that decision with their families through a nationwide campaign with the 
message “Organ and Tissue Donation: Share Your Life, Share Your Decision.SM”  
NOTDI also enjoins hospitals and health professionals to expedite their identification of deaths that could 
result in organ donation, and to ensure the referral of identified potential donors to the OPOs in their 
region. 
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61.9% for liver transplants and 56.2% for heart transplants. The Medicare programme 
shouldered 11.5% and 19% of the costs, respectively, of liver and heart transplants in 1997. 
 
8.4. The Adoption of Kidney Transplantation 
8.4.1. Japan 
In Japan, there were 264,473 patients with renal failure at the end of 2006 (Japanese 
Society for Dialysis Therapy 2006). As shown in Figure 8-6, the number of patients with 
chronic renal failure who require dialysis or transplant increases every year. During 2006, 
21,034 patients died of CRF. 
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Figure 8-6. The number of patients living with dialysis therapy (in pmp) (1983-2006) 
 
Data sources: Japanese Society for Dialysis Therapy (2008) 
 
As summarised in the above section, there have been some major turning points in the 
history of organ transplantation in Japan. Since 1980, when the Cornea and Kidney 
Transplant Act was passed, the number of kidney transplant procedures rapidly increased 
until 1984. During that time, a new immunosuppressant, Cyclosporine A, was introduced in 
Japan. When the Ministry of Health and Welfare declared the brain death criteria in 1985 
(the Takewochi Criteria), the number of kidney transplants both from living and cadaveric 
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donors rose remarkably until the end of the 1980s. In 1990, the Ad Hoc Committee on 
Brain Death was organised to draw up brain death criteria, and the committee submitted a 
final report to the Ministry of Health and Welfare in 1992, where it defined brain death.  
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Figure 8-7. The number of kidney transplants performed (1971-2006) 
Data Sources: 1) Japan Organ Transplant Society,  http://www.medi-net.or.jp/tcnet/JST/fact_06/fact06_03. 
html accessed on 30 March 2008 
2) Cosmos Charity Fund for Organ Transplantation, http://cosmoskikin.org/jinzou.html 
accessed 30 March 2008  
 
As shown in Figure 8-7, since 1990, the number of kidney transplants with living 
donors quickly decreased in the circumstance accepting brain death following the 
establishment of the Ad Hoc Committee on Brain Death in 1990.  
A controversial phenomenon is the increase in the number of kidney transplants 
performed using kidney donations from living donors, and the decrease in the number of 
kidney transplants performed using kidney donations from cadaveric donors, following the 
passage of the Organ Transplant Act of 1997. Patients who might have been expected to 
receive organ donations from cadaveric donors became more likely to receive organs from 
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living donors. Contrary to expectations, the enactment of a law authorising organ 
transplantation from brain-dead donors was delayed because medical professionals 
hesitated to perform organ transplantation using organs from deceased persons. Although 
the Organ Transplant Act regularised brain death and transplantation using organs from 
cadaveric donors, there was no attempt to carry out organ transplantation with cadaveric 
donor until February 1999.  
 
In Japan, considerable controversy surrounded the first case of brain death organ 
transplantation. Although public attitudes on the use of organs of deceased persons in 
transplantation appear to be positive, there are practical impediments to organ 
transplantations using organs from cadaveric donors. First, although  opinion polls 
suggested positive views on the transplantation of an organ from a deceased person 
(Minichi Daily News, 13 May 1999), the preparedness  to donate an organ when they 
become potential donors was weak (Asahi Newspaper, 26 August 2000). Second, the law 
limited harvesting organs from a deceased person if his or her relatives objected, even when 
the deceased left consent (Higara et al 2000).  
 
Table 8-4. Kidney transplants by donor types 
Year Cadaveric 
donor 
Living donor Total 
Blood line  Non-blood line Unknown 
 
Sub-
total 
~1970  37 131 43 (24.7%)*  174  
~1994  2,724 6,796 241 (3.4%) 20 7,057 9,801 
1983~1997  2,649 5,511 249 (4.3%)  5,760 8,918 
1998  143 430 35 (7.4%) 5 470 613 
2000  146 517 68 (11.3%) 15 600 746 
Data sources: 1) Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in 
Japan as of Dec. 31, 2006. http://docs.jsdt.or.jp/overview/ppt/jsdt2006.ppt accessed 
28 April 2008 
2) Japan Organ Transplant Society,  http://www.medi-
net.or.jp/tcnet/JST/fact_06/fact06_03.html accessed on 30 March 2008 
3) Cosmos Charity Fund for Organ Transplantation, http://cosmoskikin.org/jinzou.html 
accessed 30 March 2008  
4) The Japan Society for Transplantation (2001). Results from 1999 follow-up survey. 
The Japanese Journal of Transplantation, Vol. 36(2): 91-105. [Japanese]  
 
Note: the number in the blank refers the reference for the data source 
* The percentage refers the fraction of unrelated among total living donors. 
 
 
204
Table 8-4 indicates the number of non-blood line donor transplants in Japan. Most of 
non-blood line donors were spouses. According to The Japan Society for Transplantation 
(The Japan Socisty for Transplantation 2001), all 43 non-blood line donors were spouses up 
to 1970. Among 68 non-blood line donors in 2000, 50 were spouses. Another report (Mori 
1992) indicated that almost all non-blood line donors were related relatives like mother’s 
sister or relatives outside the guideline suggested by Japan Transplantation Society. 
Accordingly, unrelated donor transplants were very few in Japan. As Haruki reported 
(Hiruki 2004), however, there might be cases involving commercial dealing. The brokerage 
in matching donor and recipient has never been reported and only a small number of cases 
were allegedly involved in commercial dealing. 
 
 
8.4.2. Korea 
 
By the end of 2006, 16,324 kidney transplants had been carried out in Korea since the 
first successful case was transplanted in 1969. Among them, living donor transplants, 
14,195 cases dominated (87%) with cadaveric donor transplants amounting to 2,129 cases 
(13% of total).  
As shown in Figure 3, there were significant increases in 1979 and from 1984 through 
1992. The increase was highest in 1989 with big decreases in 1993 and 1994. The primary 
base for the take-up since 1984 is due to the adoption of cyclosporine A. One of the 
remarkable changes since 1991 is the increase of cadaveric donor transplant from 1991 
through 1999. Following the introduction of Organ Transplantation Act in 2000, both living 
and cadaveric donor kidney transplants decreased with a significant drop in the donation 
from the deceased. The increases in 1979 and 1989 can be attributed to the expansion of the 
insurance coverage with historical events of commencement of health insurance 
programme based on social insurance system on 1979 and coverage of full population on 
1989. The increase in 1992 was largely related to the involvement of non-governmental 
organizations (NGOs) in the matter, including Korean Organ & Tissue Donor Programme 
(KOTDP) launched in 1991. These were actively involved in the task of matching the 
patients with the volunteer donors. In this vein, KOTDP operated a donor swap programme, 
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which exchanged donors in the donor-sharing pool to ensure the high quality of HLA 
matching. The live donor exchange programme is an established method to resolve donor 
shortage in Korea. As an example, of total 411 living donor kidney transplants in Hanyang 
University Hospital between January 1991 and December 1997, 61 patients received grafts 
from exchange donors that were equivalent to 14.4% (Kwak et al 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-8. Kidney transplantation in Korea (1969-2003) 
Data Sources: 1) The Korean Organ Transplantation Coordinators Society (1997). 3rd Academic Meeting of 
Organ Transplantation Coordinators, Seoul, July 13–14.  
2) Korean Transplantation Society (1997). Organ transplantation report on 1996. Korean 
Journal of Organ Transplantation, Vol. 11(2): 183-199 [Korean] 
3) Korean Transplantation Society (1998). Organ transplantation report on 1997. Korean 
Journal of Organ Transplantation, Vol. 12(2): 152-160 [Korean] 
4) Korean Transplantation Society (1999). Organ transplantation report on 1998. Korean 
Journal of Organ Transplantation, Vol. 13(2): 185-194 [Korean] 
5) KONOS, 2006 Annual Report. [Korean] 
 
The rapid increase by 1992 was also promoted by the private brokerage in matching the 
patients with the donors. Although attempts were made to ban commercial dealing in their 
matches, it was impossible to screen all the donors disguised as volunteers. At the same 
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time, private brokers organised nationwide networks, and some opened offices. 
Accordingly, the increases in the early 1990s were stimulated by the NGOs’ campaign for 
organ donation and by the flourishing business of brokers involved in commercial dealing 
of human organs. To tackle commercial dealing in human organs and the involvement of 
brokerage, Severance Hospital, a major kidney transplant centre in Korea, launched a 
“donor investigation programme” in October 1992. The programme reviewed a large 
number of matched cases and the review identified suspected cases on the basis of 
examining matched cases which were rejected. Since the hospital had been carried out the 
vast majority of kidney transplants in Korea, the programme caused a great repercussion 
and cutailed a large number of transplant cases and the effort directly resulted in a 
remarkable reduction in national statistics in 1993. Reflecting on the effect of the screening 
programme, a television documentary programme discovered the problems related to 
kidney transplants and pointed an accusing finger at the flourishing business of private 
brokers. Immediately after the programme, the police investigated the brokerage in kidney 
transplants and arrested five private brokers. As a result, kidney transplants significantly 
declined in 1994. Brokerage businesses were not completely wiped out, though their 
networked activities were largely destroyed.  
The brokerage scandal propelled public debates on brain death, and the NGOs drew 
attention to organ donation from brain-dead donors. Their campaign contributed to 
promoting cadaveric-donor transplants. As seen in Figure 3, the number of kidney 
transplants from cadaveric donors rapidly increased after police involvement was reported.  
The issues on brain death were provoked by the Korean Society of Nephrology, the 
Korean Society of Transplantation, and the Seoul National University Hospital. They 
initiated public debates on cadaveric transplants in March 1988, when a proposal requiring 
brain stem death legislation was conjointly issued to the Korean Medical Association. The 
first case of cadaveric kidney transplant, performed on January 25, 1990, focused public 
concern on brain death and organ procurement from the deceased person. The first 
successful transplant case motivated medical professionals to rush into the practice of 
cadaveric organ transplant although there was no regulation legalising organ procurement 
from cadaveric donor. Seoul National University Hospital’s issuance of brain stem death 
criteria on December 2, 1992 spurred debates on brain stem death. Subsequently, the 
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Korean Medical Association released its Decree on Brain Death on March 4, 1993. Since 
then, most teaching hospitals carrying out organ transplantation have transplant 
coordinators in place to enhance integrated collaboration among the transplant teams within 
the hospital. Transplant coordinators also cooperate with the transplant teams in other 
hospitals, and with voluntary organisations, in terms of organ procurement and delivery.  
The Ministry of Health and Welfare endorsed the Korean Medical Association studies 
of brain stem death. Debates on brain stem death among the public have also become 
fiercer, as organ procurement from the deceased is strongly opposed by the Academy of 
Confucianism. The Academy of Confucianism strongly stands against brain stem death and 
cadaveric-organ transplant. The Confucian tradition regards any hurt or harm inflicted on a 
person’s body as an act of impiety against the deceased. 
Although there was significant resistance against cadaveric-organ transplantation, the 
legal basis for the use of organs procured from cadaveric donors was introduced in 1995. 
The Cadaver Anatomy and Preservation Act of 1995 authorised the use of tissue and organs 
from the deceased for the purpose of research and treatment. The Act authorised the use of 
human organs and tissues with the consent of the deceased person’s family or relatives, and 
thereby legalised cadaveric-organ transplantation. Before the law was enacted, organ 
transplantation had been performed under an implicit consensus accepting that the results 
of organ transplantation are desirable for individual patients and for the society as a whole 
insofar as it does not cause any harm to the persons who donate organs.  
 
Contrary to expectations, the number of kidney transplants sharply  decreased after 
the Organ Transplantation Act was introduced in January 2000. Many commentators 
pointed out that the legal requirement to secure family consent discouraged organ donation 
from the deceased person. The much lower number of transplants in Korea using organs 
from the deceased as compared to that in Western countries is primarily attributed to the 
passive attitude of the Korean public towards organ donation. According to Lee and Kim 
(2003), 66.7% of the respondents disagree to cadaveric-organ donation because they regard 
it as an act that impairs the body of the deceased person, a belief that is supported by 
precedent research (Kim 1999). This attitude towards the deceased is closely related to 
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cultural tradition, which emphasizes the body of the dead should be respectfully treated 
without any harm. 
The most distinctive feature in Korea is the world highest level of living donor 
transplantation with a significant fraction of unrelated donors, as depicted in Figure 4. 
Transplants using kidneys from unrelated living donors are also numerous in Korea. Of the 
total, 42.3% of living-donor kidney transplants in Korea from 1991 to 1993 were performed 
with unrelated donors (Koean Transplantation Society 1999).  
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Figure 8-9. The composition of kidney transplantation by donor type (1996-2006). 
 
Data sources: 1) Korean Transplantation Society, 1998 
    2) Korean Transplantation Society, 1999 
           3) KONOS, 2006 
 
The fact that 71.8% of total living donor transplants performed in a Catholic University 
Hospital from 1989 through 1991 were unrelated donors (Yoon 1992) suggests that the 
most of living donor transplants were involved in commercial dealing. Insofar as there is no 
scientific investigation in place to confirm the relationship of the kidney donor and the 
recipient, the data relating to such relationships are not reliable. Many cases were reported 
of counterfeit rings being arrested by police in Korea especially following the introduction 
of Organ Transplantation Act of 2000, who forged passports of donors involved in 
commercial dealing of organs. By forging passports, commercial donors attempted to show 
the donor as a member of family of the recipient. Figure 4 shows significant decreases in 
unrelated live donor transplantation since 2000, suggesting that the Organ Transplant Act 
of 2000 successfully eradicated commercial dealing of organs for transplantation. In reality 
many cases went to China to evade the law in Korea.  
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8.4.3. UK 
The number of kidney transplants in the UK most significantly increased in 1984 and 
1989. The number reached its highest level in 1989, as shown in Figure 8-10. Although the 
number of such transplants increased in 1995, the general trends show that the number of 
kidney transplants using organs from cadaveric donors has declined while the number of 
those that use organs from living donors has increased significantly since the Human Organ 
Transplant Act was introduced. 
 
Figure 8-10. The number of kidney transplants in the UK (1980-2003). 
Data sources: 1) UK Transplant, Transplant Activity Report 2001 
2) UK Transplant, Transplant Activity in the UK 2002-2003 
3) UK Transplant, Transplant Activity in the UK 2003-2004 
4) UK Transplant, Transplant Activity in the UK 2004-2005 
5) UK Transplant, Transplant Activity in the UK 2005-2006 
6) UK Transplant, Transplant Activity in the UK 2006-2007 
7) UKTSSA, Transplant Activity Report 2000 
 
The turning points in the history of kidney transplants in the UK can be summarised as 
follows: 
 there were huge increases in the number of kidney transplants in the UK in 
1984 and 1989; and 
 the number of kidney transplants using kidneys from cadaveric donors 
gradually decreased after 1989, while the number of transplants using kidneys 
from living donors remarkably increased.  
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Figure 8-11. Changes in the number of living-donor kidney transplants (1988-2006) 
Data sources: 1) UK Transplant, Transplant Activity Report 2001 
2) UK Transplant, Transplant Activity in the UK 2002-2003 
3) UK Transplant, Transplant Activity in the UK 2003-2004 
4) UK Transplant, Transplant Activity in the UK 2004-2005 
5) UK Transplant, Transplant Activity in the UK 2005-2006 
6) UK Transplant, Transplant Activity in the UK 2006-2007 
7) UKTSSA, Transplant Activity Report 2000 
 
The reasons behind these characteristics are explained in the following statements. First, 
the increase in 1984 is interpreted as reflecting the adoption of the immunosuppressant 
cyclosporine. Afterwards, kidney transplants were well accepted as having superior 
benefits over any other treatment modality for ESRD patients in terms of both cost 
effectiveness and life-saving effect. Second, there was a new legal development. The 
figures, which show the transplant numbers in 1989 and 1990, were influenced by the 
controversies in the process of legalising the technology. The debates at this time promoted 
cadaveric-organ transplants while condemning commercial dealing in human organs. In 
1988, a strong emphasis was placed on spurring medical professionals to increase organ 
donations, and on a campaign to encourage people to carry donor cards. In 1989, there were 
extensive efforts to ban commercial dealing in human organs as a result of the scandal 
involving organ sale solicitation in a Turkish newspaper for transplants in London. While 
there was strong opposition to commercial dealing in human organs, there were also active 
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movements encouraging cadaveric and unrelated living donations. On November 5, 1989, 
The Times reported that “organ donations have doubled because of the recent publicity.”  
The decline in the number of kidney transplants in the 1990s is largely associated with 
the following two elements: the shortage of available organs, and the shift in the 
reimbursement policy for dialysis. There have been both theoretical discussions of explicit 
rationing and open initiatives to target dialysis for rationing (Stanton 1999). As a 
consequence, owing to the public efforts to increase organ donation from living donors, the 
increases in the number of living-donor kidney transplants in the 1990s were considerable, 
as shown in Figure 8-11. 
 
Table 8-5 shows that the number of living-donor kidney transplants performed in the 
UK has risen over the last decade in both the related- and unrelated-donor groups. 
Table 8-5. Living-donor kidney transplantation in the UK (adult only) 
 Related Unrelated (% of total) 
1993 119   3 (2.4) 
1994 121   1 (0.8) 
1995 150   6 (3.8) 
1996 177   6 (3.2) 
1997 164  11 (6.2) 
1998 225  20 (8.1) 
1999 232  37 (13.7) 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
267 
285 
285 
311 
314 
406 
438 
 68 (20.2) 
 87 (23.3) 
 91 (24.2) 
102 (24.6) 
113 (26.4) 
136 (25.0) 
203 (31.6) 
Data sources: 1) UK Transplant, Transplant Activity Report 2001 
2) UK Transplant, Transplant Activity in the UK 2002-2003 
3) UK Transplant, Transplant Activity in the UK 2003-2004 
4) UK Transplant, Transplant Activity in the UK 2004-2005 
5) UK Transplant, Transplant Activity in the UK 2005-2006 
6) UK Transplant, Transplant Activity in the UK 2006-2007 
7) UKTSSA, Transplant Activity Report 2000 
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8.4.4. US 
In 2000, 13,372 kidney transplants were performed in the US, and a considerable 
number of recipients were older patients.213 Each year in the United States, more than 
50,000 people are diagnosed with ESRD (USRDS 1998). Diabetes is the most common 
cause of ESRD, resulting in about one-third of the new ESRD cases. The incidence rate of 
ESRD patients in 1996, which pertains to the number of patients who started medical 
treatment for ERSD, was estimated at 270 pmp. The total ESRD patients in the same year, 
pertaining to the accumulated number of ESRD patients at the end of the year, were 1,041 
pmp. 
 Of all the ESRD patients, 27.41% were living with a functioning graft while the 
majority of the patients were living with dialysis, as shown in Figure 8-12. Among the 
patients living with dialysis, the largest group consisted of those who were living with 
hospital haemodialysis (84.27%). The next largest group was that consisting of patients the 
group with CAPD and CCPD (23.28%).  
 
 
 
 
 
 
 
 
 
 
Figure 8-12. Changes in the number of patients in each treatment modality 
Data Sources: United States Renal-Data System (USRDS) (1998). The USRDS 1998 Annual-Data Report. 
 
The number of ESRD patients increased by 108.95% from 1988 to 1996. The increase 
was greater in the number of patients living with a functioning graft (114.28% from 1998). 
                                                 
213 The recipients aged 50 years and older received 36% of all the cadaveric-donor kidneys in 1996, up from 
27% in 1988. This age group also received 24% of the living-donor kidneys in 1996, an increase from 
11% in 1988.  
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The increase in the patients living with dialysis was also considerably high, although lower 
than that in the patients living with a functioning graft.  
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Figure 8-13. Total number of kidney transplants and organ donors by year (1988-
2003) 
Data sources: The Organ Procurement and Transplantation Network, Donors Recovered in the U.S. 
by Donor Type: Jan. 1, 1988- Jan. 31. 2008 
 
As shown in Figure 8-13, the total number of kidney transplants has increased more 
than the number of cadaveric donors has since 1991. Thus, the gap between the two 
fractions has become wider over time.  
 
The increase of organ donation among the living donors was due to a huge increase in 
the number of unrelated donors, as shown in Figure 8-14. While organ donation from 
people with a direct bloodline relation to the recipient has been in a steady state, that from 
unrelated donors and extra-lineal relatives has constantly increased, accounting for 10.5% 
of all the living-donor transplants from 1988 to 2003 
Various events in the US in the 1980s might have affected kidney transplantation in the 
country, as follows:  
 the introduction of the new immnumosuppressive drug cyclosporine, which 
was approved by FDA in 1983; 
 the passage of the National Organ Transplant Act (NOTA) by the US Congress 
in 1984; 
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 the introduction of the Organ Procurement and Transplantation Network 
(OPTN) in 1986; 
 the passage of the Omnibus Budget Reconciliation Act of 1986, which 
mandated that all organisations involved in organ procurement and transplant 
be members of OPTN, and which obliged medical professionals to ask all 
potential organ donors if they have an intention to donate their organs upon 
their demise. This has been termed as “required request” or “routine inquiry”;  
 the awarding to UNOS in 1986 of the first contract to operate OPTN; and 
 the taking over by UNOS of the full operation of OPTN on October 1, 1987; 
 
 
Figure 8-14. Living-donor relation to the recipient (1988-2003) 
Data sources: The Organ Procurement and Transplantation Network, Donors Recovered in the U.S. 
by Donor Type: Jan. 1, 1988- Jan. 31. 2008 
 
Figure 8-15 shows the trend in kidney transplants from 1981 to 2003. The proportion 
of ESRD patients with functioning grafts stayed at the same level from 1988 to 1992 
(26.73% of the total ESRD patients). The number increased by 28.29% in 1996, as the 
increase in transplants has prevailed over the increase in the patients with dialysis since 
1992. As shown in the figure, the number of kidney transplants rapidly increased from 
1984 to 1986, and has shown a steady increase since the early 1990s.  
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Figure 8-15. Major events and kidney transplants (1981-2003) 
Data sources: 1) from 1981 to 1987: Schuck, P.H. (1989). Government funding for organ    
transplants.Journal of Health Politics, Policy and Law, Vol. 14(1): 169-190 
2) from 1988 to 2003:The Organ Procurement and Transplantation Network, Donors 
Recovered in the U.S. by Donor Type: Jan. 1, 1988- Jan. 31. 2008, 
http://www.optn.org/latestData/rptData.asp retrieved 8 April 2008. 
 
The “required request” approach has not significantly increased organ donation in the 
long term, although there is some evidence that the law has contributed to increasing organ 
donation for a short period after the enactment (Anderson and Fox 1988).214 The 
arrangements regarding the improvement of organ transplantation activities were settled in 
legal and organisational terms. The efforts have been focused on increasing organ donation 
from the deceased. Since the early 1990s, public efforts in kidney transplantation from 
cadaveric donors have been focused on the fair allocation of organs for transplantation.  
While the demand for kidneys and other organs is rapidly increasing, the number of 
those donating organs upon death (cadaveric donors) is increasing only slightly. The total 
number of people who were on waiting list for a kidney donation increased by 8.5% from 
                                                 
214 In New York, where the “required request” law was passed in 1985, heart donations increased by 94%, 
liver donations by 96%, and kidney donations by 23%. The director of the Regional Organ Procurement 
Agency in Los Angeles stated that in the first year of the implementation of the “required request” 
approach, the number of referrals increased, but the number of donors largely remained the same. Then, 
the number of local referral calls dropped by over 500 in 1987.  
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the last day of 1999 to the end of 2000. The number of kidney transplants performed in the 
United States increased by 6.5% from 1999. The increase in transplants using kidneys from 
cadaveric kidney donors was only 0.7%, while the increase in the number of cadaveric 
donors between 1999 and 2000 was 16%. 
In a similar vein, the increases in the number of kidney transplants performed in the 
1990s were mainly due to the rise in the number of living-donor transplants. From 1991 to 
2000, living-donor kidney transplants increased by 119.7%, while the increase in the 
number of cadaveric-donor organ transplants in the US was only 10.9%.  
 
8.5. Conclusion 
 
Kidney transplants provide great benefits to patients suffering from irreversible organ 
failure by extending and improving the patient’s quality of life. As kidney transplants not 
only require human organs either from someone alive or deceased, but also entail high costs, 
there has been much debate on issues about organ procurement and compensation by third 
party payers. With wide variation across the countries, it has been regulated on various 
levels, especially relating to organ procurement and allocation, as a way of dealing with 
commercialization. 
Three non-transplant approaches have been adopted as alternatives to kidney 
transplants to manage ESRD patients; continuous ambulatory peritoneal dialysis (CAPD), 
home dialysis, and hospital dialysis. The choice whether to switch from dialysis depends on 
the availability of an organ donor, physical condition of patient, and the ability to pay for 
the transplant.  
Globally, the ratio of ESRD patients living with a functioning graft varies greatly, 
particularly high in northern Europe including Norway, Sweden, the UK, Austria, the 
Netherlands, and Luxemburg. The ratio is less than 1 % in Japan. In general, the proportion 
of ESRD patients living with functioning grafts is much higher in countries where health 
services are traditionally financed by a global budget system with financial resources 
collected from taxes. 
 
Kidney transplants are generally more cost-effective and the least costly method of 
treatment compared to other conventional dialysis approaches. Empirical studies on costs 
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and benefits of treatments for patients with ESRD consistently show kidney transplants as 
the most effective option. Besides an improved QoL, extended life of a patient, the time 
saved that would otherwise have been spent on dialysis as well as lower the risk of 
infection are additional benefits gained from a kidney transplant.   
 
The coverage for kidney transplant varied across the selected countries. In Japan, the 
cost of a kidney transplant has been covered by public health insurance since 1978. The 
programme covers all follow-up medical procedures after the transplant approximately 
£7,800- £10,500 a year. Since kidney transplants are categorised as a ‘Sophisticated High 
Technology’, the public insurance programme covers overall costs exceeding £332. The 
insurance also covers the cost of dialysis and patients receive public funding during the 
time on dialysis based on the Disabled Act. 
In Korea, the public health insurance programme remunerates the costs on an FFS 
schedule. Although public health insurance covers some of the costs, patients still end up 
paying about £10,000 out of pocket, which includes the procedural costs related to the 
kidney donor. 
In the UK, the NHS regards all solid organ transplants (except liver transplants related 
to alcoholic liver disease) to be cost-effective, particularly in relation to the amount NHS 
spends (Anyanwu et al., 2002). 3 % of the NHS budget is spent on kidney failure 
treatments. The NHS reference cost 2000 put a kidney transplant at £10,249 for elective 
and £11,397 for non elective surgery per patient per transplant. The costs for the patients 
with renal failure vary by procedures (Roderick et al., 2002); about £20,000 per patient per 
year for peritoneal dialysis, about £34,500 for haemodialysis, and about £3,500 in the first 
year and £23,500 in subsequent years following kidney transplant. The cost benefit of a 
kidney transplant compared to dialysis over a period of nine years (the median graft 
survival time) is about £191,000 to £21,200 per year the kidney transplanted functions. In 
2002-03, the NHS saved about £37.6m in dialysis costs each year the kidneys of the 1,775 
people that benefited from a kidney transplant continued to function. (UK Transplant, 
Activity Report 2002-2003). 
In the US, the primary source of payment for transplants varies greatly. Though 
Medicare covers all kidney transplants, private insurance plans finance a large proportion 
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of kidney transplants. In 1997, Medicare covered 59.1 % of cadaveric donor kidney 
transplants and 38.35 % of living donor kidney transplants. In the case of live donor kidney 
transplants, private insurance plans covered 48.7 % of the total. Medicare has two types of 
coverage: Part A and Part B. Part A covers 100 % of most inpatient expenses and is 
guaranteed for those who made Social Security payments. Part B of Medicare pays only 
80 % of outpatient treatment after of an annual deductible, so additional insurance is 
necessary to cover the remaining 20 % of outpatient-based medications. Medicare pays 
80% of immunosuppressant medications for 44 months following kidney transplantation. 
As for dialysis, Medicare pays inpatient hospital stay and Medicare also pays 80% of the 
monthly amount after the patient pays $100 yearly deductible (Health Care Financing 
Administration, 2001). 
  
In terms of regulation, legislation has been instituted to regularise organ procurement 
and ban commercial trade of organs in each country. With public funds, public authorities 
are involved in the procurement and allocation of organs to promote organ donation 
especially from the deceased and ensure fair allocation of harvested organs. Organisations 
for organ procurement and allocation have been established and operated by public 
authorities in all the four case study countries; JOTNW in Japan, KONOS in Korea, UK 
Transplant in the UK, and UNOS in the US. Public involvement in organ transplantation is 
generally favoured within the public welfare context, although there are differences in 
terms of when they were established and range of activities.  
In Japan, a centralized, nationwide kidney transplant network JNOS was launched in 
1995. This network expanded according to the Organ Transplant Law of 1997, which 
enabled multi-organ transplants. With a centralized office, the network has seven regional 
kidney transplant centres. Through these facilities, the Ministry of Health and Welfare 
seeks to improve the equity and appropriateness of organ distribution by selecting 
transplant candidates based on universal standards. There are 44 kidney banks used to 
promoting kidney transplants, especially from cadaveric donors. Public involvement has 
lagged in Japan compared to western countries mainly due to a lack of success during early 
attempts at organ transplants. The first heart transplant performed in 1968 received public 
criticism as many were not willing to accept brain death. The second attempt performed in 
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1984 involving a mentally disabled donor worsened public sentiment surrounding organ 
transplants. Reflecting world wide views, a joint movement between the Japanese 
government and the National Assembly sought to regularise organ transplants from 
cadaveric donors starting in the early 1990s.  
In Korea, the Organ Transplant Act of 2000 authorised transplants with cadaveric 
donors. The national organisation, KONOS, was established to oversee organ procurement 
and allocation. KONOS manages the matching of recipients and donors, and authorises 
organ transplants. To rule out commercial dealing especially regarding live donor 
transplants, KONOS reviews records submitted by individual transplant centres and 
selectively authorises transplant cases having determined it is not a commercial 
arrangement between the donor and recipient. With a long history of organ 
commercialisation, public authorities have been cautious. Recently, there have been many 
cases involving the selling of organs from China, a major concern in Korea. 
In the US, the first successful human kidney transplant was performed by Dr. Joseph 
Murray of the Harvard Medical School in 1954 at the Peter Bent Brigham Hospital. Six 
years later, the pioneering living kidney donor operation was carried out at Edinburgh 
Royal Infirmary in the UK. Immediately after the first procedure, authorisation of organ 
transplants was given through the Human Tissue Act 1961 and public involvement soon 
followed with the establishment of the UKTSSA in 1968 to coordinate organ transplant 
activities. UK Transplant, which succeeded UKTSSA, oversees overall activities related to 
organ transplants. After a public scandal over the sale of organs to a private hospital in 
London in 1988, the Human Organ Transplant Act was enacted in 1989, banning the 
commercialization of human organs. By law, the Unrelated Live Transplant Regulatory 
Authority (ULTRA) assesses live donor candidates receiving monetary benefits who are 
unrelated, and penalises anyone in commercial transactions. The National Organ Donor 
Register launched on 1994 played a significant role by promoting organ donation 
registration, which currently has registered 20 % of the total population.  
In the US, the Uniform Anatomical Gift Act of 1968 authorised organ transplants using 
organs of deceased donors. In October 1984, the NOTA introduced the Task Force on 
Organ Procurement and Transplantation and an Organ Procurement and Transplantation 
Network (OPTN). The Act banned commercialization of organ transplants. All organ 
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transplant centres are mandated to join OPTN as a member by Omnibus Budget 
Reconciliation Act (OBRA) of 1986, otherwise they are not eligible for public insurance 
programmes including Medicare and Medicaid that are the major third party payers for 
kidney transplants. The OBRA also has significant importance in the US organ transplant 
history, as it requires medical professionals to make inquires on  all potential donors if 
they have an intention to donate organs, called “required request” or “routine inquiry.” As 
such, UNOS provides OPTN with overall management of data and organ matching and 
placement process. 
Approaches to promote kidney transplants have been expanded, particularly in the UK 
and the US. Primary concerns focus on extending donor availability while preventing 
commercialization and relieving cost burdens. In the UK, public authorities at the national 
level have carefully regulated the approaches in both legal and financial terms. Similar to 
the UK, public authorities in the US have supported initiatives to promote kidney transplant 
activities and garner support from public insurance programmes, including Medicare and 
Medicaid. Different from the UK, the system for organ procurement and allocation has 
been localised and recently integrated into a singular system networking the entire country. 
In both Japan and Korea, public involvement lagged behind compared to the situation in the 
UK and US. This was largely due to the traditional belief that a deceased person should be 
respected and not to be harmed. Subsequently, the government was hesitant in publicly 
raising the issue of organ procurement from deceased donors. As demand from both 
professional groups and patients has increased coupled with the instances of organ 
trafficking scandals, legislations have been introduced to permit organ harvesting from 
deceased donors and prevent commercial trade of organs. Laws were passed in 1997 in 
Japan and in 2000 in Korea. Different from the general approach of excluding costly 
medical procedures from public insurance plans, social insurance programmes in both 
countries covered organ transplants at an early stage of adoption. 
Figure 8-16 shows the variation among the selected four countries, the US by far the 
highest followed by UK with Korea and the Japan at much lower levels. While the level of 
adoption has been consistently upward in the US, the other three countries have shown little 
growth since around 1990. 
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Figure 8-16. The trends of kidney transplants in selected countries (pmp) 
 
Rapid expansion internationally during the 1980s and early 1990s was primarily 
attributable to the newly introduced immunosuppressant ‘cyclosporine A.’ Since then, the 
variations between countries are mainly due to organ availability, which depends on the 
country’s public initiatives, legislation, and reimbursement policies of third party payers for 
the treatment modalities of ESRD including renal transplants. 
 
As summarised in Table 8-6, the number of kidney transplants pmp is the highest in the 
US among the selected four countries. Although the number in terms of pmp is higher in 
the US than the other tree countries, the ratio of having transplantation amongst total 
patients with renal failure is much lower in the US than the UK and even lower than Korea. 
Japan is by far at the lowest while prevalence of patients with renal failure is at the highest 
among four countries. 
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Table 8-6. Comparisons of the incidence and prevalence of ESRD and functioning 
transplant 
 Incidence of 
ESRD (pmp) 
Prevalence of 
ESRD (pmp)  
Transplant 
ratiosa(pmp) 
Prevalence of functioning 
transplant (pmp) 
Japan   252 1,726  5.94 0.85 
Korea  114 701   15.2        29.6 
UK   103 640 29.8 45.3 
US  336 1,446       51.2 25.9 
Data sources: 1) USRDS, 2004 Annual Data Report. Available at http://www.usrds.org/adr_2004.htm 
accessed 6 May 2008 
2) UK Renal Registry, UK Renal Registry Report 2003. Bristol, UK. Available at 
http://www.renalreg.org/Report%202003/RenalReg2003AnnualReport_Colour_For_Web_With_Li
nksv2.pdf accessed 6 May 2008. 
3) USRDS, 2004 Annual Data Report. 
4) UK Renal Registry, Report 2003. 
5) Korean Society of Nephrology, 1996 
 
In the US, most of the transplant growth has been from living donor, with the greatest 
rate of increase involving living and unrelated or distantly related donors. During 1988-
1999 period, the transplants steadily declined. In the UK, the increase in kidney transplants 
is mainly attributed to the growth of live donor transplants, especially from the mid- 1990s. 
Following the National Organ Donor Register launched on October 6, 1994, live donor 
transplants increased; from 8.9 % in 1995 to 24.5 % in 2003 of the total.  
The most different figures are observed in Korea and Japan. 88.9 % of total kidney 
transplants were performed with live donors in Korea on average since the first kidney 
transplant in 1969. The proportion of live donor transplants was also very high in Japan at 
72.7 % of total from 1978 to 2002. The US is in a unique position among western countries 
with a greater level of live donor kidney transplant, 45.3 % of total kidney transplant during 
1988-2003 periods. In Korea, the proportion of live donor transplant is the highest among 
selected countries. The main reasons are that 1) organ procurement from the deceased is not 
legalised and 2) there is no legislation prohibiting commercial dealing in human organs 
resulting in high proportion of unrelated live donor kidney transplantation.  
In contrast with other three countries, the proportion of unrelated donors is 
extraordinarily high in Korea, as indicated in Table 8-7. Among unrelated live donor, a 
substantial amount is suspected to be commercially driven. The fact that 5 people were 
arrested in 1994 for brokering organs of live donors, supported the suspicion that organ 
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commercialisation was wide spread. Criminal investigations were carried out in 2003 in 
which the offenders involved in a nation-wide organ dealing network were apprehended. 
 
Table 8-7. Comparisons of donor-recipient relationship in live donor transplant in 
four countries, various years 
 Periods All live 
donors 
Unrelated 
donors 
% of unrelated donor 
Japan 1983-1998 6,190 284 4.5 
Koreaa 2002 98 70 71.4 
UK 1993-2000 1,607 152 9.4 
US 1988-2003 64,985 7,277 11.2 
Data sources: 1) Data Source: UKTSSA, Transplant Activity Report 2000 
2) The Organ Procurement and Transplantation Network, Donors Recovered in the U.S. by 
Donor Type: Jan. 1, 1988- Jan. 31. 2008, http://www.optn.org/latestData/rptData.asp 
retrieved 8 April 2008. 
3) The Japan Society for Transplantation (1995). Annual progress report from the Japanese 
Renal Transplant Registry, 1994. The Japanese Journal of Transplantation, Vol. 30(4): 428-
449. [Japanese]  
4) The Japan Society for Transplantation (2000). Annual progress report from the Japanese 
Renal Transplant Registry, 1999. The Japanese Journal of Transplantation, Vol. 35(2): 43-48. 
[Japanese]  
5) The Japan Society for Transplantation, 2000 report on transplant registration, Transplantation, 
Vol. 36(5): 91-105, 2001 
6) Korean Transplantation Society (1999). Organ transplantation report on 1996. Korean 
Journal of Organ Transplantation, Vol. 11(2): 183-199 [Korean] 
7) Korean Transplantation Society (1999). Organ transplantation report on 1997. Korean 
Journal of Organ Transplantation, Vol. 12(2): 152-160 [Korean] 
8) Korean Transplantation Society (1999). Organ transplantation report on 1998. Korean 
Journal of Organ Transplantation, Vol. 13(2): 185-194 [Korean] 
9) Han. Y.S. (2002). The way to improve organ transplant and evaluation system. Research 
Report 2002-8, Korea Institute of Health and Social Affairs 
Note: a. The number does not include all live donor transplant but limited to the response on the survey. 
 
Aside having two of the world’s highest level of live donor transplants, there appears to 
be significant variations between Japan and Korea. Cadaveric renal transplants accounted 
for about 30 % of the total renal transplants in Japan. With a public outcry following a 
patient suffered brain death in 1985, the number of cadaveric renal transplants levelled off. 
After the public became more open, the number of renal transplants involving cadaveric 
donors increased subsequent 5 years before declining to the present levels. Live donor 
transplants also had been falling off until JOTNW began its activities. The level of renal 
transplants in Japan is the lowest among OECD countries. This is primarily attributed to the 
negative perception on organ transplants that stemmed from the failure of the first case in 
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1968, in which the surgeon was blamed and called a murderer. The second case worsened 
the situation, as it was performed with a mentally disabled cadaveric donor. The attention 
these cases received needs to be set in the context of societal values in Japan sees organ 
transplants with unease. 
The adoption of cadaveric transplants in Korea lagged far behind. Indebted to active 
involvement of a voluntary agency –Korean Organ & Tissue Donation Programme 
(KOTDP)- in promoting organ donation, especially from deceased donors, cadaveric renal 
transplants increased until the Organ Transplant Act of 2000 came into effect. Even though 
organ procurement became legitimate in Japan and Korea, transplants from cadaveric 
donors did not increase; it actually decreased in Korea following the enactment. This is 
because of weak public consensus on organ donation from the deceased, which primarily 
stems from Confucianism. Due largely to that belief, the role of KONOS has mainly been 
focused on authorising kidney transplantation from live donors. Activities to promote organ 
donation from cadaveric donors have been circumscribed.  Three reasons are pinpointed. 
First, the law blocked the involvement of non-governmental organisations from all 
activities related to matching donors and recipients including with cadaveric donor. By law, 
the matching of recipients with live donors was done anonymously activities to promote 
organ donation from cadaveric donor halted. Second, more significantly, any form of 
involvement in commercial dealing of organs was considered unlawful. Third, the organ 
procurement system distorted cadaveric organ donations. The hospital based organ 
procurement (HOPO) is responsible for organ procurement activities. The system is 
currently being circumscribed due to financial disincentive towards HOPO. There are 22 
assigned HOPOs across Korea, taking into account medical capability and accessibility at 
the local level. When a potential cadaveric donor is found, a visit is made to the donor and 
given a pre-examination. They transfer the donor to their HOPOs when suitable. If the 
potential donor is found not to be suitable, as happens in 30 % of all cases, the HOPO bears 
all the costs incurred in the process, which otherwise the recipient pays for.  
Other conditions have had a temporary impact. The upward trend until 1992 was 
primarily attributed to the expansion of the number of people covered by the insurance and 
sufficient supply of organs, which mainly come from commercial sources. At the time, 
commercial trade in organs was thought to be widespread.  
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In the UK, following factors have affected the supply of organ donors (New et al., 
1994):    
 death rates from relevant causes; 
 level of funding; 
 organ procurement arrangements; 
 cultural factors. 
 
The level of funding has been a more significant factor in instigating the level of organ 
transplant. Simple regression analysis reveals that the level of funding, as considered in 
terms of net revenue cash limits per capita for regional health authorities, was significant in 
determining the level of organ transplant.  
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Chapter 9: Discussion 
 
This chapter draws together the findings of the case studies. Given the characteristics 
of the data and method of analysis, a qualitative rather than quantitative type of testing can 
be applied. Testing in this sense involves empirical plausibility as a guide to further 
explanation. Based on the empirical assessment, various important paradoxes are identified 
that kindle further exploration. This should be sufficient to indicate the extent to which the 
“micro” and “macro” aspects and associated models are sufficient to explain the observed 
differences. And should they be insufficient, it may be possible to identify paradoxical 
cases and speculate on the other, “residual” factors involved.  
 
9.1. Assisted reproductive technologies (ARTs) 
 
The introduction of ARTs in mainstream medical practice posed a number of 
challenges to health care providers, particularly due to the cost. Key issues for health 
administrators and policy-makers face were; deciding on what resources can be allocated to 
ART services, defining who can access to such services, and striking the right balance 
between investment in prevention and in cure (Fathalla, 2001). In addition, the emergence 
of ART raised issues of genetic cohesion and integrity of the traditional family identity 
(Dickens, 1990), triggering conservative responses.  
Since infertility is not considered a disease and does not threaten a patient’s life or 
physical health, third party payers including public health insurance programme have 
generally excluded it from coverage. The debate on ARTs is intertwined with complex 
scientific, cultural and ethical concerns including the status of an embryo and the 
involvement of a third party (Fathalla, 2001). Accordingly, ARTs lack public support on 
fee reimbursement by health insurance. ART costs were generally paid privately in all four 
countries. Social insurance programmes in Japan and Korea do not cover ARTs. In the UK, 
a large proportion of infertile couples seek ARTs in the private sector, for which they pay 
out of pocket or through their private insurance policy. Recently in the UK, however, an 
increasing number of Health Authorities purchase ARTs on a specific fertility contract 
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basis. The process of reimbursement is complicated, while in Scotland, up to three IVF-ET 
cycles are publicly funded. According to NICE (2004), about 25% of total cost in England 
is funded by the NHS. The NICE guideline of 2004 recommended that couples should be 
offered up to 3 cycles of IVF on the NHS for over 10% chance of success. In the US, most 
health plans do not provide coverage for the technology. Accordingly, most couples 
seeking fertility treatment pay out of pocket. Collins and colleagues (1995) estimated that 
approximately 85 % of total ART expenditure is paid by the patient. Though 14 states have 
mandated insurers to provide some form of infertility care, only 6 states out of the 14 oblige 
insurers to cover infertility treatment. The states where the provision of ART services is 
mandated are Hawaii, Illinois, Maryland, Massachusetts, Montana and Ohio.  
 
The following elements may be responsible for higher adoption of ARTs in the UK. 
First, as the first country that has succeeded in engineering the IVF-ET technology, ARTs 
have been widely accepted in the UK among both infertile couples and obstetricians. 
Second, the cultural background regarding a baby as a child of God in Christian tradition 
may have facilitated support for those technologies that do not emphasize the continuation 
of blood lines, such as donor insemination, egg donation and surrogacy. In the UK, all 
those treatment activities have been regularised from the early stages of technology 
development. Third, although the NHS does not generally provide fund for infertility 
treatment, the cost itself may not be a serious barrier for infertile couples to access ART 
treatments as the procedures are not expensive relative to income. On the other hand, the 
market-orientation of ARTs might have facilitated their spread. 
The factors facilitating the adoption of ARTs were largely similar in Japan and Korea. 
ARTs involving semen and egg donation have not been generally accepted in both Japan 
and Korea due to cultural traditions that emphasize the continuance of bloodlines in 
succeeding generations. Competition between providers triggered the adoption of newer 
technologies like ICSI in both Japan and Korea. Under competitive circumstances, 
obstetricians promote their advanced capabilities by adopting innovative technologies 
earlier than their competitors. Faster adoption in Japan and Korea also resulted in lower 
costs for using ARTs compared to the UK and US, easing their adoption. 
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The following may have contributed to the US lagging in the adoption ARTs. First, 
insurance programmes did not cover the cost associated with ARTs. Second, The 
Fertilisation Clinic Success Rate and Certification Act (FCSRCA) of 1992 required 
infertility clinics to report exact numbers of procedures and success rates resulting in live 
births. ART providers had to keep high success rates in a competitive market where clients 
consider success rates in choosing the clinics. Third, competition among clinics per se also 
has led ART providers to increase success rates. To attract clients, many clinics offered 
options of paying under a “shared risk,” “warranty,” or “outcome basis” plan. Under these 
arrangements, obstetricians could choose couples carefully on the basis of whether they 
were liable to successfully gestate.  
 
In summary, traditional ART was accepted in countries with a Christian culture 
including the UK and US, while countries based on Confucian culture including Japan and 
Korea took a reluctant stance on donor insemination. Cultural factors helped to facilitate 
the adoption of ARTs related to genetic handling in the UK, which include donor 
insemination, egg donation and surrogate motherhood (van den Akker, 2000). The UK, the 
leader in developing ARTs, have established sophisticated regulations and supported the 
adoption of all available methods. In the US, legal arrangements and competition 
circumscribed overuse of ARTs. Clinics and practitioners in the US had to be cautious in 
deciding whether they provided infertility cycles. The situations in Japan and Korea are 
compatible. In both countries, cultural factor respecting the success of bloodline is a barrier 
to the adoption of ARTs. Public insurance programmes did not cover ART. Infertility 
clinics charged fees on a FFS basis. The adoption of ARTs was not monitored by any 
external authority, resulting in a lack of responsibility for the outcome on the part of 
infertility service providers. Except cultural barriers related to genetic continuance, the 
external environments in Japan and Korea are favourable towards the adoption of ARTs.  
 
9.2. Caesarean section delivery 
 
The caesarean birth ratio is significantly associated with the cost reimbursement 
scheme used each health system. The cost for ceasarian birth is compensated on a fee-for-
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service basis in both Japan and Korea. There were huge variations however in caesarean 
section ratios between the two countries. The differences are primarily attributed to 
coverage policy of health insurance programmes. Both caesarean section delivery and 
natural birth are covered by health insurance in Korea while health insurance does not 
provide natural delivery with coverage.  
Judicial rulings have had a strong influence on encouraging physicians to choose 
caesarean section deliveries. Defensive practices to avoid malpractice claims are widely 
regarded as a factor contributing to increasing caesarean section ratios (Danforth, 1985; 
Shiono et al., 1987; Sachs, 1989; Localio et al., 1993). In Korea, which has the highest 
caesarean ratio, 80 % of caesarean section deliveries were performed on recommendation 
of the physician. Physicians tend to recommend caesarean section deliveries expecting 
economic gains and avoidance of malpractice litigation. In recent years, the increases of 
caesarean section ratios in Japan and in the UK may also reflect judicial rulings which have 
often gone against physicians in malpractice rulings regarding birth procedures.  
In the UK, the most common reasons offered in the absence of obstetric indications 
were maternal request, followed by fear of litigation, and the practice of evidence-based a 
study (Cotzias et al., 2001). This is different from the 1980s when the majority of 
obstetricians refused a maternal request as reason for performing a caesarean section during 
pregnancy without complications (Johnson et al., 1986; Hall, 1987), reflects the increased 
acceptance of the NHS’s protection of consumer rights. 
UK policy recommends maternal choice in obstetric decision-making. A shortage of 
commissioning midwives pushed women to go to hospitals for deliveries, spurring 
caesarean delivery. The increasing caesarean delivery ratio seems primarily a result of the 
UK’s policy and manpower215.  
 
In pursuit of protecting woman’s health, citizen groups have actively tryied to reduce 
the caesarean section delivery ratio in Korea. NGOs have played a significant role in Korea. 
They awakened concern that unnecessary caesarean deliveries could have adverse affects 
on women’s health and impose unnecessary costs. They have also pressured the Korean 
                                                 
215 To reduce non-clinical choices and also nationwide variations, NICE has been commissioned to produce 
clinical guideline on caesarean section delivery (Parliamentary Office of Science and Technology, 2002) 
and National Service Frameworks were introduced in care through setting national standards. 
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government to establish appropriate measures to constrain caesarean deliveries. Initiatives 
such as publicly profiling the caesarean ratio of individual clinics and hospital have raised 
public awareness about caesarean deliveries, which has helped to decrease the ratio from 
43 % in 1999 to 38.6 % in 2000. 
In the US, caesarean section deliveries were preferred among those who have private 
insurance policy, and less so among those who have public health insurance or no insurance. 
Patients who had private or HMO insurance were nearly seven times more likely to have a 
repeat caesarean delivery as an elective procedure compared to patients with Medicaid or 
self-pay schemes (Hanley et al., 1996). To tackle the issue of rising caesarean deliveries, 
many of private insurance plans and state Medicaid plans attempted to equalise physician 
fees between caesarean and vaginal deliveries. In 1993, Medicare introduced the RBRVS 
(Resource Based Relative Value Scale) to make higher payments for vaginal deliveries 
compared to caesarean deliveries based on a physician’s workload by the product of time. 
The scheme raised vaginal delivery costs slightly higher than caesarean costs (Keeler and 
Brodie, 1993). Due to a lower compensation for caesarean delivery, many private 
practitioners turned away patients with public insurance or no insurance at all. Caesarean 
section ratios for HMOs are similar to private insurances where obstetricians are commonly 
paid on a fee-for-service basis.  
Public interest in cesarean ratios stems from the National Institutes of Health 
Consensus Conference held in 1981 (National Institutes of Health 1981). Since repeat 
cesarean deliveries were the second largest contributor to the cesarean ratio, attention was 
focused on fostering Vaginal Births After Cesarean (vaginal birth after caesarean section) 
to decrease the national cesarean ratio. Clinicians and investigators advocated that the way 
to decrease the repeat cesarean ratio was to deter primary cesarean deliveries (Paul and 
Miller 1995; Sachs et al. 1999). Third-party payers and accrediting bodies began 
monitoring cesarean ratios as a measure of hospital performance and as a measure of 
maternal health care quality (American College of Obstetricians and Gynecologists 2000). 
Healthy People 2000 (DHHS, 1991) proposed a national ratio of 15 %, which was widely 
criticized because it appeared to be arbitrary and did not attempt to address issues related to 
patient safety or case mix (Sachs et al. 1999). Healthy People 2010 was revised to reflect 
the importance of case mix, by focusing the national reduction goal to low-risk nulligravid 
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women (Healthy People 2010). Healty People 2010 set as a specific objective to “reduce 
caesarean deliveries among low risk (full-term, singleton, vertex presentation) women from 
17.8 % in 1997 to 15.5 % by 2010.” The American College of Gynaecology (ACOG) has 
also made recommendations to address this issue. ACOG focused its recommendations on 
decreasing primary caesarean ratios and defining a stronger role for trial labour and vaginal 
births after caesarean within a framework of individual patient risk assessment. 
 
9.3. Haematopoietic stem cell transplantations  
 
HSCTs have evolved from an experimental treatment for a small group of diseases to a 
standard procedure for a wide range of blood and haematopoietic disorders and solid 
tumours. HSCTs are currently accepted as an established form of treatment for various 
kinds of haematopoietic diseases and solid tumours. In terms of both length of hospital stay 
and average hospital charges, stem cell transplants were preferred to conventional 
chemotherapies.  
 
Various factors plausibly have affected the diffusion of HSCT in the four countries 
including:  
 Incidence rates of the diseases treatable by HSCTs; 
 Reimbursement policies; 
 Organisations supporting HSCT activities to improve donor availability; 
 Charity support. 
 
Each of these factors is discussed as follow. First, the incidence rates of leukaemia 
greatly vary among the selected countries as detailed in Table 9-1. Huge variation between 
the Japan and Korea and the UK and US can be regarded as mainly stemming from 
differences in incidence of leukaemia, which HSCT has been mainly applied for. The 
incidence rates are about double in the UK and the US in comparison with those in the 
Japan and Korea with the highest in the US. The expanding use of HSCTs on solid tumours 
and increased adoption of cord blood transplants have been major factors contributing to 
the overall implementation of HSCTs, especially in Japan and the US. 
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Table 9-1. Incidence of leukaemia (pmp) 
 Japana Koreab UKc USd 
Incidence per year 154 (1997)* 138 (1998) 282 (1992) 321 (1998) 
Data sources: 1) Oshima A. (ed.), 1998: Progress Report of the Research Group for Population-based Cancer 
Registration in Japan, 1998  
2) National Cancer Institute, The Surveillance, Epidemiology, and End Results (SEER) 
Program, SEER Cancer Statistics Review, 1973-1998 2001 
3) Department of Health, Referral Guidance for Suspected Cancer, 2001.  
4) Department of Disease Control, 2000 
Note:  a. include malignant lymphoma, multiple myeloma and hematopoietic tissue diseases 
b. includes overall haematopoietic cancers 
c. includes leukaemias, NHL, Hodgkin’s, myeloma 
d. includes leukaemias, NHL, Hodgkin’s, myeloma for adult only 
* The number in the blank refers to the year relevant to the data  
 
Second, due to its high cost, third party payers have been very cautious about 
insurance coverage for BMT. Health insurances in Japan cover HSCTs regardless of the 
condition and age of the patients. They also do not limit the coverage on account of the 
quality of HLA matching.  
In Korea, health insurance programmes started to cover autologous BMTs in 1985, 
then expanded coverage for allogenic BMTs for patients under aged 40 in 1992. Coverage 
for allogenic BMTs was expanded to those aged up to 50. Health insurance programmes 
also provided coverage for autologous peripheral blood stem cell transplantation from 1997. 
However, eligibility for insurance coverage is strictly screened by a committee of 
haematologists who determine suitable cases. Insurance programmes in Korea started to 
cover umbilical cord blood transplants in 2003 for cases approved by the screening 
committee. In addition, charities have been very active to support the patients undergoing 
HSCTs. During 1999, charities provide full or partial financial support for about 20 % of 
total patients. 
In the UK, the majority of transplants in the UK are performed according to 
standardised protocols. Following the implementation of the new NHS and the 1997 NHS 
(Primary Care) Act, cash-limiting gradually extended into primary health care, especially 
general practice. Policy-makers have provided clear direction about how to ration NHS 
resources. The ’Child B‘ case, whose funding for BMT was rejected by the regional health 
authority, became an epitome of public debate about NHS rationing (Ham and Pickard, 
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1998; Pickard and Sheaff, 1999). As hospital trusts currently carry out BMT in accordance 
with the agreement with PCTs within financial limits, they are cautious not to exceed the 
agreed budget.  
In the US, the overall landscape for insurance coverage plan is difficult to 
illuminate for the HSCTs because funding is largely through private plans. Various health 
plans have different policies on HSCT coverage. As some states require health plans to 
cover HSCTs, there are increasingly more lawsuits against limits on insurance coverage, as 
often found in the media including Internet sources. Except umbilical cord blood 
transplants, many health plans are increasingly expanding coverage policies for other 
HSCTs. 
 
Third, public support promotes donor recruitment whereas marrow donor shortage 
has been a major impediment. In Japan, the government has actively promoted donor 
recruitment in line with the programme to support Japanese victims of atomic bombings 
during the Second World War216. To facilitate BMT activities, the Japanese government 
introduced compensation programmes for bone marrow donors. If a bone marrow donor 
dies during marrow donation, the health insurance programme provides a compensation of 
£550,000 for the donor. If any problems occur on the donor requiring medical treatment, 
health insurance provides a compensation of £30 per day during admission and £17 per day 
for OPD follow ups. Bone marrow donors are also excused from their work with official 
leave. By the end of 2000, JMDP provided 3,083 unrelated donors for BMT since its 
involvement 8 years ago.  
The Korean government appropriates Korean Marrow Donor Programme (KMDP) 
about £400,000 (\ 700 million) a year to cover costs related to donor typing and operating 
the agency. In Korea, KMDP arranged 149 unrelated BMTs including 26 cases from Japan 
by November 2000. 
                                                 
216 The actions supporting the victims began immediately after the Second World War with “The Assistance 
Act of 1952 for the Bereaved Family of the Deaths in the War.” “The Special Treaty Act for the Victims 
of Atomic Bomb of 1968” provided a comprehensive support package including medical care and 
financial support for the victims. AT the passing of the 50th anniversary of the bombing, the Japanese 
government revised the law in 1994 to provide comprehensive support for the victims and their off-
springs, extending coverage for all medical costs. The Radiation Effects Study Foundation identified 
(1997) 176 people among the victims who died of leukaemia.   
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In the UK, HSCT adoptions escalated amid market reforms, although rationing 
issues raised public debate on BMT, which was further fuelled by the ‘Child B’ case of 
1995. In the following year, the adoption of HSCT was temporarily hampered. The impacts 
of the 1997 NHS reforms, which intensified coordination of financial resources for primary 
and acute care to get the most value while reflecting the health care needs of the people, 
have yet to be studied. The Anthony Nolan Bone Marrow Trust, founded in 1974 as the 
first volunteer marrow donor registry, plays a significant role in the promotion of BMT. 
The Anthony Nolan Bone Marrow Register had a pool of 43,000 potential donors in 1982, 
which increased to 345,000 registered donors as of September 2003. It matches over 300 
donors for patients every year  
In the US, public organizations established by the National Organ Transplant Act of 
1984 and its subsequent amendment played a significant role in recruiting donors and 
matching with recipients on national level. The National Marrow Donor Programme began 
to operate in 1986 and developed the Search Tracking and Registry (STAR) in 1992 to 
improve the system for matching patients with marrow donors. As summarised in Table 9-2, 
the bone marrow donor registry in the US has the largest pool among the four countries. 
Table 9-2. The number of bone marrow donors in pmp inhabitants 
Country No. of registered bone marrow 
donors 
No. of registered donors pmp 
inhabitants 
ABDR AR+ABDR ABDR AR+ABDR 
Japan 115,564 125,448 920 990 
Korea 21,385  465  
UK 255,809 415,436 4,510 7,030 
US 1,741,938 3,019,381 6,390 11,100 
Data sources:  
a. For Japan, UK and US from Bone Marrow Donor Worldwide, Bone Marrow Donor Worldwide-
Annual Report 1999,  
b. For Korea from Korean Marrow Donor Programme 20 Dec. 2000 Newsletter 
 
Fourth, financial supports from charities have been active for the patients 
undertaking HSCTs, especially in Korea. More than 10 charities support about £5 million a 
year for patient’s share in HSCTs and chemotherapies. In other three countries, charities for 
supporting HSCTs and chemotherapies seem to be less active but it was impossible to 
investigate the situations.   
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In addition, the leading role in the advent of HSCT of a country influences the adoption. 
Major advancements in the development of HSCT technology have been recorded in the 
US, where the adoption of HSCT is at the highest. The application of HSCTs has been 
significantly expanded from haematological malignancies including leukaemia to a wide 
range of solid tumours. As detailed in Table 2-2 of chapter 2, about 60 % of total HSCTs in 
the US from the beginning of transplant registry through recent were applied for 
haematological malignancies. Remaining about 40 % were applied for other diseases 
including solid tumours and the applications other than haematological malignance keep 
growing Expanding the application has mainly been pioneered in the US.  
Due to its high unit cost, third-party payers have been reluctant to provide coverage for 
HSCTs in all countries except Japan. Because of historical events, the Japanese government 
has supported any medical approach that helped treat leukaemia. The highest level of 
HSCT adoption in the US is paradoxical but may suggest that insurance coverage can 
promote certain forms of technology diffusion, such as for cancer. Similar to assisted 
reproductive technology, the case studies on HSCTs suggest that a leading role of a country 
in developing a technology has significant influence on the diffusion.  
 
9.4. Cochlear implant 
 
In summary, hearing impairments are commonly regarded as a major concern in terms 
of welfare public in all the four countries. However, approaches for supporting cochlear 
implants varied among four countries. In the UK, the cost of cochlear implants was 
supported by special funds allocated in the national health services budget. The US 
government encouraged early detection of hearing impairments and various public funds 
support at the state level. In Japan, public support funds finance almost the entire cost of 
cochlear implants for both children and adults, subsidised within the context of welfare 
benefits. In Korea, a public support plan was recently set out by the central government. 
Public support plans have directly financed implants and the insurance coverage has been 
extended, but only to a certain extent due to concerns surrounding equity in health 
insurance finance. 
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As indicated by the case studies, the adoption of cochlear implants is the highest in the 
UK in pmp, followed by the US, Japan and Korea, respectively. The number of adoptions 
has rapidly increased during the past decade; the number in Japan was the highest expanded 
four times from 1996 to 2003. The adoption in the UK is nearly 50 % higher than that of 
the US and 3 times than Japan. Although it is difficult to accurately make a comparison 
between the number of potential candidates and actual implants in the four countries, public 
authorities or professional groups in each country estimate the number of candidates that 
stand to benefit from an implant may be 673 in Japan, 897 in Korea, 67 in the UK and 
1,717 in the US in pmp. Considering the number of cochlear implants carried out so far, 
potential candidates make up about half the population among those who may need 
cochlear implants in the UK, while less than 5 % of the total candidates have received 
implants in other three countries.  
 
In the four countries, public concerns for the potential candidates are currently well 
established and included in national welfare programmes though the extent varied. Public 
programmes support the early detection of cochlear implant in the UK and provide full 
funding. In the US, the Joint Committee of Infant Hearing (1994) mandated all infants with 
hearing loss should be identified be the age of 3 months. “Health People 2000” project also 
pursues to identify all children with permanent hearing loss before 12 months of age. Public 
supports for early identification of hearing impairment lacked in both Japan and Korea.  
Financial supports from public funds also started earlier in the UK and US than the 
Japan and Korea. In the UK, the British government began to support cochlear implantation 
with special funding from 1991 stemming from the national cochlear implant programme 
commenced in 1989/90 fiscal year. As mentioned earlier part of this section, the US 
government also provide public insurance for the disabled with hearing impairment. In the 
Japan and Korea, the cost for cochlear implant was provided insurance coverage in recent; 
1994 for 22 channel and 2000 for 24 channel in Japan, and 2005 in Korea. Without 
insurance coverage, it was hard to have cochlear implantation in Japan and Korea due to its 
high cost. 
As a technology that does not highly requires sophisticated skills but demands high unit 
cost, the result of this research suggest that the diffusion of cochlear implantation is 
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significantly influence by insurance coverage. Since the influence of residual factors such 
as cultural or historical, insurance coverage and other welfare benefit policy of a nation 
appears to be significantly important. 
 
9.5. Gamma Knife Radiosurgery 
 
In summary, case studies indicate that the adoption of Gamma knife unit is influenced 
mainly by the ability of providers to purchase the unit. The situation in the UK is notably 
different from the other three countries. First, the decision for adoption is not in the hands 
of individual health care providers but under the public authority’s control. The NHS 
budget has long been subject to complaints of under-funding and issues of equitable access. 
To overcome the cost burdens, the NHS attempted to provide funding through the “private 
finance initiative (PFI).” PFI funding for Gamma Knife technology however was halted 
after the first installation in 1989. Thus the UK lagged other countries. 
 
Funding for the other three countries share similarities. In the US, one company, GK 
Financing, LLC (GKF), played a key role in driving the adoption of the technology by 
hospitals. Hospitals are responsible for site and installation costs only. GKF charges the 
hospitals a fee of between $7,500 and $9,500 per procedure. In Japan and Korea, lease 
companies provide the equipment to hospitals through loans, and receive a return on 
contracts for 5 to 10 years. In all three countries except the UK, hospitals decide whether to 
purchase the technology, with the option of making a one time payment or paying by 
procedure.  
Market conditions are also comparable in all three countries, epitomized by intense 
competition and rivalry. An FFS based retrospective compensation scheme has been 
fuelling adoption of this HT as the fees are remunerated for each usage.  
 
There are several other reasons contributing to these trends. First, competition among 
health providers is intense in these countries. In Japan, classification of hospital beds into 
acute, long-term care, and special disease, has spurred competition especially among acute 
care hospitals. To attract patients and physicians who may refer patients, acute care 
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hospitals tend to reinforce their competitiveness with high technological equipment. In 
Korea, the entrance of a conglomerate stimulated fundamental changes in hospital industry. 
The first Gamma knife unit was adopted by a conglomerate owned hospital (Hyundai) in 
1991. Since then, company owned hospitals and university hospitals have been competing 
against each other to adopt this technology. The Asian financial crisis of 1997 caused by 
lack of foreign exchange holdings led to an economic downturn in Korea, weakened the 
purchasing power for expensive equipment. The increase in the number of adoptions halted 
for until 2001 when the economy began to recover. Insofar as the use of Gamma Knife unit 
had not been covered by insurance, health care providers were free from external 
monitoring. In tandem with insurance coverage, adoption tends to be accelerated by 
increasing demand on the patients’ side both in Japan and Korea. 
 
9.6. Kidney transplantation 
 
The major findings can be summarised as follows. First, the number of organ 
transplants performed depends on the availability of organs for transplant rather than 
economic advantage, and this trend is more obvious where health services are provided 
based on free competition market mechanism. In the US, the number of organ transplants is 
more closely correlated with the number of hospitals involved in transplant than in the UK. 
This is primarily resulted from the UNOS’s guidelines requiring transplant centres to 
perform certain number of transplants to be a member of OPTN, which is essential in order 
to receive qualification for Medicare reimbursement.  
Second, the number of organ transplants performed is greatly influenced by income 
level in terms of GDP. This trend is more obvious in the US and Korea, where the patients 
should bear a large amount of the costs for transplant. The more costly the procedure, the 
more the procedure is significantly correlated with income level. In the UK, the levels of 
organ transplants are higher than in the US as compared with health expenditure in terms of 
per capita power purchasing parity. Particularly, the number of liver transplants performed 
was much higher, which indicates that financing measures in the UK are more benevolent 
but of inferior approach in terms of cost-effectiveness. This also applies where cross-
subsidies are minimised and the costly measures of health services are likely to be 
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restrained. In the UK, preventive approaches to reduce coronary heart disease result in a 
decreasing number of heart transplants. This indicates that if the central government is a 
third-party payer, it may be more effective to avoid costly treatments by preventing people 
from becoming patients who will require expensive medical choices. To achieve this, the 
government can engage in national campaigns. Such policies are generally hard to 
implement in a free competition market. Insofar as the insured can switch over the insurer 
and the insurers can enjoy reverse selection of the insured, it is hard to implement 
consistent approaches across the country.  
 
In summary, organ transplants are significantly affected by both health care law and the 
measures for financing health services. As for the health care law, the characteristics in 
authorising organ procurement and how to operate organsational infrastructures have 
significant influences. Since the number of organ transplants performed largely dependend 
on the availability of organs, lesgislative and organisational arrangements for organ 
transplant are essential elements in organ transplant levels. In all case study countries, the 
choices of organ transplants are not likey to be based on economic advantages in terms of 
cost-effectiveness, but largely driven by clinical advantages with life-saving effects at the 
front.  
The number of organ transplants performed are greatly affected by the level of income, 
and the more costly transplant procedures are much more significantly influenced by 
income level. The level of income is more significantly influential in the circumstances 
where cross-subsidies within or amongst insurers are minimised.   
 
The four comparison has shown; 1) big difference in the level of kidney transplant with 
highest in the US, followed by UK and Korea, especially Japan at low levels, 2) these 
differences do not appear to be due to the micro characteristics of the technology which 
offers major gains in terms of life expendency, QoL, and good cost effectiveness, 3) the 
procedure is generally covered by public or social insurance although the patient has to 
bear a considerable % of cost in Korea, 4) the low levels in Korea and Japan reflect 
religious views specifically Confucian tradition that requires not to make deceased body 
any harm. 
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Chapter 10: Conclusion and research recommendations 
This chapter aims to draw conclusions from the work reported in previous chapters in 
order to identify research recommendations. It does this by considering the case studies 
against the model outlined in chapter 2.  
 
10.1. Findings 
10.1.1. Micro characteristics of HTs 
Micro factor analysis proved that cochlear implant and kidney transplant are more cost-
effective compared to compatible approaches. For the remaining four technologies, it was 
impossible to prove cost-effectiveness in terms of QALY in comparison with alternative 
choices. The evaluation for assisted reproductive technologies was not possible to compare 
with natural conception but available to discriminate by unit costs and success rates 
amongst the procedures. Since the choice of procedure is largely determined by the 
condition of infertile couple, the evaluation of micro factor influence in the diffusion is 
inevitably limited. Regarding caesarean section delivery, it was impossible to make cost-
effectiveness comparable with natural birth. Economic evaluation was done by comparing 
the unit cost between caesarean section and normal birth. Regarding HSCTs, micro factor 
evaluations in the literature reviews have not yet confirmed. In terms of cost, peripheral 
blood stem cell transplantation costs higher than chemotherapy but less costly compared to 
bone marrow transplant. The advantage of HSCTs in terms of prolongation of life and 
improvement of QoL also has not yet been proved both in bone marrow and peripheral 
stem cell transplantation. Gamma knife radiosurgery offers the lower cost per treatment 
than open surgery due to shorter hospitalisation. In addition, less pain and shorter period of 
time for recovery also become major reason to choose Gamma Knife radiosurgery. In 
clinical aspects, Gamma knife radiosurgery is often chosen when the surgical approach is 
impossible mainly because of its location. The main impediment for the installation of 
Gamma Knife unit is high capital cost. 
The adoption of ARTs and caesarean section delivery seem to have been motivated 
mainly to meet individual desire. Caesarean section delivery has been preferred by both of 
obstetricians and women. For the obstetrician, caesarean section delivery makes it possible 
 
 
244
to schedule for labour time and help to avoid malpractice litigation while bequeath better in 
income. For the women it offers less pain during labour. In addition, in some countries, it 
enables women to give birth in “lucky” days. Patients choose HSCTs in the hope of a cure 
for fatal diseases. Gamma knife bestows shorter length of stay and less time for recovery on 
patients but it requires initial high capital costs to install.  
 
According to economic incentive of adopters and the principal value of a 
technology, the 6 HTs can be categorised into two groups; welfare-oriented versus private 
benefit -oriented technologies, as shown in Figure 10-1, below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-1. Classification of HTs by economic and benefit function 
 
Cochlear implant and kidney transplant are clustered into welfare-oriented 
technology for two reasons; first, the candidate who gets benefit from the technology is 
regarded as a disabled perspm who benefits from of the  national welfare programme, and 
second, the cost for the adoption is largely subsidised by the public fund. In all four 
countries the patients with ESRD and those who were profoundly deaf are regarded as 
disabled by law. In Korea, a special fund subsidised cochlear implant until health insurance 
commenced to provide coverage. Early detection programmes for the profoundly deaf have 
Public welfare 
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been established under national plans in Japan, in the UK, and in the US. Regarding kidney 
transplant, the support from public sector has commonly focused on promoting organ 
donation as well as including the transplant procedure within coverage.  
ARTs, caesarean section delivery, Gamma knife units, and HSCTs can be classed as  
private benefit oriented technologies because they are preferred by providers who pursue 
profit or by patients seeking to avoid pain, even though their cost-effectiveness is poor or 
yet to be confirmed.  
ARTs are unique. To promote birth which is sometimes linked to population growth, 
ARTs were subsidised by public funds in many countries. ARTs could be seen as being a 
transition from private benefit oriented technology to welfare oriented technology. In the 
past, infertility has not been regarded as a disease, so that insurance coverage has not 
generally included ART. This may be changing however. 
Caesarean section delivery is clearly a matter of choice of which the selection is 
spurred by provider or patient, and often by both. Excepting Japan where the caesarean 
section delivery ratio is relatively low, the other three countries have been struggling to 
limit or reduce the caesarean birth ratio. 
HSCTs have been experimental until recent. Due to their high cost, applications for 
use have been restricted particularly in the UK. HSCT has required prior approval in Korea 
and most of private health plans in the US before the procedure. Japan, due to its history, 
appears to have a more favourable approach to HSCT.  
Gamma knife requires high capital cost for installation and has high unit cost. 
Third-party payers have generally been reluctant to pay for it but applications for use have 
been recognized in economic terms. It offers benefits for patients including shorter LOS 
and recovery with less pain. However, it is not yet generally approved due to its high cost 
and its use has therefore become a matter of choice. 
 
10.1.2. Interactions between micro and macro factors in the diffusion of health 
technology 
The results show that health providers under national planning systems tend to 
prefer cost effective treatments while those in more market systems tend to adopt 
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technologies that may contribute to improving revenue. The much higher level of cochlear 
implantation and the greater proportion of patients with renal failure living with functioning 
grafts in the UK provide the best example.  
In contrast, health providers under national health planning system tend to be unable 
to purchase costly medical equipment unless they get special budgets, for example Gamma 
knife unit in the UK. The adoption of Gamma knife units has been much more extensive in 
health systems that are more market oriented. Distinctions between national health planning 
systems and health systems with market mechanisms are summarised in Table 10-1. 
 
Table 10-1. Motives of HT adoption in national plan and market mechanism 
 National plan Market mechanism 
Positive motive for 
HT adoption 
- Cost-effectiveness 
- Cost saving for 
provider 
- Accomplish public 
welfare 
- High income for provider 
- Personal desire 
accomplishment of user 
- Time saving for provider 
and/or user  
Negative motive 
for HT adoption 
- High capital cost 
- High cost for use Income reduction for provider 
 
The number of ARTs performed was highest in the UK. Limited to IVF-ET that 
includes ICSI, the adoption level has surpassed by Japan and Korea at the end of 1990s. 
There have not been any specific changes in terms of either payment system or regulation 
which would account for this. The costs for ARTs are only partly funded by the NHS and 
therefore couples seeking fertility treatment must pay most of the cost out of their pocket, 
which is same in the other three countries. This is a something paradox, since the UK was a 
leader in this area, but seems to be due to infertility not being seen as a disease or ART not 
being seen as a welfare oriented health technology. The recommendation by NICE of 
limited NHS provision of ART may signal changes in the status of ART. 
 
The ratio of caesarean section deliveries is lower in the UK compared to the other 
countries except Japan. Recent increases are largely a result of the NHS guidelines that 
advice obstetricians to respect maternal request for caesarean section deliveries in respect 
of the consumers’ rights, in addition to the fear of a malpractice litigation. Under a market 
principle, unrestricted discretion towards caesarean section deliveries has led to a rapid 
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increase in the number of procedures, especially in Korea. Coupled with cultural reasons, 
the ratio in Korea is the world’s highest. It is however interesting that Japan has the lowest 
ratio. Due to the shortage of obstetricians and womens’ change in attitude regarding pain in  
labour and safety in birth, however, the ratios rapidly increased to 21.4% of hospital births 
in 2005.  
 
HSCTs are very expensive but the effectiveness in clinical terms is yet to be 
confirmed. Insofar as the procedures are often undertaken as a last resort and the majority 
of the candidates are children, there have been active public supports in all four countries 
which are limited to bone marrow or cord blood donation. Without public financial support, 
the majority of the costs are financed privately, although charities provide significant 
financial support in some countries. HSCTs adoptions are much higher in the US compared 
with those in the UK. Due to expanding insurance coverage and donor matches, HSCT 
adoptions are getting increased in both Japan and Korea. 
   
Kidney transplants are recognised to have better outcomes in terms of cost-
effectiveness in comparison with compatible treatments. In terms of the prevalence of 
functioning graft, the level of adoption is the highest in the UK among the selected 
countries. Although the level in terms of pmp is the highest in the US, the interpretation 
should go with the prevalence of functional graft against total prevalence of ESRD patients. 
Accordingly, it also support that the adoption of welfare-oriented technology is preferred 
by health systems under national health plan. High level of kidney transplantation in the US 
insinuates that the procedure is profitable due to its high fees. As kidney transplant requires 
human organ to transplant, it is significantly influenced by cultural tradition. Confucian 
tradition among far eastern countries that regards the deceased person should not be harmed, 
hamper organ donation from the deceased person.  
In summary, this research attempted to examine the interaction between micro and 
macro factor in the adoption of HTs. In published researches exploring the determinants for 
HT adoption, the concerns were mainly focused on external factors which are termed 
“macro” factors in the present research. Some studies separated internal and external or 
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intrinsic and extrinsic factors similar to “micro” and “macro” in the present research, few 
effort has examined interaction between micro and macro factors.  
This research suggests that clustering HTs into “welfare oriented technology” and 
“private benefit oriented technology” by taking into account economic incentive of 
adopters. Private benefit oriented technologies are those which adopters expect to increase 
income from provider side or meet personal desire by consumer side. For welfare oriented 
technology, adoption decision is dominated by the aim of public welfare.  
 
As presumed by the model, among the selected HTs, the adoption levels of cochlear 
implant and kidney transplant were higher in the UK where health services are provided 
under national plan than other three countries that have market condition in health service 
provision. The adoption levels of Gamma knife unit and caesarean section delivery are 
much higher in those countries under market condition. The case of caesarean section 
delivery in Japan was exceptional, where caesarean section delivery is the lowest among 
the countries while situated in market condition. Japan is the only country that health 
insurance programmes do not cover natural birth as they do not regard the delivery as 
medical practice. The highest level of caesarean section delivery in the world recorded in 
Korea was primarily attributed to market mechanism that allow both women giving birth 
and obstetricians to choose caesarean section delivery in their own decision. Furthermore, 
cultural tradition of which people believe the fate of a person is determined by the time of 
birth almost certainly led to the remuneration system being so structured. Almost all 
Korean parents want their children to be born at a “good time” and hence many try to 
schedule delivery times in consultation with fortune-tellers. This provides an interesting 
example of the interaction of micro (parents’ wishes) and macro (remuneration methods). 
The high level of ART adoptions in the UK is also consistent with interaction of 
micro and macro factors. ARTs can be classified as private benefit oriented technology, and 
accordingly presumed to be higher in market condition. Contrary to expectations, the 
adoption levels of ARTs were much lower in the market oriented health system of Japan 
and Korea. This can be attributed to the UK’s leading position in the development of the 
technology and the cultural traditions in Japan and Korea. The UK has been the leading 
country for the advent of ARTs, while ART applications have been restricted in Japan and 
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Korea due to the cultural traditions which respect blood line. The family host system in 
both Japan and Korea means that the man who has success in extending the family blood 
line can be the family host.  
The installation of Gamma knife units shows the most typical distinction in micro 
and macro interaction in HT adoption. To adopt, it requires enormous capital cost which 
needs special budget in NHS, while the adopters in three other countries try to install the 
unit earlier than others to acquire competitiveness. As a technology that can be classified 
into private benefit oriented technology, the adoption of Gamma knife units has been 
mainly promoted in pursuit of income. The adoption behaviours were much more active 
before health insurance provides coverage for the use of Gamma knife unit, when external 
inspection for the use (eg, from third-party payer) is minimal and providers have discretion 
for deciding the fees.   
Incentives for health providers in adopting HTs differ according to the health 
system. The adopters under national health planned systems such as NHS financed by 
general tax are more likely to adopt welfare oriented technologies while those health 
systems which are market oriented tend to adopt private benefit oriented technologies. The 
result implies that some HTs who might be of benefit are neglected under market condition. 
Health providers however can be restrained by public control. For example, the world’s 
highest caesarean section delivery ratio in Korea has stopped rising due to the inspection 
programme of Health Insurance Review Agency (HIRA) which investigates whether the 
choice of caesarean section is clinically appropriate. Relatively lower caesarean section 
ratio in the US can be attributed to legal regulation that requires peer review for the rational 
choice of caesarean section delivery NIH has taken action to encourage vaginal births after 
caesarean. The lower caesarean section ration in Japan may be due to limits on insurance 
coverage. Since health insurance in Japan does not cover natural birth, health providers, 
especially private, prefer to choose normal delivery which has no external inspection.  
10.2. Limitations 
As this research deals with 6 topics in 4 countries, it comprises 24 case studies. 
Limitations were inevitable. First on data, the study required time-series and cross-sectional 
data but it was unable to obtain them with same quality for each of 24 examples. Table 10-
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2 summarises the data quality for each HT. The data for cochlear implant in the US 
estimates by professionals based on statistics obtained from suppliers.  
 
Table 10-2. Data quality 
 Japan Korea UK US 
Source    
DQ 
Source DQ Source DQ Source DQ 
ART JSOG IC KSOG IC  HFEA C ASRM C 
caesarean 
section 
delivery 
MHLW C NHIC C DOH C CDC, NCHS C 
HSCT JSHCT C HSCT Nurse 
Association 
C BSBMT C ABMTR, 
IBMTR 
IC 
 
Cochlear 
implant 
ACITA C Local agents C D. Marshall C A.Q. 
Summerfield 
IC 
Gamma 
Knife 
Manufacture 
(Elekta) 
JGMSA 
C Manufacture 
(Elekta) 
 
C Manufacture 
(Elekta) 
 
C Manufacture 
(Elekta) 
 
C 
Kidney 
transplant 
JOTS C KONOS C UKTSSA C UNOS C 
Note: ‘C’ refers complete data and ‘IC’ refers incomplete data 
The data for HSCTs in the US was also partial although ABMTR (Autologous 
Blood and Marrow Transplant Registry) collect on regular basis. ART statistics for both 
Japan and Korea were based on surveys and so represented only for those involved in 
survey although it covers over 90 %. Although the US has registration system for HSCT, 
about half of facilities were joint rather than individual registrations. Overall, however, the 
data are believed to be of sufficient quality to draw the conclusions outlined. 
Second, the methods of micro factor evaluation for each HT varied and some of 
them were impossible to compare with compatible options. As seen on Table 10-3, the 
result of micro factor evaluation in caesarean section delivery is impossible to compare 
with normal delivery. The only available measure was overall cost, the incidence of 
complication, and LOS, but technical advantages, such as for women, avoiding pain, and 
for obstetricians, income and availability of scheduling, were impossible to estimate. It is 
impossible to measure micro factor influence to a comparable standard across the range of 
HTs. Nonetheless, the advantages of micro factor could be roughly assessed through the 
comparison of overall cost, QoL, success rate, and/or survival rate. 
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Table 10-3. Availability of micro factor evaluation 
Topic Method of micro factor evaluation 
Comparableness Economic Clinical 
ARTs WTP 
Overall cost per cycle 
 
Success rate 
Among ARTs 
caesarean section 
delivery 
Overall cost per procedure  
× 
HSCTs Overall cost per procedure Survival rate 
QoL 
Among HSCTs 
and with chemo 
therapy 
Cochlear implant Costs per QALY,  
Costs per life year gained 
QoL With other 
hearing aids 
Gamma knife Costs per QALY,  
Costs per life year gained 
Successful 
outcomes 
With open 
surgery 
Kidney transplant Costs per QALY,  
Overall costs per procedure 
Survival rate QoL With dialysis 
 
Third, the macro factor evaluation mainly focused on the provision of insurance 
coverage and/or public funding. The interpretation of legal environment was limited to 
ARTs and kidney transplant, linked to concerns for the use of human organs and control 
over genetics 
  
The frailty of this model is essentially attributed to the scope of evaluation 
especially for macro factors, which is hard to confirm in quantitative terms. In reality, the 
component constitute macro factor is actually impossible to define. Accordingly, 
reimbursement plan of third-party payers, public subsidy, and regulation that may have 
influence on the technology are of possible evaluation. As found, cultural factor and 
leading position in the development of health technology has nothing to do with legal 
aspect although they are parts of environments for HT adoption. 
 
10.3. Conclusion and recommendations 
 
It has been a great concern to policy makers why some health technologies spread 
faster than others, especially on the international level. Language barriers and 
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inconsistencies in the quality of data have been major obstacles. The main weaknesses of 
comparative studies regarding the dissemination of HT essentially stem from the lack of 
theory, and parochialism that has led to comparison within the limited context such as those 
limited to European countries. Few HT diffusion studies spanned globe. Existing researches 
focused on one country or the countries sharing common languages, cultural traditions and 
institutional similarities.  
The research is primarily was designed to cope with these two shortcomings by an 
empirical study comparing four prominent countries – Japan, Korea, UK, and US - with 
very circumstances in terms of health systems and cultural tradition. Given the minimal 
literature available, inclusion of the two East Asian countries merits the attention of those 
interested in further developing the discipline. These countries offer unique insights into the 
diffusion of HT in rapidly developed economies and countries with health systems financed 
by social insurance. In this study, these countries were compared with the UK and the US, 
which have been the main subjects in assessing the determinants of HT dissemination.   
  
In general, the tax funded NHS had tighter control especially a capital spending. 
More market oriented health systems had more rapid diffusion of HTs offering profit 
potential and /or meeting patient preferences. Accordingly, this model may be useful for 
policy makers to recognise what sorts of HTs are more likely to be disseminated in each  
country. On the other hand, it may be also useful to forecast what kinds of HTs are likely 
circumscribed in adoption. This model also can be of use for the manufactures of HTs to 
appraise the opportunity for marketing.  
However, there were some paradoxes. First, the caesarean section delivery ratio is 
the lowest in Japan where the health services are provided under market mechanism. As 
mentioned already, natural birth is not covered by insurance allowing obstetricians to be 
free from external monitoring, which offers more financial advantages.  
Second, overall ART adoptions are the highest in the UK although IVF-ET 
procedures including ICSI were greater in Japan and Korea. The UK lead is due to its 
leading position of the development of technology. Specific practice codes outlined by 
Human Fertilisation and Embryology Act facilitate ARTs. As procedures related to genetic 
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linkage such as donor insemination and egg donation have been restricted by the 
professional community in Japan and Korea, dissemination has been lower and slower. 
Third, the adoption of cochlear implants was higher in the US than the UK. The 
relatively high adoption level is primarily attributed to the public insurance plans in the US 
including Medicare and Medicaid which cover about 80 % of total patients undertaking the 
procedure. In addition, legal obligation to diagnosis hearing impairments soon after birth is 
also regarded to facilitate medical interventions. However, the level of adoption is still 
higher in the UK than the US in terms of the ratio of the implanted against the estimated 
population that might benefit. 
Fourth, kidney transplant adoption was significantly high in the US in terms of pmp, 
but much lower than the UK if assessed in terms of the prevalence of functional graft. In 
the US, patients suffering from ESRD are included in Medicare, which regards it as a 
disability 
A health system paradox is that the adoption of welfare oriented technology is high 
in the US. Although the health system in the US is market driven in terms of health care 
services delivery, it has a great deal of public involvement, especially in compensating 
health providers via public insurance programmes including Medicare and Medicaid, as 
indicated in Table 2-4 in Chapter 2.  
 
Table 10-4. Level of HT adoptions of each country 
     Health 
system 
 
Technolgy 
adoption 
National plan Market mechanism 
UK Japan Korea US 
High 
ARTs 
HSCTs 
CI 
KT 
ARTs 
Gamma Knife 
 
CS delivery 
Gamma Knife 
HSCTs 
CI 
Gamma Knife 
KT 
Medium 
CS delivery CI 
HSCTs 
CI 
HSCTs 
KT 
ARTs 
CS delivery 
Low 
Gamma Knife KT 
CS delivery 
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Overall, the levels of HT adoptions in the UK and US were higher compared to the 
Japan and Korea shown in Table 10-4. The UK and the US have following characteristics 
against the Japan and Korea; 
 Higher income in terms of GDP at power purchasing parity 
 Leading position in the advent of HTs (especially for ARTs, HSCTs, cochlear 
implant, and kidney transplant) 
 Christian culture 
 
In any further explorations, the impacts of the following factors need to be carefully 
considered. First, cultural traditions have critical influences for certain technologies like 
caesarean section deliveries in Korea. Second, the influence of personal income also needs 
to be considered as confirmed in the kidney transplant case, particularly when patients have 
to pay some or all of the cost provably. Third, patient involvement in the decision making 
as well as issues of patient rights may be increasing influences for technology adoption, as 
instanced in the NHS.  
 
These countries provide a good reference point to widen academic interest beyond 
the existing set of 6 HTs in reckoning the determinants of HT diffusion. The scarcity of 
empirical evidence on the interactions between micro and macro factor may also further 
research particularly on pharmaceuticals.  
The present research attempted comparative studies exploring patterns of HT 
diffusion in four different countries. Depending on literature reviews and data analysis, its 
main frailties include difficulties in establishing cause and effect especially in explaining 
the interactions between micro and macro factors.  
The trajectory of each HT is complex and often unique. It may be not be possible to 
find a model that can be applied to all kinds of HT, which reflects the influence of health 
systems, inherent characteristics of HT, and other possible factors. Case studies show the 
attempts to recognise the diffusion of HTs reckoning micro and macro factor to be useful 
but limited. Case studies also uncover other factors of importance but which vary by 
country and technology. The findings suggests that Japan and Korea are different not only 
health systems but also in ways that culture and HTs interact.  
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To be generalised as a tool analyse HT diffusion, more research is needed with 
more HTs and in more countries with wider variety of health systems and cultural tradition.  
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